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General Introduction 
 
Ryōji Noyori in “Asymmetric Catalysis in Organic Synthesis”, John Wiley&Sons, New 
York, 1994 wrote: “Life depends on chiral recognition, because living systems interact 
with enantiomers in decisively different manner”. 
 
We know that the majority of biological processes take place as a consequence of the 
different ways in which enantiomers with different configuration react with receptors 
and life itself is in many ways chiral. Nature provides a vast diversity of chiral species 
in several classes of compounds, including “inter alia” aminoacids, carbohydrates, 
terpenes, carboxylic acids and alkaloids, several in great abundance, and the chiral 
information is derived from enantiomerically pure building blocks enzymatically 
synthesized by various organisms. 
Interestingly, chiral biomolecules usually exist in Nature prevalently as one of the two 
possible enantiomeric forms, e.g., amino acids in the L-form and sugars in the D-form. 
Chirality is an important factor in determining bioactivity. The recognition that 
enantiomers often have different bioactivity and metabolic fates1 in a number of chiral 
chemicals with important pharmacological activity led to a significant increase in the 
development of chiral pharmaceuticals, chirality becoming a major concern in the 
modern pharmaceutical industry.2  
This interest can be attributed largely to a deeper awareness that enantiomers of a 
racemic drug may have different pharmacological activities, as well as different 
pharmacokinetic and pharmacodynamic effects.  
Each racemic drug could interact differently and metabolize each enantiomer by a 
separate pathway to produce different pharmacological activity.  
Thus, one isomer may produce the desired therapeutic effect, the other one being 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 D.E. Drayer, Clin. Pharmacol. Theor., 1986, 40 125. 
2  S. Lam and G. Malikin, Chirality, 1992, 4, 395; I.W. Wainer (Editor), Drug Stereochemistry Analytical Methods and 
Pharmacology, Marcel Dekker, Inc., New York, New York, 1993.	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inactive or, in worst cases, noxious. For example, the (L)-Thyroxine, an amino acid 
produced by thyroid gland, is known to speed up metabolic processes, causing 
nervousness and loss of weight, while its enantiomer, (D)-Thyroxine served to lower the 
cholesterol levels. 
HO
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(L)-Thyroxine                                                  (D)-Thyroxine 
Figure 1 
The use of thalidomide (n-phthalyl-glutamic acid imide), which was marketed as the 
racemate, led to a tragedy in the 1960s in Europe. The sedative-hypnotic drug 
thalidomide prescribed to pregnant women to counter morning sickness exhibited 
irreversible neurotoxicity and mutagenic effects. It was discovered only after hundred of 
babies were born deformed that the S-enantiomer was teratogenic. Studies later 
suggested that these effects were caused by the S-enantiomer and that the R-enantiomer 
contained the desired therapeutic activity.3 
N
NH
O
OO
O
N
NH
O
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O
	  
R- Thalidomide                     S- Thalidomide 
Figure 2 
In 1992 the U.S. Food and Drug Administration issued a guideline for chiral drugs: only 
the therapeutically active isomer could be marketed and each enantiomer should be 
studied separately for its pharmacological and metabolic pathways.4 In addition, a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Stephens TD, Fillmore BJ., Hypothesis: Thalidomide Embryopathy – Proposed Mechanism of Action.  Teratology 2000; 61: 189-
195. 
4 S.C. Stinson, Chemical and Engineering News, 1995, 70, 44. 
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rigorous justification is required for market approval of a racemate of chiral drugs. 
Currently, a large number of chiral drugs are marketed as racemic mixtures. 5 
Nevertheless, to avoid the possible undesirable effects of a chiral drug, it is imperative 
that only the pure, therapeutically active form should be prepared and marketed.  
When a chiral molecule is synthesized in an achiral environment using achiral starting 
materials, an equal mixture of the two possible enantiomers (i.e. a racemic mixture) is 
produced. The special problem of the separation of the enantiomers could be solved 
using a chiral resolving agent. This technique relies on the fact that while enantiomers 
have identical physical properties, diastereomers generally have different properties. 
Another technique is to use chiral chromatography. In this process, the racemate is run 
through a column filled with a chiral substance. The enantiomers will interact 
differently with the substance and will then elute at different rates.  
As more and more enantiomerically enriched active agents are required today,	   the 
selective synthesis of enantiomers is the subject of many research projects aimed at the 
discovery of	  reactions or reaction sequences in which one configuration of one or more 
new stereogenic elements is selectively formed. In an asymmetric synthesis, an achiral 
molecule is enantioselectively converted into a chiral molecule or a chiral molecule is 
diastereoselectively converted into a new chiral molecule that contains at least one more 
chirality element.	  In an asymmetric synthesis the enantiomers (or diastereomers) of a 
chiral product are formed in different yields. 
Thus, the study of stereoselectivity has evolved from issues of diastereoselectivity, 
through auxiliary-based methods for the synthesis of enantiomerically pure compounds 
to asymmetric catalysis. In the latter instance, enantiomers (not diastereomers) are the 
products, and highly selective reactions and modern purification techniques allow 
preparation - in a single step - of chiral substances in 99% ee for many reaction types. 
 
 Physical resolution of racemates for example using HPLC (High Performance 
Liquid Chromatography) with specific chiral columns; 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 B. Lin, X. Zhu, B. Koppenhoeffer and U. Epperlein, LC·GC, 1997,15  40. P. van Eikeren, in S. Ahuja (Editor) Chiral Separations 
Applications and Technology, American Chemical Society, Washington, D.C., 1997, Ch. 2. 
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 Indirect enantiomeric resolution, via chiral auxiliary-based approaches, 
involves the coupling of the enantiomers with an auxiliary chiral reagent to 
convert them into diastereomers. The diastereomers can then be separated by 
cromatography or other achiral separation techniques; 
 Enzymatic catalysis in which the action of an enzymatic transformation is 
exploited to obtain enantioenriched compounds; 
 Catalytic enantioselective trasformations using chiral pool as catalytic 
compounds (for example the best know catalyst is the (L)-Proline). 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 G.Lin, Y. Li, A.S.C. Chan, Principles and applications of  Asymmetric Synthesis, 2001, Wiley-Interscience. 
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1. Introduction 
 
1.1 G-protein coupled receptor (GPCR): structure, biological activation and signal 
transduction 
 
Many drugs produce therapeutic activities through interaction with G-protein-coupled 
receptors (GPCRs), which actually represent the most important biological target for 
drug discovery. 7, 8 
GPCR (G-protein coupled receptor)s constitue a superfamily of integral membrane 
proteins consisting of seven transmembrane helices connected by loops with a N-
terminal extremity always located on the extracellular side, the C-terminus being 
extended into the cytoplasm. GPCRs can be divided into different families on the basis 
of their structural and genetic properties.  
 
 Receptors of Family 1 are characterized by several highly conserved amino 
acids and a disulphide bridge that connects the first and second extracellular 
loops (ECLs). Most of these receptors at the carboxy-terminal tail present 
palmitoylated cysteine residue that bind to the membrane. They are also 
characterized by the presence of amino acids such as proline that produces a 
distortion of the helical transmembrane domain.  
 
 Family 2 GPCRs are characterized by a relatively long amino terminus, which 
contains several cysteines forming a network of disulphide bridges. Their 
morphology is similar to some family 1 receptors but lacking the palmitoylation 
site. Moreover, the conserved residues and motifs are different from the 
conserved residues in the family 1 receptors.   
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Gilchrist, A., Expert Opin. Ther. Targets,  2004, 8, 495–498 
8 Saito, Y., and Civelli, O., Int. Rev. Neurobiol. 2005, 65, 179–209 
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 Receptor of the Family 3 are characterized by a long amino terminus and 
carboxyl tail. The ligand-binding domain is located in the amino terminus. None 
of the features that characterize family 1 and 2 receptors are present in Family 3 
receptors.   
 
These receptors are activated by an external signal in form of a ligand or other signal 
mediator, including peptide (e.g. Neuropeptide S)  and non-peptide neurotransmitters, 
hormones, growth factors, odorant molecules and light. The conformational change 
created in the receptor caused activation of a G-protein. Further effect depends on the 
type of G protein. 
 
Figure 3 
The transduction of the signal through the membrane by the receptor is not completely 
understood. It is known that the inactive G protein is bound to the receptor in its 
inactive state. (Figure 4) 
 
 GPCR bound to Gαβγ complex; “G-proteins” are a trimer of α, β, and γ subunits 
(known as Gα, Gβ, and Gγ, respectively); 
 Gα complex bound to Guanosine diphosphate (GDP) when the protein is 
inactive; 
 Ligand binds to extracelluar part of GPCR (1); 
	  	   15	  
 Upon receptor activation, there is a consequent allosterically activation of the G-
protein by facilitating the exchange of a molecule of GDP for GTP at the G-
protein's α-subunit (2); 
 Once the G protein is activated, the subunits of the G-protein dissociate from the 
receptor, Gα looses affinity for βγ dimer to yield a Gα-GTP monomer and a Gβγ 
dimer, which are now free to modulate the activity of other intracellular proteins 
(3); 
 Cascade events: 
o βγ dimer stays bound to the membrane and interacts with Effectors based 
on the specific βγ subunits like Adenylyl Cyclase (4); 
o Gα GTP complex enters the cytosol and interacts with Effectors, such as 
PLC-β (4); 
 Hydrolysis of GTP, linked to Gα subunit, provides Gα-GDP (5) product that is 
inactive but more related to the βγ dimer; 
 The trimer protein are reformed (Gαβγ) (6); 
 Gαβγ complex binds to GPCR. 
 
Figure 4 
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There is another subclassification of “G-protein” in particular at the α subunit: Gαs, Gαi 
and Gαq. Activation each of them produces different cascade events.  
In Figure 5a the mechanism of signal transduction is described: Gαs protein is activated 
by a ligand; a subsequent activation of adenylate cyclase takes place increasing the 
AMPc concentration.   
The section 5b outlines the mechanism after activation of Gαq: the released 
phospholipase C (PLC) provokes the cleavage of the membrane lipid 
phosphatidylinosityl-bisphosphate (PIP2) into diacylglycerol and IP3. The latter serves 
mainly to open calcium channels of the endoplasmic reticulum (ER) leading to the 
release of Ca2+ into the cell with consequent increase of its intracellular concentration. 
These profiles representing the two activated pathways by NPS (neuropeptide S) after 
interaction with its receptor are shown below. 
 
    a.         b.   
Figure 5  
 
1.2 NPS/NPSR system 
At least 800 different genes codifying for putative GPCRs have been identified in the 
human genome, ~360 of which encode transmitter GPCRs 9. Moreover, the endogenous 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 Vassilatis, D. K., Hohmann, J. G., Zeng, H., Li, F., Ranchalis, J. E., Mortrud, M. T., Brown, A., Rodriguez, S. S., Weller, J. R., 
Wright, A. C., Bergmann, J. E., and Gaitanaris, G. A. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 4903–4908 
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ligand is known for only ~240 receptors, whereas the others are still orphans. The first 
step in understanding the function and the potential of an orphan receptor as drug target 
is the identification of its endogenous ligand.  In the last decade, the reverse 
pharmacology technique 10, i.e. the use of a recombinant orphan GPCR as a target for 
identifying its endogenous ligand, has been validated as a successful approach for the 
identification of novel transmitter systems. In particular, several novel peptide receptor 
systems have been identified through this approach, including nociceptin/orphanin FQ, 
prolactin-releasing peptide, urotensin II and many others. The latest neuropeptides 
identified by the reverse pharmacology approach was Neuropeptide S (NPS): a crucial 
discovery firstly reported in the patent literature.11 A subsequent, elegant study by Xu et 
al.12 demonstrated that hNPS (as well as the rat and mouse isoforms of this peptide) 
selectively binds and activates a previous orphan GPCR, known as GPR154, that was 
renamed NPS receptor, then abbreviated as NPSR.  
Several splice variants and multiple single nucleotide polymorphisms have been 
reported for the human NPSR. The most intensely investigated NPSR isoforms are 
hNPSR Asn107 and hNPSR Ile107. This receptor polymorphism seems to have 
functional implications since the hNPSR Ile107 receptor displayed similar binding 
affinity but higher NPS potency (by approx. 10-fold) than hNPSR Asn107.13 It is 
worthy of mention that the rat and mouse NPSR contain Ile at position 107.14  
The primary sequence of human (h) NPS, a 20-residue peptide, which is highly 
conserved across species, is reported (Figure 6). 
 
SFRNGVGTGMKKTSFQRAKS 
H-Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser-OH 
Figure 6 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10 Civelli, O. , Trends Pharmacol. Sci.,  2005, 26, 15–19 
11	  Sato, S., Shintani, Y., Miyajima, N., and Yoshimura, K. (April 18, 2002) Japan Patent WO 0231145 
12 Xu, Y. L., Reinscheid, R. K., Huitron-Resendiz, S., Clark, S. D., Wang, Z., Lin, S. H., Brucher, F. A., Zeng, J., Ly, N. K., 
Henriksen, S. J., de Lecea, L., and Civelli, O. Neuron,  2004, 43, 487–497. 
13 Reinscheid, R. K., Xu, Y. L., Okamura, N., Zeng, J., Chung, S., Pai, R., Wang, Z., and Civelli, O. J. Pharmacol. Exp. Ther. 2005, 
315, 1338–1345 
14 Reinscheid, R. K., Xu, Y. L. FEBS J. 2005, 272, 5689–5693	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The N-terminal serine residue, which is present in all the species analyzed so far, gave 
the name to this novel neuropeptide (Neuropeptide S). hNPS is cleaved from a larger 
precursor protein (ppNPS) which is expressed in few discrete brain areas. On the 
contrary, the receptor NPSR is widely distributed in the brain. This profile of receptor 
expression suggests the involvement of the NPS–NPSR system in the regulation of 
multiple central functions. 
In cells expressing the recombinant NPSR receptor, NPS selectively binds and activates 
its receptor, producing intracellular calcium mobilization and an increase of cAMP 
levels. This indicates that the increase cellular excitability, after NPSR stimulation, it is 
due to the activation of both Gq and Gs protein. In vivo studies in rodents showed that 
the supraspinal administration of NPS produced a rather unique pattern of actions: 
anxiolytic-like effects associated with the stimulation of locomotor activity and clear 
arousal promoting effects.5 Thus, NPS could be defined as an activating anxiolytic.7 
In addition, NPS has been reported to inhibit food intake, facilitate memory and elicit 
antinociceptive effects, while recent evidence suggests an involvement of the 
NPS/NPSR system in drug addiction.15 
 
	  
 
 
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
15	  Guerrini, R., Salvadori, S., Rizzi, A., Regoli, D., Calò, G. Med. Res. Rev.; 2010, 30(5):751-77.	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1.3  Structure-activity relationship study of NPS leading to identified 
peptide and non peptide ligands 
 
1.3.1.  Peptide ligands of NPSR 
 
The development of novel ligands for NPSR is required in order to determine the role 
played by the NPS-NPS receptor system in the regulation of different biological 
functions and ultimately to predict the therapeutic potential of novel drugs interacting 
with this receptor.  
Thanks to structure-activity relationship studies reported for the first time by our 
research group, we were able to identify the main requirements for biological activity in 
the primary structure of NPS.16  
Thus, single residue replacement, either by an alanine residue (Ala-scan) or by the 
corresponding enantiomer (D-scan) with N- and C-terminal truncation, demonstrated 
that the N-terminus of the peptide was of crucial importance for biological activity. In 
particular, the sequence Phe2-Arg3-Asn4 is likely to act as message domain crucial for 
receptor binding and its activation, while the sequence Gly5-Val6-Gly7 is important for 
inducing the bioactive conformation of the peptide.  
In parallel, we also performed a conformation/activity relationship study 17  that 
demonstrated that helicity can be tolerated in the C-terminal part of NPS and this 
conformational structure is not required for bioactivity and it is not tolerated around 
position Gly7. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16 Roth, A. L.; Marzola, E.; Rizzi, A.; Arduin, M.; Trapella, C.; Corti, C.; Vergura, R.; Martinelli, P.; Salvadori, S.; Regoli, D.; 
Corsi, M.; Cavanni, P.; Calo`, G.; Guerrini, R.. J. Biol. Chem. 2006, 281, 20809-20816. 
17 Tancredi, T.; Guerrini, R.; Marzola, E.; Trapella, C.; Calo, G.; Regoli, D.; Reinscheid, R. K.; Camarda, V.; Salvadori, S.; Temussi, 
P. A., J. Med. Chem., 2007, 50, 4501–4508.	  
	  	   20	  
 
Figure 7 
	  
Conformational changes induced by substituting Gly5 with the achiral R helix 
promoting amino acid Aib or with D-Ala seem to provoke a decreased agonist efficacy, 
as indicated by  structure–activity studies performed at position 5.  Therefore, we 
planned a SAR study mainly focusing at Gly5 position by replacing with a series of L- 
and D- amino acids characterized by hydrophobic aromatic and aliphatic side chains.18 
As a result, we demonstrated that substitution of Gly5 with D-amino acids bearing a 
short lipophilic-branched side chain could generate a fairly potent, pure and selective 
NPSR antagonists.  
 
a.                 H-Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser-OH 
b.               H-Ser-Phe-Arg-Asn-(D)Val-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser-OH 
c.           H-Ser-Phe-Arg-Asn-(D)Cys (tBu)-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser-OH 
Figure 8 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
18 R.Guerrini, V.Camarda, C.Trapella, G.Calò, A.Rizzi, C.Ruzza, S.Fiorini, E.Marzola, R. K.Reinscheid, D.Regoli, S.Salvadori, J. 
Med. Chem. 2009, 52, 524–529.	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Above, the structures of first two NPSR-peptide antagonists actually known in literature 
are reported, namely: [D-Val5]NPS (Figure 8b) and [D-Cys(tBu)5]NPS (Figure 8c) 
whose pharmacology activity has been evaluated in a calcium mobilization assay using 
HEK293 cells stably expressing mouse NPSR (HEK293mNPSR) and the fluorometric 
imaging plate reader FlexStation II. 
 
1.3.2   Non-peptide ligands of NPSR 
 
Non-peptide derivatives have been widely used to examine in details and improve the 
knowledge of the NPS system19. However, at the beginning of this work only ligands 
featuring an oxazol-piperazine scaffold were known able to bind the NPSR receptor.  
A series of compounds with a claimed activity at NPSR has been recently reported in a 
patent application by Takeda Pharmaceuticals Inc 20  without the support of 
pharmacological or biological data. In the patent, structures containing a 3-oxo-
tetrahydro-oxazolo[3,4-a]pyrazine scaffold mainly substituted in position 1 and 7, have 
been described to possess NPSR antagonistic activity. 
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Figure 9 
 
Two of these compounds, namely  (SHA 66 and SHA 68), differing exclusively for the 
presence of a fluoro substituent at the para position of the benzyl moiety (SHA 68), 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
19 Reinscheid R.K.. Peptides 2007, 28, 830–837; Reinscheid R.K. and Xu, Y.L.. Neuroscientist, 2005, 11, 532–538; Guerrini R., 
Salvadori S., Rizzi A., et al.. Medicinal Research Reviews, 2010, 30 (5), 751-77. 
20 Fukatzu K, Nakayama Y, Tarui N, Mori M, Matsumoto H, Kurasawa O, Banno H.; Takeda Pharmaceuticals; 2004,  
PCT/JP04/12683. 
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were prepared by Okamura et al.21 who studied their pharmacological proprieties as 
potential NPSR antagonists in vitro and in vivo. The two closely related bicyclic 
piperazines have been described as potent and selective antagonists at NPSR in vitro, 
able to antagonize NPS-induced effects in vivo. 
Thus, SHA 68 shoved selectivity for this receptor and was able to block NPS-induced 
Ca2+ mobilization in central and peripheral site after binding. However, its 
pharmacokinetic profile indicated a limited BBB penetration.  
SHA 68 (see Fig. 10b) i.e. the racemic mixture (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-
oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide represents the first 
generation of non-peptide NPSR antagonists.  
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a.        (±) SHA-66                              b.       (±) SHA-68 
Figure 10 
 
Structure–activity studies performed at position 7 of SHA 6822 have indicated that a 
potent NPSR antagonist activity required a free urea moiety since alkylation of the urea 
nitrogen or its replacement with carbon or oxygen atoms generated derivatives with a 
decreased activity. In addition, compounds with α-methyl substitution or elongated 
alkyl chains showed reduced potency, indicating a limited tolerance for position 7 
substituents. Interestingly, removal of the fluorine atom at the para position of the 
phenyl ring generated a compound (SHA 66) displaying similar potency in comparison 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
21 Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK.; J. Pharmacol. Exp. Ther., 2008, 325, 893–901. 
22 Y. Zhang, B. P. Gilmour, H. A. Navarro, S. P. Runyon, Bioorg. Med. Chem. Lett., 2008, 18, 4064–4067.	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to the parent compound, indicating that the fluorine atom does not affect receptor 
binding.	  6,7 
 
Very recently, new series of NPSR antagonists has been developed by the same group 
of researchers (Melamed et al..23 and Trotter et al..24) in order to identified new 
antagonists of the Neuropeptide S receptor (NPSR) with high potency, good 
permeability into the brain trough the brain-blood-barrier (BBB), namely: (Figure 11): 
 a quinolinone class of potent NPSR antagonists that readily cross the blood–
brain barrier (NPSR-QA1). 
 a tricyclic imidazole antagonist of NPSR, represented by NPSR-PI1, that 
demonstrates potent in vitro NPSR antagonism and central exposure in vivo. 
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NPSR-PI1                              NPSR-QA1  
Figure 11  
 
In both cases, the racemic mixture of NPSR-PI1 and NPSR-QA1 was separated using 
chiral column chromatography affording the two potent enantiomeric compounds 
showed in Figure 11, but the absolute configuration of these antagonists remained 
unknown. 
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  J. Y. Melamed, A.E. Zartman , N.R. Kett , A.L. Gotter, V.N. Uebele, D.R. Reiss, C.L. Condra, C. Fandozzi, L.S. Lubbers, B.A. 
Rowe, G.B. McGaughey, M.Henault, R. Stocco, J.J. Renger, G.D. Hartman, M.T. Bilodeau, B.W. Trotter,  Bioorg. Med. Chem. 
Lett., 2010, 20, 4700–4703.	  
24	  B. W. Trotter, K. K. Nanda, P.J. Manley, V. N. Uebele, C. L. Condra, A. L. Gotter, K. Menzel, M. Henault, R. Stocco, J.J. 
Renger, G. D. Hartman, M. T. Bilodeau,  Bioorg. Med. Chem. Lett.,  2010, 20, 15, 4704-4708 . 
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2. Aim of the project 
 
The NPS-NPSR system is a quite recent discovery and many studies are still required to 
deeply  understand its biological functions and better define the therapeutic potential of 
selective NPSR ligands. 
The availability of selective NPSR antagonists is an important target in this field and 
my work has been mostly addressed to their discovery.  
In details, this work has been maily focused in the asymmetric synthesis of chiral 2,4-
disubstituted- and 2,4,6-trisubstitued-piperazines starting from cheap, commercially 
available materials. The piperazine moiety is  a well recognized “privileged scaffold” in 
medicinal chemistry, 25  being the common structural feature of a wide range of 
biologically active natural and synthetic products. 
The variety of  synthetic methods that allow for the fast and efficient assembly of 
piperazine skeletons reported in the literature has been comprehensively surveyed in 
four excellent reviews. 26 
In this project, the asymmetric construction of the substituted piperazine ring has been 
accomplished through two efficient methodologies featuring a different way for the 
introduction of the required chirality, namely: 
 using  readily available optical active natural materials such as aminoacids 
(alanine) as starting materials; 
 using a chiral auxiliary reagent to obtain separable diastereomers. 
The first class of compounds showing antagonism activity for the NPS receptor has 
been reported in the literature by the Takeda’s group. The synthetic pathway has been 
previously described by Schanen and coworkers  in 1996.27 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
25 a) Horton, D. A.; Bourne, G. T.; Smythe, M. L., Chem. Rev., 2003, 103, 893–930; b) Tullberg, M.; Grøtli, M.; Luthman, K. J. 
Org. Chem., 2007, 72, 195–199. 
26 a) Dinsmore, C. J.; Beshore, D. C. Tetrahedron, 2002, 58, 3297–3312; Dinsmore, C. J.; b) Beshore, D. C. Org. Prepar. Proced. 
Int., 2002, 34, 367–404; c) Quirion, J.-C. Asymmetric Synthesis of Substituted Piperazines. In Targets in Heterocyclic Systems; 
Attanasi, O. A., Spinelli, D., Eds.; Italian Society of Chemistry: Roma, 2008; Vol. 12, pp 438–459; d) De Risi C., Pelà M., Pollini 
G.P., Trapella C., Zanirato V., Tetrahedron: Asymmetry, 2010, 21, 255-274. 
27 V. Schanen, M.P.Cherrier, S.Jose de Melo, J.C. Quirion, H.P. Husson, Synthesis,1996, 833-837. 
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3. Synthesis 
 
3.1 Synthesis of Takeda’s compound 
In order to obtain the first non-peptide antagonist of NPS for pharmacological 
evaluation we planned to prepare the “Takeda compound” following the Schanen’s 
synthetic approach27 even if some modifications. 
Thus, the starting move was the reaction between R-(-)phenylglycinol 1 and N-Boc-(D)-
Alanine 2 to produce amide 3 under standard condensation conditions for the peptide 
bond formation (activation via dicyclohexylcarbodiimide) introducing a defined 
stereogenic centre at the beginning of the piperazine synthon construction, differently 
from the Schanen’s approach.  
The two carbonyl functions of the intermediate 3 could be selectively reduced with 
LiAlH4 in diethylether leading to the formation of 4  and its hydroxyl function was 
subsequently protected with tert-butyldimethylsilyl chloride in THF producing the 
amine 5. Its condensation reaction with with bromoacetic acid was conveniently 
accomplished via dicyclohexylcarbodiimide activation (Scheme 1) leading to the 
bromoacetylated derivative 6 which was smoothly cyclized to the piperazinone 7 by 
treatment with NaH in a mixture of DMF/THF. 
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Reagents and conditions : (a) N-Boc-(D)-Ala-OH, CH2Cl2, WSC, room temp., Y=64%; (b) LiAlH4, Et2O, 
0°C, Y=100%; (c) TBDMS-Cl, imidazole, DMF, 0°C, Y=76%; (d) Bromoacetic acid, CH2Cl2, WSC, 
room temp., Y=35%; (e) NaH 60%, THF/DMF, room temp., Y=74%. 
Scheme 1 
 
Removal of the silyl protective group of 7 was easily achieved by action of fluorine ions 
giving rise to 8 which was treated with borane dimethyl sulfide complex  in order to 
reduce selectively the lactam moiety producing the piperazine derivative 9. It was well 
known that the alkylation at position 2 of the piperazine ring system does not occur in 
the presence of the free hydroxyl function.27 Therefore,  the alcoholic functionality has 
been protected as the corresponding methyl ether 10 using NaH and MeI.  A solution of 
this compound in freshly distilled THF was treated with sec-BuLi/TMEDA at -78 °C 
and reacted with diisopropyl ketone furnishing exclusively the trans-1,1-diisopropyl-7-
(2-methoxy-1-phenyl-ethyl)-5-methyl-hexahydro-oxazolo[3,4-a]pyrazin-3-one 11 . 
Informations about the conformation of the piperazine ring was obtained by NMR 
analysis that showed coupling constants between the proton on C2 and the adjacent 
methylene protons (on C3) of 12 and 5 Hz. These data confirm that proton in C2 was in 
axial position and consequently the alkylated substituent in equatorial conformation. 
Interestingly, the exclusive formation of trans-2,6-disubstitued product has been already 
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observed by Beak28 in the piperidine series. Thus, the synthesis of the first example of a 
non-peptide compound able to interact with the NPSR, also named “Takeda 
Compound”, was completed in nine steps with very low overall yield (~4%). 
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Reagents and conditions : (a) TBAF, THF, room temp. Y=72%; (b) (CH3)2S*BH3, THF, 0°C,Y=88%; (c) 
NaH 60%, MeI, THF/DMF, 0°C,Y=62%; (d) sec-BuLi, TMEDA, isopropyl ketone, THF,-78°C, Y=48%.  
Scheme 2 
 
3.2 Synthesis of SHA-68 compound in racemic mixture 
While this work was in progress, two small molecules described in the Takeda patent 
were also synthesized and tested by Okamura et al.21 namely, the closely related 
bicyclic piperazines SHA 66 and SHA 68 that are potent and selective antagonists at 
NPSR in vitro and are able to antagonize NPS-induced effects in vivo.	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28 Beak, P.,; Lee, W.K.; J. Org. Chem., 1993, 58, 1109. 
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SHA 66                                                          SHA 68 
Figure 12 	  
The low overall yield of the synthetic process to prepare 11 and the interesting data 
related to the two new compounds described by Okamura et al.,21 prompted us to 
explore an asymmetric synthesis of the two enantiomers of the Neuropeptide S receptor 
(NPSR) antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-
carboxylic acid 4-fluoro-benzylamide ((R/S)-SHA 68) to complete their structural 
characterization and to confirm the pharmacological evaluation. Initially, in order to 
confirm the published data, we decided to synthesize (R/S)-SHA 68 in racemic form 
envisaging a very easy pathway starting from a cheap, commercially available N-
benzylpiperazine, already possessing a synthetically suitable substituent at one of the 
two nitrogen of the heterocyclic skeleton.  
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Scheme 3 
 
The first step was the orthogonal protection of second nitrogen of the piperazine 
scaffold. As the corresponding tert-butoxycarbonyl group (Boc) and this operation was 
easily achieved under standard condition to produce quantitatively the intermadiate 13. 
The construction of the second heterocycle condensed to the piperazine ring 14 was 
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smoothly accomplished in good yield (76%) by treatment 13 with sec-
butyllithium/N,N,N’,N’-tetramethylethylene diamine (TMEDA), at -78°C, followed by 
trapping of the intermediate anion with benzophenone. As already observed by 
Okamura et al., removal of the benzyl-protecting group of  14 was unsuccessful via 
palladium catalysed hydrogenolysis, but occurred smoothly through a simultaneous 
substitution in situ of the N-benzyl function with the fluorenyl methylenoxycarbonyl 
protective group (Fmoc-) by adding FmocCl to an acetonitrile solution of 14 at room 
temperature. After approximately 10 min, the precipitated 15 could be isolated by 
filtration with 70% yield. The last step of this pathway to obtain (R/S)-SHA 68 
compound required removal of the Fmoc-protecting group by treatment of 15 with 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) followed by reaction with the commercially 
available p-fluorobenzyl isocyanate.  
N
N
N
N
O O
N
N
O O
H
N
N
N
O O
O
F
Fmoc
N
N
H
N
N
O O
O O
12
13 14 15
a cb
d
O O
(R/S)-SHA 6815 	  
Reagents and conditions: (a) Boc2O, H2O/tert-butanol, NaOH (2N), room temp.; (b) sec-BuLi, TMEDA, 
benzophenone, THF, -78°C, Y=49%; (c) Fmoc-Cl, CH3CN, 100°C, Y=65%; (d) DBU, 4-Fluorobenzyl-
isocyanate, THF, room temp., Y=59%. 
Scheme 4 
 
Quenching of the reaction mixture after 15 min allowed to obtain (R/S)-SHA 68 in 
almost quantitative yield after purification via flash cromatography (Scheme 4). 
The structure of  (R/S)-SHA 68 was fully characterized by 1H and 13C NMR and mass 
spectrometry. 
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3.3 Asymmetric Synthesis of (R)-SHA 68 and (S)-SHA 68 
 
Enantioselective synthesis of chiral compound is an important goal for organic and 
medicinal chemists and different strategies are available for the synthesis of optically 
active compounds.  
In this project aimed at the construction of optical active piperazine compounds as a 
new class of non-peptide NPSR antagonists, we envisaged the chiral auxiliary approach 
as a convenient pathway for their asymmetric synthesis as outlined retrosynthetically in 
scheme 5.  
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Scheme 5 
 
The piperazine scaffold was synthesized in seven steps utilizing as chiral auxiliaries the 
readily available S-phenyl-ethylamine and R-phenyl-ethylamine. In the following 
schemes are reported the synthetic pathway for only the S-enantiomer, the same results 
being obtained with the other one. WSC-promoted condensation of N-Boc-glycine with 
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the chiral amine give the amide 16, which underwent LiAlH4 reduction of the carbonyl 
moieties to give 17, which was acylated by action of chloro acetyl chloride in the 
presence of NaHCO3 to furnish 18. Its subsequent cyclization was performed by 
treatment with NaH at room temperature to produce the piperazinone derivative 19, 
which was subsequently reduced in a good yield at the lactame function  employing 
borane dimethyl sulfide complex.  
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Reagents and conditions : (a) Boc-Gly-OH, CH2Cl2, WSC, room temp., Y=60%; (b) LiAlH4, Et2O, 0°C, 
Y=90%; (c) Chloroacetyl-chloride, NaHCO3, AcOEt, 0°C, Y=100%; (d) NaH 60%, THF/DMF, room 
temp., Y=45%; (CH3)2S*BH3, THF, 0°C, Y=87%. 
Scheme 6 
 
First attempts to build up the second heterocycle through the key alkylation step was 
rather unexpectedly unsuccessful although we payed careful attention to the choice of 
reagents (benzophenone, TMEDA and THF were freshly distilled and a new bottle of 
sec-BuLi was opened and used immediately) and reaction conditions (anhydrous and 
under nitrogen). 
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Beside starting material, the only detectable reaction product characterized by NMR and 
mass spettroscopy was the secondary alcohol derived by reduction of benzophenone, 
which is likely to be produced by action of a residual piperazine-borane complex 
formed during the previous carbonyl reductive step. 
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Scheme 8 
 
This hypothesis has been confirmed since the dihydropyrazine 19a was obtained using 
LiAlH4 instead of borane dimethyl sulfide complex. 
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   33	  
The formation of this unexpected product could be accounted for considering the basic 
character of  H- . 
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Scheme 10 
 
Moreover, since the Boc-protective group too seemed to be the responsible for the 
unexpected formation of 20, we decided to remove it using a solution of trifluoroacetic 
acid (TFA) in CH2Cl2. The reduction of  amide group carried out on the derived free 
amine 19b using LiAlH4 gave the desired piperazine 19c, subsequently protected at the 
second nitrogen atom as the Boc-derivative 20 in quantitative yield.  
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Reagents and conditions: (a) TFA, CH2Cl2, 0°C, Y=97%; (b) LiAlH4, Et2O, 0°C, Y=87%; (c) Boc2O, 
H2O/tert-butanol, NaOH (2N), room temp., Y=100%. 
Scheme 11 
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While this work was in progress, an interesting paper by Reginato et al.29 described the 
selective reduction of 2-oxo-piperazines as strategy to perform the easy alkylation at the 
carbon C2. Thus, treatment of 20 with sec-butyllithium/TMEDA at -78 °C, followed by 
trapping of the intermediate anion with benzophenone, the smooth formation of two 
diastereoisomers, 21a and 21b, occurred in good yield (76%) and the mixture was easily 
separated by flash cromatography. 
Further steps were similar to the ones previously used for the preparation of (R/S)-SHA 
68. The amine debenzylation was accomplished by addition of FmocCl to an 
acetonitrile solution of  21a and 21b at room temperature. After 10 min, crude 22a and 
22b were isolated as a white solids by filtration and used without further purification.  
Compounds 22a and 22b were treated with DBU and the urea moiety was formed using 
p-fluoro-benzylisocyanate to give the final products (S)-SHA 68 and (R)-SHA 68 in 
almost quantitative yield (Scheme 12). 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
29 G.Reginato, B.Credico, D.Andreotti, A.Mingardi, A.Paio, D.Donati, B.Pezzati, Al. Mordini, Tetrahedron: Asymmetry, 2010, 21, 
191–194;  
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Reagents and conditions: (a) Benzophenone, sec-BuLi, TMEDA, THF, -78°C, Y=45%; (b) Fmoc-Cl, 
CH3CN, 100°C, Y=67%; (c) DBU, p-fluorobenzyl-isocyanate, THF, room temp, 76% and 83% yields. 
Scheme 12  
4. Chiral chromatography profiles 
The structures of  the two diastereoisomers 21a and 21b and the two optical active 
compounds were fully characterized by  1H, 13C , DEPT, COSY, HMQC, HMBC, NOE, 
NMR and mass spectrometry. The enantiomeric excess of (R)-SHA 68 and (S)-SHA 68 
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were determined by chiral HPLC analysis. The Figure 6 shows the chromatograms for 
the single enantiomers (S)-SHA 68 (first eluted component, red line) and (R)-SHA 68 
(second eluted species, blue line), no trace of (R)-SHA 68 in the chromatogram 
corresponding to the elution of (S)-SHA 68, nor of (S)-SHA 68 in that of (R)-SHA 68 
could be detected. The optical purity of the two enantiomers was further supported by 
values of the reported peaks area . 
 
 
Figure 13 
 
In Figure 14 we compare the chromatographic analytical profiles of the two enantiomers 
with the racemate. 
 
 
 
 
 
(R)-SHA 68 
(S)-SHA 68 
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Figure 14 
5. NMR spectrometry profile 
In Figure 8 the enlarged [1H]NMR spectra of the C9 proton region of the (R)-SHA 68 is 
reported. Evaluation of the coupling constants between the proton Hx on C9 and the two 
adjacent protons Ha/Hb on C8 was useful to define the conformation of the enantiomer. 
The coupling constant values of Hx with Ha/Hb protons were 11.2 and 3.7 Hz for (R)-
SHA 68. These data confirms that the proton on C9 was in axial position and 
consequently the alkylated substituent in equatorial position. 
 
  (S)-SHA 68 
(R/S)-SHA 68 
(R)-SHA 68 
(S)-SHA 68 
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J ax 
J bx 
 
Figure 15 
 
6.  X ray spectroscopy analysis 
 
In order to define the absolute configuration of the C9 chiral centre crystals of the 
diastereoisomer 21b were produced using ethanol/ethyl acetate as crystallization 
solvents. The absolute configuration of the enantiomer (R)-SHA 68 has been assigned 
by reference to the configurations of the two stereogenic centers present in the 
diastereoisomer 21b.  
As shows in figure 16, knowing the unchanged chiral centre C10 (in configuration S) of 
the compound 21b we can determine the configuration of the chiral centre C9, that 
shows a configuration R. 
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Figure 16 
 
Figure 17 represents another angulation of the X ray structure of the diestereoisomer (S, 
R) 21b; the piperazine ring assumes a perfect chair conformation and we can confirm 
that the proton bind at C9 is placed in axial position as demonstrate by NMR analysis.
  
Figure 17 
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7. Biological activity 
Next, in collaboration with the pharmacology researchers of the "Università degli Studi 
di Ferrara” we planned a study able to furnish information about the biological activity 
of this new class of compounds.  
We evaluated and compared the in vitro NPSR antagonist properties of (R/S)-SHA 68, 
(R)-SHA 68 and (S)-SHA 68. The three compounds were tested in calcium 
mobilization studies performed on HEK293 cells expressing the murine NPSR or the 
two isoforms of the human receptor (hNPSRAsn107 and hNPSRIle107).13 
The natural peptide NPS was able to induce calcium mobilization in a concentration 
dependent manner in HEK 293 mNPSR (pEC50 8.97 ± 0.11; Emax 250 ± 11%), 
hNPSRAsn107 (pEC50: 9.07 ± 0.11; Emax 316 ± 13%) and hNPSRIle107 (pEC50: 9.17 ± 
0.15; Emax 333 ± 17%).  
(R/S)-SHA 68 inhibited in a concentration dependent manner the stimulatory effect of 
NPS showing similar high values of potency (pKB ≅ 8). These values of potency are 
superimposable to those previously published. 21,30  
(R)-SHA 68 was also able to antagonize in a concentration dependent manner the 
stimulatory effect of NPS displaying values of potency similar or slightly higher than 
the racemic mixture.  
By contrast, (S)-SHA 68 showed a slight inhibitory effect only at micromolar 
concentrations.  
The values of potency of the three compounds, in the three cells lines, are summarized 
in Table 1. 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
30 C. Ruzza, A. Rizzi, C. Trapella, M. Pelà, V. Camarda, V. Ruggieri, M. Filaferro, C. Cifani, R. K. Reinscheid, G. Vitale, R. 
Ciccocioppo, S. Salvadori, R. Guerrini, G. Calò, Peptides, 2010, 31, 915-925. 
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 mNPSR hNPSR Ile107  hNPSR Asn107  
 pKB pKB pKB 
(R/S)-SHA 68 8.16 8.03 7.99 
(R)-SHA 68 8.29 8.18 8.28 
(S)-SHA 68 <6 <6 <6 
Table 1 
 
Collectively, these results demonstrated that (R)-SHA 68 is the active enantiomer while 
the contribution of (S)-SHA 68 to the biological activity of the racemic mixture is 
negligible. As already mentioned in the introduction, the relevance of ligand chirality 
for NPSR binding is also corroborated by the fact that the biological activity of 
chemically different molecules, such as the quinoline23 and the tricyclic imidazole24 
compounds, could be attributed to a single bioactive enantiomer.  
(R)-SHA 68 was demonstrated to be the active enantiomer.  
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8. Conclusions 
 
The present study described the enantioselective synthesis of 2,4-disubstituted and 
2,4,6-trisubstitued chiral piperazines.  
Initially, envisaged the synthesis of (R/S)-SHA 68 in racemic form in order to confirm 
the chemical and biological published data through  an efficient synthetic scheme which 
can be easily scaled up to multi-grams.  
Later, we focused our attention to the asymmetric synthesis of the two enantiomers (R)-
SHA 68 and (S)-SHA 68 starting from cheap commercially available reagents. 
In order to define the conformation of the piperazine ring we performed a series of 
NMR experiments leading to define a chair conformation where the substituent in C9 
was placed in equatorial position. 
To know the absolute configuration of this new chiral centre X ray analysis was 
performed on suitable crystals obtained by the diastereoisomer 21b. The new 
stereogenic centre showed (R) configuration  
Furthermore, we studied these molecules from a pharmacological point of view; 
evaluating and comparing the in vitro NPSR antagonist properties of (R/S)-SHA 68, 
(R)-SHA 68 and (S)-SHA 68. 
The results demonstrated that (R)-SHA 68 is the active enantiomer while the 
contribution of (S)-SHA 68 to the biological activity of the racemic mixture is 
negligible. 
(R)-SHA 68 was demonstrated to be the antagonist of the receptor of the neuropeptide 
S.  
Nowadays, this molecule represents the standard non peptide NPSR antagonist and 
surely will be used to investigate the biological functions controlled by the NPS / NPSR 
system and to evaluate the therapeutic potential of innovative drugs acting as NPSR 
selective ligands. 
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Chapter 2 
 “Paris’ Project” 
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I. Introduction 
In the frame of the synthesis of biological active chiral compounds I have spend nine 
months at the Pierre et Marie Curie University in Paris under the supervision of 
Professor Giovanni Poli, focusing the attention on the synthesis of natural product (-)-
Steganacin. This stage allowed me to view a different approach for the selective 
generation of new structures using a palladium catalysed domino reactions instead of 
the use of chiral auxiliaries used for the synthesis of (R) and (S)-SHA 68. 
 
The isolation and structure determination of a novel class of dibenzocyclooctadiene 
lignan lactones, represented by the antileukemic esters steganacin 23 and steganangin 
23a, was reported in 1973 by Kupchan and his collaborators. 31 
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Figure 18 
 
Steganacin and steganangin were isolated from a plant of South Africa, Steganotaenia 
araliacea Hochst (Figure 18), which was found to show significant antitumor activity in 
vivo against P388 leukemia in mice. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
31 M. Kupchan, R.W. Britton, M.F. Ziegler, C.J. Gilmore, R.J. Restivo, R.F. Bryan, Journal of the American Society, 1973, 95:4, 
21, 1335-1336.	  
	  	   45	  
In vitro both compounds inhibit the assembly of tubulin into microtubules by interacting 
with the colchicine binding site and have been shown to possess cytotoxic activity 
against several cancer cell lines.32  
 
 
 
 
 
 
 
 
Figura 19 
 
Steganacin also causes a slow depolymerization of preformed microtubules. This 
molecule inhibits the binding of colchicine to tubulin and thus resembles 
Podophyllotoxin, which also competitively inhibits colchicine binding (Figure 20).33 
Steganacin presents a trimethoxybenzene ring and probably interacts with that portion 
of the colchicine binding site that recognizes the trimethoxybenzene ring of Colchicine. 
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Figure 20 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
32 a) L. Wilson, Biochemistry, 1970, 9, 4999; b) R. W. J. Wang, L. I. Rebbun, and M. S. Kupchan, Cancer Res., 1977, 37, 3071.  
33 For the synthesis of an aza-analogue of podophyllotoxin from our group see: Poli, G.; Giambastiani, G. J. Org. Chem. 2002, 67, 
9456-9459. 
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The tubulin, the globular protein target for the Steganacin, is the fundamental unit of the 
structures of the cytoskeleton: microtubules. 
This protein is present in the cytoplasm in α / β form of the dimer and both monomers 
are able to recognize and bind GTP, but only the β subunit is able to hydrolyze this 
substrate to GDP. So, the β dimer bounds to GDP and the other one (α monomer) 
bounds GTP, the final protofilament appears to be polarized as this affinity is higher in 
the β subunit.	  	  
The process of formation of the microtubule can be divided into five distinct phase 
(Figure 21).  
 
 The first process is the nucleation in which there is aggregation between 
different tubulin structure to form a protofilaments that rappresents the 
constitutional unit.  
 In the second step is observed the aggregation of the protofilaments in the 
abundance of GTP. 
 When the concentration of GTP is low, the breakdown of microtubules is 
observed. In this phase the (-)-Steganacin explics this action hydrolyzing GTP to 
GDP with consequently disassembly of the microtubles. 
 This step is characterized by stabilization: a balance between the release speed 
of the tubulin to the negative terminal of microtubules (tubulins in the 
microtubule long hydrolyzed GTP and lost affinity for tubulin which they are 
linked) and the speed of the addition of tubulin to the positive terminal by 
nucleation. The length of the filament in this way is constant.  
 Therefore, in the presence of high concentrations of GTP a dynamic instability 
process is observed and short or very long microtubles is formed.	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Figure 21 
 
The interest of chemists for the (-)-Steganacin 23 was initially motivated by its 
antitumor activity; it is for this reason that in literature we found different total 
syntheses of this molecule. 34 
Also, different analogues of steganacin were prepared: in 1989 Koga and co-workers 
published the synthesis of an aza-analogue of this compound that presented a nitrogen 
in position 3; 35 in the 2006 different triazole derivatives were reported in the literature 
36 and the same years an hybrid structure with allocolchicine was studied.37, 38  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
34 a) Kende, A. S.; Liebeskind, L. S. J. Am. Chem. Soc., 1976, 98, 267-268. b) Becker, D.; Hughes, L. R.; Raphael, R. A. J. Chem. 
Soc., Perkin Trans. 1, 1977, 14, 1674-1681. c) Ziegler, F. E.; Fowler, K. W.; Sinha, N. D. Tetrahedron Lett., 1978, 19, 2767-2770. 
d) Ziegler, F. E.; Chliwner, I.; Fowler, K. W.; Kanfer, S. J.; Kuo, S. J.; Sinha, N. D. J. Am. Chem. Soc., 1980, 102, 790-798. e) 
Magnus, P.; Schultz, J.; Gallagher, T. J. Chem. Soc., Chem. Commun., 1984, 1179-1180. f) Ishiguro, T.; Mizuguchi, H.; Tomioka, 
K.; Koga, K. Chem. Pharm. Bull., 1985, 33, 609-617.  
35 a) Tomioka, K.; Kubota, Y.; Kawasaki, H.; Koga, K. Tetrahedron Lett. 1989, 30, 2949-2952. b) Kubota, Y.; Kawasaki, H.; 
Tomioka, K.; Koga, K. Tetrahedron 1993, 49, 3081-3090. 
36 a) Beriozkina, T.; Appukkuttan, P.; Mont, N.; Van der Eycken, E. Org. Lett. 2006, 8, 487-490. b) Imperio, D.; Pirali, T.; Galli, 
U.; Pagliai, F.; Cafici, L.; Canonico, P. L.; Sorba, G.; Genazzani, A. A.; Tron, G. C. Bioorg. Med. Chem. 2007, 15, 6748-6757. c) 
Mont, N.; Pravinchandra Mehta, V.; Appukkuttan, P.; Beryozkina, T.; Toppet, S.; Van Hecke, K.; Van Meervelt, L.; Voet, A.; 
DeMaeyer, M.; Van der Eycken, E. J. Org. Chem. 2008, 73, 7509-7516. 
37 Joncour, A.; Décor, A.; Liu, J.-M.; Tran Huu Dau, M.-E.; Baudoin, O. Chem. Eur. J., 2007, 13, 5450-5465.  
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In the last two decades of the last century a detailed SAR39 study was performed for the 
steganacin-type lignan lactones. Here are some critical structural features for the 
potency: 
 the dioxolane moiety is fundamental for the cytotoxic activity;  
 the lactone ring is not essential, although it contributes to potency;  
 the acetate is not essential as stegane is equally active;  
 the trimethoxyphenyl ring is essential for cytotoxic and antitubulic activities. 
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Figure 22 
 
In order to investigate the biological activity of this natural product and the importance 
of chirality, different enatioselective total syntheses40 were performed. 
Although these syntheses take advantage of different process to obtain the target 
molecule, the common key steps are invariably the formation of the lacton moiety and 
the oxidative coupling between the two aromantic rings. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
38 Pour une revue, voir : Appukkuttan, P.; Van der Eycken, E. Eur. J. Org. Chem. 2008, 5867-5886.	  	  
39 F. Zavala, D. Guenard, L. Robin, E. Brown, J. Med. Chem., 1980, 23, 546; b) K. Tomioka, T. Ishiguro, H. Mizuguchi, N. 
Komeshima, K. Koga, S. Tsukagoshi, T. Tsuruo, T. Tashiro, S. Tanida, T. Kishi, J. Med. Chem., 1991, 34, 54; c) K. Tomioka, H. 
Kawasaki, K. Koga, Chem. Pharm. Bull., 1990, 38, 1898. 
40 a) Tomioka, K.; Ishiguro, T.; Koga, K. Tetrahedron Lett., 1980, 21, 2973-2976. b) Tomioka, K.; Ushiguro, T.; Iitaka, Y.; Koga, 
K. Tetrahedron, 1984, 40, 1303-1312.  
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II. Aim of the project 
 
From a structural point of view the (-)-Steganacin presents a γ-lactonic skeleton 
condensed to an eight membered ring, three contiguous stereogenic centers and a 
biarylic portion. 
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Figure 23 
 
Aim of this project is the synthesis of an aza-analogue of Steganacin in which the 
lactone structure is replaced by a γ-lactam moiety.  
In 2009, Kammerer et al.41 reported an original regio- and stereoselective synthesis of 
aryl substituted pyrrolidones by a phosphine-free Pd-catalyzed allene 
carbopalladation/allylic alkylation sequence.  
To test and validate the potential of this domino "carbopalladation allene / allylic 
alkylation" sequence in a synthetic target application, we decided to synthesize a new 
aza analogue of (-)-Steganacin (Scheme 13).  
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
41	  C. Kammerer , G. Prestat, D. Madec, G. Poli, Chem. Eur. J.,  2009, 15, 4224-4227.	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III. Synthesis 
 
III.I Retrosynthetic analysis 
According to our retrosynthetic plan, (-)-Aza-steganacin 24 could be derived from 
double bond oxidative cleavage of alkene 25 followed by a diastereoselective reduction 
of the resulting ketone. Intermediate 25 was envisaged to derive from a biaryl oxidative 
coupling of 26, which could in turn originate from allene 27 via domino 
carbopalladation / allylic alkylation sequence followed by an appropriate benzylation 
step. Intermediate 27 was thought to derive from amination of allenol 28, which can in 
turn easily originate from commercially available propargyl alcohol 29 (Scheme 13). 
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III.II Synthesis of allenol intermediate 
Preparation of allenol 28 was first tackled.42 Accordingly, the hydroxyl function of 
propargyl alcohol 29 was protected as tetrahydropyranyl (THP) ether 30 so as to render 
it an active leaving group.  Subsequent hydroxymethylation of the terminal acetylene 30 
to give propargyl alcohol 31 was obtained by deprotonation with n-BuLi and 
subsequent treatment with excess para-formaldehyde. Following treatment with LiAlH4 
generated the desired allenol 28. (Scheme 14) 
OH OTHP OTHP
HO •
HO
a c
30 31 2829
b
	  
 
Reagents and conditions: a) DHP (1.2 eq), pTsOH (1 mol%), CH2Cl2, 0°C, 6h Y=71%; b) n-BuLi (1.1 
eq), (H2CO)n (3 eq) Et2O, -78°C, room temp., 12h, Y=94%; c) LiAlH4  (3 eq.), Et2O, 0°C, o.n. Y=66%. 
Scheme 14 
 
The mechanism of this reaction involves LiAlH4 mediated deprotonation of the 
propargyl alcohol to yield the corresponding aluminum alkoxide. Subsequent 
intramolecular hydride delivery to the triple bond via a SN2' mechanism generates, after 
hydrolysis of aluminium salt, the desired allenyl alcohol (Scheme 15). 
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Scheme 15 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
42 Cowie, J. S.; Landor, P. D.; Landor, S. R., J. Chem. Soc., Perkin Trans., 1973, 1, 720-724. 
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A limitation of this synthetic protocol is due to the fact that all the intermediates along 
the sequence are rather volatile. As a consequence, much attention has to be paid to 
limit product loss during purification.  
 
III.III Synthesis of cyclization precursor 
We decided, for the subsequent amination of allenol 28, to consider a protocol involving 
the transient generation of an electrophilic π-allyl vinylidene intermediate. Indeed, a 
couple of related examples have been previously reported for the synthesis of 
enantioenriched α-allenic amines43. 
Accordingly, we chose to activate the allenyl alcohol 28 as the corresponding phenyl-
acetate, so as to combine a high reactivity in its oxidative addition to Pd(0) and a 
relatively high molecular weight of the allylic precursor. In the event, treatment of 
allenyl alcohol 28 with phenylacetyl chloride in the presence of Et3N gave the desired 
phenyl-acetate 32 in 84% yield.  
In order to synthesized the lactam moiety we planned a Pd(0)-catalyzed amidation of 
the allylic ester 32. Thus, the amidation reaction of ester 32 with N-
benzyltrifluoroacetamide, previously deprotonated by sodium hydride, was carried out 
in the presence of a catalytic amount of Pd (PPh3)4 in THF. After 24h at 55° C, the 
desired trifluoroacetamide 33 was obtained in a yield of 60%. 
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Reagents and conditions: a) Phenyl-acetyl chloride (3 eq.), Et3N (3 eq.), CH2Cl2, 0°C, o.n., Y=84%; b) 
LiHMDS (1.3 eq.), BnNHCOCF3 (1.2 eq.), Pd(PPh3)4 (2.5% mol), THF, room temp., o.n., Y=60%. 
Scheme 16 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
43 a) Trost, B. M.; Fandrick, D. R.; Dinh, D. C., J. Am. Chem. Soc,. 2005, 127, 14186-14187; b) Imada, Y.; Nishida, M.; Kutsuwa, 
K.; Murahashi, S.-I.; Naota, T., Org. Lett., 2005, 7, 5837-5839. 
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From a mechanistic point of view, the allenyl precursor is expected to coordinate to the 
Pd(0) complex via the internal double bond and oxidatively add to the metal to yield a 
fugitive π-allyl vinylidene intermediate. Attack to the distal position of this latter by the 
nitrogen nucleophile generates the desired allenyl-amine product and regenerates the 
catalytic species (Pd0) (Scheme 17).	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Scheme 17 
 
Cleavage of the trifluoroacetamide group was effected in a mixture of methanol / water, 
saturated with potassium carbonate.44 After 16h at 50°C, the free amine 35 was isolated 
in 85% yield. Subsequent treatment of 35 with 3-chloro-3-methyl oxopropionate in the 
presence of triethylamine in dichloromethane afforded the desired cyclization precursor 
27 in 76% yield. (Scheme 18) 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
44 Rückle, T.; Biamonte, M.; Grippi-Vallotton, T.; Arkinstall, S.; Cambet, Y.; Camps, M.; Chabert, C.; Church, D. J.; Halazy, S.; 
Jiang, X.; Martinou, I.; Nichols, A.; Sauer, W.; Gotteland, J.-P., J. Med. Chem., 2004, 47, 6921-6934. 
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Reagents and conditions: a) Satd K2CO3 MeOH / H2O (10:1), 50 °C, 16h, Y=85%; b) methyl 3-chloro-3-
oxopropanoate (3 eq.), Et3N (3 eq.), CH2Cl2,  room temp., 16 h, Y=76%. 
Scheme 18 
 
III.IV Phosphine-free Pd-catalyzed Domino Sequence and benzylation reaction 
The key domino carbopalladation / allylation sequence was next tackled. To this 
purpose, we directly selected the reaction conditions optimized by our group in the 
methodological study,41 as they were the result of a through optimization work. Thus, 
after a relative straightforward experimentation we found satisfactory conditions for this 
key step. In the event, a phosphine-free Pd0 complex was generated in DMSO from 
PdCl2(CH3CN)2, by using n-BuLi (2 equiv) as an in situ reducing agent 45 and the 
aromatic iodide 36 was added in the presence of TBAB. After treatment with NaH 60%, 
the malonamide 27 was added to the reaction mixture and after 16 hours the desired 
styryl pyrrolidone 37 was obtained in 74% yield as a single diastereoisomer. As in the 
previous methodological study, the domino sequence turned out to be completely regio- 
and stereoselective in favor of the 5-exo trans product. 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
45 a) E. Negishi, T. Takahashi, K. Akiyoshi, J. Chem. Soc. Chem. Commun., 1986, 1338 – 1339; b) M. Bottex, M. Cavicchioli, B. 
Hartmann, N. Monteiro, G. Balme, J. Org. Chem. 2001, 66, 175 – 179.).	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Scheme 19 
 
A mechanistic sequence for the carbopalladation/allylic alkylation domino sequence is 
proposed in Scheme 20: Oxidative addition of the Pd0 complex to the aryl iodide, forms 
the electrophilic aryl palladium(II) complex. Coordination of one of the double bonds 
of the deprotonated allene to the electrophilic complex (PdII) and subsequent 
carbopalladation affords the corresponding σ-allyl complex. Isomerisation of this latter 
generates the corresponding electrophilic π-allyl complex, which is intramolecularly 
trapped by the deprotonated active methylene in a 5-exo cyclization mode. 
Decoordination of the thus formed Pd(0) complex releases the final product and the 
active catalytic species therby closing the catalytic cycle. 
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Scheme 20 
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The anion of 4-styryl pyrrolidin-2-one 37 was treated with the desired benzyl bromide 
in degassed DMF. After 24 hours at 100°C the product 38 was obtained with a yield of 
73% as a single diastereoisomer having a trans relative configuration between the two 
benzyl substituents. This diastereoselectivity can be rationalized by assuming approach 
of the electrophile from the less hindered enolate face. 
NO
MeOOC
O
O
Bn
NO
MeOOC
 Bn
37 38
O
OO
O
O
a
 
Reagents and conditions: a) 5-Bromomethyl-1,2,3-trimethoxy-benzene (3 eq.), NaH 60% (1.2 eq.), 
degassed DMF, 100 °C, 24h, Y=73%. 
Scheme 21 
 
III.V Removal of the methoxycarbonyl group 
In order to remove the methoxycarbonyl group several strategies were tried.  
In the first assay, compound 38 was subjected to Krapcho decarbometoxylation 
reaction46 in the presence of sodium chloride and water in DMSO. Unfortunately, after 
24h at 150°C, only traces of desired product 4 have been observed. 
So, we decided to change pathway and try an ester hydrolysis / decarboxylation 
sequence. Accordingly, treatment of 38 with 20 equivalents of KOH in EtOH47 for 4h at 
80°C gave the corresponding acid and the transesterification product in a 70:30 report. 
Using methanol as the co-solvent for the hydrolysis gave the desired acid with only 
25% conversion.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
46 a) Krapcho, A. P., Synthesis, 1982, 805-822; b) Krapcho, A. P., Synthesis, 1982, 893-914; c) Krapcho, A. P., Arkivoc, 2007, 1-53; 
d) Krapcho, A. P., Arkivoc, 2007, 54-120.	  
47 R. Shintani, M. Murakami, T. Hayashi, Org. Lett., 2009, 11, 2, 457-459.	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Finally, heating compound 38 at reflux for 20 minutes in the presence of 20 equivalents 
of KOH in ethylene glycol gave the desired decarboxylated product 26 in 60% yield. 
(Scheme 22) 
a
NO
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 Bn
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O
O
NO
 Bn
26
O
OO
O
O
 
Reagents and conditions: a) KOH (20 eq.), ethylene glycol, 180-190 °C, 20 min. Y=60% 
Scheme 22 
 
III.VI Further steps 
Unfortunately, I did not have time enough in Paris to study the final assembling of 26 
toward the target. In any case, the concluding part of this synthesis would entail an 
oxidative coupling between the two arylic portions of the 26 to build up the 
characteristic eight membered biaryl ring system (intermediate 25). Then, an oxidative 
cleavage of the double bond followed by a diastereoselective reduction of the resulting 
ketone 39 and final alcohol acetylation 40 should afford the desired (-)-Steganacin aza-
analogue 24. 
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III. Conclusion 
 
In this work I accomplished the synthesis of an advanced intermediate of Stegancine. 
The sequence entails fifteen steps, seven of which are needed to obtain the key 
malonamidic intermediate 27 from the propargyl alcohol 29 in a 19% of overall yield.  
The crucial catalytic domino (carbopalladation/allylic alkylation) process (27 + 36   
37) was could be validated and took place in 74% yield. 
After benzylation of this key intermediate, several strategies to remove the 
methoxycarbonyl group were tested, the best solution being hydrolysis in ethylene 
glycol at high temperatures. 
Four further steps should be necessary to complete the synthesis of the desired (-)-
Steganacin aza-analogue 24. The next study will focus on the non-phenolic oxidative 
coupling between the two aromatic moieties. 
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General Methods 
Depending on the reaction, dichloromethane was distilled on CaH2 or dried on a 
Mbraun solvent purification system MB SPS-800. Diethyl ether and THF were distilled 
on sodium/benzophenone or dried on a MBraun solvent purification system MB SPS-
800. DMF was distilled over MgSO4 under reduced pressure or was dried on a MBraun 
solvent purification system MB SPS-800. Acetonitrile was dried on a MBraun solvent 
purification system MB SPS-800. DMSO was distilled over CaH2 under reduced 
pressure.  
Flash chromatography was conducted on silica gel (0.040-0.063 mm unless stated) 
(Polygram SIL G/UV254). Analytical Thin Layer Chromatographies (TLC) were 
performed on Merck precoated 60 F254 platesor. 
One-dimensional and two dimensional NMR spectra were recorded on a VARIAN 400 
MHz instrument or a Bruker Avance 400 spectrometer (BBFO probe), using the 
residual peak of deuterated chloroform as internal standard (7.27 ppm for 1H NMR and 
77.2 ppm for 13C NMR). Chemical shifts are reported in ppm and coupling constants J 
in Hertz. Abbreviations used for peak multiplicity are: s,singlet; br s, broad singlet; d, 
doublet; t, triplet; q, quadruplet; quint., quintuplet; m, multiplet.  
IR spectra were recorded on a Bruker Tensor 27 (Pike) apparatus and only the strongest 
or the structurally most important peaks were listed.  
MS analyses were performed on a ESI-Micromass ZMD 2000 and high resolution mass 
spectrometry was performed on a Thermo Fisher Scientific LTQOrbitrap (ESI).  
Optical rotation data were recorded on a Perkin-Elmer polarimeter 241.  
Melting points were measured using a Stuart Scientific SMP3 apparatus.  
The purity of the tested compounds (R/S)-SHA 68, (R)-SHA 68 and (S)-SHA 68 has 
been assessed by RP-HPLC. 
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Chiral chromatography analysis  
A micro HPLC (Agilent 1100 micro series, Agilent Technologies) equipped with a 
micro diode array detector was employed. A 150mm × 2mm stainless steel column 
packed with Lux Cellulose-1 (cellulose tris 3,5-dimethylphenylcarbamate from 
Phenomenex) was used for all the measurements. The average size of the packing 
material was 3 µm. The mobile phase was a binary mixture of hexane/isopropyl alcohol 
(80/20 v/v). Flow rate was 200uL/min. Injection volume was 3µL. Analyte solutions 
were filtered with PFTE filters (0.45µm, Supelco, Bellefonte, PA, USA) before 
injection. All chromatograms were recorded at 230 nm. The retention times for the first 
((S)-SHA 68) and second ((R)-SHA 68) eluted enantiomers were 6.5 and 7.9 min, 
respectively. 
Crystal structure determination of compound 21b 
The crystal data of compound 21b were collected at room temperature using a Nonius 
Kappa CCD diffractometer with graphite monochromated Mo-Kα radiation. The data 
sets were corrected for Lorentz and polarization effects. The structure was solved by 
direct methods and refined using full-matrix least-squares with all non-hydrogen atoms 
anisotropically and hydrogens included on calculated positions, riding on their carrier 
atoms. All calculations were performed using SHELXL-97 and PARST implemented in 
WINGX system of programs. 
Crystal Data: C26H26N2O2, orthorhombic, space group P212121, a = 11.2339(2), b = 
11.6808(3), c = 16.4783(5) Å, V = 2162.30(9) Å3, Z = 4, Dc = 1.224 g cm-3, intensity 
data collected with θ ≤ 26°, 4215 independent reflections measured, 3460 observed 
reflections [I > 2σ(I)], final R index = 0.0365 (observed reflections), Rw = 0.0904 (all 
reflections), S = 1.048. The absolute configuration has not been established by 
anomalous dispersion effects in diffraction measurements on the crystal. The 
enantiomer has been assigned by reference to an unchanging chiral centre in the 
synthetic procedure view of compound 21b is shown in Figure 16. 
CCDC deposition number: 810351. 
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Synthesis of Takeda’s compound 
 
1) [1-(2-Hydroxy-1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
(3) 
HO
NH
NH
O
C16H24N2O4
Mol. Wt.: 308,37
OO
a
b
c
d
e
f
gh
i
l
m
n
o
p
 
To a stirred solution of (D)-Boc-Ala-OH (2 g, 14.6 mmol) in CH2Cl2 (20 mL), WSC 
(1.86 g, 9.8 mmol) and (R)-phenylaminoglycinol (2.76 g, 14.6 mmol) were added. After 
24 h at room temperature the reaction was monitored by TLC (EtOAc/light petroleum 
4:1). The organic layer was washed with brine (10 mL) and the product was purified by 
crystallization with ethyl ether to obtain 3 in 43% yield.  
 
1H NMR (CD3OD, 400 MHz): 7.35-7.29 (m, 5H, Hd,e,f); 4.95 (bs, 1H, Hb); 4.15 (q, 
J= 7.0 Hz, 1H, Hi); 3.79-3.68 (m, 2H, Ha); 1.44 (s, 9H, Hp); 1.32 (d, J=  7.0 Hz, 3H, 
Hl). 
13C NMR (CD3OD, 100MHz): δ =  175.8 (Ch), 155.7 (Cn), 141.2 (Cc), 129.6 (Cd or 
Ce), 128.5 (Cf), 128.1 (Cd or Ce), 80.8 (Co), 66.3 (Ca), 57.1 (Cb), 51.8 (Ci), 28.9 (Cp), 
18.4 (Cl). 
MS (ESI): [M+H]+ = 309. 
[α]D20 = -17 (c = 0.121g/100 ml, methanol ). 
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2) [2-(2-Hydroxy-1-phenyl-ethylamino)-1-methyl-ethyl]-carbamic acid tert-butyl 
ester (4) 
HO
NH
NH
C16H26N2O3
Mol. Wt.: 294,39
OO
 
To a stirred suspension of LiAlH4 (296 mg, 7.792 mmol) at 0°C in anhydrous THF, a 
solution of 3 (800 mg, 2.59 mmol) was added drop wise. The reaction was monitored by 
TLC (EtOAc/light petroleum 4:1) and  after 24 hours the excess of hydride was 
quenched with water and the salts were filtered trough a celite pad. The solvent was 
evaporated in vacuo and the crude product 4 was obtained in quantitative yield and used 
in the next step without further purification. 
 
3)  {2-[2-(tert-Butyl-dimethyl-silanyloxy)-1-phenyl-ethylamino]-1-methyl ethyl} 
carbamic acid tert-butyl ester (5) 
O
NH
NH
Si
OO
C22H40N2O3Si
Mol. Wt.: 408,65
a
b
c
d
e
f
g
h
i
l
m
n
o
p
j
k
q  
To a stirred solution of 4 (980 mg, 3.33 mmol) in DMF (10 mL) at 0°C, imidazole  (453 
mg, 6.66 mmol) was added. After 10 min, tert-buthyldimethysilil chloride (551 mg, 3.6 
mmol) solubilized in DMF (5ml) was slowly added. The reaction was monitored by 
TLC (EtOAc/light petroleum 4:1) and after 3 h at room temperature the reaction was 
termined. The excess of tert-buthyldimethysilil chloride was hydrolized by adding  
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water. After complete elimination of solvent reaction with low pressure pomp the 
residue was eluited with Et2O and washed with 10 ml of water. The combined organic 
phases were concentrate to dryness to obtain 1.03 gr of 5 in 76% yield.  
1H NMR (CDCl3, 400 MHz): δ = 7.32-7.25 (m, 5H, Hg,h,i); 5.00-4.96 (m, 1H, Hl); 
4.59 (bs, 1H, Hn); 4.23 (bs, 1H, Hj); 3.87 (dd, 1H, J= 4.4Hz, Hd or Hd’); 3.77(dd, 1H, 
J= 4.0Hz, Hk or Hk’); 3.73 (dd, 1H, J= 3.6Hz, Hk’ or Hk); 3.65 (dd, 1H, J= 4.0Hz, Hd’ 
or Hd); 3.55-3.50 (m, 1H, He); 1.44 (s, 9H, Hq); 1.07 (s, 3H, Hm); 0.89 (s, 9H, Ha); 
0.01 (s, 6H, Hc). 
13C NMR (CDCl3, 100MHz): δ = 155.85 (Co), 141.01 (Cf), 128.39 (Ch or Cg),  127.75 
(Cg or Ch),  127.34 (Ci), 70.69 (Cp), 68.46 (Cd), 66.29 (Ck), 64.14 (Ce), 54.66 (Cl), 
28.51 (Cq), 25.98 (Ca), 19.27 (Cm), 18.34 (Cb), -5.37 (Cc). 
MS (ESI): [M+H]+ = 409.  
[α]D20 = - 9 (c = 0.24 g/100 ml, Chloroform). 
 
4) (2-{(2-Bromo-acetyl)-[2-(tert-butyl-dimethyl-silanyloxy)-1-phenyl-ethyl]-amino} 
-1-methyl-ethyl)-carbamic acid tert-butyl ester (6) 
O
N
NH
O
Br
Si
OO
C24H41BrN2O4Si
Mol. Wt.: 529,58
a
b
c
d
e
f
g
h
i
l m
n
o
pj
k q
 
 
To a stirred solution of  bromoacetic acid (681 mg, 4.9 mmol) in CH2Cl2 (20 mL), WSC 
(470 mg, 2.45 mmol) and the silyl intermediate 5 (1 g, 2.45 mmol) were added. After 24 
h at room temperature the reaction was monitored by TLC (EtOAc/light petroleum 2:8). 
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The organic phase was concentrate to dryness and the crude product was purified by 
column chromatography (EtOAc/ light petroleum 2:8) to yield 6 (450 mg, 35%). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.35-7.25 (m, 5H, Hg,h,i), 5.15-5.13 (m, 2H, Hd), 
4.13-4.10 (m, 4H, Hj and Hq), 3.87 (m, 1H, He), 2.84-2.76 (m, 2H, NH and Hk), 1.38 
(s, 9H, Hq), 0.87 (s, 12H, Ha and Hl); 0.08 (s, 6H, Hc). 
13C NMR (CDCl3, 100MHz): δ = 170.15 (Cp), 155.35 (Cm), 135.6 (Cf), 129.08 (Ch or 
Cg), 128.87 (Ci), 127.87 (Cg or Ch), 70.69 (Cn), 62.05 (Cd), 61.78 (Ce), 47.48 (Ch), 46.30 (Cj), 
41.94 (Cq), 28.45 (Co), 25.85 (Ca), 19.06 (Cl), 18.21 (Cb), -5.37 (Cc). 
MS (ESI): [M+H]+ = 409.  
[α]D20 = - 33 (c = 0.10 g/100 ml, Chloroform). 
 
5) 4-[2-(tert-Butyl-dimethyl-silanyloxy)-1-phenyl-ethyl]-2-methyl-5-oxo-piperazine 
-1-carboxylic acid tert-butyl ester (7) 
O
N
N
O
Si
OO
C24H40N2O4Si
Mol. Wt.: 448,67
a
b
c
d
e
f
g
h
i
l
m
n
o
p
j
k
q
 
To a stirred suspension of NaH 60% (61 mg, 2.55 mmol) in a mixture of THF/DMF 1/1 
(10 mL) at 0°C, a solution of 6 (450 mg, 0.85 mmol) in THF/DMF 1/1 (10 mL) was 
added. After 24 h the reaction was quenched by adding NH4Cl satured solution (5 mL) 
and the solvent was removed in vacuo. The residue was dissolved in EtOAc (10 mL) 
and washed twice with water (5 mL). The organic layer was dried, evaporated under 
reduced pressure and the crude product purified by flash chromatography (eluent: 
EtOAc/light petroleum 2:8) to obtain 7 in 74% yield. 
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1H NMR (CDCl3, 400 MHz): δ = 7.31-7.25 (m, 5H, Hg,h,i), 5.76 (dd, 1H, J= 5.6Hz, 
He), 4.30 (d, 1H, J= 18.4Hz, part of AB system, Hd), 3.80 (d, 1H, J= 18.6Hz, part of 
AB system, Hd’), 4.18-3.91 (m, 3H, Hj and Hk), 3.17 (m, 2H, Hm), 1.42 (s, 9H, Hq), 
1.24 (s, 3H, Hl), 0.86 (s, 9H, Ha),  0.06 (s, 6H, Hc). 
MS (ESI): [M+H]+ =449 
 
6) 4-(2-Hydroxy-1-phenyl-ethyl)-2-methyl-5-oxo-piperazine-1-carboxylic acid tert-
butyl ester (8) 
HO
N
N
O
OO
C18H26N2O4
Mol. Wt.: 334,41
a
b
c
d
e
f
g
h
i l
m
n
k
j
 
To a solution of compoud 7 (268 mg, 0.598 mmol) in 10 ml of anhydrous THF, cooled 
at 0°C, was added TBAF (566 mg, 1.795 mmol). The reaction was stirred at room 
temperature for 1 h and after this time the solvent was removed under vacuum. The 
residue was diluited with EtOAc and washed twice with water. The organic layer was 
dried and concentrated under reduced pressure to give the crude product, which was 
purified by flash chromatography to obtain compound 8 (144 mg, yield 72%). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.35-7.25 (m, 5H, Hd,e,f), 5.7 (q, 1H, J= 6.8Hz, Hh), 
4.35 (d, 1H, J= 18.4Hz,  part of AB system, Ha), 3.85 (d, 1H, J= 18.6Hz, part of AB 
system, Ha’), 4.10 (s, 2H, Hj), 3.14 (dd, 1H, J=12.6, 4.2Hz, Hd), 2.93 (dd, 1H, J=12.5, 
2.6Hz, Hd’), 2.66 (bs, 1H, OH), 1.43 (s, 9H, Hn), 1.18 (d, 3H, J= 6.8Hz, Hi). 
13C NMR (CDCl3, 100MHz): δ = 167.56 (Ck), 153.56 (Cl), 135.72 (Cc), 128.94 (Cd or 
Ce), 128.37 (Cf) , 128.19 (Ce or Cd), 80.73 (Cm), 61.85 (Ca), 58.99 (Cb), 48.02 (Cg), 
45.24 (Cj), 45.17 (Ch), 28.42 (Cl), 16.00 (Cb). 
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MS (ESI): [M+H]+ = 335.  
[α]D20 = - 33 (c = 0.10 g/100 ml, Chloroform). 
 
7) 4-(2-Hydroxy-1-phenyl-ethyl)-2-methyl-piperazine-1-carboxylic acid tert-butyl 
ester (9) 
HO
N
N
OO
C18H28N2O3
Mol. Wt.: 320,43
a
b c
d
e
f
g
h
i l
m
n
k
j
 
 
Under argon atmosphere 144 mg (0.431 mmol) of compound 8 were suspended in 
anhydrous THF, the reaction mixture was cooled at 0°C and under vigorously stirring 
(CH3)2S*BH3 (124 µl, 1.293 mmol) was added drop wise. The reaction mixture was 
heated at reflux for 30 minutes. After this time the reaction was acidified (citric acid 
sat.) and quenched with NaOH 2N, the THF was removed in vacuo and the aqueous 
layer extracted twice with EtOAc (10ml each). The organic layer was dried, 
concentrated in vacuo and purified by flash chromatography (EtOAc/light petroleum, 
3/1) to afford compound 9 in 88% yield. 
 
1H NMR (CDCl3, 400 MHz): δ =  7.37-7.22 (m, 5H, Hd,e,f), 4.25 (bs, 1H, OH), 4.00-
3.96 (m, 2H, Ha), 3.85-3.78 (m, 2H, Hj), 3.25-3.20 (m, 1H, Hb), 3.10-3.05 (m, 1H, Hh), 
2.87-2.80 (m, 2H, Hk), 2.28-2.20 (m, 2H, Hg), 1.39 (s, 9H, Hn), 1.18 (d, 3H, J= 6.8Hz, 
Hi). 
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13C NMR (CDCl3, 100MHz): δ =  154.26 (Cl), 133.28 (Cc), 129.34 (Cd or Ce), 128.90  
(Cf), 128.75 (Ce or Cd), 80.73 (Cm), 69.87 (Cb), 60.26 (Ca), 51.85 (Cg), 50.70 (Ck), 
46.19 (Ch), 38.27 (Cj), 28.37 (Cl), 15.47 (Cb). 
MS (ESI): [M+H]+ = 321.  
[α]D20 = - 36 (c = 0.10 g/100 ml, Chloroform). 
 
8) 4-(2-Methoxy-1-phenyl-ethyl)-2-methyl-piperazine-1-carboxylic acid tert-butyl 
ester (10) 
O
N
N
OO
C19H30N2O3
Mol. Wt.: 334,45
a b
c
d
e
f
g
h
i
l
m
n
k
j
o
 
 
A solution of the compound 9 (121 mg, 0.378 mmol) in a mixture of THF/DMF 1/1 (10 
mL) at 0°C, was added drop wise to a stirred suspension of sodium hydride 60% (27.21 
mg, 1.134 mmol) in 5 ml a mixture of THF/DMF 1/1. The reaction mixture was left in 
the same conditions for half an hour, then a solution of methyl iodide (70.61 µl, 1.134 
mmol) in a mixture of THF/DMF 1/1 was added. After 24 h at room temperature, the 
reaction was termined, the DMF was removed under vacuum and the residue was 
diluited with 5 ml of Brine and extracted three times with EtOAc. The organic layers 
were combined, dried and evaporated under reduced pressure to give a crude product 
than purified by flash chromatography (EtOAc/light petroleum 1:4) to obtain compound 
10 (78 mg, yield 62%). 
1H NMR (CDCl3, 400 MHz): δ = 7.30-7.25 (m, 5H, He,f,g), 4.15-4.10 (m, 1H, Hc), 
3.84-3.68 (m, 2H, Hb or Hh or Hk or Hj), 3.60-3.41 (m, 2H, Hb or Hh or Hk or Hj), 
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3.28 (s, 3H, Ha), 3.18-2.99 (m, 2H, Hb or Hh or Hk or Hj), 2.49-2.41 (m, 1H, Hi), 2.18-
2.02 (m, 2H, Hb or Hh or Hk or Hj), 1.42 (s, 9H, Hn), 1.16 (d, 3H, J= 6.8Hz, Ho). 
MS (ESI): [M+H]+ = 335.  
[α]D20 = - 57 (c = 0.098 g/100 ml, Chloroform). 
 
9) 1,1-Diisopropyl-7-(2-methoxy-1-phenyl-ethyl)-5-methyl-hexahydro-oxazolo[3,4-
a]pyrazin-3-one (11) 
N
N
O
O
O
C22H34N2O3
Mol. Wt.: 374,52 
 
To a stirred solution of 10 (80 mg, 0.239 mmol) in anhydrous THF (5 mL), TMEDA 
(180 µl, 1.195 mmol) was added. The reaction was cooled at -78°C and sec-BuLi 1.4M 
in exane (513 µl, 0.718 mmol) was added. The reaction was heated at -35°C and after 2 
h a solution of diisopropyl ketone (102 µl, 0.718 mmol) in anhydrous THF (7 mL) was 
added drop wise. The reaction became green and was stirred at room temperature for 24 
h. After this time the reaction was monitorated by TLC (EtOAc/light petroleum 1:4) and 
quenched by adding NH4Cl satured solution (5 mL). The solvent was removed in vacuo 
and the aqueous phase extracted 3 times with EtOAc (10 mL). The combined organic 
layer was dried and evaporated to dryness. The crude product was purified by flash 
chromatography using EtOAc/light petroleum 1:4 as eluent to obtain 11 in 48% yield. 
MS (ESI): [M+H]+ = 375.  
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Synthesis of SHA-68 compound in racemic mixture 
 
10) 4-Benzyl-piperazine-1-carboxylic acid tert-butyl ester (13) 
N
N
O O
C16H24N2O2
Mol. Wt.: 276,37
a
b
c
d
e
f
g h
i
l
m
n  
 
A solution of N-benzyl-piperazine (1.96ml, 11.35 mmol) in a mixture of water and tert-
butanol 1:2 (90 ml), cooled at 0°C, was treated with di-tert-butyl-dicarbonate (2.72 g, 
12.48 mmol) in presence of NaOH 1N. The reaction mixture was stirred at room 
temperature and it was monitorated by TLC (EtOAc/light petroleum 1:1); after an hour 
the reaction was termined. The solvent was removed under vacuum and the crude 
material dissolved in EtOAc; the organic layer was washed twice with citric acid, dried 
and concentrated to obtain the product 13 in quantitative yield. The compound 13 was 
used in the next step without further purification. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.30-7.27 (m, 5H, Ha,b,c), 3.50 (s, 2H, He), 3.42 (t,  
4H, J= 5.2, Hg and Hh), 2.34 (t,  4H, J= 5.2, Hf and Hi), 1.44 (s, 9H, Hn). 
13C NMR (CDCl3, 100MHz): δ = 154.84 (Cl), 137.88 (Cd), 129.21 (Cb or Cc), 128.32 
(Ca), 127.21 (Cc or Cb), 79.59 (Cm), 63.11 (Cf, Ci), 52.91 (Cg, Ch), 42.41 (Ce), 28.48 
(Cn). 
MS (ESI): [M+H]+ = 277 
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11) 7-Benzyl-1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-one (14) 
N
N
O
O
C25H24N2O2
Mol. Wt.: 384,47
a
b
c
d
e
f
g
h
il
m
n
o
p
q
 
 
To a stirred solution of 13 (2 g, 7.24 mmol) in anhydrous THF (10 mL), TMEDA (2.94 
ml; 19.54 mmol) was added. The reaction was cooled at -78°C and sec-BuLi 1.4M in 
exane (14 ml, 19.54 mmol) was added. The reaction was heated at -35°C and after 2 h a 
solution of benzophenone (2.60 g; 14.28 mmol) in anhydrous THF (10 mL) was added 
drop wise. The reaction became green and was stirred at room temperature for 24 h. 
After this time the reaction was monitorated by TLC (EtOAc/light petroleum 1:2) and 
quenched by adding NH4Cl satured solution (5 mL). The solvent was removed in vacuo 
and the aqueous phase extracted 3 times with EtOAc (15 mL). The combined organic 
layer was dried and evaporated to dryness. The crude product was purified by flash 
chromatography using EtOAc/light petroleum 1:2 as eluent to obtain 1.34 g of 14 in 
49% yield. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.52-7.21 (m, 15Ha,b,c,o,p,q), 4.55 (ddd, 1H, J= 
10.6, 3.6Hz, Hl), 3.80 (dd, 1H, J= 13.6, 3.4, 1.2Hz, Hg), 3.50 (d, 1H, J= 13.2Hz, part of 
AB system, He), 3.30 (d, 1H, J= 13.2Hz, part of AB system, He’), 3.10 (dt, 1H, J=12.6, 
3.6 Hz, Hg’), 2.69 (td, 1H, J=11.2, 3.6, 1.6Hz, Hf), 2.57 (dd, 1H, J=11.2, 3.6, 1.6Hz, 
Hm), 1.95 (dt, 1H, J=12, 3.6 Hz, Hf’), 1.60 (t, 1H, J=12Hz, Hm’). 
13C NMR (CDCl3, 100MHz): δ =  156.13 (Ch), 142.35 (Cn), 138.77 (Cn’), 137.34 
(Cd), 128.99 (Carom), 128.62 (Carom), 128.51 (Carom), 128.43 (Carom), 128.33 
(Carom), 127.94 (Carom), 127.44 (Carom), 126.05 (Carom), 125.86 (Carom) 85.36 
(Ci), 63.03 (Ce), 61.27 (Cl), 55.57 (Cm), 50.67 (Cf), 41.59 (Cg). 
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MS (ESI): [M+H]+ = 384.7 
 
12) 3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 9H-
fluoren-9-ylmethyl ester (15) 
N
N
O
O
O O
C33H28N2O4
Mol. Wt.: 516,59
 
 
To a solution of 14 (1.34 g; 3.48 mmol) in acetonitrile (20ml) was added FmocCl (991 
mg; 3.84 mmol) in one portion, and the mixture was brought to reflux at 90°C. After 
approximately 10 min, a white precipitate formed in the reaction flask. The suspension 
was allowed to stir at reflux for an additional 5 h, after which the mixture was cooled 
and vacuum filtered. The precipitate was washed with an additional portion of cold 
acetonitrile (20 ml). The crude white solid 15 (1.08 g, 65%) was then used without 
further purification. 
MS (ESI): [M+H]+ = 517.1 
 
13) 3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-
fluoro-benzylamide (R/S -SHA-68) 
N
N
O
O
H
N O
F
C26H24FN3O3
Mol. Wt.: 445,49
a
b
c
d
e f g
h
i
l
m
n
o
p
q
r s
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To a mixture of 14 (1.18 g; 2.28 mmol) and 4-fluorobenzyl isocyanate (581 µl; 4.56 
mmol) in THF (20 ml) was added 1,8- diazabicyclo[5.4.0]undec-7-ene (375 µl; 2.51 
mmol) drop-wise. The reaction was stirred for 15 min at room temperature, quenched 
by addition of saturated aqueous NH4Cl (10 ml), extracted with ethyl acetate (40 ml), 
dried (Na2SO4), filtered, and concentrated. The product was purified by crystallization 
with ethyl ether to obtain in a solid form (R/S)-SHA 68 in 59% yield.  
 
m.p. = 85-86°C 
1H NMR (CDCl3, 400 MHz): δ = 7.51-6.98 (m, 14H, Hb,c,q,r,s), 4.80 (bs, 1H, Hf), 
4.41 (dd, 1H, J= 11.2, 3.6Hz, Hn), 4.43-4.30 (m, 2H, He), 4.02 (ddd, 1H, J= 13.2, 3.6, 
1.2Hz, Ho’), 3.83 (dd, 1H, J= 13.2, 2.4Hz, Hi), 3.63 (td, J=13.2, 3.6, 2.0Hz, Hh’), 3.07 
(dt, 1H, J=12.4, 3.6Hz, Hi), 2.91 (dt, 1H, J=12.4, 3.6Hz, Hh), 2.15 (dd, 1H, J=13.6, 
11.2Hz, Ho). 
 13C NMR (CDCl3, 100MHz): δ = 163.47 (Ca), 161.02 (Cd), 157.08 (Cg), 156.06 (Cl), 
141.81 (Cp or Cp), 138.29 (Cp or Cp’), 129.52 (Cb), 128.79 (Cq or Cq’), 128.70 (Cq or 
Cq’), 128.33 (Cc or Cc’), 125.96 (Cr or Cr’), 125.83 (Cr or Cr’), 115.74 (Cs or Cs’), 
115.52 (Cs or Cs’), 85.81 (Cm), 60.51 (Cn), 46.54 (Co), 44.50 (Ce), 43.78 (Ch), 41.34 
(Ci). 
19F-NMR (CDCl3): δ = -114.699 
MS (ESI): [M+H]+ = 446 
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Asymmetric Synthesis of (R)-SHA 68 and (S)-SHA 68 
 
14) [(1-Phenyl-ethylcarbamoyl)-methyl]-carbamic acid tert-butyl ester (16).  
 
 
 
To a stirred solution of Boc-Gly-OH (5 g, 28.5 mmol) in CH2Cl2 (50 mL), WSC (3.64 
g, 19 mmol) and (S)-phenylethyl amine (3.45 g, 28.5 mmol) were added. After 24 h at 
room temperature the reaction was monitored by TLC (EtOAc/light petroleum 2:1). The 
organic layer was washed with 10% citric acid (20 mL), 5% NaHCO3 (20 mL) and 
brine (20 mL). The organic phase was dried, concentrated in vacuo and purified by flash 
chromatography (EtOAc/light petroleum 2:1) to obtain 16 in 60% yield.  
 
1H NMR (CDCl3, 400 MHz): δ = 7.31-7.24 (m, 5H, Hd,e,f); 6.62 (bs, 1H, Hg); 5.31 
(bs, 1H, Hl); 5.11 (q, J= 6.8 Hz, 1H, Hb); 3.75 (m, 2H, Hi); 1.47 (d, J= 6.8 Hz, 3H, Ha); 
1.42 (s, 9H, Ho). 
13C NMR (CDCl3, 100MHz): δ = 168.6 (Ch), 156.2 (Cm), 143.0 (Cc), 128.7 (Cd or 
Ce), 127.4 (Cf), 126.1 (Cd or Ce), 80.2 (Cn), 48.7 (Cb), 44.6 (Cl), 28.3 (Co), 21.9 (Ca). 
MS (ESI): [M+H]+ =279. 
[α]D20 = -41 (c = 0.121g/100 ml, chloroform).  
 
NH
NH
O O
O
C15H22N2O3
Mol. Wt.: 278,35
a
b c
d
e
f
gh
i
l
m
n
o
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15) [2-(1-Phenyl-ethylamino)-ethyl]-carbamic acid tert-butyl ester (17).  
NH
NH
O O
C15H24N2O2
Mol. Wt.: 264,36
a
b c
d
e
f
g
h
i
l
m
n
o  
To a stirred suspension of LiAlH4 (0.85g, 22.38mmol) at 0°C in anhydrous THF, a 
solution of 16 (3.11 g, 11.19 mmol) was added drop wise. The reaction was monitored 
by TLC (EtOAc/light petroleum 3:1) and  after 24 hours the excess of hydride was 
quenched with water and the salts were filtered trough a celite pad. The solvent was 
evaporated in vacuo to yield 17 (2.66 g, 10.07 mmol) in 90% yield.  
 
1H NMR (CDCl3, 400 MHz): δ =  7.32-7.27 (m, 5H, Hd,e,f); 4.96 (bs, 1H, Hl); 3.75 (q, 
J=6.6 Hz, 1H, Hb); 3.16-3.13 (m, 2H, Hi); 2.59-2.51 (m, 2H, Hh); 1.75 (bs, 1H, Hg); 
1.42 (s, 9H, Ho); 1.35 (d, J=6.6 Hz, 3H, Ha).  
MS (ESI): [M+H]+ = 265.  
[α]D20 = -29° (c = 0.11 g/100 mL, chloroform). 
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16) {2-[(2-Chloro-acetyl)-(1-phenyl-ethyl)-amino]-ethyl}-carbamic acid tert-butyl 
ester (18). 
NH
N
O O
Cl
O
C17H25ClN2O3
Mol. Wt.: 340,84
a
b c
d
e
f
g
h
i
l
m
n
o
p
 
 
To a stirred solution of 17 (1.94 g, 7.34 mmol) in EtOAc (50 mL)  at 0°C, of satured 
solution of NaHCO3 (5 mL) was added. After 10 min, chloroacetyl chloride (1.17 mL, 
14.68 mmol) was added drop wise. The reaction was monitored by TLC (EtOAc/light 
petroleum 3:1) and after 24 h at room temperature, NaHCO3 (2 mL) was added to the 
organic phase. The organic layer was separated and the aqueous phase was extracted 
twice with EtOAc (50 mL). The combined organic phases were concentrate to dryness 
to obtain 18 in quantitative yield.  
 
1H NMR (CDCl3, 400 MHz): δ = 7.22-6.98 (m, 5H, Hd,e,f); 5.59-5.43 (q, J=8 Hz, 1H, 
Hb); 4.85 (bs, 1H, Hi); 4.10-3.97 (m, 2H, Hh); 3.76 (s, 2H, Hp); 3.18-3.15 (m, 2H, Hg); 
1.40-1.25 (d, J=8 Hz, 3H, Ha); 1.06 (s, 9H, Hn).  
13C NMR (CDCl3, 100MHz): δ = 170.12 (Co), 155.85 (Cl), 139.47 (Cc), 128.45 (Cd o 
Ce), 128.20 (Cd o Ce), 128.03 (Cf), 80.69 (Cm), 59.44 (Cp), 42.86 (Cb), 41.14 (Cg or 
Ch), 38.24 (Cg or Ch), 27.48 (Cn), 19.98 (Ca).  
MS (ESI): [M+H]+ = 341.  
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17) 3-Oxo-4-(1-phenyl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester (19).  
N
N
O O
O
C17H24N2O3
Mol. Wt.: 304,38
a
b c
d
e
f
g
h
i
l
m
n
o
p
 
To a stirred suspension of 60% NaH (1.14 g, 28.61 mmol) in a mixture of THF/DMF 
1/1 (20 mL) at 0°C, a solution of 18 (3.25 g, 9.54 mmol) in THF/DMF 1/1 (10 mL) was 
added. After 24 h the reaction was quenched by adding NH4Cl satured solution (15 mL) 
and the solvent was removed in vacuo. The residue was dissolved in EtOAc (50 mL) 
and washed twice with water (20 mL). The organic layer was dried, evaporated under 
reduced pressure and the crude product purified by flash chromatography (eluent: 
EtOAc/light petroleum 1:1) to obtain 19 in 45% yield. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.36-7.28 (m, 5H, Hd,e,f), 6.08 (q, 1H, J= 8Hz, Hb); 
4.20 (d, 1H, J= 20Hz, part of AB system, Hp), 4.10 (d, 1H, J= 20Hz, part of AB 
system, Hp’), 3.62 (bs, 1H, Cg), 3.27 (bs, 1H, Cg’), 3.19 (bs, 1H, Ch); 2.83 (bs, 1H, 
Ch’), 1.52 (d, J= 8Hz, 3H, Ca), 1.45 (s, 9H, Cn).  
13C NMR (CDCl3, 100MHz): δ =  165.44 (Co), 153.78 (Cl), 139.41 (Cc), 128.63 (Cd), 
127.68 (Ce), 127.36 (Cf), 80.69 (Cm), 50.08 (Cb), 47.98 (Cg), 40.24 (Ch), 28.32 (Cn), 
15.34 (Ca).  
MS (ESI): [M+H]+ = 305. 
[α]D20 = -116.0 ° (c = 0.318 g/100 mL, chloroform).  
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18) 1- (1-Phenyl-ethyl)-piperazin-2-one (19b). 
N
H
N O
C12H16N2O
Mol. Wt.: 204,27
 
1.31g of compound (19) (4.30 mmol) was solubilized in CH2Cl2 and 3.30 ml of TFA 
(43.04 mmol) was added at 0°C, the reaction was completed in 1 hour. NaHCO3 satured  
was added and the acqouos phase was extractet several time with EtOAc and the 
organic phases were combined, dried and evaporated under vacuum to give compound 
(19b) in 97% yield. 
MS (ESI): [M+H]+ = 205 
 
19) 1-(1-Phenyl-ethyl)-piperazine (19c). 
N
H
N C12H18N2
Mol. Wt.: 190,28
 
 
To a stirred suspension of LiAlH4 (331 mg, 8.73 mmol) at 0°C in anhydrous THF, a 
solution of 19b (890 mg, 4.36 mmol) was added drop wise. The reaction was monitored 
by TLC (EtOAc/light petroleum 1:1) and after 24 hours the excess of hydride was 
quenched with water and the salts were filtered trough a celite pad. The solvent was 
evaporated in vacuo to yield 19c in 87% yield.  
MS (ESI): [M+H]+ = 191 
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20) 4- (1-Phenyl- ethyl)-piperazine-carboxylic acid tert-butyl ester (20). 
N
N
O O
C17H26N2O2
Mol. Wt.: 290,40
a
b c
d
e
f
g
h
i
l
m
n
o
p
 
 
A solution of 19c (520 mg; 2.73 mmol) in a mixture of water and tert-butanol 1:2 (60 
ml), cooled at 0°C, was treated with di-tert-butyl-dicarbonate (650 mg, 3 mmol) in 
presence of NaOH 2N. The reaction mixture was stirred at room temperature for 12 
hours and monitorated by TLC (EtOAc/light petroleum 1:1); after an hour the reaction 
was termined. The solvent was removed under vacuum and the crude material dissolved 
in EtOAc; the organic layer was washed twice with citric acid, dried and concentrated in 
vacuo. 
The product 20 was obtained by flash cromatography (EtOAc/ light petroleum 1:2) in 
quantitative yield. 
 
1H NMR (CDCl3, 400 MHz):  δ = 7.31-7.25 (m, 5H, Hd,e,f), 3.41-3.35 (m, 5H, 
Hb,g,o), 2.39-2.34 (m, 4H, Hh,p), 1.43 (s, 9H, Hn), 1.35 (d, 3H, J= 7, Ha). 
MS (ESI): [M+H]+ =291 
[α]D20 = + 42.4° (C = 0.0125g/100 ml, cloroformio). 
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21) 1,1-Diphenyl-7-(1-phenyl-ethyl)-hexahydro-oxazolo[3,4-a] pyrazin-3-one (21a 
and 21b).  
N
N
O
O
C26H26N2O2
Mol. Wt.: 398,50 N
N
O
O
a
b c
d
e
f
g
h
i
l
m
n
o
p
r
q
a
b c
d
e
f
g
h
i
l
m
n
o
p
r
qs s
 
 
To a stirred solution of 20 (380 mg, 1.31 mmol) in anhydrous THF (5 mL), TMEDA 
(0.53 mL, 3.54 mmol) was added. The reaction was cooled at -78°C and sec-BuLi 1.4M 
in exane (2.53 mL, 3.54 mmol) was added. The reaction was heated at -35°C and after 2 
h a solution of benzophenone (480 mg, 2.62 mmol) in anhydrous THF (7 mL) of was 
added drop wise. The reaction became green and was stirred at room temperature for 24 
h. After this time the reaction was monitorated by TLC (EtOAc/light petroleum 1:2) and 
quenched by adding NH4Cl satured solution (20 mL). The solvent was removed in 
vacuo and the aqueous phase extracted 3 times with EtOAc (30 mL). The combined 
organic layer was dried and evaporated to dryness. The crude diastereomers mixture 
was purified by flash chromatography using EtOAc/light petroleum 1:2 as eluent to 
obtain the fast running diastereomer 21a in 40% yield and the low running distereomer 
21b in 45% yield. 
 
Compound 21a: 
1H NMR (CDCl3, 400 MHz): δ = 7.50 - 7.14 (m, 15H, Hd,e,f,,q,r,s),  4.44 (dd, 1H, J = 
10.9, 3.6 Hz, Hn), 3.82 (ddd, 1H, J = 12.8, 3.5, 1.6 Hz, Hh’), 3.48 (q, 1H, J = 6.8 
Hz,Hb), 3.11 (ddd, 1H, J = 13.0, 12.0, 3.81 Hz, Hh), 2.76 (td, 1H, J = 12, 3.6 Hz, Hg), 
2.44 (ddd, 1H, J = 11.5, 3.5, 1.6 Hz, Ho’), 2.02 (td, 1H, J = 11.7, 3.6 Hz, Hg’), 1.50 (t, 
1H, J= 11.2Hz, Ho), 1.27 (d, 3H, J = 6.8 Hz, Ha).  
13C NMR (CDCl3, 100MHz): δ = 156.20 (Cl), 142.48 (Cp or Cp’), 142.28 (Cp or Cp’), 
138.81 (Cc), 128.65 (C arom.), 128.51 (C arom.), 128.32 (C arom.), 127.98 (C arom.),  
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127.59 (C arom.), 127.28 (C arom.), 126.11 (C arom.),  125.92 (C arom.), 125.84 (C 
arom.), 85.39 (Cm), 63.86 (Cb), 61.67 (Cn), 53.24 (Co), 47.58 (Cg), 42.11 (Ch), 17.16 
(Ca).  
MS ESI [M+H+]= 399.  
[α]D20= -132°(c = 0.11 g/100 mL, chloroform). 
Compound 21b: 
1H NMR (CDCl3, 400 MHz): δ = 7.55 - 7.14 (m, 15H, Hd,e,f,,q,r,s), 4.51 (dd, 1H, J = 
10.9, 3.6 Hz, Hn), 3.74 (ddd, 1H, J = 12.8, 3.5, 1.6 Hz, Hh’), 3.34 (q, 1H, J = 6.8 Hz, 
Hb), 3.04 (ddd, 1H, J = 13.0, 12.1, 3.6 Hz, Hh), 2.70 - 2.61 (m, 2H, Ho’,g’), 1.86 (td, 
1H, J = 12, 3.6 Hz, Hg), 1.46 (t, 1H, J= 11.2Hz, Ho), 1.22 (d, 3H, J = 7.2 Hz, Ha).  
13C NMR (CDCl3, 100MHz): δ = 156.17 (Cl), 142.85 (Cp or Cp’), 142.52 (Cp or Cp’), 
138.91 (Cc), 128.69 (C arom.), 128.58 (C arom.), 128.50 (C arom.), 128.35 (C arom.),  
128.01 (C arom.), 127.51 (C arom.), 127.37 (C arom.),  126.19 (C arom.), 125.95 (C 
arom.), 85.50 (Cm), 64.52 (Cb), 61.56 (Cn), 52.66 (Co), 49.30 (Cg), 42.07 (Ch), 19.34 
(Ca).  
MS ESI [M+H+]= 399.  
[α]D20= +216 (c = 0.108 g/100 mL, chloroform). 
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22) 3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 9H-
fluoren-9-ylmethyl ester (22a and 22b). 
N
N
O
O
O O
N
N
O
O
O O
C33H28N2O4
Mol. Wt.: 516,59
 
 
To a stirred solution of 21a or 21b (200 mg, 0.52 mmol) in acetonitrile (10 mL) at 
reflux, Fmoc-Cl (148 mg, 0.57 mmol) dissolved in acetonitrile (7 mL) was added. The 
reaction, monitored by TLC (EtOAc/light petroleum 1:2), was completed in 12 h. The 
desired precipitate was filtered off to obtain 22a or 22b in about 67% yield and pure 
enough to be used in the next reaction. 
 
23) 3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-
fluoro-benzylamide ((S)-SHA 68 and (R)-SHA 68).  
N
N
O
O
H
N O
F
C26H24FN3O3
Mol. Wt.: 445,49
a
b
c
d
e
f
g
h
i
l
m
n
o
p
r
q s
N
N
O
O
H
N O
F a b c
d
e
f
g
h
i
l
m
n
o
p
r
q s
 
 
To a stirred solution of 22a or 22b (55 mg, 0.11 mmol) in anhydrous THF (15 mL) p-
fluoro-benzylisocianate (34.4 mg, 0.228 mmol) and DBU (19.2 mg, 0.126 mmol) were 
added. The reaction was monitored by TLC (EtOAc/light petroleum 1:2) and by mass 
spectrometry. After 24 h the reaction was treated and the organic phase was dried and 
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evaporate to dryness to give (S)-SHA 68 and (R)-SHA 68 in 83% and 76% yield 
respectively, after column chromatography using EtOAc/light petroleum 1/1 as eluent.  
 
1H NMR (CDCl3, 400 MHz): δ =  7.51-6.98 (m, 14H, Hb,c,q,r,s), 4.95 (bs, 1H, Hf), 
4.43 (dd, 1H, J= 11.2, 3.6Hz, Hn), 4.43-4.30 (m, 2H, He), 4.03 (ddd, 1H, J= 13.5, 3.5, 
1.2Hz, Ho’), 3.81 (dd, 1H, J= 13.1, 2.7 Hz, Hi), 3.69 (td, J=13.2, 3.6, 2.0Hz, Hh’), 3.05 
(dt, 1H, J=12.7, 3.7Hz, Hi), 2.91 (dt, 1H, J=12.4, 3.6Hz, Hh), 2.14 (dd, 1H, J=13.3, 
11.2Hz, Ho).  
13C NMR (CDCl3, 100MHz): δ =163.47 (Ca), 161.02 (Cd), 157.20 (Cg), 156.11 (Cl), 
141.81 (Cp or Cp), 138.30 (Cp or Cp’), 129.48 (Cb), 128.82 (Cq or Cq’), 128.72 (Cq or 
Cq’), 128.37 (Cc or Cc’), 125.99 (Cr or Cr’), 125.83 (Cr or Cr’), 115.70 (Cs or Cs’), 
115.48 (Cs or Cs’), 85.90 (Cm), 60.55 (Cn), 46.58 (Co), 44.47 (Ce), 43.76 (Ch), 41.37 
(Ci).  
MS ESI [M+H+]= 445.9.  
(S)-SHA 68 : 
[α]D20= -91 (c= 0.12 g/100 mL, MeOH). 
 (R)-SHA 68 
[α]D20= +92 (c= 0.1 g/100 mL, MeOH). 
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Synthesis of (-)-Steganacin aza analogue 
 
24) 2-[(1,1-Dimethylprop-2-yn-1-yl)oxy]tetrahydro-2H-pyran (30) 
 
O
O
C10H16O2
Mol. Wt.: 168,23
a b
c
d
e
f g
h
i
 
 
3,4-Dihydro-2H-pyran (30.1 mL, 330 mmol, 1.1 equiv.) was added dropwise to a 
solution of 3-methylbut-1-yn-3-ol 29 (29 mL, 300 mmol, 1 equiv.) and p-
toluenesulfonic acid (571 mg, 3 mmol, 1 mol%) in dichloromethane (300 mL), cooled 
to 0°C. The resulting mixture was stirred at 0°C for 5h and solid potassium carbonate 
K2CO3 was then introduced. Dichloromethane was evaporated under reduced pressure 
and the residue was distilled over silicon oil to afford the expected protected alcohol 30 
in 71% yield (35.8 g) as a colorless oil. 
 
b.p.: 70°C (23 mmHg) 
1H NMR (CDCl3, 400 MHz): δ = 5.08-5.06 (m, 1H, He), 3.98-3.93 (m, 1H, Hi'), 3.54-
3.48 (m, 1H, Hi), 2.43 (s, 1H, Ha), 1.87-1.51 (m, 12H, Hd, f, g, h).  
13C NMR (CDCl3, 100 MHz): δ = 96.2 (Ce), 86.5 (Cb), 72.0 (Ca), 71.0 (Cc), 63.4 (Ci), 
32.0 (Cf), 30.7 (Cd’), 29.9 (Cd), 25.5 (Cg or Ch), 20.5 (Cg or Ch). 
IR (neat): 3293, 2985, 2940, 2869, 2108 cm-1 
HRMS (ESI+) m/z calcd for C10H16O2Na1 (M+Na+) 191.10425. Found: 191.10426. 
Commercially available product. 
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25) 4-Methyl-4-(tetrahydro-2H-pyran-2-yloxy)pent-2-yn-1-ol (31) 
 
O
O
HO
C11H18O3
Mol. Wt.: 198,26
a b c d
e
f
g h
i
j
 
 
n-Butyllithium (41 mL, 97 mmol, 1.1 equiv., 2.38 M solution in hexanes) was added 
dropwise to a solution of protected propargyl alcohol 30 (14.8 g, 88 mmol, 1 equiv.) in 
freshly distilled diethyl ether (140 mL), cooled to -78°C. The temperature of the 
solution was carefully maintained below -50°C during the addition. The reaction 
mixture was stirred at -78°C during 45 min and paraformaldehyde (7.95 g, 264 mmol, 3 
equiv.) was then added. The reaction was vigorously stirred and allowed to slowly reach 
room temperature overnight. The reaction medium was smoothly quenched with a 
mixture of ice and water, and the aqueous layer was extracted with diethyl ether. The 
combined organic layers were washed with brine, dried on MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography on silica gel eluting 
with a gradient of pentane/Et2O 85:15 to 70:30. The expected alcohol 31 was obtained 
in 94% yield (10.5 g) as a yellow oil. 
 
1H NMR (CDCl3, 400 MHz): δ = 5.06-5.04 (m, 1H, Hf), 4.25 (d, J = 6.0 Hz, 2H, Ha), 
3.95-3.91 (m, 1H, Hj'), 3.52-3.46 (m, 1H, Hj), 3.26 (t, J = 6.0 Hz, 1H, HOH), 1.85-1.45 
(m, 12H, He, g, h, i). 
13C NMR (CDCl3, 100 MHz): δ = 95.7 (Cf), 87.5 (Cc), 82.7 (Cb or Cd), 71.0 (Cb or 
Cd), 63.0 (Cj), 50.7 (Ca), 31.9 (Cg), 30.5 (Ce’), 30.0 (Ce), 25.4 (Ch or Ci), 20.1 (Ch or 
Ci). 
IR (neat): 3414, 2938, 2866, 1440, 1361 cm-1 
HRMS (ESI+) m/z calcd for C11H18O3Na1 (M+Na+) 221.11482. Found: 221.11437. 
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26) 4-Methylpenta-2,3-dien-1-ol (28) 
 
•
HO
C6H10O
Mol. Wt.: 98,14a
b
c
d e
 
 
Propargyl alcohol 31 (6.6 g, 33 mmol, 1 equiv.) diluted in freshly distilled diethyl ether 
(60 mL) was added dropwise to a suspension of powdered lithium and aluminium 
hydride LiAlH4 (3.81 g, 100 mmol, 3 equiv.) in distilled diethyl ether (100 mL), cooled 
to 0°C. The resulting reaction mixture was allowed to reach room temperature over 5h 
(the completion of the reaction was monitored by 1H NMR). The excess lithium and 
aluminium hydride was hydrolyzed at 0°C by adding successively water (3.2 mL), an 
aqueous NaOH solution (3.2 mL, 15% w/w) and water (7 mL) again. The biphasic 
mixture was then stirred vigorously during 1h. The resulting white suspension was 
filtered on celite and washed several times with diethyl ether. The combined organic 
layers were dried on MgSO4 and concentrated in vacuo. The crude product was purified 
by flash chromatography on silica gel eluting with pentane/Et2O 80:20 to afford the 
expected allenol 28 in 66% yield (2.17 g) as a pale yellow oil. 
 
1H NMR (CDCl3, 400 MHz): δ = 5.20 (tsept, J= 3.0, 5.5 Hz, 1H, Hb), 4.08 (d, J= 5.5 
Hz, 2H, Ha), 1.73 (d, J= 3.0 Hz, 6H, He), 1.45 (br s, 1H, HOH). 
13C NMR (CDCl3, 50 MHz): δ = 200.7 (Cc), 98.7 (Cd), 90.1 (Cb), 61.1 (Ca), 20.7 
(Ce). 
IR (neat): 3307, 2981, 2909, 2856, 1968 cm-1 
HRMS (ESI+) m/z calcd for C6H11O1 (M+H+) 99.08044. Found: 99.08017. 
Data in agreement with: Richey, H. G. Jr.; Moses, L. M. J. Org. Chem. 1983, 48, 4013-
4017.  Commercially available product. 
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27) Phenyl-acetic acid 4-methyl-penta-2,3-dienyl ester (32) 
 
•
O
O
C14H16O2
Mol. Wt.: 216,28
ab
c
d
e
fg
h
i
j
k
	  
 
Triethylamine (9.22 mL, 66 mmol, 3 equiv.) were successively added to a solution of 
allenyl alcohol 31 (2.17 g, 22 mmol, 1 equiv.) in dichloromethane (110 mL). Phenacyl 
chloride (8.7 mL, 66 mmol, 3 equiv.) was then introduced dropwise at 0°C and the 
resulting mixture was stirred for 2.5h at room temperature. The reaction was quenched 
with a saturated solution of NH4Cl and the aqueous layer was extracted with 
dichloromethane. The combined organic layers were washed with a saturated solution of 
NaHCO3, dried on MgSO4 and carefully concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel eluting with cyclohexane/AcOEt 95:5 to 
afford the expected allenol 32 in 84% yield (4 g) as a pale yellow oil. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.32-7.28 (m, 5H, Hi,j,k), 5.08 (m, 1H, Hd), 4.53 (d, 
2H, J= 7.0 Hz, He), 3.64 (s, 2H, Hg), 1.68 (d, 6H, J= 3.0 Hz, Ha). 
13C NMR (CDCl3, 100 MHz): δ = 203.64 (Cc), 171.6 (Cf), 134.4 (Ck), 129.8 (Cd), 
129.0 (Cj or Ci), 127.4 (Cj or Ci), 97.7 (Cb), 85.1 (Cd), 63.9 (Ce), 41.7 (Cg), 20.5 (Ca). 
IR (neat): 2984, 2940, 2912, 1972, 1739, 1218 cm-1 
HRMS (ESI+) m/z calcd for C14H16O2Na1 (M+Na+) 239.2648. Found: 239.1043. 
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28) N-benzyl-2,2,2-trifluoroacetamide (33) 
 
F3C NH
O
C9H8F3NO
Mol. Wt.: 203,16
a
b
c
d
e
f
g  
 
Trifluoroacetic anhydride (6.25 mL, 45 mmol, 1 equiv.) was added dropwise at 0°C to a 
solution of 4-N,N-dimethylaminopyridine (DMAP) (550 mg, 4.5 mmol, 10 mol%) and 
benzylamine (10.8 mL, 99 mmol, 2.2 equiv.) in dichloromethane (150 mL). The 
resulting mixture was stirred at room temperature overnight. The reaction was quenched 
with a saturated solution of NH4Cl and the aqueous layer was extracted with 
dichloromethane. The combined organic layers were washed with a saturated solution of 
NaHCO3, dried on MgSO4 and concentrated in vacuo. The crude product was 
recrystalized in toluene to afford 7.51 g of the expected product 33 (82 %) as white 
crystals. 
 
m.p.: 73°C 
1H NMR (CDCl3, 400 MHz): δ = 7.53-7.23 (m, 5H, He, f, g), 6.51 (br s, 1H, HNH), 
4.55 (d, 2H, J= 6.0 Hz, Hc).  
13C NMR (CDCl3, 100 MHz): δ = 157.3 (Cb), 136.0 (Cd), 129.1 (Ce or Cf), 128.4 
(Cg), 128.1 (Ce or Cf), 116.0 (Ca), 44.0 (Cc). 
IR (neat): 3292, 3091, 3035, 1697, 1557, 1164 cm-1 
HRMS (ESI+) m/z calcd for C9H8O1N1F3Na1 (M+Na+) 226.04502. Found: 226.04506. 
Commercially available product. 
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29) N-benzyl-(4’-methylpenta-2’,3’-dienyl)-trifluoroacetamide (34) 
 
F3C N
O
•
C15H16F3NO
Mol. Wt.: 283,29
a
b
c
d
e
f g
h i
j
k
l
 
 
LiHMDS (9.02 ml, 9.02 mmol, 1.3 equiv., 1M in THF) was slowly added to a solution 
of  N-benzyltrifluoroacetamide 33 (1.69 g, 8.33 mmol, 1.2 equiv.) in dry THF (18 mL) 
at 0°C. The resulting mixture was stirred at room temperature for 10 min. Allenyl ester 
32 (1.5 g, 6.9 mmol, 1 equiv.) diluted in dry THF (8 mL) was added via cannula, 
followed by Pd(PPh3)4 (200 mg, 0.17 mmol, 2.5 mol%). The resulting yellow mixture 
was stirred at 55°C for 4h and the completion of the reaction was monitored by TLC. 
The reaction was quenched with a saturated solution of NH4Cl and the aqueous layer 
was extracted with diethyl ether. The combined organic layers were dried on MgSO4 
and concentrated in vacuo. The crude material was purified by flash chromatography on 
silica gel eluting with a gradient of pentane/Et2O 98:2 to 95:5 to afford 1.17 g of the 
expected product 34 (60%) as a colorless oil and as a 63:37 mixture of rotamers. 
 
Major rotamer: 
1H NMR (CDCl3, 400 MHz): δ = 7.41-7.22 (m, 5H, Hj,k,l), 4.94 (m, 1H, Hd), 4.67 (s, 
2H, Hh), 3.86 (d, 2H, J= 6.0 Hz, Hc), 1.75 (d, 6H, J= 3.0 Hz, Hg). 
13C NMR (CDCl3, 100 MHz): δ = 203.3 (Ce), 157.3 (Cb), 135.6 (Ci), 129.0 (Cj or Ck), 
128.5 (Cj or Ck), 127.5 (Cl), 116.8 (Ca), 98.8 (Cf), 84.2 (Cd), 48.6 (Ch), 45.9 (Cc), 20.3 
(Cg). 
Minor rotamer: 
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1H NMR (CDCl3, 400 MHz): δ = 7.41-7.22 (m, 5H, Hj, k, l), 4.94 (m, 1H, Hd), 4.62 
(s, 2H, Hh), 3.87 (d, 2H, J= 6.0 Hz, Hc), 1.71 (d, 6H, J= 3.0 Hz, Hg). 
13C NMR (CDCl3, 100 MHz): δ = 202.6 (Ce), 157.0 (Cb), 135.0 (Ci), 129.0 (Cj or Ck), 
128.3 (Cl), 128.1 (Cj or Ck), 116.8 (Ca), 98.6 (Cf), 83.0 (Cd), 49.9 (Ch), 44.8 (Cc), 20.4 
(Cg). 
Mixture of rotamers: 
IR (neat): 2911, 1970, 1688, 1451, 1200, 1137 cm-1 
 
30) N-Benzyl-4-methylpenta-2,3-dien-1-amine (35) 
 
C13H17N
Mol. Wt.: 187,28
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Allenyl trifluoroacetamide 34 (1.19 g, 4.19 mmol, 1 equiv.) was diluted in a mixture of 
methanol (28 mL) and water (3 mL) and potassium carbonate K2CO3 was added until 
saturation of the solution. The resulting mixture was heated at 50°C and the completion 
of the reaction was monitored by TLC. After 16h, water was added to the reaction 
mixture and methanol was removed in vacuo. The resulting aqueous phase was 
extracted with dichloromethane, and the combined organic layers were dried on MgSO4 
and concentrated in vacuo. The crude product was purified by flash chromatography on 
silica gel eluting with a gradient of cyclohexane/AcOEt 90:10 to pure AcOEt to afford 
the expected amine 35 in 85% yield (690 mg) as a pale yellow oil. 
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1H NMR (CDCl3, 400 MHz): δ = 7.34-7.25 (m, 5H, Hh, i, j), 5.08 (m, 1H, Hd), 3.83 (s, 
2H, Hf), 3.23 (d, 2H, J= 6.0 Hz, He), 1.73 (d, 6H, J= 3.0 Hz, Ha), 1.64 (br s, 1H, HNH). 
13C NMR (CDCl3, 100 MHz): δ = 201.9 (Cc), 140.4 (Cg), 128.5 (Ch or Ci), 128.4 (Ch 
or Ci), 127.0 (Cj), 96.5 (Cb), 87.9 (Cd), 53.0 (Cf), 48.2 (Ce), 20.8 (Ca). 
IR (neat): 3315, 2978, 2907, 1967, 1603, 1451 cm-1 
HRMS (ESI+) m/z calcd for C13H18N1 (M+H+) 188.14338. Found: 188.14331. 
Data in agreement with: Shibata, T.; Kadowaki, S.; Takagi, K. Heterocycles 2002, 57, 
2261-2266. 
 
31) N-Benzyl-(4’-methylpenta-2’,3’-dienyl)-3-methoxy-3-oxopropionamide (27) 
 
C17H21NO3
Mol. Wt.: 287,35
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Triethylamine (1.5 mL, 10.8 mmol, 3 equiv.) was added to a solution of allenylamine 35 
(670 mg, 3.58 mmol, 1 equiv.) in distilled dichloromethane (36 mL). Methyl 3-chloro-
3-oxopropionate (1.15 mL, 10.8 mmol, 3 equiv.) was introduced dropwise at 0°C and 
the reaction was stirred at room temperature for 16h. The reaction was quenched with a 
saturated solution of NH4Cl and the aqueous layer was extracted with dichloromethane. 
The combined organic layers were washed with a saturated solution of NaHCO3, dried 
on MgSO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography on silica gel (0.015-0.040 mm) eluting with pentane/Et2O 75:25 to 
afford the expected product 27 in 76% yield (780 mg) as a pale yellow oil and as a 
71:29 mixture of rotamers. 
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Major rotamer: 
1H NMR (CDCl3, 400 MHz): δ = 7.39-7.19 (m, 5H, Hl, m, n), 4.90 (m, 1H, Hf), 4.61 
(s, 2H, Hj), 3.78 (s, 3H, Ha), 3.74 (d, 2H, J= 5.0 Hz, He), 3.55 (s, 2H, Hc), 1.72 (d, 6H, 
J= 3.0 Hz, Hi). 
13C NMR (CDCl3, 100 MHz): δ = 202.1 (Cg), 168.4 (Cb or Cd), 166.5 (Cb or Cd), 
137.2 (Ck), 128.7 (Cm or Cl), 128.2 (Cm or Cl), 127.5 (Cn), 99.4 (Ch), 84.8 (Cf), 52.6 
(Ca), 48.5 (Cj), 46.7 (Ce), 41.0 (Cc), 20.5 (Ci). 
Minor rotamer: 
1H NMR (CDCl3, 400 MHz): δ = 7.39-7.19 (m, 5H, Hl, m, n), 4.97 (m, 1H, Hf), 4.55 
(s, 2H, Hj), 3.98 (d, 2H, J= 6.5 Hz, He), 3.72 (s, 3H, Ha), 3.46 (s, 2H, Hc), 1.67 (d, 6H, 
J= 3.0 Hz, Hi). 
13C NMR (CDCl3, 100 MHz): δ = 203.2 (Cg), 168.1 (Cb or Cd), 166.3 (Cb or Cd), 
136.3 (Ck), 129.1 (Cm or Cl), 127.8 (Cn), 126.5 (Cm or Cl), 97.1 (Ch), 84.3 (Cf), 52.6 
(Ca), 50.7 (Cj), 45.5 (Ce), 41.4 (Cc), 20.6 (Ci).  
Mixture of rotamers: 
IR (neat): 2910, 1968, 1741, 1647, 1435 cm-1 
HRMS (ESI+) m/z calcd for C17H21O3N1Na1 (M+Na+) 310.14136. Found: 310.14166. 
 
32) 5-iodo-1,3-benzodioxole (36) 
 
O
O
I
C7H5IO2
Mol. Wt.: 248,02 
 
Benzodioxole (1.7 mL, 15 mmol, 1 equiv.) was added to a solution of N-
iodosuccinimide (3.54 g, 15.75 mmol, 1.05 equiv.) in distilled acetonitrile, in a flask 
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protected from light. Trifluoroacetic acid (1.16 mL, 15 mmol, 1 equiv.) was then added 
dropwise and the resulting mixture was stirred at 50°C for 72h (the completion of the 
reaction was monitored by 1H NMR). The reaction was quenched with a saturated 
solution of Na2S2O3 and the resulting precipitate was filtered off. The aqueous layer was 
extracted with diethyl ether and the combined organic layers were washed with a 
saturated solution of NaCl, dried on MgSO4 and concentrated in vacuo. The crude 
product was purified by flash chromatography on silica gel (0.015-0.040 mm) eluting 
with pure pentane to afford 2.78 g of the expected product 36 (75%) as a pale yellow 
oil. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.14 (m, 2H, Hc,e), 6.61 (d, 1H, J= 8.0 Hz, Hf), 5.96 
(s, 2H, Ha). 
13C NMR (CDCl3, 100 MHz): δ = 148.9 (Cb or Cg), 148.8 (Cb or Cg), 130.7 (Ce), 
117.8 (Cc), 110.6 (Cf), 101.5 (Ca), 82.3 (Cd). 
IR (neat): 2889, 2775, 1498, 1469, 1225, 1030 cm-1 
Commercially available product. 
 
33) (3,4-trans)-1-Benzyl-3-(methoxycarbonyl)-4-(1’-(1,3-benzodioxol-5-yl)-2’-
methylprop-1’-en-1’-yl)-pyrrolidin-2-one (37) 
 
NO
O
O
C24H25NO5
Mol. Wt.: 407,46
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Sodium hydride (16 mg, 0.4 mmol, 1.2 equiv., 60% dispersion in mineral oil) was 
added to a solution of allenyl amide 27 (94 mg, 0.33 mmol, 1 equiv.) in freshly distilled 
DMSO (3 mL) under argon atmosphere. The resulting mixture was stirred at room 
temperature for 20 min. In another flask, n-butyllithium (29 µL, 0.07 mmol, 20 mol%, 
2.28 M solution in hexanes) was added dropwise to a solution of 
dichlorobis(acetonitrile) palladium PdCl2(MeCN)2 (8.6 mg, 0.03 mmol, 10 mol%) in 
freshly distilled DMSO (2 mL) under argon atmosphere. The resulting solution, initially 
yellow, became dark orange. The 5-iodo-1,3-benzodioxole (98 mg, 0.4 mmol, 1.2 
equiv.) and tetrabutylammonium bromide (21.3 mg, 0.06 mmol, 20 mol%) were then 
successively added, and the solution containing the enolate of 27 was added via 
cannula. The resulting mixture was stirred at 55°C. The completion of the reaction was 
monitored by TLC and the reaction was quenched with a saturated solution of NH4Cl. 
The aqueous layer was extracted with dichloromethane. The combined organic layers 
were washed with a saturated solution of NaCl, dried on MgSO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography on silica gel eluting 
with cyclohexane/AcOEt 75:25 to afford the expected product 37 (99 mg, 74% yield) as 
a yellow oil. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.33-7.27 (m, 3H, Hu, v), 7.16 (d, 2H, J= 7.0 Hz, 
Ht), 6.76 (d, 1H, J= 8.0 Hz, Hp), 6.37 (s, 1H, Hl), 6.32 (d, 1H, J= 8.0 Hz, Hq), 5.96 (s, 
2H, Hn), 4.53 (d, 1H, J= 15.0 Hz, part of AB system, Hr'), 4.19 (d, 1H, J= 15.0 Hz, part 
of AB system, Hr), 4.10 (m, 1H, Hf), 3.82 (s, 3H, Ha), 3.42 (d, 1H, J= 10.0 Hz, Hc), 
3.32 (t, 1H, J= 9.0 Hz, He'), 3.05 (t, 1H, J=9.0 Hz, He), 1.81 (s, 3H, Hi or Hj), 1.42 (s, 
3H, Hi or Hj). 
13C NMR (CDCl3, 100 MHz): δ = 170.2 (Cb), 169.1 (Cd), 147.6 (Co), 146.2 (Cm), 
135.6 (Cs), 133.6 (Ch), 132.7 (Ck), 131.1 (Cg), 128.5 (Cu), 127.7 (Ct), 127.4 (Cv), 
122.7 (Cq), 110.1 (Cl), 108.2 (Cp), 100.8 (Cn), 52.7 (Cc), 52.4 (Ca), 48.3 (Ce), 46.5 
(Cr), 38.9 (Cf), 22.6 (Ci or Cj), 19.5 (Ci or Cj). 
IR (neat): 2913, 1737, 1689, 1485, 1430, 1331, 1230 cm-1 
HRMS (ESI+) m/z calcd for C24H25O5N1Na1 (M+Na+) 430.16249. Found: 430.16220 
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34) 4-(1-Benzo[1,3]dioxol-5-yl-2-methyl-propenyl)-1-benzyl-2-oxo-3-(3,4,5-
trimethoxy-benzyl)-pyrrolidine-3-carboxylic acid methyl ester (38) 
NO
O
O
O O
O
H3COOC
C34H37NO8
Mol. Wt.: 587,66
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Sodium hydride (11 mg, 0.27 mmol, 1.2 equiv., 60% dispersion in mineral oil) was 
added to a solution of pyrrolidin-2-one 37 (93 mg, 0.23 mmol, 1 equiv.) in freshly 
distilled and degassed DMF (4 mL) under argon atmosphere. The resulting mixture was 
stirred at 40°C for 20 min and 3,4,5-trimethoxybenzyl bromide (179 mg, 0.68 mmol, 3 
equiv.) was introduced. The reaction mixture was stirred at 100°C for 24h. The reaction 
was quenched with a saturated solution of NH4Cl and the aqueous layer was extracted 
with diethyl ether. The combined organic layers were washed with a large volume of 
water, dried on MgSO4 and concentrated in vacuo. The crude product was purified by 
flash chromatography on silica gel eluting with cyclohexane/AcOEt 70:30 to afford the 
expected product 38 in 73% yield (98 mg) as a white foam. 
 
1H NMR (CDCl3, 400 MHz): δ = 7.27-7.24 (m, 3H, Hr,s), 7.05 (dd, 2H, J= 2.5, 6.5 Hz, 
Hq), 6.67 (m, 2H, Hf and He), 6.58 (s, 1H, Hc), 6.49 (s, 2H, Hz), 5.91 (s, 2H, Ha), 4.48 
(d, 1H, J= 14.8 Hz, part of AB system, Ho’), 4.30 (d, 1H, J= 14.8 Hz, part of AB 
system, Ho), 3.84 (s, 3H, Hα), 3.80 (s, 6H, Hy), 3.53 (d, 1H, J= 14.1 Hz, part of AB 
system, Hv’), 3.51 (t, 1H, J= 8.4Hz, Hn), 3.31 (t, 1H, J=8.9 Hz, Hm), 3.23 (s, 3H, Hγ), 
3.11 (d, 1H, J= 14.1Hz, part of AB system, Hv), 2.80 (t, 1H, J= 8.4Hz, Hn), 1.52 (s, 3H, 
Hl), 1.40 (s, 3H, Hl’). 
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13C NMR (CDCl3, 100 MHz): δ = 172.6 (Cδ), 170.6 (Ct), 153.1 (Cw), 147.2 (Cb), 
146.1 (Cg), 137.2 (Cx), 135.8 (Cp or Cβ), 135.6 (Cp or Cβ), 133.7 (Cd), 131.0 (Ch), 
130.3 (Ci), 128.6 (Cq or Cr or Cs), 127.9 (Cq or Cr or Cs), 127.6 (Cq or Cr or Cs), 
123.6 (Ce), 110.8 (Cc), 108.0 (Cf), 107.6 (Cz), 100.9 (Ca), 61.1 (Cu), 60.5 (Cα), 56.1 
(Cy), 51.7 (Cγ), 48.2 (Cn), 47.2 (Co), 42.2 (Cm), 38.1 (Cv), 23.1 (Cl o Cl’), 20.5 (Cl o 
Cl’). 
 
35) 4-(1-Benzo[1,3]dioxol-5-yl-2-methyl-propenyl)-1-benzyl-3-(3,4,5-trimethoxy-
benzyl)-pyrrolidin-2-one (26) 
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Mol. Wt.: 529,62
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Ester 38 (111 mg, 0.19 mmol, 1 equiv.) was solubilized in ethylene glycol (10 mL) and 
20 equivalents of potassium hydroxide (KOH) (211 mg, 3.78 mmol) was added. The 
resulting mixture was heated at 180-190°C and the completion of the reaction was 
monitored by TLC. After 20 minutes, the reaction was quenched with HCl 20% and the 
resulting aqueous phase was extracted with diethyl ether, and the combined organic 
layers were dried on MgSO4 and concentrated in vacuo. The crude product was purified 
by flash chromatography on silica gel eluting with a gradient of cyclohexane/AcOEt 
70:30 to pure AcOEt to afford the expected pyrrolidin-2-one 26 in 60% yield (60 mg). 
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1H NMR (CDCl3, 400 MHz): δ = 7.26-7.21 (m, 3H, Hr,s), 7.03 (dd, 2H, J= 2.5, 6.5 Hz, 
Hq), 6.73 (m, 1H, J= 8.0 Hf), 6.48 (s, 2H, Hz), 6.42 (s, 1H, Hc), 6.36 (d, 1H, J= 8.0 Hz, 
He), 5.96 (s, 2H, Ha), 4.46 (d, 1H, J= 14.5 Hz, part of AB system, Ho’), 3.84 (s, 6H, 
Hy), 3.80 (s, 3H, Hα), 3.69 (m, 1H, Hm), 3.46 (d, 1H, J= 14.5 Hz, part of AB system, 
Ho), 3.21 (m, 2H, Hn and Hv), 2.95 (m, 2H, Hu and Hn’), 2.79 (m, 1H, Hv’), 1.57 (s, 
3H, Hl), 1.45 (s, 3H, Hl’). 
13C NMR (CDCl3, 100 MHz): δ = 175.2 (Ct), 153.2 (Cw), 147.4 (Cb), 146.1 (Cg), 
136.5 (Cx), 134.2 (Cp and Cβ), 133.7 (Cd), 132.2 (Ch), 128.6 (Ci), 128.1 (Cq or Cr or 
Cs), 127.5 (Cq or Cr or Cs), 122.5 (Cq or Cr or Cs), 110.2 (Cc), 108.1 (Cf), 105.9 (Cz), 
101.0 (Ca), 61.0 (Cα), 56.3 (Cy), 49.2 (Cn), 48.3 (Cu), 46.7 (Co), 38.7 (Cm), 33.1 (Cv), 
23.0 (Cl or Cl’), 20.7 (Cl or Cl’). 
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Supporting Information 
 
All the spectra were elaborated using MestreNova 6.0.2 software, and FID data are 
available on request: 
 
page 94 1H-NMR and 13C-NMR spectra of compound 21a 
page 95 DEPT-NMR and COSY-NMR spectra of compound 21a 
page 96 HMBC-NMR and HMQC-NMR spectra of compound 21a 
page 97 1H-NMR and 13C-NMR spectra of compound 21b 
page 98 DEPT-NMR and  COSY-NMR spectra of compound 21b 
page 99 HMBC-NMR and HMQC-NMR spectra of compound 21b 
page 100 1H-NMR and 13C-NMR spectra of compound (S)-SHA68 
page 101 DEPT-NMR and COSY-NMR spectra of compound (S)-SHA68 
page 102 HMBC-NMR and HMQC-NMR spectra of compound (S)-SHA68 
page 103 19F-NMR spectra of compound (S)-SHA68,  
1H-NMR spectra of compound (R)-SHA68 
page 104 13C-NMR and DEPT-NMR spectra of compound (R)-SHA68 
page 105 COSY-NMR and HMQC-NMR spectra of compound (R)-SHA68 
page 106 HMBC-NMR and 19F-NMR spectra of compound (R)-SHA68 
page 111   Chiral chromatography analysis of (R/S)-SHA68, (S)-SHA68 and  
(R)-SHA68 
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1H-NMR spectrum of compound 21a 
 
13C-NMR spectrum of compound 21a 
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DEPT-NMR spectrum of compound 21a 
 
COSY-NMR spectrum of compound 21a 
 
	  	   107	  
HMBC-NMR spectrum of compound 21a 
 
HMQC-NMR spectrum of compound 21a 
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1H-NMR spectrum of compound 21b 
 
13C-NMR spectrum of compound 21b 
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DEPT-NMR spectrum of compound 21b 
 
COSY-NMR spectrum of compound 21b 
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HMBC-NMR spectrum of compound 21b 
HMQC-NMR spectrum of compound 21b 
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1H-NMR spectrum of compound (S)-SHA68 
 
13C-NMR spectrum of compound (S)-SHA68 
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DEPT-NMR spectrum of compound (S)-SHA68 
 
COSY-NMR spectrum of compound (S)-SHA68 
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HMBC-NMR  spectrum of compound (S)-SHA68 
 
HMQC-NMR spectrum of compound (S)-SHA68 
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19F-NMR spectrum of compound (S)-SHA68 
 
1H-NMR spectrum of compound (R)-SHA68 
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13C-NMR spectrum of compound (R)-SHA68 
 
DEPT-NMR spectrum of compound (R)-SHA68 
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COSY-NMR spectrum of compound (R)-SHA68 
 
HMQC-NMR spectrum of compound (R)-SHA68 
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HMBC-NMR spectrum of compound (R)-SHA68 
 
19F-NMR spectrum of compound (R)-SHA68 
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Chiral chromatography analysis 
Column:  Lux 3u Cellulose-1, 150 x 2mm, Phenomenex 
Mobile phase:  80% Hexane : 20% Isopropanol 
Flow:    200µl/min 
Injection volume: 3µl  
All chromatograms were recorded at 230 nm. 
 
 
         Ritention Time (min)   Area (%) 
 
(R/S) SHA 68   1 6.495    51.30% 
    2 7.892    48.70% 
 (R) SHA 68    1 ------       0% 
    2 7.902     100% 
 (S) SHA 68    1 6.513     100% 
    2 ------        0% 
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Résumé de Thése 
 
Le travail effectué durant ces trois ans commence avec la synthèse énantiosélective d'un 
composé capable de se lier au récepteur NPSR.  
Le Neuropeptide S et ses NPSR récepteurs constituent une nouvelle découverte.12 Une 
fois que le récepteur NPSR a été activé par son agoniste endogène (NPS), un peptide de 
20 acides aminés, s’en suit la mobilisation du Ca2+ intracellulaire et l’augmentation du 
taux d'AMPc. Le système NPS / NPSR est impliqué dans plusieurs fonctions 
biologiques, dont la régulation des cycles veille-sommeil, l'ingestion d'aliments, 
l'anxiété et l'activité locomotrice.  
(R/S)-SHA-68 21est le premier antagoniste non peptidique sélectif au récepteur NPSR. 
Actuellement, seuls les composés à structure ossazolo-pipérazinique ont été reconnus 
capables de se lier au récepteur NPSR. (R/S)-SHA- 68 en est le principal 
analogue (l'acide 4-7-fluorobenzilammide-carboxy-(9R/S)-3-oxo-1,1-diphényl-
tétrahydro-ossazolo[3,4-a]-pyrazine). 
Cette molécule présente un centre stéréogène mais actuellement, elle est utilisée en tant 
que mélange racémique. Les excellentes propriétés pharmacologiques de ce ligand nous 
ont conduit vers la synthèse énantiosélective, la purification et la caractérisation de  
deux composés optiquement purs afin d'évaluer séparément leur activité 
pharmacologique. Après l’obtention des deux énantiomères, leur caractérisation et la 
vérification de leur pureté optique, nous avons été en mesure de comprendre la 
conformation et la configuration absolue de l'énantiomère (R) en raison des 
informations cristallographiques. Des études pharmacologiques menées dans les 
laboratoires du Dr. Calò de l’Università degli Studi di Ferrara ont permis de démontrer 
que (R)-SHA 68 est le seul énantiomère capable d'antagoniser l'activité du ligand 
endogène du récepteur NPSR. 
Dans le cadre d’une convention de co-tutelle de thèse établie entre l’Université Pierre et 
Marie Curie de Paris et l’Università degli Studi di Ferrara, on a eu l’opportunité de 
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développer une collaboration avec l’équipe du Prof. Giovanni Poli, au sein de laquelle 
j’ai pu effectuer un stage de neuf mois. 
L’équipe du Prof. Poli s’intéresse en particulier aux réactions catalysées au palladium-
appliquées à la synthèse de γ-lactones et de γ-lactames à partir de précurseurs alléniques. 
Il nous est paru intéressant appliquer cette chimie à la synthèse d’un nouvel analogue 
azoté de la (-)-Stéganacine. Ce produit naturel, isolé pour la première fois en 1973 de la 
plante Steganotaenia araliacea,31 appartient à la famille des lignanes et plus 
particulièrement des dibenzocyclooctadiènes. L’intérêt pour la (-)-Stéganacine est dû à 
son activité antitumorale34 et à sa structure complexe. Elle est composée d’une γ-lactone 
accolée à un cycle à huit chaînons et d’un motif bis-arylique polyoxygéné présentant un 
axe de chiralité configurationnellement stable à température ambiante. Par ailleurs, cette 
molécule présente trois centres stéréogènes contigus à stéréochimie relative trans, trans.  
À partir de l'alcool propargylique disponible dans le commerce, l’intermédiaire désiré 
est obtenu en 7 étapes avec un rendement global de 19%.  
La réaction clef de cette stratégie synthétique est la séquence domino « carbopalladation 
d’allène / alkylation allylique » qui a été optimisée dans les laboratoires du Prof. Poli.41 
Cette réaction nous a permis d'obtenir le γ-lactame désiré avec un rendement de 74%.  
Une réaction de benzylation et de decarboxylation nous ont ensuite permis d'obtenir le 
substrat pour l'étude de l’étape de couplage oxydant biarylique pour former le cycle à 
huit chaînons. 
La coupure oxydante de la double liaison exocyclique, suivie d’une réduction 
diastéréosélective de la cétone générée et une étape finale d’acylation devraient enfin  
permettre d’accéder à l’analogue azoté de la stéganacine. 
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Riassunto della Tesi 
 
Il lavoro svolto in questi tre anni inizia con la sintesi asimmetrica di un composto in 
grado di legare il recettore NPSR.  
Il Neuropeptide S e il suo recettore NPSR costituiscono un sistema di recente 
scoperta.12	   
In seguito all’attivazione del recettore NPSR da parte del suo agonista endogeno NPS, 
un peptide di 20 aminoacidi, si osserva una mobilitazione del Ca2+ intracellulare e un 
aumento dei livelli di cAMP nella cellula. Il sistema NPS/NPSR è implicato in diverse 
funzionalità biologiche tra cui la regolazione dei cicli sonno-veglia, del food-intake, 
dell’ansia e dell’attività locomotoria. 
(R/S) SHA-68 21è il primo antagonista non peptidico selettivo per il recettore NPSR; lo 
stato dell’arte fino ad ora evidenzia, tra i ligandi non peptidici, solo molecole a struttura 
ossazolo-piperazinica in grado di legare il recettore NPSR. (R/S) SHA-68 è il 
capostipite di questa famiglia, la 4-fluorobenzilammide dell’acido 7-carbossi-(9R/S)-3-
oxo-1,1-difenil-tetraidro-ossazolo [3,4-a] pirazina, e pur possedendo un centro 
stereogenico, viene al momento usato come  miscela racemica. 
Le ottime proprietà farmacologiche di tale ligando hanno spinto le nostre ricerche verso 
la sintesi enantioselettiva, la purificazione e la caratterizzazione dei due composti 
otticamente puri al fine di valutarne separatamente l’attività farmacologica.  
In seguito all’ottenimento dei 2 enantiomeri, grazie all’utilizzo di un ausiliario chirale, 
alla loro caratterizzazione e alla verifica del loro grado di purezza mediante HPLC con 
colonne chirali, siamo stati in grado di risalire alla conformazione e configurazione 
assoluta di uno dei due composti otticamente puri risultata essere (R). Queste 
informazioni sono supportate dai dati cristallografici fornitici dal Prof. Bertolasi 
dell’Università degli Studi di Ferrara. Gli studi farmacologici svolti presso i laboratori 
del Dr. Calò della medesima università ci hanno permesso inoltre di affermare che solo 
l’enantiomero (R)-SHA 68 è in grado di legare ed antagonizzare l’attività del 
neuropeptide S sul recettore NPSR.  
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Grazie alla convenzione di tesi in cotutela stabilita tra l’Università degli Studi di Ferrara 
e l’Université Pierre et Marie Curie di Parigi, abbiamo avuto l’opportunità di sviluppare 
una collaborazione con l’équipe del Prof. Giovanni Poli, presso la quale ho svolto uno 
stage di nove mesi. 
Il gruppo di ricerca del Prof. Poli s’interessa in particolare di reazioni catalizzate dal 
Palladio applicate alla sintesi di γ-lattoni e di γ-lattami a partire da precursori allenici. 
Ci è quindi sembrato interessante applicare questa chimica alla sintesi di un analogo 
azotato della (-)-Steganacina.  
La (-)-Steganacina è una sostanza naturale isolata per la prima volta nel 1973 dalla 
pianta Steganotaenia araliacea, 31 appartiene alla famiglia dei lignani. L’intesse per la (-
)-Steganacina è dovuto alla sua attività antitumorale34 poiché è in grado di interagire 
con il meccanismo di polimerizzazione-depolimerizzazione della tubulina e alla 
struttura chimica complessa. Questa molecola infatti presenta un nucleo γ-lattonico, un 
ciclo a 8 termini, una porzione biarilica e tre centri stereogenici contigui a stereochimica 
relativa trans, trans. A partire dall'alcool propargilico disponibile in commercio, 
l’intermedio desiderato si ottiene in 7 passaggi con una resa totale del 19%.  
La reazione chiave di questo approccio sintetico è la sequenza domino « 
carbopalladazione dell’allene / alchilazione allilica » che è stata messa a punto nel 
laboratori del Prof. Poli.41 Questa reazione ci ha permesso di ottenere il γ-lattame 
desiderato con una resa del 74%.  
Una reazione di benzilazione e di decarbossilazione ci hanno portato all’ottenimento del 
substrato necessario per lo studio dello step di coupling ossidativo biarilico per la 
formazione del ciclo a 8 termini. 
L’ossidazione del doppio legame esociclico, seguita da una riduzione diastereoselettiva 
del chetone generato e il passaggio finale di acilazione dovrebbero fornire l’analogo 
azotato della (-)-Steganacina di nostro interesse. 
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Abstract of the thesis 
 
Neuropeptide S (NPS) is the endogenous ligand of the previously orphan G-protein 
coupled receptor, recently named NPSR.12 NPS is a small peptide of 20 amino acids and 
rapresents the endogenous ligand of NPSR. In cells expressing the recombinant NPSR 
receptor, NPS selectively binds and activates its receptor, producing intracellular 
calcium mobilization and an increase of cAMP levels. The NPS-NPSR receptor system 
regulates important biological functions such as sleep/waking, locomotion, anxiety and 
food intake. 
(R/S) SHA-68 21 is the first non-peptide antagonist of NPSR receptor; actually only a 
class of molecules able to interact with NPSR are reported in the literature and they are 
the same oxazol-piperazine structure.  
Initially, in order to confirm the published data, we decided to synthesize SHA 68 in 
racemic form following the Okamura’s methodology21.  
The high selectivity of (R/S)-SHA 68 for NPSR and its good antagonist activity 
prompted us to synthesize the enantiomers of this non-peptide compound, starting from 
cheap commercially available reagents as chiral auxiliary. 
In order to define the conformation of the piperazine ring in this two enantiomers we 
performed a series of NMR experiments leading to define a chair conformation where 
the substituent in C9 was placed in equatorial position. 
To know the absolute configuration of the new chiral centre X ray analysis was 
performed on suitable crystals that show us the R configuration of the new stereogenic 
centre. 
From a pharmacological point of view (R)-SHA 68 was demonstrated to be the 
antagonist of the receptor of the Neuropeptide S.  
This new class of non-peptide NPSR antagonists provides additional tools for in vitro 
and in vivo studies required to elucidate the NPSR conformation, adding new 
informations to well know NPS-NPSR system. 
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In the frame of the synthesis of biological active chiral compounds I have spend nine 
months at the Pierre et Marie Curie University in Paris under the supervision of 
Professor Giovanni Poli, focusing the attention on the synthesis of natural product (-)-
Steganacin. This stage allowed me to view a different approach for the selective 
generation of new structures using a palladium catalysed domino reactions instead of 
the use of chiral auxiliaries used for the synthesis of (R) and (S)-SHA 68. 
Steganacin was isolated from Steganotaenia araliacea a South Africa’s plant.31 The 
interest of chemists for the (-)-Steganacin was initially motivated by its antitumor 
activity; 34 it is for this reason that in literature we found different total syntheses of this 
molecule. 
From a structural point of view the (-)-Steganacin presents a γ-lactonic skeleton 
condensed to an eight membered ring, a biarylic portion and three contiguous 
stereogenic centers with a relative stereochemistry trans, trans.  
Aim of this project is the synthesis of an aza-analogue of Steganacin in which the 
lactone structure is replaced by a γ-lactam moiety.  
The synthetic process starts from a commercially available propargyl alcohol to afford 
in seven steps the desired cyclization precursor in 19 % yield. 
The key step of our project was previously studied in the laboratories of Prof. Giovanni 
Poli and reported in literature by Kammerer et al. in 2009.41 This is an original regio- 
and stereoselective synthesis of aryl substituted pyrrolidones by a phosphine-free Pd-
catalyzed allene carbopalladation/allylic alkylation sequence. This reaction allowed us 
to obtain the key intermediate in 74% yield.  
After benzylation of this key intermediate, several strategies to remove the 
methoxycarbonyl group were tested, the best solution being hydrolysis in ethylene 
glycol at high temperatures. The next study will focus on the non-phenolic oxidative 
coupling between the two aromatic moieties to formed an eight membered ring. 
Then, an oxidative cleavage of the double bond followed by a diastereoselective 
reduction of the resulting ketone and final alcohol acetylation should afford the desired 
(-)-Steganacin aza-analogue. 
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 Both authors equally contributed to this work.Twelve derivatives of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP) antagonist 1-benzyl-N-{3-[spi-
roisobenzofuran-1(3H),40-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide (Comp 24) were synthesised
and tested in binding experiments performed on CHOhNOP cell membranes. Among them, a novel inter-
esting NOP receptor antagonist (compound 35) was identiﬁed by blending chemical moieties taken from
different NOP receptor ligands. In vitro in various assays, Compound 35 consistently behaved as a pure,
highly potent (pA2 in the range 8.0–9.9), competitive and NOP selective antagonist. However compound
35 was found inactive when challenged against N/OFQ in vivo in the mouse tail withdrawal assay. Thus
the usefulness of the novel NOP ligand compound 35 is limited to in vitro investigations.
 2009 Elsevier Ltd. All rights reserved.1. Introduction Recently, a novel non-peptide NOP antagonist, 1-benzyl-N-{3-Nociceptin/orphanin FQ (N/OFQ)1,2 modulates different biologi-
cal functions via activation of the N/OFQ peptide receptor (NOP).3
Few non-peptide molecules have been reported to selectively
interact with the NOP receptor: these include the NOP agonist Ro
64-6198,4 and the antagonists J-1133975 and SB-6121116 (see
Chart 1). However, the chemical synthesis of such molecules,
which are characterized by two chiral centres, is extremely com-
plex, time consuming and of low yield, making the availability of
these tools to the scientiﬁc community very limited.ll rights reserved.
hloride; Boc2O, di-tert-butyl-
ormal butyllithyum; DCC, N,
; DMF, N,N0-dimetilformam-
2O, diethylether; EtPt, light
roxy-benzotriazole; i-PrOH,
; NSB, non-speciﬁc binding;
tyldimethylsilylchloride; TFA,
layer chromatography; WSC,
ochloride.
x: +39 0532 455953.[spiroisobenzofuran-1(3H),40-piperidin-1-yl]propyl} pyrrolidine-
2-carboxamide, has been reported by Banyu researchers (as Comp
24).7 Comp 24 binds with high afﬁnity (pIC50 9.57) to the human
recombinant NOP receptor showing an impressive selectivity
(>3000-fold) over classical opioid receptors. Comp 24 behaves as
a pure NOP antagonist in the [35S]GTPcS assay with very high po-
tency (pIC50 9.82). Moreover, in vivo in mice Comp 24 at 10 mg/kg
sc completely reverses the locomotor inhibitory effect elicited by a
NOP receptor agonist.7 Recently this molecule was synthesized and
characterized in our laboratories conﬁrming its excellent in vitro
pharmacological proﬁle in terms of high antagonist potency and
selectivity of action over classical opioid receptors.8 Moreover, in
the mouse tail withdrawal assay, Comp 24 at 10 mg/kg ip did not
modify per se tail withdrawal latencies but prevented the pronoci-
ceptive and antinociceptive effects of 1 nmol N/OFQ given suprasp-
inally and spinally, respectively.8 Collectively, these studies
demonstrate that Comp 24 behaves as a pure, highly potent, selec-
tive and competitive NOP antagonist.
Interestingly, Comp 24 displays some chemical characteristics
typical of N/OFQ related peptides (see Chart 1), these include: (i)
a spacer of 12 atoms between the two phenyl rings which matches
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Chart 1. Chemical formulae of nociceptin/orphanin FQ receptor ligands.
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an amide bond which is quite uncommon in non-peptide NOP li-
gands; (iii) a N-benzyl amino acid, a chemical moiety also present
in the N-terminal of the NOP receptor peptide antagonists
[Nphe1]N/OFQ(1-13)-NH29 and UFP-101.10 Based on these consid-
erations, in the present study, the importance of the N-benzyl D-
Pro of Comp 24 was assessed by replacement with L- or D-Phe,
and Nphe. In addition, the amide bond of Comp 24 was substituted
with other amide bond isosters. Moreover, the spiroisobenzofurane
nucleus of Comp 24 was replaced with chemical moieties derived
from other non-peptide NOP ligands that is, Ro 64-6198,4
SB-6121116 and J-1133975 (Chart 1). The novel molecules were
evaluated for their ability to bind the human recombinant NOP
receptor expressed in CHO cell (CHOhNOP) membranes. The mole-N
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Scheme 1. Reagents and conditions: (a) n-BuLi 2.5 M, 78 C, N-benzyl-piperidine-4-on
(d) N-Boc-3-bromo-propyl amine DMF, 60 C, 3 h, then DCM TFA 1 h; (e) L-Phe, D-Ph
(CH3)2S
* BH3, THF, 0 C to reﬂux O.N.; (h) CH3I, NaH, DMF, 0 C to rt, O.N.cule with the highest afﬁnity, that is, compound 35 has been fur-
ther characterized in vitro at the recombinant human NOP in
[35S]GTPcS binding and calcium mobilization assays and at native
NOP receptors expressed in isolated animal (mouse, rat, guinea-
pig) tissues. Finally compound 35 was assayed in vivo against the
effects elicited by N/OFQ in the mouse tail withdrawal assay.2. Chemistry
Compound 24 was synthesized following procedures reported
by Goto et al.7 The key intermediate 5 (Scheme 1) was obtained
starting from commercially available benzanilide 1 that reacts with
n-butyllithium at 78 C and subsequentially with the N-benzyl-N
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e, 0 C, THF; (b) (CH3)2S * BH3, THF, 0 C to reﬂux; (c) H2, C/Pd 10%, EtOH, overnight;
e, Nphe or N-Bn-D-Pro, DMF, HOBt. WSC, 0 C to rt, 24 h; (f) TFA, 0 C, 1 h; (g)
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was reduced with borane dimethyl sulﬁde complex in THF to give
the corresponding isobenzofurane 3. The deprotection of the piper-
idine nitrogen using H2 in presence of palladium on charcoal 10%
afforded the desired spiroisobenzofurane piperidine 4 in good
yield.
Alkylation with N-Boc-3-bromo-propyl amine followed by
TFA treatment gave the free amine 5. The substitution in com-
pound 24 of the D-Pro amino acid with the D-Phe, L-Phe and
Nphe was achieved using compound 5 and the corresponding
protected aminoacid for the coupling reaction, removing the
Boc protected group from the amino function with TFA at
0 C. This allowed us to obtain compounds 9, 10 and 11
(Scheme 1).
The N-methyl alkylation or the reduction of the amide bond of
compound 24 produced the ﬁnal compounds 12 and 13.
The substitution of the amide bond in Comp 24 with ester or
ether bond was achieved following Scheme 2. 3-Bromo-1-propa-
nol, was protected as TBDMS derivative (14) and reacted with 4
in DMF at 60 C in the presence of potassium carbonate to obtain
compound 15. Treatment of 15 with TBAF in THF allows us to ob-
tain the corresponding alcohol 16 which was condensed with the
N-Bn-D-Pro using the Steglich esteriﬁcation11 to obtain the desired
ester 17Br OH
Br O
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Scheme 2. Reagents and conditions: TNDMS-Cl, imidazole, THF, rt, 24 h; (b) (4), K2CO3,
tosyl chloride, Et3N, CH2Cl2, 0 C to rt, O.N.; (f) (15) TBAI, NaH, DMF, 0 C to rt, O.N.
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Scheme 3. Reagents and conditions: (a) NaH, DMSO, 77 C 40 min, than N-Bn-D-Pro at 0
O.N.All the attempt to prepare the tosylate of 16 using tosyl chloride
and Et3N, generated the corresponding chloride 18, which is em-
ployed in the esteriﬁcation reaction12 with Bn-D-prolinol 19 using
tetrabutyl ammonium iodide as an exchanging agent to obtain the
ether 20.
The replacement of the amide bond present in Comp 24 with a
oleﬁn moiety was the most difﬁcult procedure, in particular, all
the attempts to prepare the desired oleﬁn via Wittig13 or Horner–
Wadsworth–Emmons14 reaction on the N-Bn-Prolinale15 using the
(3-carboxy-propyl)-triphenylphosphonium bromide 21, failed. In
contrast, using the dimethylsulfynil anion16,17 to generate the corre-
sponding ylide allowed us to obtain the corresponding oleﬁn 22 in
moderate yield.
Compound 22 was reacted with 4 in the presence of WSC/HOBt
and the amide bond of 23 reduced using borane dimethylsulﬁde
complex to obtain the desired oleﬁn derivative 25 as a inseparable
mixture of E/Z isomers (Scheme 3).
The synthesis of compound 28 (Scheme 4) started from the
commercially available 1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-
one 26 that was alkylated using the conditions previously reported
for 5 with N-Boc-3-bromo-propyl amine to obtain in a good yield
the derivative 27. Deprotection of tert-butoxycarbonil moiety and
the coupling with N-Bn-D-Pro allowed us to obtain the chimeric
compound 28 as depicted in Scheme 4.N
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Scheme 4. Reagents and conditions: (a) DMF, BocNH-(CH2)3-Br, K2CO3, 60 C, 1 h; (b) (i) TFA, 0 C, 1 h; (ii) N-Bn-D-Pro, DMF, HOBt, WSC, 0 C to rt, O.N.
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Scheme 5. Reagents and conditions: (a) EtOH, Pip, rt, O.N.; (b) NaOH 35%, EtOH, reﬂux, O.N.; (c) NH4OH, 200 C, 6 h; (d) (CH3)2S * BH3, THF, 0 C to reﬂux O.N.; (e) DMF K2CO3,
BocNH-(CH2)2-Br, 60 C, O.N., then TFA; (f) DMF, HOBt, WSC, N-Bn-D-Pro, 0 C to rt, O.N.; (g) DMF, HOBt, WSC, N-Bn-L-Pro, 0 C to rt O.N.
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from the reaction of 2,6-dichloro-benzaldehyde 29 with ethyl ace-
toacetate to give the diester 30. Hydrolysis under basic conditions
of 30 allowed us to obtain the corresponding diacid 31 that was
treated with ammonia at 200 C for 6 h to gave the immide 32.
Reduction using borane dimethyl sulﬁde complex of 32 gave theH
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Scheme 6. Reagents and conditions: (a) CH2Cl2, (Boc)2O, DMAP; (b) (i) DMF, EtBr, NaH, 0
1 h; (d) DMF, HOBt, N-Bn-D-Pro, 0 C to rt, O.N.desired 4-(2,6-dichloro-phenyl)-piperidine 33 in moderate yield.
The ﬁnal compounds 35 and 36 were prepared using 33 following
procedures reported in Scheme 2d (Scheme 5).
The compound 41was prepared starting from the tert-butyloxy-
carbonyl protection of the commercially available 1-piperidin-4-yl-
1,3-dihydro-benzoimidazol-2-one37. N3ethylationof38withethylN N N
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N N
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N N N
O
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c
C to rt, 5 h; (ii) TFA, 1 h,rt; (c) (i) DMF, K2CO3, BocNH-(CH2)3-Br, 60 C, 1 h; (ii) TFA,
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gave compound 39. The reaction of 39with N-Boc-3-bromo-propyl
amine followed by deprotection and acylation with N-Bn-D-Pro
allowed us to obtain the ﬁnal compound 41 (Scheme 6).
Compound 35 was selected as the most interesting molecule of
this series. It was obtained with an overall yield of 21%. This value
is similar to the overall yield of Comp 24 (25% in our laboratories8,
31% in Banju laboratories7). On the contrary the overall yield of
other NOP antagonists such as J-113397 and SB-612111 is much
lower (approx. 1–2% in our laboratories). Moreover, the synthesis
of the 2,6-dichlorophenyl-piperidine moiety of SB-612111 used
for generating compound 35 has been performed avoiding the te-
dious, money and time consuming chromatographic puriﬁcations.
In addition, the complete synthesis of compound 35 has been ob-
tained in six steps while those of Comp 24 and of SB-612111 re-
quire 8 and 12 steps, respectively.3. Results and discussion
The ability of the reference ligand, Comp 24, and the novel mol-
ecules to bind to the NOP receptor was evaluated using CHOhNOP
cell membranes (Table 1). Comp 24 produced a concentration
dependent inhibition of [3H]N/OFQ binding with a pKi value of
9.62. This result perfectly matches with that previously reported
by Goto et al.7 (pIC50 9.57). The substitution of the N-benzyl D-
Pro with D or L-Phe (compounds 9 and 10) or Nphe (compound
11) produced a profound (>100-fold) loss of NOP afﬁnity suggest-
ing a pivotal role of the N-benzyl D-Pro moiety for Comp 24 bioac-
tivity. This result is not surprising since the simple inversion of Pro
chirality was reported to generate an analogue 200-fold less potent
than Comp 24.7
Modiﬁcations of the amide bond obtained by N-methylation
(compound 12) or by replacement with a methyleneamino (com-
pound 13), an ester (compound 17), a methyleneoxy (compound
20), or an alkene bond (compound 25), produced a drastic reduc-
tion in NOP receptor binding or, in the case of compound 25, a
complete loss of afﬁnity. These results indicated that the amide
bond represents a chemical feature crucial for the bioactivity of
Comp 24. It is worthy of note, that an amide bond is a relatively
uncommon chemical feature in non-peptide NOP ligands. How-
ever, this chemical bond is also present in the NOP receptor antag-
onist JTC-801 and its chemical modiﬁcation (i.e., N-methylation
and retro-inverso bond) was reported to be detrimental for binding
afﬁnity.18 Thus, the amide bond might play a similar important
role in both Comp 24 and JTC-801. In particular, according to the
non-peptide NOP ligand pharmacophoric model proposed by
Zaveri,19 the amide bond may be part of the B-moiety that links
and contributes to the maintainance of the correct spatial arrange-
ment of the A-moiety (important for ligand afﬁnity and selectivity)
and the C-moiety (important for ligand efﬁcacy).
Next, we considered replacement of the benzoisofurane group
in position 4 of the Comp 24 piperidine scaffold with chemical
moieties taken from the some position of other high afﬁnity NOP
receptor ligands. The substitution with 1-phenylimidazolidin-4-
one, the chemical group of the NOP receptor agonist Ro 64-6198
(compound 28), or with 1-ethylbenzoimidazol-2-one, the chemical
group of the NOP receptor antagonist J-113397 (compound 41), in
position 4 generated inactive molecules. In contrast, the insertion
of the piperidine scaffold of the 2,6-dichlorophenyl moiety (com-
pound 35), the pharmacophore of the NOP receptor antagonist
SB-612111, in position 4 generated a molecule with high afﬁnity
for the NOP receptor (pKi 9.14). In particular compound 35 is only
threefold less potent than Comp 24. The results obtained with this
limited series of chimeric compounds suggest that it is possible to
combine pharmacophoric moieties taken from different NOPreceptor ligands to generate novel biologically active molecules.
In particular, the chemical groups benzoisofurane and 2,6-dichlo-
rophenyl seem to contribute to NOP receptor binding in a very
similar manner. This is corroborated by the ﬁnding that the substi-
tution of D-Pro with L-Pro in the chimeric molecule compound 36
produced a 100-fold reduction in receptor afﬁnity. This result is
in agreement with compounds 22 and 23 of the Goto series.7 Thus,
D chirality of the Pro residue represents a crucial requirement for
high afﬁnity NOP receptor recognition for both Comp 24 and com-
pound 35.
Based on its high afﬁnity for the NOP receptor, compound 35
was selected for further pharmacological characterization in vitro
and in vivo. As shown in Figure 1 (top left panel) in CHOhNOP cell
membranes N/OFQ concentration dependently stimulated
[35S]GTPcS binding with pEC50 and Emax values of 8.91 and
10.93 ± 0.18 (stimulation factor), respectively. Over the concentra-
tion range of 1–100 nM, compound 35 was inactive per se but pro-
duced a rightward shift of the concentration response curve to N/
OFQ in a parallel manner and without modifying the agonist max-
imal effect. Schild analysis of these data (Fig. 1 top right panel) is
compatible with a competitive type of antagonism and a pA2 value
of 9.91 was derived. This potency value is close to that previously
reported for Comp 24 by Goto et al. (pIC50 9.82)7 and by us (pA2
9.98).8 These results suggest that the benzoisofurane and 2,6-
dichlorophenyl moieties of Comp 24 and compound 35 play a sim-
ilar role not only in receptor binding but also in determining phar-
macological activity that is, pure and competitive antagonism. This
may be derived from the common ability of the spiro junction
(Comp 24) and of the 2,6-dichloro substitution (compound 35) to
favour an orthogonal spatial disposition between their piperidine
and phenyl nuclei. Therefore, this conformational feature may
likely be crucial for both NOP receptor binding and antagonist
activity.
The pharmacological actions of compound 35 were further as-
sessed at the hNOP receptor coupled to calcium signalling via the
chimeric protein Gaqi5; this assay has been previously validated
with a large panel of NOP receptor full and partial agonists and
antagonists.20 In CHO cells stably expressing the hNOP receptor
and the Gaqi5 protein, N/OFQ produced a concentration dependent
stimulation of intracellular calcium with a pEC50 of 9.24 and Emax
of 198 ± 12% over the basal values. Compound 35 was inactive
per se up to 10 lM while inhibiting the stimulatory effect of
10 nM N/OFQ in a concentration dependent manner. A pKb value
of 8.47 was derived from these experiments (Table 2). This potency
value is approx threefold lower than that obtained with Comp 24
(pKb 9.03).8
The competitive antagonist behaviour of compound 35 was
conﬁrmed at the native NOP receptor expressed in the mouse vas
deferens. In this preparation, N/OFQ inhibited electrically evoked
twitches in a concentration dependent manner with pEC50 and
Emax values of 7.49 and 80 ± 2%, respectively (Fig. 1, right top
panel). Compound 35 was inactive per se but caused a concentra-
tion dependent (10–1000 nM) and a parallel rightward shift of the
concentration response curve to N/OFQ without modifying the
agonist maximal effects. The relative Schild plot, depicted in Figure
1 right bottom panel, demonstrated a competitive type of antago-
nism with a pA2 value of 8.00. This value of potency is close to that
previously reported for Comp 24 that is, 8.24.8 Similar results were
obtained in other N/OFQ sensitive preparations such as the rat vas
deferens and guinea pig ileum where compound 35 at 100 nM was
inactive per se while antagonizing N/OFQ inhibitory actions with
pKb values of 8.06 and 8.84, respectively (Table 2).
Finally the selectivity of action of compound 35 over classical
opioid receptors was assessed in animal tissues expressing native
receptors and at recombinant human proteins. Compound 35 at
1 lM was inactive per se and did not modify the inhibitory effects
Table 1
Binding afﬁnities at CHOhNOP cell membranes of Comp 24 and related compounds
Compound Structure pKi
Comp 24
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Table 1 (continued)
Compound Structure pKi
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35
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<5
Data are means ± sem of four separate experiments performed in duplicate.
5086 C. Trapella et al. / Bioorg. Med. Chem. 17 (2009) 5080–5095elicited by the DOP selective agonist DPDPE in the mouse vas def-
erens (control pEC50 8.38 (CL95% 8.20–8.56), Emax 98 ± 1%; 1 lM
compound 35 pEC50 8.44 (CL95% 8.26–8.62), Emax98 ± 1%) or those
produced by the MOP agonist dermorphin in the guinea pig ileum
(control pEC50 8.52 (CL95% 8.35–8.69), Emax 90 ± 3%; 1 lM
compound 35 pEC50 8.44 (CL95% 8.19–8.69), Emax 85 ± 5%). Results
obtained with compound 35 and the universal opioid receptor
antagonist naloxone in selectivity studies performed with receptor
binding and calcium mobilization assays are summarized in Tables
3 and 4, respectively. Compound 35 up to 10 lM did not displace
[3H]DPN from DOP sites and showed very low afﬁnity (less than
300-fold compared to NOP) at MOP and KOP sites (Table 3). In con-
trast, naloxone did not bind to the NOP receptor up to 10 lM, while
it displaced [3H]DPN at classical opioid receptors showing very
high afﬁnity for MOP and lower afﬁnities for KOP and DOP (Table
3). Similar results were found in functional studies measuring cal-
cium mobilization in CHO cells stably expressing the hNOP recep-
tor or classical opioid receptors and the Gaqi5 protein (Table 4).
Dermorphin, DPDPE and dynorphin A were used in these experi-
ments as agonists for MOP, DOP and KOP receptors, respectively;
they produced a concentration dependent stimulation of intracel-
lular calcium with the following pEC50 values: 7.93 (CL95% 7.67–
8.19), 8.82 (CL95% 8.43–9.21) and 8.47 (CL95% 8.16–8.78). Naloxone
inhibited the effects of these agonists with higher potency at MOP
than KOP and DOP while being inactive against N/OFQ (Table 4).
Thus, compound 35 was at least 300-fold less potent at classical
opioid receptors than at the NOP receptor (Table 4).
These in vitro results demonstrated that compound 35 behaves
as a pure, potent and competitive NOP receptor antagonist. More-
over selectivity studies indicated that the substitution of the ben-zoisofurane with the 2,6-dichlorophenyl moiety not only allows
maintenance of high afﬁnity and antagonist potency but also of
high selectivity over classical opioid receptors.
Finally the pharmacological activity of compound 35 was as-
sessed in vivo using the mouse tail withdrawal assay. In this test
N/OFQ was reported to elicit opposite effects depending on the
route of administration: the peptide induced pronociceptive ac-
tions when injected intracerebroventricularly (icv) while antinoci-
ceptive effects were reported after intrathecal (i.t.) injection (see
for reviews3,21 and for results obtained in our laboratories22,23).
As shown in Figure 2 left panel, mice injected with saline dis-
played similar tail withdrawal latencies (6 s) over the time
course of the experiment. N/OFQ 1 nmol given icv produced a
clear but short lasting pronociceptive effect. Compound 35 at
10 mg/kg given intraperitoneally 30 min before icv injection, did
not modify tail withdrawal latencies per se and did not affect
the pronociceptive action of the peptide. When 1 nmol N/OFQ
was given i.t., the peptide elicited a robust antinociceptive effect
(Fig. 2 right panel). Again compound 35 at 10 mg/kg did not mod-
ify the effect of N/OFQ. Thus, in the mouse tail withdrawal assay
compound 35 at 10 mg/kg was found inactive against the prono-
ciceptive and antinociceptive effects of N/OFQ injected supraspi-
nally and spinally, respectively. Under these same experimental
conditions Comp 24 at 10 mg/kg signiﬁcantly counteracted the
actions of N/OFQ8, while SB-612111 already at 1 mg/kg fully pre-
vented the effects of the peptide.24 Thus, despite a very similar
in vitro pharmacological proﬁle, the three NOP antagonists dis-
played very different in vivo potency that is, SB-612111 > Comp
24 compound 35. Although the reasons for such variable
in vivo potency are at present unknown, they might be due to
Table 2
Compound 35 afﬁnity/antagonist potency in various pharmacological assays
CHOhNOP cell membranes CHOhNOP/Gaqi5 cells Electrically stimulated tissues
Receptor binding [35S]GTPcS binding Ca2+ mobilization Mouse vas deferens Rat vas deferens Guinea pig ileum
Compound 35 9.14 (9.04–9.24) 9.91 (9.23–10.59) 8.47 (8.31–8.63) 8.00 (7.32–8.68) 8.06 (7.58–8.54) 8.84 (8.64–9.04)
Data are expressed as means (CL95%) of at least four separate experiments.
Table 3
Afﬁnities of compound 35 and naloxone at NOP and classical opioid receptors expressed in CHO cell membranes
Receptor radioligand NOP [3H]N/OFQ MOP [3H]DPN DOP [3H]DPN KOP [3H]DPN
Naloxone <6 9.25 (9.04–9.46) 7.67 (7.59–7.75) 8.35 (8.20–8.50)
Compound 35 9.14 (9.04–9.24) 6.72 (6.47–6.97) <6 6.50 (6.37–6.63)
Data are expressed as mean (CL95%) of four separate experiments. Naloxone data at classical opioid receptors are obtained from Vergura et al.33
Table 4
Antagonist potencies of compound 35 and naloxone evaluated in calcium mobilization experiments performed in CHO cells expressing NOP or classical opioid receptors and the
Gaqi5 protein
Receptor agonist NOP N/OFQ 10 nM MOP dermorphin 100 nM DOP DPDPE 100 nM KOP dynorphin A 100 nM
Naloxone <6 9.09 (8.73–9.45) 7.32 (6.80–7.84) 7.14 (6.60–7.68)
Compound 35 8.47 (8.31–8.63) 6.11 (5.92–6.30) <6 <6
Data are expressed as mean (CL95%) of four separate experiments performed in duplicate.
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Figure 1. Concentration–response curve to N/OFQ in the absence and presence of increasing concentrations of compound 35 for [35S]GTPcS binding to CHOhNOP cell
membranes (top left panel) and in electrically stimulated mouse vas deferens (bottom left panel). The corresponding Schild plots are shown in the right panels. Data are
means ± SEM of four separate experiments.
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cules. Therefore the blending of Comp 24 and SB-612111
chemical moieties to generate compound 35 did not affect phar-macodynamics (i.e., receptor afﬁnity, antagonist potency and
selectivity of action) while it seems to have a detrimental effect
on pharmacokinetics.
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Figure 2. Mouse tail withdrawal assay. Effects of compound 35 (10 mg/kg ip, 30 min pre-treatment) on the pronociceptive or antinociceptive effects induced by 1 nmol N/
OFQ injected icv (left panel) or i.t. (right panel). Data are mean ± SEM of four separate experiments.
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The present study demonstrated that the N-benzyl D-Pro moi-
ety as well as the amide bond of Comp 24 is essential for biological
activity. In contrast the spirobenzoisofurane can be replaced with
2,6-dichlorophenyl moiety without signiﬁcant loss of ligand po-
tency, antagonist activity and selectivity of action. Thus by blend-
ing chemical moieties taken from known molecules (Comp 24 and
SB-612111) we were able to identify compound 35 as a novel non-
peptide selective NOP antagonist. While the in vitro pharmacolog-
ical proﬁle of compound 35 is similar to that of Comp 24 and SB-
612111, the in vivo activities of these compounds are substantially
different with the following order of antagonist potency SB-
612111 > Comp 24 compound 35. This limits the usefulness of
compound 35 to in vitro investigations.
5. Experimental
5.1. Materials
Melting points (uncorrected) were measured with a Buchi-Tot-
toli apparatus, and 1H, 13C, and NMR spectra were recorded on a
VARIAN400 MHz instrument unless otherwise noted. Chemical
shifts are given in ppm (d) relative to TMS and coupling constants
are in hertz. MS analyses were performed on a ESI-Micromass ZMD
2000. Infrared spectra were recorded on a Perkin–Elmer FT-IR
Spectum 100 spectrometer. Flash chromatography was carried
out on a silica gel (Merck, 230–400 Mesh). Elemental analyses
were performed at the analytical laboratories of the Department
of Chemistry, University of Ferrara.
5.2. Synthetic procedure
5.2.1. 10-Benzyl-spiro[isobenzofuran-1(3H),40-piperidin]-3-one
(2)
To a stirred solution of 1 (5 g, 25.38 mmol) in anhydrous THF
at 78 C and in argon atmosphere, n-BuLi (25.98 mL,
64.97 mmol) was added drop wise. The reaction was warmed
at 0 C for 1 h until a red-orange color appeared. At this time,
N-benzyl-piperidone (10.68 mL, 57.61 mmol) was added and
the reaction stirred at room temperature overnight. The reaction
was checked by TLC (EtOAc/light petroleum, 3:2), quenched withHCl 3 N and the aqueous layer partitioned in chloroform and ex-
tracted three times with chloroform (30 mL each). The organic
layer was dried and concentrated in vacuo to afford a yellow so-
lid after crystallization with Et2O (6.54 g, 22.345 mmol, yield
88%). mp = 210–215 C. MS (ESI): [MH]+ = 294. 1H NMR (CDCl3):
d 7.872 (td, 1H, J = 8, 0.9 Hz); 7.660 (dt, 1H, J = 7.4, 1.2 Hz);
7.51 (dt, 1H, J = 7.4, 0.8 Hz); 7.42 (td, 1H, J = 7.6, 0.7 Hz); 7.38–
7.31 (m, 4H); 7.29–7.25 (m, 1H); 3.62 (s, 2H); 2.92 (dd, 2H,
J = 9, 2.2 Hz); 2.56 (dt, 2H, J = 12, 2.4 Hz); 2.23 (dt, 2H, J = 13.2,
4.4 Hz); 1.71 (dd, 2H, J = 14.4, 2.4 Hz). 13C NMR (CDCl3):
168.80; 151.37; 135.09; 131.33 (2C); 130.36; 130.21; 129.53
(2C); 126.14 (2C); 124.80; 121.79; 81.56; 61.31; 48.92 (2C);
33.02 (2C).
5.2.2. 10-Benzyl-spiro[isobenzofuran-1(3H),40-piperidine] (3)
Under argon atmosphere 6.54 g (22.34 mmol) of compound 2
were suspended in anhydrous THF, the reaction mixture cooled
at 0 C and under vigorously stirring (CH3)2S * BH3 (4.30 mL,
44.68 mmol) was added drop wise. The reaction mixture was
heated at reﬂux overnight. After this time the reaction was acidi-
ﬁed (HCl 10%) until pH 2 and heated again at reﬂux for 4 h. The
reaction was quenched with NaOH 2 N until pH 12, the THF was re-
moved in vacuo and the aqueous layer extracted twice with EtOAc
(30 mL each). The organic layer was dried, concentrated in vacuo
and puriﬁed by ﬂash chromatography (EtOAc/light petroleum,
1:1) to afford compound 3 in 55% yield. MS (ESI): [MH]+ = 280.
1H NMR (CDCl3): d 7.39–7.15 (m, 9H); 5.07 (s, 2H,); 3.60 (s, 2H);
2.85 (dd, 2H, J = 10, 2 Hz); 2.44 (dt, 2H, J = 12, 2.4 Hz); 2.01 (dt,
2H, J = 13.2, 4.4 Hz); 1.76 (dd, 2H, J = 14.4, 2.4 Hz). 13C NMR
(CDCl3): 145.78; 138.98 (2C); 129.43 (2C); 128.28 (2C); 127.59;
127.38; 127.10; 121.10; 120.89; 84.81; 70.78; 63.54; 50.21 (2C);
36.64 (2C).
5.2.3. Spiro[isobenzofuran-1(3H),40-piperidine] (4)
A solution of 3 (3.43 g, 12.29 mmol) in 200 mL of ethanol was
hydrogenated in the Parr apparatus (50 psi) in the presence of
10% palladium on charcoal (0.1 g) for 48 h. Filtration of the catalyst
through a Celite pad and solvent evaporation gave (4) (2.20 g,
11.64 mmol, yield 70%) as a colorless oil. MS (ESI): [MH]+ = 190.
1H NMR (CDCl3): d 7.31–7.28 (m, 2H); 7.23–7.21 (m, 2H); 5.79
(br, 1H); 5.06 (s, 2H); 3.40–3.87 (m, 2H); 2.75–2.65 (m, 2H);
2.37–2.28 (m, 2H); 1.83–1.81 (m, 2H).
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propylamine (5)
To a stirred solution of 4 (2 g, 10.58 mmol) in DMF a solution of
N-Boc-3-bromo-propyl-amine (2.99 g, 12.59 mmol) in 10 mL of
DMF was added followed by addition of K2CO3 (2.92 g,
21.16 mmol); the reaction was warmed at 60 C for 1 h. The reac-
tion was concentrated and the residue was diluted with EtOAc
and washed twice with NH4Cl saturated solution (30 mL each)
and brine (30 mL). The organic layer was dried and evaporated un-
der reduced pressure. The crude material (3.45 g, 9.99 mmol) was
treated with TFA at 0 C for 1 h. NaOH 2 N was added until pH
12–14, the aqueous phase was extracted several times with EtOAc
and the organic phases were combined, dried and evaporated un-
der vacuum to give compound 5 (2.32 g, 9.417 mmol, 95% yield).
MS (ESI): [MH]+ = 247. 1H NMR (CDCl3): d 7.27–7.24 (m, 2H);
7.20–7.14 (m, 2H); 5.06 (s, 2H); 2.89 (dd, 2H, J = 9.4, 2 Hz); 2.81
(t, 2H, J = 6.8 Hz); 2.50 (t, 2H, J = 7.2 Hz); 2.38 (t, 2H, J = 12.4 Hz);
2.23 (br, 2H); 1.98 (dt, 2H, J = 12.4, 4.4 Hz); 1.79–1.70 (m, 4H).
5.2.5. (D)-1-{3-[Spiro[isobenzofuran-1(3H),40-piperidin-1-yl]-pro-
pylcarbamoyl}-2-phenyl-ethyl)-carbamic acid-tert-butyl estere
(6)
To a stirred solution of Boc-D-Phe-OH (539 mg, 2.032 mmol) in
DMF at 0 C, HOBt (373 mg, 2.44 mmol) and WSC (467 mg,
2.44 mmol) were added and the reaction stirred for 10 min. After
this time compound 5 (500 mg, 2.032 mmol) dissolved in DMF
(20 mL) was added and the reaction mixture stirred for 24 h. The
DMF was removed in vacuo and the product partitioned between
EtOAc and NaHCO3 5%. The organic phase was dried, concentrated
in vacuum and the crude product puriﬁed by ﬂash chromatography
(EtOAc/NH4OH, 10:0.3) to give compound 6 in 30% yield. MS (ESI):
[MH]+ = 494. 1H NMR (CDCl3): d 7.42 (br, 1H); 7.28–7.15 (m, 9H);
5.83 (br, 1H); 5.03 (s, 2H); 3.43 (s, 1H); 3.55–3.16 (m, 3H); 3.08–
2.95 (m, 2H); 2.90–2.80 (m, 3H); 2.50–2.44 (m, 4H); 1.76–1.68
(m, 4H); 1.36 (s, 9H). 13C NMR (CDCl3): 173.02; 171.38; 144.70;
138.62; 136.946; 129.35 (2C); 128.63 (2C); 128.54; 127.83;
127.56; 126.82; 121.05 (2C); 83.92; 70.90; 60.41; 56.31; 50.498;
49.88; 39.06; 38.38; 35.82; 35.72; 28.29 (3C); 24.67. ½a20D = 8
(c = 0.1 g/100 mL, chloroform).
5.2.6. (L)-1-{3-[Spiro[isobenzofuran-1(3H),40-piperidin-1-yl]-pro-
pylcarbamoyl}-2-phenyl-ethyl)-carbamic acid-tert-butyl estere
(7)
This product was obtained as reported for 6 using Boc-Phe-OH
instead of Boc-D-Phe-OH. The crude product was puriﬁed by ﬂash
chromatography (EtOAc/NH4OH, 10:0.3) to give compound 7 in
30% yield. MS (ESI): [MH]+ = 494. 1H NMR (CDCl3): d 7.42 (br,
1H); 7.28–7.15 (m, 9H); 5.83 (br, 1H); 5.03 (s, 2H); 3.43 (s, 1H);
3.55–3.16 (m, 3H); 3.08–2.95 (m, 2H); 2.90–2.80 (m, 3H); 2.50–
2.44 (m, 4H); 1.76–1.68 (m, 4H); 1.36 (s, 9H). 13C NMR (CDCl3):
173.02; 171.38; 144.70; 138.62; 136.946; 129.35 (2C); 128.63
(2C); 128.54; 127.83; 127.56; 126.82; 121.05 (2C); 83.92; 70.90;
60.41; 56.31; 50.498; 49.88; 39.06; 38.38; 35.82; 35.72; 28.29
(3C); 24.67. ½a20D = +8 (c = 0.1 g/100 mL, chloroform).
5.2.7. Benzyl-({3-[spiro[isobenzofuran-1(3H),40-piperidin-1-yl]-
propylcarbamoil}-methyl)-carbamic acid tert-butyl estere (8)
To stirred solution of (benzyl-tert-butoxycarbonyl-amino)acetic
acid (200 mg, 0.754 mmol) in DMF, at 0 C, HOBt (138 mg,
0.905 mmol) and WSC (173 mg, 0.905 mmol) were added and the
reaction stirred for 10 min. After this time compound 5 (188 mg,
0.754 mmol) dissolved in DMF (20 mL) was added and the reaction
mixture stirred for 24 h. The DMF was removed in vacuo and the
product partitioned between EtOAc and NaHCO3 5%. The organic
phase was dried, concentrated in vacuum and the crude product
puriﬁed by ﬂash chromatography (EtOAc/MeOH/NH4OH,9.5:0.5:0.3) to give compound 8 in 22% yield. MS (ESI):
[MH]+ = 494. 1H NMR (CDCl3): d 7.31–7.18 (m, 9H); 5.05 (s, 2H);
4.58–4.43 (m, 6H); 3.82–3.76 (m, 4H); 3.46–3.32 (m, 4H); 2.98–
2.65 (m, 4H); 2.38 (br, 1H); 1.45 (s, 9H). 13C NMR (CDCl3):
169.96; 156.34; 143.97; 138.51; 137.65; 128.68; 128.13; 128.00;
127.76; 127.46; 127.08; 121.14 (2C); 84.25; 80.79; 79.92; 71.13;
54.86; 51.67; 50.78; 50.28; 49.56; 36.96; 34.53; 28.40 (3C);
24.46; 14.25.
5.2.8. (D)-2-Amino-N-{3-[spiro[isobenzofuran-1(3H),40-piperidin-
1-yl]]-propyl}-3-phenyl-propyl-amide (9)
Compound 6 (160 mg, 0.324 mmol) was dissolved in TFA (5 mL)
at room temperature for 1 h, after cooling at 0 C the reaction was
basiﬁed with NaOH 2 N until pH 13 and the aqueous layer was ex-
tracted three times with EtOAc (20 mL each). The solvent was
evaporated under reduced pressure and the crude material was
puriﬁed by ﬂash chromatography (EtOAc/MeOH/NH4OH, 9.5/0.5/
0.3) to give compound 9 as oil in quantitative yield. MS (ESI):
[MH]+ = 394. 1H NMR (CDCl3): d 7.27–7.19 (m, 9H); 5.06 (s, 2H);
3.61–3.20 (m, 6H); 2.98–2.65 (m, 4H); 2.54–2.38 (m, 5H); 1.80–
1.73 (m, 5H). 13C NMR (CDCl3): 174.36; 145.72; 140.72; 138.88;
138.082; 129.40; 128.73; 127.73; 127.48; 126.83; 121.18;
120.80; 84.43; 70.89; 60.48; 57.11; 56.92; 50.371; 41.42; 38.48;
36.34; 25.89; 21.15; 14.27. ½a20D = +15 (c = 0.2 g/100 mL, chloro-
form). Anal. (C24H31N3O2) C, H, N.
5.2.9. (L)-2-Amino-N-{3-[spiro[isobenzofuran-1(3H),40-piperidin-
1-yl]]-propyl}-3-phenyl-propyl-amide (10)
Compound 7 was treated as for obtaining 9 to give compound
10 in quantitative yield. MS (ESI): [MH]+ = 394. 1H NMR (CDCl3):
d 7.27–7.19 (m, 9H); 5.06 (s, 2H); 3.61–3.20 (m, 6H); 2.98–2.65
(m, 4H); 2.54–2.38 (m, 5H); 1.80–1.73 (m, 5H). 13C NMR (CDCl3):
174.36; 145.72; 140.72; 138.88; 138.08; 129.40; 128.73; 127.77;
127.48; 126.83; 121.18; 120.80; 84.43; 70.89; 60.48; 57.11;
56.92; 50.37; 41.42; 38.48; 36.34; 25.89; 21.15; 14.27.
½a20D = 15 (c = 0.2 g/100 mL, chloroform). Anal. (C24H31N3O2) C,
H, N.
5.2.10. 2-Benzylamino-N-{3-[spiro[isobenzofuran-1(3H),4’-pipe-
ridin-1-yl]]-propyl}-acetamide (11)
Compound 8 was treated as for obtaining 9 to give 11 in quan-
titative yield. MS (ESI): [MH]+ = 394. 1H NMR (CDCl3): d 7.35–7.19
(m, 9H); 7.20–7.19 (m, 1H); 5.05 (s, 2H); 3.80 (s, 2H); 3.32–3.29 (m,
5H); 3.25–3.21 (m, 2H); 2.94–2.82 (m, 4H); 2.19–2.10 (m, 2H);
1.91–1.82 (m, 4H). 13C NMR (CDCl3): 173.72; 145.30; 140.09;
139.72; 129.68 (2C); 129.61 (2C); 129.24; 128.67; 128.55;
122.34; 121.68; 84.28; 71.90; 56.31; 54.06; 51.59; 50.92 (2C);
37.77; 35.85 (2C); 26.44. Anal. (C24H31N3O2) C, H, N.
5.2.11. (D)-1-Benzyl-pirrolidin-2-carboxilic acid {3-[spiro[iso-
benzofuran-1(3H ),40-piperidin-1-yl]]-propyl}-methyl-amide
(12)
A solution of the Comp 24 (200 mg, 0.460 mmol) in DMF
(10 mL) was added was added to a stirred suspension of sodium
hydride 60% (20.276 mg, 0,5069 mmol) in DMF (5 mL) dropwise
at 0 C. The reaction mixture was left in the same conditions for
half an hour, then a solution of methyl iodide (38 ll, 0.599 mmol)
in DMF (1 mL) was added. After 24 h at room temperature, the
reaction was monitored by TLC (EtOAc/MeOH/NH3 9.5:0.5:0.3).
The DMF was removed under vacuum and the residue was diluted
with Brine (5 mL) and extracted thrice with EtOAc. The organic lay-
ers were combined, dried and evaporated under reduced pressure
to give a crude product as a yellow oil. This was puriﬁed by ﬂash
chromatography to obtain compound 12 (53 mg, 0.118 mmol, yield
26%). MS (ESI): [MH]+ = 448. 1H NMR (CDCl3): d 7.80–7.25 (m, 9H);
5.07 (s, 2H); 3.78–3.29 (m, 10H); 2.95–2.87 (m, 4H); 2.56–2.12 (m,
5090 C. Trapella et al. / Bioorg. Med. Chem. 17 (2009) 5080–50956H); 2.06–1.69 (m, 6H). 13C NMR (CDCl3): 175.37; 171.47; 162.61;
141.82; 138.36; 138.25; 132.65; 129.390; 129.22; 128.70; 128.06;
127.54; 121.42; 81.22; 81.05; 71.47; 67.08; 66.69; 59.985; 58.04;
54.63; 45.77; 36.56; 36.25; 36.12; 31.45; 30.97; 24.18. Anal.
(C28H37N3O2) C, H, N.
5.2.12. (1-Benzyl-pirrolidin-2-yl-methyl)-{3-[spiro[isobenzofu-
ran-1(3H),40-piperidin-1-yl]]-propyl}-amine (13)
In a two neck round bottom ﬂask, under argon atmosphere,
Comp 24 (150 mg, 0.346 mmol) was suspended in anhydrous
THF (50 mL) and (CH3)2S * BH3 (100 ll, 1.038 mmol) was added
drop wise. The reaction was heated at reﬂux overnight and moni-
tored by TLC (EtOAc/light petroleum/NH3 9:1:0.3). The mixture
was cooled at 0 C and acidiﬁed with HCl 10%. Then it was heated
again at reﬂux and, after 4 h, it was cooled at 0 C and basiﬁed with
NaOH 2 N. THF was evaporated under reduced pressure and the
remaining aqueous layer was extracted three times with EtOAc.
The organic layers were combined, dried and evaporated under
vacuum to obtain the crude product, which was puriﬁed by ﬂash
chromatography to give compound 13 (20 mg, 0.239 mmol, yield
69%). MS (ESI): [MH]+ = 420. 1H NMR (CDCl3): d 7.34–7.23 (m,
9H); 5.05 (s, 2H); 3.84–3.59 (m, 1H); 3.70–3.65 (m, 2H); 3.59 (m,
1H); 2.99–2.87 (m, 4H); 2.61–2.35 (m, 8H); 2.06–1.92 (m, 2H);
1.83–1.79 (m, 4H); 1.71–1.65 (m, 4H). 13C NMR (CDCl3): 145.18;
139.28; 138.99; 128.92; 128.59; 127.81; 127.49; 127.43; 121.23;
120.69; 84.31; 70.83; 62.87; 61.88; 59.69; 57.89; 55.14; 51.69;
50.99; 49.85; 49.74; 36.28; 36.11; 29.96; 29.06; 24.14; 23.29. Anal.
(C27H37N3O) C, H, N.
5.2.13. (3-Bromo-propyloxi)-tert-butyl-dimethyl-silane (14)
Amixture of 3-bromo-propanol (5 mL, 57.190 mmol), imidazole
(11.68 g, 171.57 mmol) and TBDMS-Cl (11.206 g, 74.347 mmol) in
anhydrous THF (100 mL) was stirred at room temperature for
24 h. The reaction was monitored by TLC (EtOAc/light petroleum
1:3). The solvent was removed under reduced pressure and the res-
idue was diluted with water and extracted three times with DCM.
The organic layers were combined, washed with Brine, dried and
evaporated to obtain compound 14 in quantitative yield. 1H NMR
(CDCl3): d 3.73 (t, 2H, J = 2.8 Hz); 3.51 (t, 2H, J = 3.2 Hz); 2.07–
1.99 (m, 2H); 0.89 (s, 9H); 0.06 (s, 6H).
5.2.14. 1-[3-(tert-Butyl-dimethyl-silan-yl-oxi)-propyl]-spiro
[isobenzofuran-1(3H),40-piperidine] (15)
To a stirred solution of 4 (1 g, 5.71 mmol) in DMF (50 mL) com-
pound 14 (1.72 g, 6.8 mmol) and K2CO3 (1.58 g, 11.43 mmol) dis-
solved in DMF (10 mL) were added. The reaction was stirred and
warmed at 60 C for an hour and it was monitored by TLC
(EtOAc/light petroleum/NH3 5:1:0.3). The solvent was removed
under vacuum and the residue was dissolved in EtOAc and washed
twice with saturated NH4Cl and once with Brine. The organic layer
was dried and evaporated under reduced pressure to give the crude
product as a red-orange oil. This was puriﬁed by ﬂash chromatog-
raphy to obtain compound 15 (1.93 g, 5.35 mmol, yield 94%). MS
(ESI): [MH]+ = 362. 1H NMR (CDCl3): d 7.28–7.13 (m, 4H); 5.06 (s,
2H); 3.67 (t, 2H, J = 6 Hz); 2.91–2.83 (m, 2H); 2.53–2.36 (m, 4H);
1.99 (dt, 2H, J = 6, 4 Hz); 1.81–1.73 (m, 4H); 0.89 (s, 9H); 0.05 (s,
6H). 13C NMR (CDCl3): 145.77; 138.97; 127.60; 127.40; 121.08;
120.88; 84.82; 70.79 (2C); 61.68; 55.73; 50.30 (2C); 36.69 (2C);
30.32; 26.06 (3C); 5.29 (2C).
5.2.15. 3-{Spiro[isobenzofuran-1(3H),40-piperidin-1-yl]}-pro-
pan-1-ol (16)
To a solution of compound 15 (1.930 g, 5.346 mmol) in anhy-
drous THF (35 mL), cooled at 0 C, TBAF (5.06 g, 16.038 mmol)
was added. The reaction was stirred at room temperature for
24 h and the solvent removed under vacuum. The residue was di-luted with EtOAc and washed twice with water. The organic layer
was dried and concentrated under reduced pressure to give the
crude product, which was puriﬁed by ﬂash chromatography to ob-
tain compound 16 (1.239 g, 5.015 mmol, yield 94%). MS (ESI):
[MH]+ = 248. 1H NMR (CDCl3): d 7.29–7.13 (m, 4H); 5.06 (s, 2H);
3.84 (t, 1H, J = 5.2 Hz); 3.61–3.60 (m, 1H); 3.08–3.01 (m, 2H);
2.72 (t, 1H, J = 5.6 Hz); 2.51–2.44 (m, 3H); 2.05–1.95 (m, 3H);
1.82–1.72 (m, 4H). 13C NMR (CDCl3): 145.20; 138.87; 127.78;
127.52; 121.14; 120.89; 84.46; 70.88; 64.64; 62.85; 59.16; 50.42;
36.55; 32.83; 27.16.
5.2.16. (D)-1-Benzyl-pirrolidin-2-carboxilic acid {3-[spiro[iso-
benzofuran-1(3H),40-piperidin-1-yl]-propyl}estere (17)
To a solution of 1-benzyl-pirrolidin-2-carbossilic acid (264 mg,
1.288 mmol) in DMF, cooled at 0 C, HOBt (236 mg, 1.546 mmol)
and DCC (319 mg, 1.546 mmol) were added. After 10 min com-
pound 16 (350 mg, 1.417 mmol) dissolved in DMF was added.
The reaction mixture was stirred at room temperature for 24 h
and monitored by TLC (EtOAc/light petroleum/NH3 4:1:0.3). The
solvent was evaporated under vacuum and the residue was basi-
ﬁed with NaHCO3 5% and extracted with EtOAc. The organic layers
were combined, dried and concentrated under reduced pressure to
obtain the crude product, which was puriﬁed by ﬂash chromatog-
raphy to obtain compound 17 (170 mg, 0.392 mmol, yield 30%). MS
(ESI): [MH]+ = 435. 1H NMR (CDCl3): d 7.31–7.23 (m, 9H); 5.04 (s,
2H); 4.12 (dt, 2H, J = 6.6, 2.4 Hz); 3.91 (d, 1H, J = 12.6 Hz); 3.57
(d, 1H, J = 12.8 Hz); 3.27–3.20 (m, 2H); 3.03–2.95 (m, 2H); 2.86–
2.81 (m, 2H); 2.51–2.33 (m, 5H); 1.90–1.72 (m, 8H). 13C NMR
(CDCl3): 174.21; 145.52; 138.85; 138.41; 129.177 (2C); 128.19
(2C); 127.61; 127.39; 127.09; 121.06; 120.83; 84.62; 70.76;
65.27; 63.10; 58.65; 55.29; 53.20; 50.16 (2C); 36.51 (2C); 29.38;
26.26; 23.03. ½a20D = +23 (c = 0.1 g/100 mL, Chloroform). Anal.
(C27H34N2O3) C, H, N.
5.2.17. 1-(3-Chloro-propyl)-4-spiro[isobenzofuran-1(3H),
40-piperidine] (18)
In a two neck round bottom ﬂask compound 16 (200 mg,
0.81 mmol) was dissolved in dry DCM (10 mL) and cooled at 0 C,
tosylchloride (170 mg, 0.89 mmol) and Et3N (90 mg, 0.89 mmol)
were added drop wise. The reaction was stirred at room tempera-
ture for 24 h and after evaporation, the crude material was dis-
solved in 20 mL of EtOAc. The organic phase was washed twice
with NaHCO3 saturated solution (20 mL each), the combined or-
ganic phases were concentrated to dryness and the product puri-
ﬁed by ﬂash chromatography (EtOAc/MeOH/NH4OH, 9:1:0.3) to
obtain compound 18 (85 mg, 0.320 mmol, yield 40%). MS (ESI):
[MH]+ = 266. 1H NMR (CDCl3): d 7.27–7.14 (m, 4H); 5.05 (s, 2H);
3.61 (t, 2H, J = 6.6 Hz); 2.85–2.80 (m, 2H); 2.55 (t, 2H, J = 7.2 Hz);
2.40 (dt, 2H); 2.04–1.95 (m, 4H); 1.79–1.78 (m, 2H).
5.2.18. 1-[3-(1-Benzyl-pirrolidin-2-ylmetoxy)-propyl]-4-spiro-
[isobenzofuran-1(3H),40piperidine] (20)
To a stirred suspension of sodium hydride (14 mg, 0.34 mmol)
in anhydrous THF at 0 C, a solution of 19 (60 mg, 0.31 mmol) in
THF was added. After 30 minutes, a catalytic amount of TBAI was
added followed by drop wise addiction of compound 18 (85 mg,
0.31 mmol) dissolved in THF. After 24 h at room temperature, the
reaction was heated at reﬂux for 12 h, the solvent was removed
in vacuo, diluted with Et2O and the resulting precipitate ﬁltrated
on Celite pad. The solvent was concentrated to dryness and the
crude material puriﬁed by ﬂash chromatography (EtOAc/MeOH/
NH4OH, 9.5:0.5:0.3) to give compound 20 in 56% yield. MS (ESI):
[MH]+ = 421. 1H NMR (CDCl3): d 7.32–7.21 (m, 9H); 5.03 (s, 2H);
4.12 (dt, 2H, J = 6.6, 2.4 Hz); 3.91 (d, 1H, J = 12.6 Hz); 3.57 (d, 1H,
J = 12.8 Hz); 3.45–3.21 (m, 2H); 3.27–3.20 (m, 2H); 3.03–2.95 (m,
1H); 2.86–2.81 (m, 2H); 2.51–2.33 (m, 5H); 1.90–1.72 (m, 8H).
C. Trapella et al. / Bioorg. Med. Chem. 17 (2009) 5080–5095 509113C NMR (CDCl3): 145.52; 138.85; 138.41; 129.17 (2C); 128.19
(2C); 127.61; 127.39; 127.09; 121.06; 120.83; 84.62; 74.34;
70.76; 65.27; 63.10; 58.65; 55.29; 53.20; 50.16 (2C); 36.51 (2C);
29.38; 26.26; 23.03. ½a20D = +21 (c = 0.2 g/100 mL, chloroform).
Anal. (C27H36N2O2) C, H, N.
5.2.19. 5-(1-Benzyl-pirrolidin-2-yl)-pent-4-enoic acid (22)
In a two neck round bottom ﬂask, under argon atmosphere, was
placed NaH 60% (12.57 g, 64.31 mmol) and washed ﬁve times with
anhydrous pentane (20 mL each). The resulting white solid was
dried ﬂushing argon and anhydrous DMSO (50 mL) was added;
the mixture was heated at 77 C for 40 min. At this time, the reac-
tion was cooled at 0 C and the (3-carboxy-propyl)-triphenyl-phos-
phonium bromide 21 (12.55 g, 29.23 mmol) dissolved in DMSO
was added drop wise. When the reaction becomes a brown-red col-
or, 1.105 g (5.85 mmol) of 1-benzyl-pirrolidine-2-carbaldheyde
were added drop wise. The reaction was checked by TLC (EtOAc/
MeOH/NH4OH, 9:1:0.3), the DMSO was removed under vacuum
and the crude material dissolved in EtOAc (60 mL) and washed
with a 10% solution of citric acid (30 mL). The organic phases were
dried and evaporated to dryness, the compound was puriﬁed by
ﬂash chromatography (EtOAc/MeOH/NH4OH, 9:1:0.3) to give com-
pound 22 (350 mg, 1.135 mmol, yield 23%). MS (ESI): [MH]+ = 260.
1H NMR (CD3OD): d 7.76–7.32 (m, 5H); 5.95–5.86 (m, 1H); 5.60–
5.50 (m, 1H); 4.45–4.39 (m, 2H); 4.16–4.10 (m, 1H); 3.34–3.29
(m, 6H); 2.40–2.39 (m, 4H). 13C NMR (CD3OD): 177.93; 139.63;
132.54; 131.91; 131.02; 130.47; 124.63; 66.22; 57.71; 53.82;
50.47; 40.62; 35.48; 31.32; 25.01; 22.35. ½a20D = 7.14 (c = 0.21 g/
100 mL, ethanol). IR: 3398.72; 2993.34; 1658.97; 1560.22;
1435.77; 1405.21; 1315.37; 1211.62; 1159.59; 1124.14; 1013.97;
952.12; 752.60; 701.61.
5.2.20. 5-(1-Benzyl-pirrolidin-2-yl)-1-[spiro[isobenzofuran-1(3H),
40-piperidin-1-yl]]-pent-4-en-1-one (23)
Compound 22 (590 mg, 2.278 mmol) was dissolved in DMF
(50 mL) and at 0 C HOAt (372 mg, 2.773 mmol), WSC (524 mg,
2.733 mmol) and compound 4 (430 mg, 2.278 mmol) were added.
After 12 h at room temperature, the solvent was removed by evap-
oration under reduced pressure and the residue diluted with EtOAc
(50 mL); the organic layer washed with NaHCO3 5% (10 mL) and
the aqueous phase extracted three times with EtOAc (30 mL each).
The combined organic phases were dried and concentrated in va-
cuo. The crude product was puriﬁed by ﬂash chromatography
(EtOAc/light petroleum/NH4OH, 1:1:0.3) to obtain compound 23
(783 mg, 1.822 mmol, yield 80%). MS (ESI): [MH]+ = 431. 1H NMR
(CDCl3): d 7.2967.22 (m, 9H); 5.67–5.58 (m, 1H); 5.51–5.44 (m,
1H); 5.08 (s, 2H); 4.67–4.61 (m, 1H); 4.04–3.98 (m, 1H); 3.86–
3.80 (m, 1H); 3.67 (t, 1H, J = 6.4 Hz); 3.57 (t, 1H, J = 6.4 Hz); 3.22–
2.89 (m, 4H); 2.55–2.44 (m, 4H); 1.95–1.55 (m, 8H). 13C NMR
(CDCl3): 170.73; 144.70; 139.43; 138.86; 133.47; 130.75; 129.11;
128.19; 127.97; 127.58; 126.85; 121.30; 120.69; 84.76; 71.03;
61.94; 58.52; 53.28; 44.99; 42.61; 38.73; 37.09; 36.19; 33.39;
31.40; 29.97; 23.84; 22.10. ½a20D = +18 (c = 0.1 g/100 mL,
chloroform).
5.2.21. (D)-1-Benzyl-pirrolidin-2-carboxilic acid {3-[spiro[iso-
benzofuran-1(3H),40-piperidin-1-yl]]-propyl}-amide (Comp 24)
To a stirred solution of N-Bn-D-Pro (860 mg, 3.496 mmol) in
DMF (20 mL) cooled at 0 C, HOBt (642 mg, 4.195 mmol), WSC
(804 mg, 4.195 mmol) were added and the reaction stirred for
10 min. After this time compound 5 (716 mg, 3.496 mmol) dis-
solved in DMF (20 mL) was added and the reaction mixture was
stirred for 24 h. The DMF was removed in vacuo and the product
partitioned between EtOAc and NaHCO3 5%. The organic phase
was dried, concentrated in vacuum and the crude product puriﬁed
by ﬂash chromatography (EtOAc/MeOH/NH4OH, 9.5:0.5:0.3) togive Comp 24 in 37% yield. MS (ESI): [MH]+ = 434. 1H NMR (CDCl3):
d 7.60 (br, 1H); 7.30–7.20 (m, 9H); 5.05 (s, 2H); 3.87 (d, 1H,
J = 12.8 Hz); 3.48 (d, 1H, J = 12.8 Hz); 3.42–3.16 (m, 4H); 3.09–
3.00 (m, 1H); 2.87–2.80 (m, 2H); 2.48–2.29 (m, 5H); 2.23–2.13
(m, 3H); 2.03–1.87 (m, 2H); 1.77–1.65 (m, 4H). 13C NMR (CDCl3):
174.62; 145.61; 138.94; 138.64; 128.81 (2C); 128.56 (2C);
127.62; 127.38 (2C); 121.10; 120.79; 84.69; 70.79; 67.61; 60.02;
56.76; 54.07; 50.54; 50.21; 37.67; 36.60 (2C); 30.78; 26.99;
24.09. ½a20D = +43 (c = 0.1 g/100 mL, chloroform). Anal.
(C27H35N3O2) C, H, N.
5.2.22. 1-[5-(1-Benzyl-pirrolidin-2-yl)-pent-4-enyl]-spiro[iso-
benzofuran-1(3H),40-piperidine] (25)
In a round-bottomed ﬂask under argon atmosphere, to a stirred
solution of 23 (140 mg, 0.325 mmol) in anhydrous THF (10 mL)
cooled at 0 C, was added drop wise to a solution of borane dimeth-
ylsulﬁde complex (0.094 mL, 0.977 mmol) dropwise. The solution
was heated at reﬂux overnight, after this time, cooled at 0 C and
HCl 10% was added until pH 2. The resulting solution was stirred at
reﬂux for 4 h, basiﬁed with NaOH 2 N and the solvent was removed
under vacuum. The crude product was puriﬁed by ﬂash chromatog-
raphy (EtOAc/light petroleum/NH4OH, 2:1:0.3) to give 25 (35 mg,
0.084 mmol, yield 26%). 1H NMR (CDCl3): d 7.326–7.216 (m, 9H);
5.42–5.37 (m, 2H); 5.06 (s, 2H); 4.09 (t, 1H, J = 6.4 Hz); 3.77 (s, 1H);
3.67 (t, 1H, J = 6.4 Hz); 2.91–2.86 (m, 2H); 2.68–2.34 (m, 4H);
2.09–1.96 (m, 4H); 1.80–1.50 (m, 8H); 1.24–1.15 (m, 2H). 13C NMR
(CDCl3): 145.70; 141.23; 138.93; 130.53; 130.06; 128.44; 128.19;
127.63; 127.43; 126.95; 121.09; 120.92; 84.77; 70.83; 64.34;
62.38; 59.00; 54.08; 50.27; 49.80; 36.60; 32.51; 30.40; 29.87;
27.88; 27.71; 26.48; 25.143. ½a20D = +1.67 (c = 0.31 g/100 mL, chloro-
form). Anal. (C28H36N2O) C, H, N.
5.2.23. [3-(4-Oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-8-yl)-pro-
pyl]-carbamic acid tert-butyl estere (27)
To a stirred solution of 26 (500 mg, 2.62 mmol) in DMF, was
added N-Boc-3-bromo-propyl-amine (612 mg, 2.57 mmol) in
10 mL of DMF and K2CO3 (596 mg, 4.32 mmol), the reaction was
warmed at 60 C for 1 h. Most of the solvent was removed and
the residue was diluted with EtOAc and washed twice with NH4Cl
saturated solution (30 mL each) and brine (30 mL). The organic
layer was dried and evaporated under reduced pressure. The crude
product was crystallized from Et2O to give the ﬁnal compound
(535 mg, 1.38 mmol, yield 64%). mp = 163–165 C. MS (ESI):
[MH]+ = 389. 1H NMR (CDCl3): d 7.31–7.23 (m, 3H); 6.90–6.84 (m,
2H); 5.38 (br, 2H); 4.73 (s, 2H); 3.23–3.19 (m, 2H); 2.82–2.45 (m,
8H); 1.75–1.66 (m, 4H); 1.41 (s, 9H). 13C NMR (CDCl3): 178.14;
156.20; 143.21; 129.37 (2C); 119.02 (2C); 115.50 (2C); 79.00;
59.50; 59.38; 56.98; 49.84 (2C); 40.16; 29.31; 28.55 (3C); 26.91.
5.2.24. Acid-(D)-1-benzyl-pirrolidin-2-carboxilic-[3-(4-oxo-1-
fenyl-1,3,8-triaza-spiro[4.5]dec-8-yl)-propyl]-amide (28)
Compound 27 (535 mg, 1.37 mmol) was treated with TFA
(5 mL) at 0 C for 1 h. NaOH 2 N was added until pH 12–14, the
aqueous phase was extracted several times with EtOAc and the or-
ganic phases were combined, dried and evaporated under vacuum
to give the free amine (395 mg, 1.37 mmol) in 100% yield. This
product was condensed with N-Bn-D-Pro in a similar manner as re-
ported for Comp 24. The crude product was puriﬁed by ﬂash chro-
matography (EtOAc/MeOH/NH4OH, 9.5:0.5:0.3) to give 28 in 56%
yield. MS (ESI): [MH]+ = 476. 1H NMR (CDCl3): d 7.94–7.83 (m,
2H); 7.35–6.86 (m, 10H); 4.72 (s, 2H); 3.84 (d, 1H, J = 13 Hz);
3.51 (d, 1H, J = 13 Hz); 3.27–3.19 (m, 3H); 3.07–2.81 (m, 6H);
2.76–2.47 (m, 2H); 2.36–1.66 (m, 10H). 13C NMR (CDCl3): 178.00;
175.06; 143.32; 138.80; 129.52 (2C); 128.91 (2C); 128.74 (2C);
127.54; 125.82; 119.61; 116.19 (2C); 115.30; 67.58; 60.17;
59.59; 56.04; 54.33; 49.86; 37.55; 30.98; 29.90; 29.34; 27.22;
5092 C. Trapella et al. / Bioorg. Med. Chem. 17 (2009) 5080–509524.37. ½a20D = +24 (c = 0.1 g/100 mL, chloroform). Anal. (C28H37
N5O2) C, H, N.5.2.25. 2-(2,6-Dichloro-phenyl)-4-hydroxy-4-methyl-6-oxo-cy-
clohexane-1,3-dicarboxylic acid diethyl ester (30)
Compound 29 (5 g, 28.57 mmol) and ethyl aceto-acetate
(7.22 mL, 57.14 mmol) were dissolved in 20 mL of ethanol 96%.
At this stirred solution was added piperidine (0.5 mL) and the reac-
tion mixture was stirred at room temperature overnight.
The solvent was removed under reduced pressure and the prod-
uct was crystallized from Et2O to give compound 30 with a quan-
titative yield. mp = 112–115 C. MS (ESI): [MH]+ = 418. 1H NMR
(CDCl3): d 12.50 (s, 1H); 7.28–7.18 (m, 2H); 7.05 (t, 1H, 8 Hz);
5.01 (d, 1H, J = 11 Hz); 4.05–3.83 (m, 5H); 3.10 (d, 1H,
J = 11.4 Hz); 2.48 (s, 2H); 1.32 (s, 3H); 0.98 (t, 3H, 7.4 Hz); 0.85 (t,
3H, 7 Hz). 13C NMR (CDCl3): 174.77; 171.11; 170.52; 138.03;
137.03; 134.28; 130.16; 128.04; 127.90; 98.09; 69.35; 61.36;
60.29; 50.85; 41.72; 38.28; 28.05; 13.83; 13.39.
5.2.26. 3-(2,6-Dichloro-phenyl)-pentane-dioic acid (31)
Compound 30 (7 g, 16.79 mmol) dissolved in ethanol 96%
(55 mL), NaOH 35% (40.75 mL) and of water (16.3 mL) were added.
The reaction mixture was stirred at reﬂux for 3 h. The solvent was
removed under reduced pressure, the resulting aqueous layer was
acidiﬁed at 0 C with HCl 20% and extracted with ethyl acetate. The
organic layers were combined, dried and evaporated under vac-
uum to obtain the crude product, which was crystallized from
ethyl ether to give 31 (4.026 g, 14.53 mmol, yield 87%).
mp = 153–155 C. MS (ESI): [MH]+ = 278. 1H NMR (CDCl3): d
12.20 (s, 2H); 7.41 (t, 2H, J = 8 Hz); 7.23 (t, 1H, J = 8 Hz); 3.43–
3.32 (m, 1H); 2.92–2.70 (m, 4H). IR: 2918.07; 1713.09; 1560.58;
1438.02; 1310.02; 1226.35; 1202.58; 1085.05; 903.48; 779.13.
5.2.27. 4-(2,6-Dichloro-phenyl)-piperidin-2,6-dione (32)
Compound 31 (4.026 g, 15.60 mmol) was dissolved in NH4OH
(40 mL). The solvent was evaporated under vacuum and the solid
residue was heated at 200 C for 6 h. At the crude product was
added DCM (150 mL) and was washed twice with Na2CO3
0.1 M. The organic layer was dried and concentrated in vacuum
to obtain a crude product, which was crystallized from ethyl
ether to give 32 with a quantitative yield. mp = 155–157 C. MS
(ESI): [MH]+ = 259. 1H NMR (CDCl3): d 8.20 (br, 1H); 7.36–7.13
(m); 4.43–4.30 (m, 1H); 3.60 (dd, 2H, J = 18, 13.5 Hz); 2.69 (dd,
2H, J = 17.7, 4.6 Hz). IR: 3208.19; 3078.49; 2921.50; 2385.98;
2342.76; 1696.60; 1560.07; 1437.89; 1361.16; 1271.72;
1150.48; 1079.12; 770.20; 731.23.
5.2.28. 4-(2,6-Dichloro-phenyl)-piperidine (33)
Compound 32 (4 g, 15.5 mmol) was suspended, under argon
atmosphere, in anhydrous THF (150 mL) and (CH3)2S * BH3
(14.9 mL, 155 mmol) added at 0 C under stirring. The reaction
was heated at reﬂux overnight. The solution was cooled at 0 C,
HCl 10% (66.6 mL) was added until pH of the solution was strongly
acidic and the solution was left at reﬂux for 4 h. The reaction mix-
ture was cooled again at 0 C, basiﬁed with NaOH 2 N and moni-
tored by TLC (EtOAc/light petroleum 3:2). The THF was
evaporated under vacuum and the aqueous layer was extracted
with ethyl acetate. The organic layers were combined, dried and
concentrated under vacuum to obtain the crude product, which
was crystallized with ethyl ether to give 33 (1.23 g, 5.348 mmol,
yield 35%). mp = 210–215 C. MS (ESI): [MH]+ = 231. 1H NMR
(CDCl3): d 9.77 (br, 1H); 7.28–7.25 (m, 2H); 7.089 (t, 1H,
J = 8 Hz); 3.78–3.72 (m, 1H); 3.67–3.64 (m, 2H); 3.13–3.02 (m,
4H); 1.82–1.79 (m, 2H). 13C NMR (CDCl3): 137.08; 135.21;
130.67; 128.65 (2C); 44.73 (2C); 38.30 (2C); 24.80 (2C).5.2.29. 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-yl]-propylamine
(34)
To a stirred solution of33 (284 mg, 1.236 mmol) inDMF (5 mL),N-
Boc-3-bromo-propyl-amine (350 mg, 1.471mmol) and K2CO3
(341.77 mg, 2.473 mmol) were added. The reactionmixturewas stir-
red at 60 C for 1 h and than evaporated under vacuum, the residue
was dissolved in EtOAc and washed twice with a saturated solution
ofNH4Cl andoncewithBrine. Theorganic layerwasdriedandconcen-
trated under reduced pressure to obtain the product as a red-orange
oil. This crude product was then puriﬁed by ﬂash chromatography
(EtOAc/light petroleum/NH4OH 5:1:0.3) (yield 94%). At the product
so obtained (1.163mmol), cooled at 0 C, was added drop wise 1 mL
of TFA. The reaction was monitored by TLC (EtOAc/light petroleum
5:1) and after about 1 h was cooled at 0 C and basiﬁed with NaOH
2 N. The aqueous layer was extracted three times with EtOAc and
the organic layers were combined, dried and evaporated under vac-
uum to give compound 34 with a quantitative yield. MS (ESI):
[MH]+ = 288. 1H NMR (CDCl3): d 7.25–7.00 (m, 3H); 3.53–3.46 (m,
1H); 3.36 (br, 2H); 3.116 (dd, 2H, J = 9.6, 4 Hz); 2.90 (t, 2H,
J = 6.8 Hz); 2.67–2.56 (m, 2H); 2.50 (t, 2H, J = 6.8 Hz); 2.05 (dt, 2H,
J = 10, 2.4 Hz); 1.75 (t, 2H, J = 6.4 Hz); 1.58 (d, 2H, J = 12.4 Hz).
5.2.30. (D)-1-Benzyl-pirrolidin-2-carbossilic acid {3-[4-(2,
6-dichloro-phenyl)-piperidin-1-yl]-propyl}-amide (35)
N-Bn-D-Pro and compound 34 were condensed in the same
experimental condition as for Comp 24 yielding 35 (48 mg,
0.101 mmol, yield 65%). MS (ESI): [MH]+ = 475. 1H NMR (CDCl3):
d 7.56–7.52 (br, 1H); 7.35–7.24 (m, 7H); 7.03 (t, 1H, J = 8 Hz);
3.86 (d, 1H, J = 13.2 Hz); 3.50 (d, 1H, J = 13.2 Hz); 3.28–3.17 (m,
2H); 3.07–3.03 (m, 3H); 2.69–2.64 (m, 2H); 2.47–2.34 (m, 3H);
2.27–2.19 (m, 2H); 2.06–2.01 (m, 2H); 1.92–1.90 (m, 2H); 1.75–
1.72 (m, 4H); 1.56 (d, J = 12.8 Hz). 13C NMR (CDCl3): 174.71;
138.67; 130.41; 128.76 (2C); 128.57 (2C); 127.78 (2C); 127.35
(2C); 67.52; 59.95 (2C); 56.41; 54.64; 54.10; 40.57; 37.43 (2C);
30.78 (2C); 27.64; 26.80; 24.14 (2C). ½a20D = +27 (c = 0.1 g/100 mL,
chloroform). Anal. (C26H33Cl2N3O) C, H, N, Cl.
5.2.31. (L)-1-Benzyl-pirrolidin-2-carboxilic acid {3-[4-(2,
6-dichloro-phenyl)-piperidin-1-yl]-propyl}-amide (36)
N-Bn-Pro and compound 34were condensed in the same experi-
mental condition as for Comp 24. yielding 36 (48 mg, 0.101 mmol,
yield 35%). MS (ESI): [MH]+ = 475. 1H NMR (CDCl3): d 7.53 (br, 1H);
7.33–7.25 (m, 7H); 7.03 (t, 1H, J = 8 Hz); 3.86 (d, 1H, J = 13.2 Hz);
3.50 (d, 1H, J = 13.2 Hz); 3.30–3.17 (m, 3H); 3.07–3.03 (m, 2H);
2.67–2.64 (m, 2H); 2.42–2.32 (m, 3H); 2.24–2.19 (m, 2H); 2.07–2.01
(m, 3H); 1.88–1.85 (m, 2H); 1.78–1.67 (m, 3H); 1.57–1.54 (m, 2H).
13C NMR (CDCl3): 174.69; 138.69; 130.40; 128.73 (2C); 128.57 (2C);
127.74 (2C); 127.35 (2C); 67.53; 59.95 (2C); 56.51; 54.68; 54.09;
40.64; 37.47 (2C); 30.78 (2C); 27.74; 26.86; 24.14 (2C). ½a20D =27
(c = 0.1 g/100mL, chloroform). Anal. (C26H33Cl2N3O) C, H, N, Cl.
5.2.32. 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-
1-carboxylic acid tert-butyl ester (38)
To a stirred solution of compound 37 (1 g, 4.60 mmol) in DCM
(50 mL) at 0 C, a catalytical amount of DMAP and (Boc)2O
(1.57 g, 6.9 mmol) were added. After 6 h at room temperature,
water (100 mL) was added and the organic layer washed with citric
acid 10% (10 mL  3), NaHCO3 saturated solution (10 mL  3) and
brine (10 mL  3). The organic phase was dried and concentrated
in vacuo to give compound 38 in quantitative yield pure enough
to be used in the next step without further puriﬁcation.
5.2.33. 1-Ethyl-3-piperidin-4-yl-1,3-dihydro-benzoimidazol-2-
one (39)
To a suspension of sodium hydride (92 mg, 3.79 mmol) in anhy-
drous DMF (5 mL), compound 38was added dropwise at 0 C. After
C. Trapella et al. / Bioorg. Med. Chem. 17 (2009) 5080–5095 509330 minutes, ethyl bromide (413 mg, 3.79 mmol) was added, and
the reaction mixture was allowed to stir at room temperature
overnight. The DMF was removed in vacuo and the salts were dis-
solved in water, the aqueous layer was extracted with EtOAc
(25 mL  3), dried and concentrated in vacuo. The crude material
was dissolved in 5 mL of TFA and stirred for 1 h; after this time,
the TFA was evaporated and the solution was basiﬁed with NaOH
20% until pH 12. The aqueous layer was extracted twice with EtOAc
(30 mL each), concentrated to dryness and puriﬁed by ﬂash chro-
matography using EtOAc/light petroleum/NH4OH: 2:1:0.3 as elu-
ent to give 0.84 g of desired compound (yield 75%). MS (ESI):
[MH]+ = 246.3 1H NMR (CDCl3): d 7.25 (m, 1H); 7.07–7.00 (m,
3H); 4.43 (m, 1H); 3.98–3.87 (q, 2H, J = 6 Hz); 3.22 (br s, 2H);
2.79 (dt, 2H, J = 15.6 Hz, J = 2.4 Hz); 2.37–2.30 (dq, 2H, J = 8.4 Hz,
J = 4.2 Hz); 1.85 (bs, 2H); 1.32 (t, 3H, J = 7.4 Hz).
5.2.34. 1-[1-(3-Amino-propyl)-piperidin-4-yl]-3-ethyl-1,3-di-
hydro-benzoimidazol-2-one (40)
To a stirred solution of 39 (92 mg, 0.375 mmol) in DMF (5 mL),
N-Boc-3-bromo-propyl-amine (106 mg, 0.447 mmol) and K2CO3
(103 mg, 0.750 mmol) were added. After 1 h at 60 C, most of the
solvent was removed and the residue diluted with EtOAc and
washed twice with NH4Cl saturated solution (30 mL each) and
brine (30 mL). The organic layer was dried and evaporated under
reduced pressure. The crude material was treated at 0 C with
TFA (5 mL) for 1 h and then treated with NaOH 2 N until pH 12–
14. The aqueous phase was extracted several times with EtOAc
and the organic phases were combined, dried and evaporated un-
der vacuum to give compound 40 in 80% yield. The product was en-
ough pure to be used in the next step without further puriﬁcation.
5.2.35. 1-Benzyl-pyrrolidine-2-carboxylic acid {3-[4-(3-ethyl-2-
oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-
amide (41)
N-Bn-D-Pro and compound 40 were condensed in the same
experimental condition as for Comp 24 yielding 41 in 24% yield
after puriﬁcation by ﬂash chromatography (EtOAc/MeOH/NH4OH,
9.5:0.5:0.3). MS (ESI): [MH]+ = 490. 1H NMR (CDCl3): d 7.58–7.52
(m, 1H); 7.29–7.25 (m, 5H); 7.04–7.01 (m, 4H); 4.58–4.42 (m,
1H); 3.92 (q, 2H, J = 7.2 Hz); 3.866–3.560 (dd, a–b sistem, 2H,
J = 13 Hz); 3.24–3.09 (m, 5H); 2.59–2.19 (m, 9H); 1.87–1.72 (m,
7H); 1.315 (t, 3H, J = 7.2 Hz). 13C NMR (CDCl3): 175.07; 153.40;
138.58; 129.14; 128.71; 128.586; 127.87; 127.39; 121.06;
120.98; 109.80; 107.67; 67.41; 59.95; 55.44; 54.17; 53.00; 52.92;
49.83; 36.93; 35.95; 30.77; 28.11; 26.36; 24.13; 13.62. Anal.
(C29H39N5O2) C, H, N.
5.3. Cell culture and cell membrane preparation
CHOhNOP cells were cultured in DMEM and Hams F-12 (1:1)
supplemented with 5% foetal calf serum, penicillin (100 IU/mL),
Streptomycin (100 lg/mL) and Fungizone (2.5 lg/mL). Stock cul-
tures were further supplemented with geneticin (G418, 200 lg/
mL) and Hygromycin B (200 lg/mL) as described previously.25
CHO cell lines stably expressing the human MOP, DOP, KOP and
NOP receptors and the C-terminally modiﬁed Gaqi526 were gener-
ated as described previously8 and maintained in Dulbecco Mini-
mum Essential Medium (DMEM) and Hams F-12 (1:1)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
200 lg/mL Geneticin and 100 lg/mL Hygromicin B. Cells were cul-
tured at 37 C in 5% carbon dioxide humidiﬁed air, and used when
conﬂuent.
For binding experiments membranes were prepared from
freshly harvested cell suspensions in Tris–HCl (50 mM), Mg++
(5 mM) pH 7.4 ([3H]N/OFQ binding experiments) or in Tris–HCl
(50 mM), EGTA (0.2 mM) pH 7.4 ([35S]GTPcS binding experiments)via homogenisation and centrifugation at 13,500 rpm for 10 min at
4 C. The ﬁnal protein concentration was determined according to
Lowry.27
5.4. Receptor binding
[3H]N/OFQ binding experiments. 5 lg of CHOhNOP homogenate
protein was incubated in 0.5 mL volumes of Tris-HCl (50 mM) buf-
fer supplemented with 10 lM peptidase inhibitors (amastatin,
bestatin, captopril and phosphoramidon), 0.5% bovine serum albu-
min (BSA), increasing concentrations of compounds under study
and approximately 200 pM [3H]-N/OFQ. Total radiolabel bound
was 10%. Non-speciﬁc binding was determined in the presence
of 1 lM unlabeled N/OFQ. In all experiments Comp 24 was in-
cluded as a reference ligand. Reactions were incubated for 1 h at
room temperature and terminated by vacuum ﬁltration (Brandel
Harvester) through Whatman GF/B ﬁlters soaked in 0.5% polyethy-
lenimine (PEI). Radioactivity was determined after 8 h extraction
in scintillation cocktail. [3H]-Diprenorphine binding experiments.
50 lg (CHOhMOP), 25 lg (CHOhDOP) and 40 lg (CHOhKOP) membrane
protein were incubated in 0.5 ml buffer containing Tris-HCl
(50 mM) pH 7.4, BSA (0.5%), 0.7 nM [3H]Diprenorphine and
increasing concentrations of naloxone and compound 35. Non-spe-
ciﬁc binding was determined in the presence of 10 lM naloxone.
Reactions were incubated at room temperature for 1 h, harvesting
and determination of radioactivity were as for [3H]N/OFQ binding.
5.5. [35S]GTPcS binding
20 lg of CHOhNOP membranes were incubated in 0.5 mL buffer
containing Tris–HCl (50 mM), EGTA (0.2 mM) MgCl2 (1 mM), NaCl
(100 mM), bacitracin (0.15 mM) peptidase inhibitors (as above),
GDP (100 lM) and approximately 150 pM [35S]GTPcS. Compound
35 was pre-incubated for 15 min at 30 C. Non-speciﬁc binding
was determined in the presence of unlabeled 10 lM GTPcS. The
reaction was incubated for 1 h with increasing concentration of
N/OFQ at 30 C with gentle shaking and terminated by ﬁltration
through Whatman GF/B ﬁlters using a Brandel Harvester. PEI was
not used.
5.6. Calcium mobilization experiments
CHOhMOP, CHOhDOP, CHOhKOP and CHOhNOP stably expressing the
Gaqi5 protein were seeded at a density of 40,000 cells/well into 96-
well black, clear-bottom plates. After 24 h incubation the cells
were loaded with medium supplemented with 2.5 mM of proben-
ecid, 3 lM of the calcium sensitive ﬂuorescent dye Fluo-4 AM and
0.01% pluronic acid, for 30 min at 37 C. Afterwards, the loading
solution was aspirated and 100 lL/well of assay buffer: Hank’s Bal-
anced Salt Solution (HBSS) supplemented with 20 mM HEPES,
2.5 mM probenecid and 500 lM Brilliant Black (Aldrich) was
added. Stock solutions (1 mM) of ligands were prepared in distilled
water and stored at 20 C. Serial dilutions of ligands for experi-
mental use were made in HBSS/HEPES (20 mM) buffer (containing
0.02% BSA fraction V). After placing both plates (cell culture and
compound plate) into the FlexStation II (Molecular Device, Union
City, CA), ﬂuorescence changes were measured at room tempera-
ture. On-line additions were carried out in a volume of 50 lL/well.
5.7. Electrically stimulated isolated tissues
Tissues were taken from male Swiss mice (30–35 g), albino gui-
nea pigs (300–350 g) and Sprague-Dawley rats (300–350 g). The
mouse and the rat vas deferens and the guinea pig ileum were pre-
pared as previously described.28 Tissues were continuously stimu-
lated through two platinum ring electrodes with supramaximal
5094 C. Trapella et al. / Bioorg. Med. Chem. 17 (2009) 5080–5095rectangular pulses of 1 ms duration and 0.05 Hz frequency. The
electrically evoked contractions (twitches) were measured isoton-
ically with a strain gauge transducer (Basile 7006, UgoBasile s.r.l.,
Varese, Italy) and recorded with the PC based acquisition system
Power Lab (ADInstrument, USA).
Following an equilibration period of 60 min, the contractions
induced by electrical ﬁeld stimulation were stable. At this time,
cumulative concentration–response curves to N/OFQ were per-
formed (0.5 log unit steps) in the absence or presence of compound
35 (15 min pre-incubation time). For selectivity studies, in some
experiments the DOP selective agonist DPDPE was used in the
mouse vas deferens and the MOP selective agonist dermorphin
was used in the guinea pig ileum.
5.8. Mouse tail withdrawal assay
Male Swiss albino mice weighing 25–30 g were used. Animals
were handled according to guidelines published in the European
Communities Council directives (86/609/EEC) and Italian national
regulations (D.L. 116/92). They were housed in 425  266  155-
mm cages (Techniplast, Milan, Italy), ﬁfteen animals/cage, under
standard conditions (22 C, 55% humidity, 12-h light/dark cycle,
light on at 7:00 am) with food (MIL, standard diet; Morini, Reggio
Emilia, Italy) and water ad libitum for at least 5 days before exper-
iments began. Each mouse was used only once. Icv (2 ll/mouse) or
i.t (5 ll/mouse) injections were given according to the procedure
described by Laursen and Belknap29 and Hylden and Wilcox30,
respectively.
All experiments were started at 10:00 am and performed
according to the procedure described previously in detail.22 Brieﬂy,
the mice were placed in a holder and the distal half of the tail was
immersed in water at 48 C. Withdrawal latency time was mea-
sured by an experienced observer blind to drug treatment. A cut-
off time of 20 s was chosen to avoid tissue damage. For each exper-
iment sixteen mice were used by randomly assigning four animals
to each treatment group. The experiment was repeated four times;
therefore, each experimental point shown in Figure 2 is the mean
of the results obtained in 16 mice. Tail-withdrawal latency was
determined immediately before and 5, 15, 30, and 60 min after
icv or i.t. injection of vehicle (saline) or N/OFQ (1 nmol). Compound
35 (10 mg/kg) or its vehicle (2% DMSO and 10% encapsin) were gi-
ven i.p. 30 min before icv injection. Increased and decreased tail
withdrawal latencies compared with baseline indicated antinoci-
ceptive and pronociceptive effects, respectively.
5.9. Data analysis and terminology
All data are expressed as means ± standard error of the mean
(sem) of n experiments. For potency values conﬁdence limits 95%
were indicated. Data have been analyzed statistically using one-
way ANOVA followed by Dunnett’s test for multiple comparisons
or the Student’s t test. In competition binding studies (Tables 2
and 3), the log concentration of competitor producing 50% inhibi-
tion of speciﬁc binding (pIC50) was corrected for the competing
mass of radiolabel according to Cheng and Prusoff31 to yield pKi
values. KD values for [3H]N/OFQ in CHOhNOP was 83 pM and for
[3H]diprenorphine in MOP, DOP and KOP were 125, 323, and
134 pM, respectively.
[35S]GTPcS data are expressed as a stimulation factor that is, the
ratio between agonist-stimulated [35S]GTPcS speciﬁc (minus NSB)
binding and basal speciﬁc binding. Calcium mobilization data are
expressed as ﬂuorescence intensity units (FIU) in percent over
the baseline. Isolated tissue data are expressed as percent of the
twitch response to electrical ﬁeld stimulation.
Agonist potencies are given as pEC50 = the negative logarithm to
base 10 of the molar concentration of an agonist that produces 50%of the maximal possible effect. Antagonist potencies have been
evaluated (i) using pA2 derived from the classical Schild protocol
in [35S]GTPcS binding and mouse vas deferens experiments (Fig. 1
and Table 2), (ii) using pKb derived from the Gaddum Schild
equation:
Kb ¼ ððCR  1Þ=½antagonistÞ
assuming a slope value equal to unity, where CR indicate the ratio
between agonist potency in the presence and in the absence of
the antagonist, in rat vas deferens and guinea pig ileum experi-
ments (Table 2). Finally, (iii) using pKb values derived from the fol-
lowing equation:32
Kb ¼ IC50=ð½2þ ð½A=EC50Þn1=n  1
where IC50 is the concentration of antagonist that produces 50%
inhibition of the agonist response, [A] is the concentration of the
agonist, EC50 is the concentration of agonist producing a 50% max-
imal response and n is the Hill coefﬁcient of the concentration re-
sponse curve to the agonist in inhibition response experiments
measuring calcium mobilization (Tables 2 and 4).
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Mouse tail withdrawal assayCompound 24, 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide
was recently identiﬁed as a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) ligand. In this study,
the in vitro and in vivo pharmacological proﬁles of Compound 24 were investigated. In vitro studies were
performed measuring receptor and [35S]GTPγS binding and calcium mobilization in cells expressing the
recombinant NOP receptor as well as using N/OFQ sensitive tissues. In vivo studies were conducted using
the tail withdrawal assay in mice. Compound 24 produced a concentration-dependent displacement of
[3H]N/OFQ binding to CHOhNOP cell membranes showing high afﬁnity (pKi 9.62) and selectivity (1000 fold) over
classical opioid receptors. Compound 24 antagonized with high potency the following in vitro effects of N/OFQ:
stimulation of [35S]GTPγS binding in CHOhNOP cell membranes (pA2 9.98), calciummobilization in CHOhNOP cells
expressing the Gαqi5 chimeric protein (pKB 8.73), inhibition of electrically evoked twitches in the mouse (pA2
8.44) and rat (pKB 8.28) vas deferens, and in the guinea pig ileum (pKB 9.12). In electrically stimulated tissues,
Compound 24 up to 1 µM did not modify the effects of classical opioid receptor agonists. Finally in vivo, in the
mouse tail withdrawal assay, Compound 24 at 10 mg/kg antagonized the pronociceptive and antinociceptive
effects of 1 nmol N/OFQ given supraspinally and spinally, respectively. Under the same experimental conditions
Compound 24 did not affect the antinociceptive action of 3 nmol endomorphin-1 injected intrathecally. The
present study demonstrated that Compound 24 is a pure, competitive, and highly potent non-peptide NOP
receptor selective antagonist.© 2009 Elsevier B.V. All rights reserved.1. IntroductionNociceptin/orphanin FQ (N/OFQ) (Meunier et al., 1995; Reinscheid
et al.,1995)modulates several different biological functions via selective
activation of the N/OFQ peptide (NOP) receptor (Lambert, 2008). There
are numerous studies describing the central andperipheral actionsofN/
OFQ and selective NOP agonists. In contrast, relatively few studies are
available regarding the effects of selective NOP receptor antagonists.
This ismainly due to the fact that only few suchmolecules are described
in the literature (Chiou et al., 2007; Lambert, 2008).Moreover not all the
described NOP receptor antagonists are commercially available. Never-OP, N/OFQ peptide receptor;
3H),4′-piperidin-1-yl]propyl}
ovary; DPN, diprenorphine;
lbumin; HBSS, Hank's Balanced
n: AUC, area under the curve.
44100 Ferrara, Italy. Tel.: +39
ll rights reserved.theless, there is convincingevidence thatblockadeofNOP receptorsmay
be beneﬁcial in some conditions or pathological states. For instance,
peptide ([Nphe1]N/OFQ(1-13)-NH2 (Calo et al., 2000) and UFP-101
(Calo et al., 2002b)) and non peptide (J-113397 (Ozaki et al., 2000) and
SB-612111 (Zaratin et al., 2004))NOP antagonistswere demonstrated to
evoke antidepressant like actions in rodents (Gavioli and Calo, 2006;
Gavioli et al., 2003, 2004; Redrobe et al., 2002; Rizzi et al., 2007).
Interestingly and corroborating antagonist studies NOP−/− mice
displayed an antidepressant-like phenotype (Gavioli et al., 2003).
Moreover, in a rather elegant series of studies, it has been demonstrated
that the endogenous N/OFQ–NOP receptor signalling inhibits motor
behaviour and that NOP receptor antagonists (UFP-101, J-113397, and
Trap-101 (Trapella et al., 2006)) produce beneﬁcial effects in rodent
models of Parkinson's disease (Marti et al., 2004a,b, 2005, 2007; Viaro
et al., 2008). This indication has also been conﬁrmed in non-human
primates (Viaro et al., 2008; Visanji et al., 2008). Very recent ﬁndings
indicated that plasma N/OFQ levels in sepsis were higher in patients
who died within 30 days (Williams et al., 2008) and this parallels the
preclinical observation that the NOP receptor antagonist UFP-101
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To be fully validated and ﬁrmly attributed to the NOP receptor antagonist
class of drugs, these emerging indications should be conﬁrmed in future
studies using several chemically unrelated molecules.
A novel NOP receptor non-peptide antagonist, 1-benzyl-N-{3-
[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-
carboxamide, has been recently identiﬁed by Banyu investigators
and named Compound 24 (Goto et al., 2006). The synthesis of this
novel ligand is relatively easy and the overall yield relatively high (25%
in our laboratory, 31% in Goto et al. (2006)). This is particularly true
when compared to the synthesis of other non peptide NOP antagonists
such as J-113397 and SB-612111 whose synthesis is very difﬁcult and
of low overall yield (≈1% for both molecules in our laboratories, C.
Trapella personal communication).
Thus, the aim of the present study was the synthesis and detailed
investigation of the pharmacological proﬁle of Compound 24. The novel
ligand was investigated in vitro in receptor binding and [35S]GTPγS
experiments performed in CHOhNOP cell membranes, in calcium
mobilization experiments performed in CHOhNOP cells expressing the
Gαqi5 protein, and inN/OFQ sensitive isolated tissues. Finally, the in vivo
actions of Compound24were assessed inmiceusing the tailwithdrawal
assay.
2. Materials and methods
2.1. Cell culture and membrane preparation
CHOhNOP cells were cultured in Dulbecco Minimum Essential
Medium (DMEM) and Ham F-12 (1:1) supplemented with 5% foetal
calf serum, penicillin (100 IU/ml), Streptomycin (100 µg/ml) and
Fungizone (2.5 µg/ml). Stock cultures were further supplemented
with geneticin (G418, 200 µg/ml) and Hygromycin B (200 µg/ml) as
described previously (McDonald et al., 2003). CHOhmu, CHOhdelta,
CHOhkappa and CHOhNOP stably expressing the Gαqi5 protein were
generated as previously described (Camarda et al., 2009) and
maintained in DMEM and Ham F-12 (1:1) supplemented with 10%
fetal bovine serum, 2 mM L-Glutamine, 200 µg/ml Geneticin, 100 µg/
ml Hygromycin B. Cells were cultured at 37 °C in 5% carbon dioxide
humidiﬁed air, and used when conﬂuent. For binding experiments
membranes were prepared from freshly harvested cell suspensions in
Tris–HCl (50 mM), Mg2+ (5 mM) pH 7.4 ([3H]N/OFQ binding experi-
ments) or in Tris–HCl (50 mM), EGTA (0.2 mM) pH 7.4 ([35S]GTPγS
binding experiments) via homogenisation and centrifugation at
13,500 rpm for 10 min at 4 °C. The ﬁnal protein concentration was
determined according to Lowry et al. (1951).
2.2. Receptor binding experiments
2.2.1. [Leucyl-3H]N/OFQ binding
5µgof CHOhNOPhomogenateproteinwas incubated in0.5mlvolumes
of Tris–HCl (50 mM) buffer supplemented with 10 µM peptidase
inhibitors (amastatin, bestatin, captopril and phosphoramidon), 0.5%
bovine serum albumin (BSA), increasing concentrations of Compound
24 and approximately 200 pM [3H]–N/OFQ. Total radiolabel bound was
bb10%. Non-speciﬁc binding was determined in the presence of 1 µM
unlabelled N/OFQ. In all experiments N/OFQwas included as a reference
ligand. Reactions were incubated for 1 h at room temperature and
terminated by vacuum ﬁltration (Brandel Harvester) through Whatman
GF/B ﬁlters soaked in 0.5% polyethylenimine. Radioactivity was deter-
mined after 8 h extraction in scintillation cocktail.
2.2.2. [3H]-Diprenorphine binding
50 µg (CHOhmu), 25 µg (CHOhdelta) and 40 µg (CHOhkappa)
membrane protein were incubated in 0.5 ml buffer containing Tris–
HCl (50 mM) pH 7.4, BSA (0.5%), ~0.7 nM [3H]-Diprenorphine and
increasing concentrations of naloxone and Compound 24. Non-speciﬁc binding was determined in the presence of 10 µM naloxone.
Reactions were incubated at room temperature for 1 h. Harvesting and
determination of radioactivity were as for [leucyl-3H]N/OFQ binding.
2.3. [35S]GTPγS binding experiments
20 µg of CHOhNOP membranes were incubated in 0.5 ml buffer
containing Tris–HCl (50 mM), EGTA (0.2 mM) MgCl2 (1 mM), NaCl
(100 mM), bacitracin (0.15 mM) peptidase inhibitors (as above), GDP
(100 µM) and approximately 150 pM [35S]GTPγS (McDonald et al.,
2003). Compound 24 was pre-incubated for 15 min at 30 °C. Non-
speciﬁc binding was determined in the presence of 10 µM unlabelled
GTPγS. The reactionwas incubated for 1 h at 30 °C with gentle shaking
and terminated by ﬁltration through Whatman GF/B ﬁlters using a
Brandel Harvester.
2.4. Calcium mobilization experiments
CHOhmu, CHOhdelta, CHOhkappa and CHOhNOP stably expressing the
Gαqi5 protein were seeded at a density of 40,000 cells/well into 96-
well black, clear-bottom plates. After 24 h incubation the cells were
loaded with medium supplemented with 2.5 mM probenecid, 3 µM of
the calcium sensitive ﬂuorescent dye Fluo-4 AM and 0.01% pluronic
acid, for 30min at 37 °C. Afterwards the loading solutionwas aspirated
and 100 µl/well of assay buffer: Hank's Balanced Salt Solution (HBSS)
supplemented with 20 mM HEPES, 2.5 mM probenecid and 500 µM
Brilliant Black (Aldrich) was added. Stock solutions (1 mM) of ligands
were made in distilled water and stored at−20 °C. Serial dilutions of
ligands for experimental use were made in HBSS/HEPES (20 mM)
buffer (containing 0.02% BSA fraction V). After placing both plates
(cell culture and compound plate) into the FlexStation II (Molecular
Device, Union City, CA 94587, US), ﬂuorescence changes were
measured at room temperature. On-line additions were carried out
in a volume of 50 µl/well.
2.5. Electrically stimulated isolated tissue experiments
Tissues were taken frommale Swiss mice (30–35 g), albino guinea
pigs (300–350 g) and Sprague-Dawley rats (300–350 g). The mouse
and rat vas deferens and the guinea pig ileum were prepared as
previously described (Bigoni et al., 1999; Calo et al., 1996). Tissues
were suspended in 5 ml organ baths containing heated Krebs solution
oxygenated with 95% O2 and 5% CO2. The bath temperature was set at
33 °C for mouse vas deferens and 37 °C for rat vas deferens and guinea
pig ileum. Tissues were continuously stimulated through two
platinum ring electrodes with supramaximal rectangular pulses of
1 ms duration and 0.05 Hz frequency. A resting tension of 0.3, 1 and
1.5 g was applied to the mouse and rat vas deferens, and guinea pig
ileum, respectively. The electrically evoked contractions (twitches)
were measured isotonically with a strain gauge transducer (Basile
7006, UgoBasile s.r.l., Varese, Italy) and recorded with the PC based
acquisition system Power Lab (ADInstrument, USA).
Following an equilibration period of 60 min, the contractions
induced by electrical ﬁeld stimulation were stable. At this time,
cumulative concentration-response curves to N/OFQ were performed
(0.5 log unit steps) in the absence or presence of Compound 24
(15 min pre-incubation time). For selectivity studies, in some
experiments the delta selective agonist DPDPE was used in the
mouse vas deferens while in others the mu selective agonist
Dermorphin was used in the guinea pig ileum.
2.6. Tail withdrawal assay
Male Swiss albino mice weighing 25–30 g were used. Animals were
handled according to guidelines published in the European Commu-
nities Council directives (86/609/EEC) and Italian national regulations
Table 1
Afﬁnities of Compound 24 and naloxone at NOP and classical opioid receptors expressed
in CHO cell membranes.
Receptor NOP Mu Delta Kappa
Radioligand [3H]N/OFQ [3H]DPN [3H]DPN [3H]DPN
Naloxonea b6 9.25 (9.04–9.46) 7.67 (7.59–7.75) 8.35 (8.20–8.50)
Compound
24
9.62 (9.47–9.77) 6.72 (6.43–6.97) b6 6.47 (6.20–6.74)
a Naloxone afﬁnities at classical opioid receptors are from Vergura et al. (2006). Data
are mean (CL95%) of 3 separate experiments.
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niplast, Milan, Italy), ﬁfteen animals/cage, under standard conditions
(22 °C, 55% humidity, 12-h light/dark cycle, light on at 7:00 am) with
food (MIL, standard diet; Morini, Reggio Emilia, Italy) and water ad
libitum for at least 5 days before experiments began. Each mouse was
used only once. I.c.v. (2 µl/mouse) or i.t (5 µl/mouse) injections were
given according to the procedure described by Laursen and Belknap
(1986) and Hylden and Wilcox (1980), respectively.
All experiments were started at 10:00 am and performed
according to the procedure described previously in detail (Calo
et al., 1998). Brieﬂy, the mice were placed in a holder and the distal
half of the tail was immersed in water at 48 °C. Withdrawal latency
time was measured by an experienced observer blind to drug
treatment. A cut-off time of 20 s was chosen to avoid tissue damage.
For each experiment sixteen mice were used by randomly assigning
four animals to each treatment group. The experiment was repeated
four times; therefore, each experimental point shown in Figs. 5 and 6
is the mean of the results obtained in 16 mice. Tail-withdrawal
latency was determined immediately before and 5, 15, 30, and 60 min
after i.c.v. or i.t. injection of vehicle (saline) or N/OFQ (1 nmol) or
endomorphin-1 (3 nmol, only i.t.). Compound 24 (10 mg/kg) or its
vehicle (2% DMSO and 10% encapsin) were given i.p. 30 min before N/
OFQ or endomorphin-1 administration. Increased and decreased tail
withdrawal latencies compared with baseline indicated antinocicep-
tive and pronociceptive effects, respectively.
2.7. Drugs
The peptides used in this study were prepared and puriﬁed as
previously described (Guerrini et al., 1997). [D-Pen2,D-Pen5]enkepha-
lin (DPDPE) and endomorphin-1 were purchased from NeoMPS
(Strasbourg, France). Compound 24 was synthesized in house
following the procedures described in detail by Goto et al. (2006)
with little modiﬁcation. The structure and purity (N99%) of Com-
pound 24 was conﬁrmed by HPLC, mass spectrometry, proton and
carbon NMR and polarimetry.Fig. 1. Left panel: concentration response curves to N/OFQ obtained in the absence (control) a
binding assay performed on CHOhNOP cell membranes. The relative Schild Plot is shown in tAll tissues culture media and supplements were from Invitrogen
(Paisley, UK). [35S]GTPγS (1250 Ci/mmol) and [3H]DPN were from
Perkin Elmer Life Sciences and [3H]N/OFQ (75–133 Ci/mmol) from
Amersham Biosciences. All other reagents were from Sigma Chemical
Co. (Poole, U.K.) or E. Merck (Darmstadt, Germany) and were of the
highest purity available.
For in vitro experiments Compound 24 was solubilized in dimethyl
sulfoxide at a ﬁnal concentration of 10 mM, and the successive
dilutions were made in saline, whereas the other compounds were
solubilized distilled water; stock solutions were kept at −20 °C until
use. For in vivo studies, Compound 24 was dissolved in 2% DMSO and
10% encapsin (hydroxypropyl-beta-cyclodextrin) just before perform-
ing the experiment.
2.8. Data analysis and terminology
All data are expressed as means±standard error of the mean
(S.E.M.) of n experiments. For potency values 95% conﬁdence limits
were indicated. Data have been analyzed statistically using one-way
ANOVA followed by Dunnett's test for multiple comparisons. Receptor
binding data (Table 1) are expressed as pKi derived from the Cheng and
Prusoff (Cheng and Prusoff, 1973) equation:
pKi = IC50= 1 + R½ = Kdð Þð Þ
where [R] is the concentration of the radiolabel and Kd is the
radiolabel afﬁnity for the receptor under investigation. The [3H]N/OFQ
Kd was 83 pM while those of [3H]diprenorphine were 125, 323, and
134 pM at mu, delta, and kappa, respectively.
[35S]GTPγS data are expressed as a stimulation factor i.e., the ratio
between agonist-stimulated [35S]GTPγS speciﬁc (minus NSB) binding
and basal speciﬁc binding. Calciummobilization data are expressed as
ﬂuorescence intensity units (FIU) in percent over the baseline.
Isolated tissue data are expressed as percent of the twitch induced
by electrical ﬁeld stimulation.
Agonist potencies are given as pEC50=the negative logarithm to
base 10 of the molar concentration of an agonist that produces 50% of
the maximal possible effect. Concentration response curve to agonists
were ﬁtted with the following equation:
Effect = baseline + Emax − baselineð Þ
 1 + 10^ LogEC50 − Xð Þ4HillSlopeð Þð Þ
where X is the agonist concentration.
Antagonist potencies have been calculated in different ways. In
[35S]GTPγS binding (Fig. 1) andmouse vas deferens (Fig. 3) pA2 values
were derived from the classical Schild protocol. For rat vas deferensnd presence of increasing concentrations of Compound 24 (1–100 nM) in the [35S]GTPγS
he right panel. Data are mean±S.E.M. of 4 separate experiments.
Fig. 2. Concentration response curves to N/OFQ obtained in the absence (control) and
presence of increasing concentrations of Compound 24 (10 nM–1 µM) in the calcium
mobilization assay performed on CHOhNOP cells stably expressing the Gαqi5 protein.
Data are mean±S.E.M. of 4 separate experiments performed in duplicate. ⁎pb0.05
versus control according to ANOVA followed by Dunnett's test.
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from the Gaddum Schild equation:
KB = CR − 1ð Þ= antagonist½ ð Þ
assuming a slope value equal to unity, where CR indicate the ratio
between agonist potency in the presence and absence of antagonist.
For calcium mobilization experiments pKB values were derived from
inhibition response curves (Table 2) using the following equation:
KB = IC50 = 2 + A½ =EC50ð Þn
 1=n− 1

where IC50 is the concentration of antagonist that produces 50%
inhibition of the agonist response, [A] is the concentration of agonist,
EC50 is the concentration of agonist producing a 50% maximal
response and n is the Hill coefﬁcient of the concentration response
curve to the agonist (Kenakin, 2004). In addition the pKB for
Compound 24 evaluated at different concentrations against the
concentration response curve to N/OFQ (Fig. 2) was calculated using
the following equation:
KB = antagonist½ = slope − 1ð Þ
where slope is calculated from a double-reciprocal plot of equieffective
concentrations of agonist in the absence and presence of antagonist
(Kenakin, 2004).
For in vivo studies, raw data from tail withdrawal experiments
were converted to the area under the time versus tail withdrawal
latency curve (AUC min/s). AUC data for the time interval (0–15 and
0–30 min for i.c.v. and i.t. studies, respectively) was calculated and
used for statistical analysis.
3. Results
3.1. Receptor binding
In receptor binding experiments performed on CHOhNOP cell
membranes Compound 24 displaced [3H]N/OFQ in a concentration
dependent manner showing subnanomolar afﬁnity (pKi 9.62, Table 1).
Under the same experimental conditions, Compound 24 did not bind
the delta receptor and showed low afﬁnities for mu and kappa sites
(pKi 6.72 and 6.47, respectively). In contrast, the universal opioid
receptor ligand naloxone did not bind the NOP receptor while showed
the expected rack order of afﬁnity at classical opioid receptors i.e., mu
(pKi 9.25)Nkappa (pKi 8.35)Ndelta (pKi 7.67) (Table 1).
3.2. [35S]GTPγS binding
In CHOhNOP cell membranes N/OFQ stimulated [35S]GTPγS binding
in a concentration-dependent manner with a pEC50 value of 8.95±
0.05 and Emax of 11.71±0.37 (Fig. 1, left panel). The antagonistic
properties of Compound 24 were evaluated over the 1–100 nM
concentration range, in order to obtain data for a Schild analysis.
Compound 24 up to 10 µM did not elicit any stimulation of [35S]GTPγSTable 2
Antagonist potencies of Compound 24 and naloxone evaluated in calcium mobilization
experiments performed in CHO cells expressing NOP or classical opioid receptors and
the Gαqi5 protein.
Receptor NOP Mu Delta Kappa
Agonist N/OFQ
10 nM
Dermorphin
100 nM
DPDPE
100 nM
Dynorphin A
100 nM
Naloxone b6 9.09 (8.73–9.45) 7.32 (6.11–8.53) 7.14 (6.60–7.68)
Compound
24
9.03 (8.83–9.23) b6 b6 b6
Data are mean (CL95%) of 4 separate experiments.binding in CHOhNOP cell membranes, however it produced a
concentration dependent and parallel shift of the concentration
response curve to N/OFQ without modifying the maximal effects
induced by the agonist (Fig. 1, left panel). Schild analysis of the data
(Fig. 1, right panel) demonstrated a linear (r2=0.95) plot with a slope
not signiﬁcantly different from unity. The extrapolated pA2 value was
9.98.
3.3. Calcium mobilization
In CHOhNOP cells stably expressing the Gαqi5 chimeric protein N/
OFQ evoked a concentration dependent stimulation of calcium release
(pEC50 9.24 (CL95% 9.10–9.38)). Compound 24 was inactive per se but
in the range 0.01 nM–10 µM concentration-dependently inhibited
calcium mobilization induced by 10 nM N/OFQ with a pKB value of
9.03±0.20 (Table 2). Naloxone was inactive up to 1 µM. To assess the
selectively of action of Compound 24 similar experiments were
performed in CHO cells stably expressing Gαqi5 and classical opioid
receptors. Dermorphin, DPDPE and Dynorphin A were used in these
experiments as agonists for mu, delta and kappa receptors, respec-
tively. They produced a concentration dependent stimulation of
calcium with the following values of pEC50 and Emax:Dermorphin
7.93 (CL 95% 7.67–8.19),196±9%; DPDPE 8.82 (CL 95% 8.43–9.21),130±
10%; Dynorphin A 8.47 (CL 95% 8.16–8.78) 174±14%. Naloxone
inhibited the effects of these agonists showing higher potency at mu
(pKB 9.09) than kappa (pKB 7.14) and delta (pKB 7.32) (Table 2). In
contrast Compound 24 was inactive up to 1 µM against DPDPE,
Dynorphin A, and Dermorphin (Table 2).
To investigate the type of antagonism produced by Compound 24
in calcium mobilization experiments a Schild analysis has been
performed by testing this molecule at various concentrations (0.01, 0.1
and 1 µM) against the concentration-response curve to N/OFQ. As
shown in Fig. 2, Compound 24 produced a rightward shift of the
concentration-response curve to N/OFQ in a concentration dependent
manner. However, the maximal effects elicited by N/OFQ appear to be
slightly but signiﬁcantly reduced by Compound 24. A pKB value of 8.73
was derived from these experiments. It is worthy of mention that this
value is close to that obtained in inhibition response experiments
(9.03).
3.4. Electrically stimulated isolated tissue
Compound 24 was assessed against N/OFQ in the electrically
stimulated mouse and rat vas deferens and guinea pig ileum. In the
Fig. 3. Left panel: concentration response curves to N/OFQ obtained in the absence (control) and presence of increasing concentrations of Compound 24 (10 nM–1 µM) in the
electrically stimulated mouse vas deferens. The relative Schild Plot is shown in the right panel. Data are mean±S.E.M. of 4 separate experiments.
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ﬁeld stimulation in a concentration dependent manner (pEC50 value
7.46, Fig. 3 left panel). Compound 24, tested over the concentration
range 10 nM–1 µM, did not modify per se the electrically-induced
twitches, but displaced to the right the concentration response curve
to N/OFQ in a concentration dependent manner. Curves obtained in
the presence of Compound 24 were parallel to the control (Fig. 3, left
panel) with no modiﬁcation of the agonist maximal effect (this
parameter could not be estimated in the presence of Compound 24
1 µM because the concentration response curve to N/OFQ was still
incomplete at 10 µM concentration of peptide). The corresponding
Schild plot was linear (r2=1.00) with a slope not signiﬁcantly
different from unity, yielding a pA2 value of 8.44 (Fig. 3, right panel).
In the rat vas deferens and in guinea pig ileum Compound 24
was tested at the single concentration of 100 nM against the effects
of N/OFQ. In both preparations the concentration response curves
to N/OFQ obtained in the absence and presence of Compound 24
were parallel and reached similar maximal effects. The estimated
pKB values were 8.28±0.12 and 9.12±0.19 in the rat vas deferens
(Fig. 4, left panel) and guinea pig ileum (Fig. 4, right panel),
respectively. In these preparations, Compound 24 up to 1 µM was
per se inactive.
Finally, Compound 24 at 1 µM did not modify the inhibitory effects
of DPDPE in the mouse vas deferens (control: pEC50 (95% conﬁdence
limit) 8.38 (8.20–8.56), Emax, 98±1%; 1 µM Compound 24: pEC50 8.30
(7.80–8.80), Emax, 99±1%) or those evoked by Dermorphin in theFig. 4. Concentration response curves to N/OFQ obtained in the absence (control) and presen
guinea pig ileum (right panel). Data are mean±S.E.M. of 4 separate experiments.guinea pig ileum (control: pEC50 8.52 (8.35–8.69), Emax, 98±3%; 1 µM
Compound 24: pEC50, 8.51 (8.35–8.67), Emax, 95±3%).
3.5. Tail withdrawal assay
In tail withdrawal experiments, mice injected with vehicle (either
i.c.v. or i.t.) displayed tail withdrawal latencies of approximately 5 s
that were stable over the time course of the experiment (Fig. 5). In line
with previous studies, N/OFQ (1 nmol) applied i.c.v. signiﬁcantly
reduced tail withdrawal latency with a maximal effect (about 50%
reduction in tail withdrawal latency) obtained at 5 min (AUC[0–15 min]
vehicle 77±5; 1 nmol of N/OFQ 51±3, pb0.05). The i.p. administra-
tion of Compound 24 up to 10 mg/kg did not modify, per se, tail
withdrawal latencies (AUC[0–15 min], 80±7) but prevented the
pronociceptive effects of the natural peptide (AUC[0–15 min], 66±5)
(Fig. 5, left panel). On the other hand Compound 24 at 1mg/kg did not
modify the pronociceptive effect of i.c.v. N/OFQ (data not shown).
When the same dose of N/OFQ was administered i.t., a statistically
signiﬁcant antinociceptive effect was recorded (AUC[0–30 min] vehicle,
165±14; 1 nmol N/OFQ 346±25, pb0.05) (Fig. 5, right panel). This
antinociceptive effect was reduced by Compound 24 at 10 mg/kg
(AUC[0–30 min], 226±25) (Fig. 5, right panel) but not at 1 mg/kg (data
not shown).
In a separate set of experiments performed under the same experi-
mental conditions, the selective mu receptor agonist endomorphin-1
produced after i.t. injection a clear antinociceptive effect (AUC[0–30 min]ce of 100 nM Compound 24 in the electrically stimulated rat vas deferens (left panel) and
Fig. 5.Mouse tail withdrawal assay. Effects of Compound 24 (10mg/kg i.p., 30 min pre-treatment) on the pronociceptive or antinociceptive effects induced by 1 nmol N/OFQ injected
i.c.v. (left panel) or i.t. (right panel). Data are mean±S.E.M. of 4 separate experiments.⁎pb0.05 versus vehicle according to ANOVA followed by the Dunnett's test.
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mg/kg of Compound 24 did not produce any effect per se (AUC[0–30 min],
184±17) and did not affect the antinociceptive effects elicited by
endomorphin-1 (AUC[0–30 min], 352±35) (Fig. 6).
4. Discussion
The present study extend previous ﬁndings (Goto et al., 2006)
demonstrating that Compound 24 binds with high afﬁnity the NOP
receptor and behaves as a pure and potent NOP receptor antagonist
showing high selectivity over classical opioid receptor. These
pharmacological features of Compound 24were consistently observed
in various assays and preparations expressing the human recombinant
as well as the animal native receptors. In addition, the NOP selective
antagonist properties of Compound 24 have been conﬁrmed in vivo in
mice subjected to the tail withdrawal assay. Therefore Compound 24
represents a valuable research tool that should be included in the class
of selective NOP receptor antagonists and used in future target
validations studies.
In receptor binding studies Compound 24 displayed very high
afﬁnity for the NOP receptor; in fact, the pKi value calculated from the
present experiments (9.62) is virtually superimposable to that
previously reported by Goto et al. (2006) (pIC50 9.57). These values
of afﬁnity are similar to that reported for SB-612111 and higher than
that of J-113397 (Ozaki et al., 2000; Spagnolo et al., 2007; Zaratin et al.,
2004). In functional studies performed on the human recombinantFig. 6.Mouse tail withdrawal assay. Effects of Compound 24 (10 mg/kg i.p., 30 min pre-
treatment) on the antinociceptive effects induced by 3 nmol emdomophin-1 injected i.t.
Data are mean±S.E.M. of 4 separate experiments. ⁎pb0.05 versus vehicle according to
ANOVA followed by the Dunnett's test.receptor ([35S]GTPγS binding and calciummobilization assays) and on
animal native receptors from various species (mouse, rat, guinea pig)
Compound 24 consistently behaved as a pure NOP receptor antagonist
showing, in line with receptor binding studies, high values of potency
(range 8.28–9.12). The only result which was out of this range is that
obtained in [35S]GTPγS binding studies where Compound 24
displayed a pA2 of 9.98. However, this result, which is again
superimposable to that obtained by Goto et al. (2006)(pIC50 9.82), is
expected on the basis of what we have observed with several NOP
receptor antagonists, including the peptides [Nphe1]N/OFQ(1–13)
NH2 and UFP-101 (Calo et al., 2002a, 2005), and the non peptides J-
113397, Trap-101, and SB-612111 (Spagnolo et al., 2007; Trapella et al.,
2006), that consistently showed, in this particular assay, values of
potency approx 10 fold higher than in the other tests. As previously
suggested (Spagnolo et al., 2007), this might be due to the higher
receptor accessibility in membranes (where the [35S]GTPγS binding
assay is performed) than in whole cells or tissue preparations (where
the other assays are performed). Despite this minor difference, very
similar antagonist potency values were obtained in the different
assays for Compound 24 demonstrating the recombinant and native as
well as species-speciﬁc NOP receptors are similarly sensitive to this
antagonist. This also applies to the NOP receptors expressed in rat
periaqueductal gray slices (Yan-Yu and Chiou, 2008) and sympathetic
neurons (Ruiz-Velasco et al., 2008) although no quantitative data
were reported in these latter studies. The consistency of Compound 24
potency values among preparations and species corroborates previous
ﬁndings obtained with peptide (Calo et al., 2000, 2002a,b, 2005) and
non peptide (Bigoni et al., 2000; Ozaki et al., 2000; Spagnolo et al.,
2007; Trapella et al., 2006; Zaratin et al., 2004) NOP antagonists and
enable the following rank order of antagonist potency to be proposed:
Compound 24 (≈8.5)=SB-612111 (≈8.5)N J-113397 (≈8.0)NUFP-
101 (≈7.5) =Trap-101 (≈7.5)N [Nphe1]N/OFQ(1–13)NH2 (≈6.5) as
NOP receptor ﬁngerprint.
With respect to the type of antagonism exerted by Compound 24,
results obtained in the [35S]GTPγS binding and mouse vas deferens
assay by performing concentration response curve to N/OFQ in the
presence of increasing concentrations of antagonist are clearly
compatiblewith a competitive type of interaction between Compound
24 and N/OFQ. Similar results were obtained by testing Compound 24
in the calcium mobilization assay where a rightward displacement of
the concentration response curve to N/OFQ was recorded in response
to increasing concentration of antagonist. However in these experi-
ments Compound 24 at the highest concentrations tested produced a
slight but statistically signiﬁcant reduction of N/OFQ maximal effect.
This apparent insurmountable antagonism behaviour can be attrib-
uted to i) the transient nature of the calcium response that may not
allow equilibrium between agonist–antagonist competition to be
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presence of high concentrations of antagonist (Kenakin, 2004), ii) lack
of stirring in the 96 well plate which is another source of
hemiequilibrium conditions (Kenakin, 2004), iii) a combination of
the two factors. The observation that a truly competitive antagonist
produces a reduction of agonist maximal effects in calcium mobiliza-
tion assay is not uncommon. For instance, the urotensin-II receptor
antagonists urantide and UFP-803 competitively antagonized the
contractile effects of urotensin-II in the rat aorta bioassay while
depressed maximal responses to the agonist in calcium experiments
performed on cells expressing the rat recombinant urotensin-II
receptor (Camarda et al., 2006). On this basis, we propose to classify
Compound 24 as a competitive NOP receptor antagonist.
Selectivity of action along with high afﬁnity/potency and pure
antagonist activity is another important feature of a valuable research
tool. This property of Compound 24 has been evaluated in three sets of
experiments over classical opioid receptors. In receptor binding
studies Compound 24 displayed approximately 1000 fold selectivity
over classical opioid receptors. A superimposable value of selectivity
was found in functional studies performed measuring calcium
mobilization in cells expressing the Gαqi5 chimeric protein. Finally
at least 300 fold selectivity of Compound 24 for NOP overmu and delta
receptors was obtained in bioassay experiments. These data conﬁrm
the impressive selectivity proﬁle of Compound 24 reported by Goto
et al. (2006). Thus, in terms of selectivity over classical opioid receptor
Compound 24 seems to be similar to SB-612111 (Spagnolo et al., 2007;
Zaratin et al., 2004) and UFP-101 (Calo et al., 2002b) and certainly
more selective then J-113397 (Ozaki et al., 2000; Spagnolo et al., 2007)
for which NOP independent effects were reported in vivo (Koizumi
et al., 2004). However more comprehensive selectivity studies are
needed against a large panel of receptors and ion channels to ﬁrmly
classifying Compound 24 as a highly selective NOP receptor
antagonist.
Collectively, these in vitro data conﬁrm and extend previous
ﬁndings (Goto et al., 2006) demonstrating that Compound 24 is a
pure, competitive, selective and potent NOP receptor antagonist. This
excellent in vitro pharmacological proﬁle is associated with good brain
penetration after peripheral administration (Goto et al., 2006).
Indeed, Compound 24 was reported to be active in vivo in mice
where at 10 mg/kg it prevented the inhibitory effects on locomotor
activity of a non peptide NOP agonist (Goto et al., 2006). Here we
assessed the in vivo effects of Compound 24 in the mouse tail
withdrawal assay. N/OFQ has been repeatedly demonstrated to exert
in rodents pronociceptive and antinociceptive effects following
supraspinal and spinal injection, respectively (Zeilhofer and Calo,
2003). The present results i.e., pronociceptive and antinociceptive
response to 1 nmol N/OFQ given i.c.v. and i.t., are therefore in linewith
the literature. Both of these in vivo actions of N/OFQ are due to
selective NOP receptor activation as consistently demonstrated by
knockout (Nazzaro et al., 2007; Nishi et al., 1997) and receptor
antagonist (UFP-101 (Calo et al., 2002b; Nazzaro et al., 2007), J-113397
(Ozaki et al., 2000; Ueda et al., 2000), SB-612111 (Rizzi et al., 2007;
Zaratin et al., 2004)) studies. In linewith these ﬁndings, Compound 24
at 10 mg/kg antagonised both the pronociceptive and antinociceptive
effects evoked by N/OFQ when given spinally and supraspinally,
respectively. Moreover, in line with in vitro ﬁndings, the antagonist
action of Compound 24 in vivo is selective for the NOP receptor as
demonstrated by the lack of effect of this molecule against the
antinociceptive effects elicited by spinal injection of the mu selective
agonist endomorphin-1. These results demonstrated, on the one hand,
that Compound 24 is an effective and selective antagonist at NOP
receptors regulating pain transmission in vivo and, on the other, that
the effects of N/OFQ on pain transmission are exclusively due to NOP
receptor activation. Interestingly, Compound 24 at 10 mg/kg counter-
acted rather than fully prevented the effects of 1 nmol N/OFQ. Under
the same experimental conditions SB-612111 completely blocked theactions of the same dose of N/OFQ at ten fold lower doses (i.e., 1 mg/
kg) (Rizzi et al., 2007). Therefore SB-612111 appeared to be more
potent than Compound 24 in vivo in the mouse tail withdrawal assay.
Since the in vitro potency of the two antagonists is similar (see above),
it can be proposed that in vivo potency differences may derive from
better pharmacokinetic properties of SB-612111 than Compound 24.
However, this is merely speculation that required rigorous experi-
mental validation. Finally, the systemic administration of Compound
24 at pharmacologically active doses did not modify per se tail
withdrawal latencies. Again this is in line with previous ﬁndings
obtained with both receptor antagonists (Ozaki et al., 2000; Rizzi
et al., 2007; Ueda et al., 2000; Zaratin et al., 2004) and mice knockout
for the NOP receptor gene (Nazzaro et al., 2007; Nishi et al., 1997), and
indicates that the endogenous N/OFQ-NOP receptor system is not
activated by the mild and acute stimulus employed for evoking the
nociceptive response in this assay. However the endogenous N/
OFQergic signalling can be activated using more intense and
prolonged nociceptive stimuli such as formalin. In fact in the mouse
formalin assay the spinal antinociceptive action of endogenous N/OFQ
seems to prevail on the supraspinal pronociceptive effect as indicated
by the pronociceptive phenotype of NOP knockoutmice (Depner et al.,
2003; Rizzi et al., 2006) (recently conﬁrmed in the acetic acid-induced
writhing test by Rizzi et al. (2008)) and by the pronociceptive effects
elicited by NOP antagonists e.g. systemic J-113397 (Rizzi et al., 2006).
In conclusion the present study demonstrated that Compound 24
is a pure, competitive, selective and potent NOP receptor antagonist.
The NOP antagonist properties of Compound 24were demonstrated in
a large panel of in vitro assays and in vivo in the mouse tail withdrawal
assay. Based on its pharmacological proﬁle Compound 24 should be
included (together with J-113397, SB-612111 and UFP-101) in the list
of potent and selective NOP receptor antagonists to be tested in future
target validation studies for ﬁrmly deﬁning their therapeutic potential
as innovative drugs for treating depression, Parkinson's disease and
possibly sepsis.
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a b s t r a c t
In this study we provided a pharmacological characterization of the recently synthesized noci-
ceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-
1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4) and
investigated its antiparkinsonian properties. GF-4 inhibited N/OFQ binding to CHOhNOP cell membranes
(pKi 7.46), and antagonized N/OFQ effects in a calcium mobilization assay and electrically stimulated
isolated tissues (pKB 7.27–7.82), showing a ∼5-fold selectivity over classical opioid receptors. In vivo,
GF-4 dually modulated stepping activity in wild-type mice, causing facilitation in the 0.01–10mg/kg
dose range and inhibition at 30mg/kg. These effects were mediated by NOP receptors since GF-4 was
ineffective in NOP receptor knock-out mice. Antiparkinsonian properties of GF-4 were investigated in
6-hydroxydopamine hemilesioned rats. GF-4 ameliorated akinesia, bradykinesia and overall gait ability
in the 0.1–10mg/kg dose range, but inhibited motor activity at 30mg/kg. To investigate the circuitry
underlying motor facilitating and inhibitory effects of GF-4, microdialysis coupled to behavioral testing
(akinesia test) was performed. An anti-akinetic dose of GF-4 (1mg/kg) reduced glutamate (GLU) and
enhanced GABA release in SNr, while the pro-akinetic dose of GF-4 (30mg/kg) evoked opposite effects.
Moreover, the anti-akinetic dose of GF-4 reduced GABA and increased GLU release in ventro-medial tha-
lamus, the pro-akinetic dose decreasing GABA without affecting GLU release in this area. We conclude
that GF-4 is an effective NOP r
via inhibition of the nigro-thal
Abbreviations: 6-OHDA, 6-hydroxydopamine; AP, antero-posterior; CHO,
hinese hamster ovary; DA, dopamine; DOP, delta opioid peptide; GLU, glu-
amate; J-113397, 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-
-ethyl-1,3-dihydro-2H-benzoimidazole-2-one; KOP, kappa opioid peptide; ML,
edio-lateral; MOP, mu opioid peptide; N/OFQ, nociceptin/orphanin FQ;
OP, nociceptin/orphanin FQ peptide; PD, Parkinson’s disease; SNc, sub-
tantia nigra pars compacta; SNr, substantia nigra pars reticulata; Trap-
01, 1-[1-(cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-
-ethyl-1,3-dihydro-2H-benzimidazol-2-one; VD, ventro-dorsal; VMTh, ventro-
edial thalamus.
∗ Corresponding author at: Department of Experimental and Clinical Medicine,
ection of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44100
errara, Italy. Tel.: +39 0532 455210; fax: +39 0532 455205.
E-mail address: m.morari@unife.it (M. Morari).
196-9781/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
oi:10.1016/j.peptides.2010.03.015eceptor antagonist able to attenuate parkinsonian-like symptoms in vivo
amic pathway.
© 2010 Elsevier Inc. All rights reserved.
1. Introduction
The neuropeptide nociceptin/orphanin FQ (N/OFQ; [27,34]) is
the endogenous ligand of the N/OFQ peptide (NOP) receptor and
participates in the regulation of a number of central biological
processes such as pain perception, food intake, learning, anxiety,
reward and locomotion [16]. Although most interest is focused on
therapeutic applications of NOP receptor agonists, evidence that
NOP receptor antagonists may also be useful in some patholog-
ical conditions such as depression [33] and Parkinson’s disease
(PD; [21,22]) has been presented. The NOP receptor is particularly
expressed in substantia nigra (SN) where dopamine (DA) neurons
degenerating in PD are located [21,28]. Interestingly, N/OFQ has
been shown to inhibit the activity of DA neurons in SN compacta
M. Volta et al. / Peptides 31
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hig. 1. Structure of 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-
etrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
SNc) at the same doses required to inhibit locomotion [19]. Con-
ersely, DA loss is associated with increased N/OFQ expression
nd release [2,8,21] suggesting that DA tonically inhibits N/OFQ
ransmission. This inhibitory relationship appears relevant for PD
ince NOP receptor antagonists such as the peptide UFP-101 [4]
nd the nonpeptide J-113397 [30] alleviated akinesia/bradykinesia
n haloperidol-treated or 6-hydroxydopamine (6-OHDA) hemile-
ioned rats [20–22]. Moreover, J-113397 attenuated motor deﬁcits
n MPTP-treated mice and nonhuman primates [40,42]. In order to
evelop novel nonpeptide NOP receptor antagonists, we consid-
red to modify the structure of the reference compound, J-113397,
rst obtaining Trap-101 [39]. In vitro, Trap-101 was found slightly
∼3-fold) less potent than but as selective (>100-fold) as J-113397
racemic mixture) for NOP versus the classical opioid receptors.
n vivo, Trap-101 promoted motor activity in 6-OHDA hemile-
ioned rats and potentiated the antiparkinsonian action of l-DOPA
23]. Moreover, consistently with results obtained with J-113397,
t inhibited glutamate (GLU) release and enhanced GABA release
n SNr, while reducing GABA release in ventro-medial thalamus
VMTh; [21,23]). Based on these ﬁndings, we modiﬁed Trap-101
tructure and introduced two methyl groups in the hydroxymethyl
unction at the carbon 3 of the piperidine ring, thus obtaining GF-4
Fig. 1).
In the present study we investigated in vitro pharmacologi-
al properties of GF-4 using receptor binding assays (in CHOhNOP
ell membranes), calcium mobilization assays (in CHOhNOP-Gqi5
ells) and electrically stimulated isolated tissues (mouse and rat
as deferens). In vivo selectivity of GF-4 was studied in NOP recep-
or knock-out mice (NOP−/−). The antiparkinsonian potential of
F-4 was investigated in 6-OHDA hemilesioned rats through a bat-
ery of previously validated behavioral tests: the bar, drag and
otarod tests [21–23,40]. Finally, to unravel the circuitry involved
n motor actions of GF-4, GABA and GLU release was monitored
n the lesioned SNr and ipsilateral VMTh in animals subjected to
icrodialysis and simultaneously performing the bar test.
. Materials and methods
Animals employed in this study (see below) were kept under
egular lightingconditions (12hdark/light cycle)with freeaccess to
oodandwater. Adequatemeasureswere taken tominimize animal
ain and discomfort. This study was compliant with the European
ouncil Directive of 24November 1986 (86/609/EEC) and approved
y the Ethical Committee of the University of Ferrara and Italian
inistry of Health (licence no. 194-2008-B)..1. In vitro studies
.1.1. Cell culture and membrane preparation
Chinese Hamster Ovary cells (CHO) stably expressing the
uman NOP receptor (CHOhNOP) were cultured in medium con-(2010) 1194–1204 1195
sisting of Dulbecco’s MEM/HAM’S F-12 (50/50) supplemented with
5% foetal calf serum (FCS), penicillin (100 IU/ml), streptomycin
(100g/ml), fungizone (2.5g/ml), geneticin (G418; 200g/ml)
and hygromycin B (200mg/ml) as described previously [25]. CHO
cell stocks expressing the human delta opioid peptide (DOP;
CHODOP), the mu opioid peptide (MOP; CHOMOP), or the kappa opi-
oid peptide (KOP; CHOKOP) receptors were maintained in Ham F12
containing 10% FCS, 100 IU/ml penicillin, 100g/ml streptomycin
and 400g/ml G418. Cell cultures were kept at 37 ◦C in 5% CO2
humidiﬁed air. In all cases experimental cultures were free from
selection agents (hygromycin B, G418). Cells were sub-cultured
with trypsin/EDTA and used for experimentation once conﬂuent
(3–4 days).
CHO cell lines stably co-expressing NOP receptors and the C-
terminally modiﬁed Gqi5 were generated as described in [3]. CHO
cell lines co-expressing MOP, DOP or KOP and Gqi5 were obtained
in similar way, as described in [9].
Membranes were prepared from freshly harvested cell suspen-
sions in Tris–HCl (50mM),Mg++ (5mM) pH7.4 via homogenization
andcentrifugationat13,500 rpmfor10minat4 ◦C. Theﬁnalprotein
concentration was determined according to [17].
2.1.2. Receptor binding experiments
[Leucyl-3H]N/OFQ binding: 5g of CHOhNOP homogenate
protein was incubated in 0.5ml of Tris–HCl (50mM) buffer sup-
plemented with 10M peptidase inhibitors (amastatin, bestatin,
captopril and phosphoramidon), 0.5% bovine serum albumin (BSA),
increasing concentrations of competing ligands and approximately
200pM [3H]N/OFQ. Total radiolabel bound was <10%. Non-speciﬁc
binding was determined in the presence of 1M unlabelled
N/OFQ. In all experiments, N/OFQ was included as a reference
ligand. Reactions were incubated for 1h at room temperature
and terminated by vacuum ﬁltration (Brandel Harvester) through
Whatman GF/B ﬁlters soaked in 0.5% polyethylenimine. Radioac-
tivity was determined after 8h extraction in scintillation cocktail.
[3H]Diprenorphine binding: 50g CHOhMOP, 25g CHOhDOP and
40g CHOhKOP membrane protein were incubated in 0.5ml
buffer containing Tris–HCl (50mM) pH 7.4, BSA (0.5%), ∼0.7nM
[3H]Diprenorphine and increasing concentrations of competing
ligands. Non-speciﬁc binding was determined in the presence of
10M naloxone. Reactions were incubated at room temperature
for 1h. Harvesting and determination of radioactivity were as for
[Leucyl-3H]N/OFQ binding.
2.1.3. Calcium mobilization experiments
CHOhMOP, CHOhDOP, CHOhKOP andCHOhNOP stably expressing the
Gqi5 protein were seeded at a density of 40,000 cells/well into
96-well black, clear-bottom plates. After 24h incubation, the cells
were loadedwithmedium supplementedwith 2.5mMprobenecid,
3M of the calcium sensitive ﬂuorescent dye Fluo-4 AM and 0.01%
pluronic acid, for 30min at 37 ◦C. Afterwards the loading solu-
tion was aspirated and 100l/well of assay buffer Hank’s Balanced
Salt Solution (HBSS) supplemented with 20mM HEPES, 2.5mM
probenecid and 500M Brilliant Black (Aldrich) was added. Serial
dilutions of ligands for experimental useweremade inHBSS/HEPES
(20mM) buffer (containing 0.02% BSA fraction V). After placing
both plates (cell culture and compound plate) into the FlexSta-
tion II (Molecular Device, Union City, CA 94587, US), ﬂuorescence
changes were measured at room temperature. On-line additions
were carried out in a volume of 50l/well.2.1.4. Electrically stimulated isolated tissues
Tissues were taken from male Swiss mice (30–35g) and
Sprague–Dawley rats (300–350g). The mouse and rat vas deferens
were prepared as previously described [1]. Tissueswere suspended
in 5ml organ baths containing heated Krebs solution (composition
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n mM: NaCl 118.5, KCl 4.7, KH2PO4 1.2, NaHCO3 25, glucose 10
nd CaCl2 2.5 for mouse and 1.8 for rat tissues) oxygenated with
5% O2 and 5% CO2. The bath temperature was set at 33 ◦C for
ousevasdeferens and37 ◦C for rat vasdeferens. Tissueswere con-
inuously stimulated through two platinum ring electrodes with
upramaximal rectangular pulses of 1ms duration and 0.05Hz fre-
uency. A resting tension of 0.3 and 1g was applied to the mouse
nd rat vas deferens, respectively. The electrically evoked contrac-
ions (twitches) were measured isotonically with a strain gauge
ransducer (Basile 7006, Ugo Basile s.r.l., Varese, Italy) and recorded
ith the PC based acquisition system Power Lab (ADInstrument,
SA).
Following an equilibration period of 60min, the contractions
nduced by electrical ﬁeld stimulation were stable. At this time,
umulative concentration–response curves to N/OFQ were per-
ormed (0.5 log unit steps) in the absence or presence of the
ntagonist under investigation (15min pre-incubation time).
.2. In vivo studies
.2.1. Naïve mice
To investigate the in vivo speciﬁcity of GF-4, motor activity was
valuated in CD1/C57BL6J/129 NOP+/+ and NOP−/− mice (25–30g;
2–15weeksold; [21]) bymeansof thedrag test. This testmeasures
he ability of the animal to balance its body posture with forelimbs
n response to an externally imposed dynamic stimulus (dragging
ackwards; [21]), and is a modiﬁcation of the ‘wheelbarrow test’
36]. It gives information regarding the time to initiate (akinesia)
nd execute (bradykinesia) a movement. The animal was gently
ifted from the tail allowing the forepaws to rest on the table, and
ragged backwards at a constant speed (about 20 cm/s) for a ﬁxed
istance (100 cm). The number of steps made with each paw was
ecorded by two distinct observers.
.2.2. 6-OHDA hemilesioned rats
.2.2.1. 6-OHDA lesion. Unilateral lesion of DA neurons [21] was
nduced in isoﬂurane-anesthetized male Sprague–Dawley rats
150g; Harlan Italy; S. Pietro al Natisone, Italy). Eight micrograms
f 6-OHDA (in 4l of saline containing 0.02% ascorbic acid) were
tereotaxically injected according to the following coordinates
rom bregma: AP=−4.4mm, ML=−1.2mm, VD=−7.8 below dura
32]. The rotational model was used to select the rats which had
een successfully lesioned. Two weeks after surgery, rats were
njected with amphetamine (5mg/kg i.p., dissolved in saline) and
nly those rats performing >7 ipsilateral turns/min were enrolled
n the study. This behavior has been associated with >95% loss of
triatal extracellular DA levels and tyrosine-positive terminals [22].
xperiments were performed 6–8 weeks after lesion.
.2.2.2. Behavioral analysis. Motor activity was evaluated in 6-
HDAhemilesioned rats bymeans of three behavioral tests speciﬁc
or different motor abilities, as previously described [21,22]: the
ar, drag and rotarod test. The three tests were repeated in a ﬁxed
equence (bar, drag and rotarod) before and after drug injection
starting at 15 and at 70min after treatment). Animalswere trained
or approximately 10 days to the speciﬁc motor tasks until their
erformance became reproducible.
.2.2.3. Bar test. Originally developed to quantify morphine-
nduced catalepsy [15], this test measures the ability of the animal
o respond to an externally imposed static posture.
The rat was placed gently on a table and forepaws were placed
lternatively on blocks of increasing heights (3, 6 and 9 cm). The
ime (in s) that each paw spent on the block (i.e. the immobility
ime) was recorded (cut-off time of 20 s).(2010) 1194–1204
2.2.2.4. Drag test. This test was performed as described above (in
mice).
2.2.2.5. Rotarod test. The ﬁxed-speed rotarod test [35] measures
different motor parameters such as motor coordination, gait abil-
ity, balance, muscle tone and motivation to run. It was employed
according to a previously described protocol [19]. Brieﬂy, rats were
tested in a control session at four increasing speeds (15, 20, 25
and 30 rpm; 180 s each), causing a progressive decrement of per-
formance to ∼40% of the maximal response (i.e. the experimental
cut-off time).
2.2.2.6. Microdialysis. Two microdialysis probes (1mm dialyzing
membrane, AN69, Hospal, Bologna, Italy) were implanted in the
lesioned SNr (AP −5.5, ML −2.2, VD −8.3) and ipsilateral VMTh (AP
−2.3, ML −1.4, VD −7.4) of isoﬂurane-anesthetized hemiparkin-
sonian rats. Twenty-four hours after implantation, probes were
perfused (3l/min) with a modiﬁed Ringer solution (in nM: CaCl2
1.2; KCl 2.7; NaCl 148 andMgCl2 0.85) and sample collection (every
15min) started after a 6–7h wash-out period. GF-4 was adminis-
tered systemically (i.p.) and GLU and GABA levels were monitored
for 90min. At the end of the experiments ratswere killed and probe
location veriﬁed by microscopic examination.
2.2.2.7. Behavioral testing during microdialysis. To correlate
changes of amino acid dialysate levels with motor activity, rats
undergoing microdialysis were challenged in the bar test [20,22]
every 15min. The bar test was performed essentially as described
above. Rat forepaws were placed alternatively on blocks of increas-
ing heights (3, 6 and 9 cm) and the immobility time was recorded
(cut-off time of 20 s).
2.2.2.8. Amino acid analysis. GLU and GABA levels in the dialysate
were measured by HPLC coupled to ﬂuorometric detection
[22]. Brieﬂy, 40l samples were pipetted into glass microvials
and placed in a thermostated (4 ◦C) Triathlon autosampler
(Spark Holland, Emmen, The Netherlands). Thirty-ﬁve l of o-
phthaldialdehyde/mercaptoethanol reagent were added to each
sample, and 60l of the mixture injected onto a Chromsep ana-
lytical column (3mm inner diameter, 10 cm length; Chrompack,
Middelburg, TheNetherlands). The columnwas eluted at aﬂowrate
of 0.48ml/min (Beckman 125 pump; Beckman Instruments, Fuller-
ton, CA, USA)with amobile phase containing 0.1M sodium acetate,
10% methanol and 2.5% tetrahydrofuran (pH 6.5). GLU and GABA
were detected bymeans of a Jasco ﬂuorescence spectrophotometer
FP-2020 Plus (Jasco, Tokyo, Japan). GLU and GABA retention times
were 3.5±0.2 and 18±0.5min, respectively. The limit of detection
was about 1nM for GLU and 0.5nM for GABA.
2.3. Data presentation, statistical analysis and terminology
For in vitro experiments data are expressed asmeans± standard
error of the mean (SEM) of n experiments. For potency values
95% conﬁdence limits were indicated. Receptor binding data are
expressed as pKi derived from the Cheng and Prusoff [5] equation:
pKi =
IC50
1 + ([R]/Kd)
where [R] is the concentration of the radiolabel and Kd is
the radiolabel afﬁnity for the receptor under investigation. The
Kd of [3H]N/OFQ at NOP receptors was 83pM while those of
[3H]Diprenorphine at MOP, DOP, and KOP receptors were 125, 323,
and 134pM, respectively [13].
Calcium mobilization data are expressed as ﬂuorescence inten-
sity units (FIUs) in percent over the baseline. Isolated tissues data
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re expressed as percent of the twitch induced by electrical ﬁeld
timulation.
Agonist potencies are given as pEC50 = the negative logarithm to
ase 10 of the molar concentration of an agonist that produces 50%
f the maximal possible effect. Concentration response curves to
gonists were ﬁtted with the following equation:
ffect = baseline + (Emax − baseline)
(1 + 10ˆ((log EC50 − X) × HillSlope)
here X is the agonist concentration.
For isolated tissues experiments antagonist potencies were
erived from the Gaddum Schild equation:
B =
CR − 1
[antagonist]
ssuming a slope value equal to unity, where CR indicates the
atio between agonist potency in the presence and the absence
f antagonist. For calcium mobilization experiments, pKB values
ere derived from inhibition response curves using the following
quation:
B =
IC50
(2 + ([A]/EC50)1/n − 1
here IC50 is the concentration of antagonist that produces 50%
nhibition of the agonist response, [A] is the concentration of ago-
ist, EC50 is the concentration of agonist producing a 50% maximal
esponse and n is the Hill coefﬁcient of the concentration response
urve to the agonist [12].
For in vivo experiments,motor performancehas been calculated
s time spent on bar or on rod (in s) and number of steps (drag test)
nd expressed as percent of the control session. In microdialysis
tudies, GLU and GABA release has been expressed as percent-
ge± SEM of basal values (calculated as mean of the two samples
efore the treatment).
Statistical analysis has been performed on percent data by two-
ay repeated measure (RM) analysis of variance (ANOVA). In case
NOVA yielded to a signiﬁcant F score, post hoc analysis has been
erformed by contrast analysis to determine group differences.
n case a signiﬁcant time x treatment interaction was found, the
equentially rejective Bonferroni’s test was used (implemented on
xcel spreadsheet) to determine speciﬁc differences (i.e. at the
ingle time point level) between groups. P values <0.05 were con-
idered to be statistically signiﬁcant.
.4. Materials
Amphetamine and 6-OHDA were purchased from Sigma
hemical Company (St. Louis, MO, USA). GF-4 (1-[1-cyclo-
ctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-
yridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one) was
ynthesized in our laboratories by modiﬁcation of the last step
f the Trap-101 (1-[1-(cyclooctylmethyl)-1,2,3,6-tetrahydro-
-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-benzi-
idazol-2-one) synthesis [39]. In particular, methyl magnesium
romidewasused insteadof lithyumaluminiumhydride to produce
able 1
eceptor binding proﬁle of GF-4 to human recombinant NOP, MOP, DOP, and KOP recepto
pKi values (CL95%)
CHOhNOP CHOhMOP
N/OFQ Endomorphin-1
Standard ligand 9.27 (9.07–9.47) 8.41 (8.15–8.67)
GF-4 7.46 (7.09–7.83) 6.78 (6.57–6.99)(2010) 1194–1204 1197
the tertiary alcohol. The peptides used in this study were prepared
and puriﬁed as previously described [11]. [D-Pen2,5]enkephalin
(DPDPE) was purchased from NeoMPS (Strasbourg, France). All
tissues culturemedia and supplementswere from Invitrogen (Pais-
ley, UK). [3H]Diprenorphine was from Perkin-Elmer Life Sciences
and [3H]N/OFQ (75–133Cimmol−1) from Amersham Biosciences.
All other reagents were from Sigma Chemical Company or Merck
(Darmstadt, Germany) and were of the highest purity available.
For in vitro experiments, stocks solutions (10mM) of J-113397
(1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-
ethyl-1,3-dihydro-2H-benzimidazol-2-one), Trap-101 and GF-4
were made in dimethyl sulfoxide, and ﬁnal concentrations reached
with saline; the other compounds were solubilized in distilled
water. Stock solutions were kept at −20 ◦C until use.
For in vivo experiments drugs were freshly dissolved in isoos-
motic saline solution just prior to use. GF-4 was vortexed and
sonicated until fully dissolved.
3. Results
3.1. In vitro studies
3.1.1. Receptor binding assay
In receptor binding experiments performed on CHOhNOP
cell membranes, GF-4 displaced [3H]N/OFQ in a concentration-
dependent manner showing afﬁnity in the nanomolar range (pKi
7.46, Ki 34.7nM; Table 1). In parallel experiments, the nonpeptide
antagonists J-113397 and Trap-101 displayed pKi values of 8.58 (Ki
2.6nM) and 8.36 (Ki 4.4nM). Under the same experimental condi-
tions, GF-4 showed lower afﬁnities for MOP (pKi 6.78, Ki 166.0nM)
and KOP (pKi 6.84 and Ki 144.5nM) receptors and did not bind to
the DOP receptor (Table 1).
3.1.2. Calcium mobilization assay
In CHOhNOP cells stably expressing the Gqi5 chimeric protein,
N/OFQ evoked a concentration-dependent stimulation of calcium
release displaying high potency (pEC50 9.24; CL95% 9.10–9.38) and
efﬁcacy (∼200% over the basal values; Fig. 2A).
J-113397, Trap-101 and GF-4 did not evoke calcium release up
to 10M. Inhibition response experiments were then performed
by challenging increasing concentrations of J-113397, Trap-101
and GF-4 (10 pM-10M) against a ﬁxed concentration of N/OFQ
(10nM), close to its EC80. As shown in Fig. 2B-D, J-113397, Trap-
101 and GF-4 were able to inhibit in a concentration-dependent
manner the stimulatory effect of N/OFQ, showing similar pKB val-
ues of 7.88, 7.93 and 7.27, respectively (see also Table 2; J-113397
data not shown).
To assess the in vitro selectivity of GF-4, similar experiments
were performed in CHO cells stably expressing Gqi5 and classi-
cal opioid receptors (Fig. 3). Dermorphin, DPDPE and Dynorphin A
were used as agonists for MOP, DOP and KOP receptors, respec-
tively. They evoked concentration-dependent calcium rise with
the following pEC50 and Emax values: Dermorphin 7.93 (CL95%
7.67–8.19), 196±9%; DPDPE 8.82 (CL95% 8.43–9.21), 130±10%;
Dynorphin A 8.47 (CL95% 8.16–8.78) 174±14%. GF-4, inactive up
to 10M against DPDPE and Dynorphin A, inhibited the effect of
rs expressed in CHO cells. Data are mean (CL95%) of three separate experiments.
CHOhDOP CHOhKOP
Naltrindole Norbinaltorphimine
9.46 (9.12–9.80) 9.93 (9.8–10.06)
<6 6.84 (6.52–7.16)
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Fig. 2. GF-4 inhibited N/OFQ-induced calcium mobilization. Concentration–response curve to N/OFQ in calcium mobilization experiments performed in CHOhNOP cells stably
expressing the Gqi5 protein (A). N/OFQ effect was expressed as percent over the baseline. Inhibition experiments obtained by challenging 10nMN/OFQ with increasing
concentrations of J-113397 (B), Trap-101 (C) and GF-4 (D). Data are means± SEM of four separate experiments performed in duplicate.
Table 2
Antagonist potencies (pKB values) of naloxone, Trap-101 and GF-4 evaluated in calcium mobilization experiments performed in CHO cells expressing NOP or classical opioid
receptors (MOP, DOP and KOP) and the Gqi5 protein. Data are mean (CL95%) of 4 separate experiments.
NOP MOP DOP KOP
N/OFQ 10nM Dermorphin 100nM DPDPE 100nM Dynorphin A 100nM
9.45)
6.58)
6.89)
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(22.2±0.8 steps) paw so data were pooled together. GF-4 given i.p.
dually modulated motor activity in NOP+/+ mice, facilitating step-
ping activity in the 0.01–10mg/kg dose range and inhibiting it at
30mg/kg. The facilitation induced by the 0.01mg/kg dose was only
Table 3
Antagonist potencies (pKB values) of J-113397, Trap-101 and GF-4 against N/OFQ in
the electrically stimulated mouse and rat vas deferens.
Electrically stimulated tissuesNaloxone <6 9.09 (8.73–
Trap-101 7.93 (7.25–8.61) 6.24 (5.90–
GF-4 7.27 (6.69–7.85) 6.48 (6.07–
ermorphin with pKB value of 6.48. In parallel experiments, Trap-
01 inhibited the effect of Dermorphinwith a similar potency value
pKB 6.24; Fig. 3, Table 2). Naloxone was inactive up to 10M
gainstN/OFQand inhibited theeffects of the classical opioid recep-
or agonists with higher potency at MOP (pKB 9.09) than KOP (pKB
.14) or DOP (pKB 7.32) receptors (Table 2).
.1.3. Electrically stimulated isolated tissues
J-113397, Trap-101 and GF-4 were assessed against N/OFQ in
he electrically stimulated mouse and rat vas deferens. N/OFQ
nhibited the twitch response to electrical ﬁeld stimulation in
concentration-dependent manner in both the mouse (pEC50
.55, Emax 76±2%; Fig. 4A–C) and rat (pEC50 7.51, Emax 78±2%;
ig. 4D–F) vas deferens. The NOP receptor antagonists did not
odify the electrically induced twitch response up to 1M.
hen tested at 100nM, they produced a rightward shift ofhe concentration–response curve to N/OFQ without signiﬁcantly
ffecting the maximal agonist response both in the mouse and rat
as deferens. The pKB values for J-113397, Trap-101 and GF-4 were
.13, 7.46 and 7.82 in the mouse (Fig. 4; Table 3) and 7.37, 7.53 and
.30 in the rat (Fig. 4; Table 3), respectively.7.32 (6.11–8.53) 7.14 (6.60–7.68)
<6 <6
<6 <6
3.2. In vivo studies
3.2.1. Effects of GF-4 on motor activity in naïve mice
To investigate the in vivo selectivity of GF-4, NOP+/+ and NOP−/−
mice were challenged in the drag test (Fig. 5). Basal motor activity
in naïve mice was similar at the left (23.1±0.9 steps) and rightMouse vas deferens Rat vas deferens
pKB pKB
J-113397 8.13 (7.69–8.57) 7.37 (6.88–7.86)
Trap-101 7.46 (6.97–7.92) 7.53 (6.73–8.33)
GF-4 7.82 (7.61–8.03) 7.30 (6.58–8.02)
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aig. 3. High concentrations of GF-4 inhibited calcium mobilization induced by MO
ermorphin (A–C), DPDPE (D–F) and Dynorphin A (G–I) with increasing concentr
xpressing the classical opioid receptors (CHOhMOP; CHOhKOP; CHOhDOP) and the G
etected 15min after injection. The effects of higher doses were
onger lasting anddetectedup to90minafter injection.GF-4, tested
nly at high doses (10 and 30mg/kg), was ineffective in NOP−/−
ice.
.2.2. Effects of GF-4 on motor activity in 6-OHDA hemilesioned
ats
To investigatewhetherGF-4 has antiparkinsonian potential, GF-
was administered systemically (i.p.) to 6-OHDA hemilesioned
ats and motor activity evaluated by the bar, drag and rotarod
ests (Fig. 6). 6-OHDA lesioning producedmotor asymmetrymostly
ffecting the paw contralateral to the 6-OHDA injection side.
ndeed, the immobility time (bar test, in s) and the number of
teps (drag test) were 27.6±3.9 and 11.4±0.7 at the ipsilateral
aw, and 37.7±3.5 and 3.8±0.6 at the contralateral one. Overall
otarod performance (0–55 rpm range) of 6-OHDA hemilesioned
ats (537±112.5 s) was also reduced compared to sham-operated
nimals (1176±64 s; [23])ot DOP or KOP receptors. Inhibition experiments obtained by challenging 100nM
of Trap-101 and GF-4 in the calcium mobilization assay performed in CHO cells
tein. Data are mean± SEM of four separate experiments performed in duplicate.
In the bar test (Fig. 6A), GF-4 (0.1–30mg/kg) dually affected the
immobility time at the contralateral paw 15min after injection,
reducing it at 1 and 10mg/kg and increasing it at 30mg/kg. After
70min from administration, only motor facilitation induced by the
1mg/kg dose was detected. GF-4 also affected the immobility time
at the ipsilateral paw, causing a short-lasting increase at 30mg/kg.
In the drag test (Fig. 6B), GF-4 produced a long lasting increase in
stepping activity at the contralateral paw in the 0.1–10mg/kg dose
range and a long lasting reduction at 30mg/kg. GF-4 also elevated
stepping activity at the ipsilateral paw at 10mg/kg and reduced it
at 30mg/kg. Finally, GF-4 dually modulated rotarod performance
(Fig. 6C), causing improvement at 1 and 10mg/kg and inhibition at
30mg/kg.3.2.3. Effects of GF-4 on nigral and thalamic amino acid levels in
6-OHDA hemilesioned rats
To investigate the neuronal circuitry underlying motor actions
of GF-4, microdialysis was performed in rats undergoing the bar
1200 M. Volta et al. / Peptides 31 (2010) 1194–1204
Fig. 4. GF-4 counteracted N/OFQ inhibition of the electrically induced contraction in mouse and rat vas deferens. Concentration–response curves to N/OFQ, obtained in the
absence and presence of 100nM J-113397, Trap-101 and GF-4, in the electrically stimulated mouse (A–C) and rat (D–F) vas deferens. Values are means± SEM of four separate
experiments.
Fig. 5. GF-4 dually modulated motor activity in naïve NOP+/+ mice, being ineffective in NOP−/− mice. GF-4 was administered systemically (i.p.) and motor activity evaluated
in the drag test. Each experiment consisted of three different sessions: a control session followed by two other sessions performed 15 and 90min after saline or GF-4
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Gdministration (see Section 2). Data are expressed as percentages of motor activity i
ctivity values in the drag test are given in text (Section 3.2.1). Statistical analysis w
onferroni’s test. p** < 0.01 signiﬁcantly different from saline.
est. GF-4 was administered systemically (i.p.) at low (1mg/kg),
otor facilitating, and high (30mg/kg), motor inhibitory, doses.
mino acid release was monitored in SNr and ipsilateral VMTh
imultaneouslywithbehavioral testing.GF-4 (1mg/kg) caused long
asting reduction of immobility time at the contralateral (Fig. 7A)
ut not ipsilateral (Fig. 7B) forepaw in the bar test. The higher dose
f GF-4 (30mg/kg) had the opposite effect, namely an increase in
he time spent on the blocks with both the contralateral (Fig. 7A)
nd ipsilateral (Fig. 7B) paws. The percentage increase was greater
t the ipsilateral paw possibly due to lower immobility time (i.e.
ess akinesia) compared to the contralateral one.
The anti-akinetic dose of GF-4 (1mg/kg) increasedGABA release
Fig. 8A) and reduced GLU release (Fig. 8B) in SNr while the
ro-akinetic dose (30mg/kg) had opposite effects. Finally, the anti-
kinetic dose of GF-4 reduced GABA release (Fig. 8C) and increased
LU release (Fig. 8D) in VMTh while the pro-akinetic dose elevated
ABA release but did not affect GLU release in this area.control session and are means± SEM of 6–9 determinations per group. Basal motor
formed by RM-ANOVA followed by contrast analysis and the sequentially rejective
4. Discussion
GF-4 is a novel NOP receptor antagonist generated from the
Trap-101 structure. In vitro, GF-4 antagonized N/OFQ actions
at human recombinant and rodent native NOP receptors in a
concentration-dependent andcompetitivemanner (pKB 7.27–7.88)
without exerting primary effects. The afﬁnity at recombinant NOP
receptors (∼35nM, pKi 7.45) is ∼100-fold lower than those of the
most potent nonpeptide NOP receptor antagonists thus described,
namely Compound 24 (0.27nM; [10]) and SB-612111 (0.33nM;
[43]), ∼10-fold lower than that of J-113397 and Trap-101 (see also
[30,38,43]) and closer to that of JTC-801 (8.2nM [37]; 30.8nM
[43]). In vitro potency values in recombinant and native prepa-
rations are in line with this rank order, although the differences
are less pronounced. For instance, in calcium mobilization assay,
GF-4 was ∼57-fold less potent than Compound 24 [9] and ∼5-fold
less potent than Trap-101. In the mouse vas deferens, GF-4 was
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Fig. 6. GF-4 attenuated motor deﬁcits in 6-OHDA hemilesioned rats. GF-4
(0.1–30mg/kg) was administered systemically (i.p.) and motor activity evaluated
in the bar (A), drag (B) and rotarod (C) tests. Each experiment consisted of three
different sessions: a control session followed by two other sessions performed 15
and 70min after saline or GF-4 administration (see Section 2). Data are expressed
as percentages of motor activity in the control session and are means± SEM of 6–8
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Fig. 7. Systemic GF-4 modulated akinesia in animals undergoing microdialysis.
Hemiparkinsonian rats implanted in SNr and VMTh were challenged in the bar test
(described in Section 2) following systemic administration (i.p., arrow) of saline
(n=7) or GF-4. Both motor facilitating (1mg/kg; n=8) and inhibitory (30mg/kg;
n=8) doses of GF-4 were administered. Akinesia was evaluated at the contralateral
and ipsilateral forepaws every 15min for up to 90min. Data are expressed as mean
percentages± SEM of baseline motor activity. Basal activity levels at the ipsilateraleterminations per group. Basal motor activity values in the bar, drag and rotarod
ests are given in text (Section 3.2.2). Statistical analysis was performed by RM-
NOVA followed by contrast analysis and the sequentially rejective Bonferroni’s
est. *p<0.05 and **p<0.01 signiﬁcantly different from saline.
nly ∼5-fold less potent than SB-612111 [38] and Compound 24
9], and ∼2-fold less potent than J-113397. In this preparation, GF-
was found ∼2-fold more potent than Trap-101 (see also [39])
hile in the rat vas deferens the reverse was true, Trap-101 being
ore potent than GF-4. Since no species differences with respect
o responsiveness to NOP receptor ligands have been observed in
hese preparations, it is likely that these slight discrepancies in
otency are due to experimental variability. Therefore, Trap-101
nd GF-4 can be considered equipotent in isolated tissues. Orig-
nal binding and functional experiments in recombinant systems
30] revealed that J-113397 is at least 350-fold selective over MOP
nd >1000-fold selective over DOP and KOP receptors. More recent
tudies [38,43], conﬁrmed the high selectivity over DOP recep-
ors but found the selectivity over KOP (30-fold) and, particularly,
OP (∼10–15-fold) receptors to be much lower than previously
eported. Introduction of a double bond in the J-113397 molecule
i.e. elimination of chirality) did not change selectivity as shown
y a comparative study between J-113397 and Trap-101 [39]. Con-
ersely, the introduction of a tertiary alcohol function had dramaticand contralateral forepaw were 8.5±0.4 and 39.8±1.4 s, respectively. Statistical
analysis was performed by RM-ANOVA followed by contrast analysis. **p<0.01,
signiﬁcantly different from saline.
effects, since selectivityoverMOPreceptorsdropped from∼49-fold
(Trap-101) to ∼6-fold (GF-4). This ﬁnding questions about the use-
fulness of GF-4 in in vitro experiments. However, despite its poor
in vitro selectivity, GF-4 was selective for NOP receptors in mice
in vivo up to 30mg/kg. Interestingly, as previously shown for J-
113397 [40] and Trap-101 [23], GF-4 was able to exert dual control
over stepping activity, namely facilitation at low doses and inhi-
bition at high ones, through blockade of NOP receptors. In fact, no
motor changes were observed in NOP−/− mice following admin-
istration of high doses of GF-4. No major differences in efﬁcacy
were found among J-113397, Trap-101 and GF-4. Nevertheless,
these compounds showed different potencies and ranges of activ-
ity. Thus, facilitation was observed in the 0.1–1mg/kg dose range
for J-113397 [40], in the 1–10mg/kg dose range for Trap-101 [23]
and in the 0.01–10mg/kg dose range for GF-4. Despite the lower-
ing of threshold formotor facilitation, GF-4 inhibitedmotor activity
in the same range of doses as J-113397 (10mg/kg) and Trap-101
(30mg/kg). Thus, structural changeswidened themotor facilitating
dose range without changing the threshold for motor inhibition.
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Fig. 8. Systemic GF-4 modulated GLU and GABA release in SNr and ipsilateral VMTh. Two microdialysis probes were implanted in the lesioned SNr and ipsilateral VMTh of
hemiparkinsonian rats, and GABA (A and C) and GLU (B and D) release monitored while rats were undergoing the bar test (see Fig. 7). Rats were treated systemically (i.p.,
arrow) with saline (n=6) or motor facilitating (1mg/kg; n=7) and inhibitory (30mg/kg; n=8) doses of GF-4. Data are expressed as mean percentages± SEM of pre-treatment
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abasal) values. Basal GLU and GABA levels (nM) in the dialysate from the lesioned SN
2.8±8.2, 4.4±0.3 (GF-4 30mg/kg). Basal GLU and GABA levels (nM) in the dialysat
6.3±1.7 (GF-4 1mg/kg); 92.2±13.7, 19.2±0.7 (GF-4 30mg/kg). Statistical analy
igniﬁcantly different from saline.
t is possible these changes may be related to pharmacokinetic rea-
ons, such as greater brain penetrability or resistance to metabolic
egradation.
Consistent with that found in mice, GF-4 was found more
otent than expected on the basis of the in vitro data in 6-
HDA hemilesioned rats. Previous studies in this model showed
hat NOP receptor antagonists such as the peptide UFP-101 and
he nonpeptides J-113397 and Trap-101 [21–23] mimicked the
ffects of l-DOPA and attenuated parkinsonian-like motor impair-
ent. In these studies, J-113397 promoted motor activity in
he 0.1–3mg/kg dose range, being ∼10 times more potent than
rap-101 (1–30mg/kg; [21–23]), and caused motor inhibition at
0mg/kg [40]. The dose response curve to GF-4 thus overlaps
hat to J-113397, with the difference that highest potency was
bserved in the drag and not bar test, as for J-113397. This dif-
erence may rely on experimental reasons since rats treated with
-113397 showed a slightly greater immobility time at the con-
ralateral paw (∼50 s; [21,22]) than rats treated with Trap-101
∼44 s) or GF-4 (∼37 s), although no difference was observed in
asal stepping activity at the contralateral paw between groups
∼2–3 steps). Alternatively, this difference may reﬂect a different
bility of J-113397 and GF-4 to discriminate between NOP recep-
ors modulating akinesia (bar test) rather than bradykinesia (drag
est).
Previous microdialysis studies carried out with a number of
eptide ([Nphe1]N/OFQ(1-13)-NH2; UFP-101) and nonpeptide (J-
13397, Trap-101) NOP receptor antagonists, given systemically or
erfused into SNr, have pointed out that NOP receptor blockade
n SNr caused inhibition of GLU release. This effect was observed
n naïve [18], haloperidol-treated [20,21] and 6-OHDA hemile-
ioned [21–23] rats. Inhibition of GLU release in parkinsonian
nimals correlated with attenuation of akinesia, suggesting thatre, respectively: 80.9±28.7, 3.2±0.8 (saline); 85.1±23.7, 5.7±0.6 (GF-4 1mg/kg);
the ipsilateral VMTh were, respectively: 71.5±19.9, 19.2±0.7 (saline); 53.7±6.1,
s performed by RM-ANOVA followed by contrast analysis. *p<0.05 and **p<0.01
normalization of pathologically elevated nigral GLU transmission
is the mechanism underlying the antiparkinsonian action of NOP
receptor antagonists [19,21,22]. Nevertheless, the ﬁnding that J-
113397, Trap-101 and, now, GF-4 also elevated GABA release in
SNr simultaneously reducing GABA release in ipsilateral VMTh
suggests that their antiparkinsonian action is the results of a
combined reduction of excitatory GLU inputs and enhancement
of inhibitory GABA inputs upon nigro-thalamic GABA neurons.
Reduction of GABA inﬂuence over thalamic ﬁlter is expected to
cause thalamic disinhibition [7], i.e. increased activity of thalamo-
cortical pathways leading to increased motor cortical output. The
novel ﬁnding that the anti-akinetic dose of GF-4 elevated GLU
release in VMTh, conﬁrms this view. Indeed, the main source of
GLU release in VMTh is represented by cortico-thalamic projec-
tions [26] and an increase in thalamic GLU release may lead to
motor activation [14]. Alternatively, increased GLU release may
arise from disinhibition of GLU nerve terminals from an inhibitory
intrathalamic GABAergic tone (possibly mediated by GABAB recep-
tors; [29]). The failure of 30mg/kg GF-4 to affect GLU release
in spite of increasing GABA release may be related to the satu-
ration of inhibitory presynaptic GABA receptors caused by tonic
activity of nigro-thalamic neurons. Thus, further increases in nigro-
thalamic activity and GABA release would not cause GLU release
inhibition.
The neurobiological mechanisms underlying the dual action of
NOP receptor antagonists on motor activity and neurotransmit-
ter release in SNr and VMTh are presently under investigation.
Different populations of NOP receptors located along functional
opposing motor pathways, in the same or different brain areas,
may be affected at different doses of GF-4. The different sensitiv-
ity to GF-4 may rely on receptor saturation by endogenous N/OFQ,
afﬁnity for GF-4 (splice variants of the NOP receptors have been
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eported [6,31]) or relevance of the targeted pathway in motor
ehavior. Alternatively, an ingravescent blockade of a single pop-
lation of NOP receptors may trigger biochemical/neurochemical
vents leading to an initialmotor facilitation (lowantagonist doses)
ollowed by inhibition (higher antagonist doses). Based on the ﬁnd-
ngs that: (i) themotor inhibition inducedbyhighdoses of J-113397
10mg/kg) in MPTP-treated mice was reversed into facilitation by
he D2/D3 receptor antagonist raclopride [41], and (ii) NOP recep-
or antagonists elevate striatal DA release [19] we put forward
he hypothesis that high doses of NOP receptor antagonist inhibit
ovement via stimulation of D2 receptors [41]. To which extent
his holds true also in 6-OHDA rats, i.e. rats bearing almost com-
lete destruction of the nigro-striatal DA projection, it remains to
e established.
. Concluding remarks
GF-4 is a Trap-101 derivative obtained by introducing two
ethyl groups in the hydroxymethyl function at the position 3 of
he piperidine nucleus. Such chemical modiﬁcation did not alter
he pharmacological activity of the compound (a pure and compet-
tive NOP receptor antagonist) but slightly reduced its potency at
ecombinant NOP receptors and, more dramatically, in vitro selec-
ivity over classical opioid receptors. Nevertheless, GF-4 was NOP
eceptor selective in vivo, replicating the antiparkinsonian effect
nd neurochemical changes typical of its parent compounds, and
eing as potent as J-113397. Further studies are needed to elucidate
hether the in vivo gain in potency is due to greater metabolic sta-
ility, possibly to greater resistance to cytochrome oxidation [24]
s predicted on the basis of the structural changes made [39]. The
resent data offer new insights into the structural requirements for
ptimal antagonist activity at NOP receptors and selectivity over
lassical opioid receptors. Moreover, they conﬁrm that NOP recep-
or antagonists are able to attenuate parkinsonian-like symptoms
ia re-setting of GLU and GABA inputs upon nigro-thalamic GABA
rojection neurons [21–23].
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Neuropeptide S (NPS) regulates various biological functions by selectively activating the NPS receptor
(NPSR). Previous studies demonstrated that the non-peptide molecule SHA 68 acts as a selective NPSR
antagonist. In the present study the pharmacological proﬁle of SHA 68 has been further investigated in
vitro and in vivo. In cells expressing the mouse NPSR SHA 68 was inactive per se up to 10M while
it antagonized NPS-stimulated calcium mobilization in a competitive manner showing a pA2 value of
8.06. In the 10–50mg/kg range of doses, SHA 68 counteracted the stimulant effects elicited by NPS, but
not those of caffeine, in mouse locomotor activity experiments. In the mouse righting reﬂex assay SHAPS receptor
HA 68
alcium assay
n vivo studies
68 fully prevented the arousal-promoting action of the peptide. The anxiolytic-like effects of NPS were
slightly reduced by SHA 68 in the mouse open ﬁeld, fully prevented in the rat elevated plus maze and
partially antagonized in the rat defensive burying paradigm. Finally, SHA 68 was found poorly active in
antagonizing theNPS inhibitory effect onpalatable food intake in rats. In all assays SHA68didnot produce
any effect per se. In conclusion, the present study demonstrated that SHA 68 behaves as a selective NPSR
antagonist that can be used to characterize the in vivo actions of NPS. However the usefulness of this
y its presearch tool is limited b
. Introduction
Neuropeptide S (NPS, human sequence SFRNGVGTGMKKTS-
QRAK) is the endogenous ligand of the 7TM receptor NPSR [39,45].
n cells expressing the recombinantNPSR, NPS displayedhigh afﬁn-
ty and stimulated calcium mobilization and cAMP accumulation
uggestingGqandGs coupling for theNPSR [35,45]. In vitro, inbrain
issuepreparations,NPShasbeenreported tocontrolneuronal elec-
rophysiological properties [19,25] and neurotransmitter release
34]. In vivo, in rodents, NPS has been shown to control several
iological functions including wakefulness [6,37,45], locomotor
ctivity [8,15,30,37,41,45], stress andanxiety [22,30,37,44,45], food
ntake and gastrointestinal functions [3,9,11,17,41], memory pro-
esses [18,19,25,27], drug abuse [2,7,24,30], and nociception [23].
o deeply investigate these NPS-sensitive biological functions and
∗ Corresponding author. Tel.: +39 0532 455 221; fax: +39 0532 455 205.
E-mail address: g.calo@unife.it (G. Calo’).
196-9781/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
oi:10.1016/j.peptides.2010.02.012oor pharmacokinetic properties.
© 2010 Elsevier Inc. All rights reserved.
to identify the therapeutic potential of drugs interactingwithNPSR,
potent and selective ligands are required (for a recent review in this
ﬁeld see [16]).
SHA 68, i.e. the racemic mixture (9R/S)-3-oxo-1,1-diphenyl-
tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-ﬂuoro-
benzylamide has been identiﬁed by Takeda researchers [12]
and characterized pharmacologically in vitro and in vivo by
Okamura et al. [28]. In radioligand ([125I][Tyr10]NPS) binding
experiments performed in HEK293hNPSR cells SHA 68 displayed
high afﬁnity (pKi 7.3). In calcium mobilization experiments SHA
68 was inactive per se while antagonizing NPS stimulatory effects
in a concentration-dependent and competitive manner. Similar
high pA2 values were obtained with SHA 68 at Ile107 (7.6) and
Asn107 (7.8) hNPSR isoforms expressed in HEK293 cells. SHA 68
appeared to be selective for NPSR since it did not affect signaling
at 14 unrelated G-protein-coupled receptors [28]. In vivo in mice
SHA 68 reached pharmacologically relevant levels in plasma and
brain after i.p. administration. Despite this, SHA 68 (50mg/kg i.p.)
was only able to partially counteract NPS-induced stimulation
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f locomotor activity [28]. In a separate study [19], bilateral
ntra-amygdala administrations of SHA 68 exerted functionally
pposing responses compared to NPS: in fact the peptide induced
nxiolytic-like effects in the open ﬁeld test while anxiogenic-
ike effects were measured in response to SHA 68. Finally, NPS
reatment attenuated MK-801-induced vacuolization in the rat
etrosplenial cortex and this protective effect of NPS could be
locked by systemic administration of SHA 68 [29].
In the present study the pharmacological proﬁle of SHA 68 was
urther investigated in vitro in calcium mobilization experiments
erformed on HEK293 cells expressing the mouse NPSR and in vivo
n a rather large panel of assays sensitive to NPS including locomo-
or activity (LA), righting reﬂex (RR) and open ﬁeld behavior (OF)
n mice, and elevated plus maze (EPM), defensive burying (DB) and
alatable food intake (PFI) paradigms in rats.
. Materials and methods
.1. Cell culture and calcium mobilization experiments
HEK293mNPSR were generated as previously described [35] and
aintained inDMEMmedium supplementedwith 10% fetal bovine
erum, 2mM l-glutamine, hygromycin B (100mg/l), and cultured
t 37 ◦C in 5% CO2 humidiﬁed air. HEK293mNPSR cells were seeded
t a density of 50,000 cells/well into poly-d-lysine coated 96-well
lack, clear-bottom plates.
The following day, the cells were incubated with medium
upplemented with 2.5mM probenecid, 3M of the calcium
ensitive ﬂuorescent dye Fluo-4 AM and 0.01% pluronic acid,
or 30min at 37 ◦C. After that time the loading solution was
spirated and 100l/well of assay buffer (Hank’s Balanced Salt
olution; HBSS) supplemented with 20mM 4-(2-hydroxyethyl)-
-piperazineethanesulfonic acid (HEPES), 2.5mM probenecid and
00MBrilliant Black (Aldrich)was added. Concentrated solutions
1mM) of NPS were made in bidistilled water and kept at −20 ◦C.
HA 68 was dissolved in 10% Tween 80 solution in saline. Serial
ilutions were carried out in HBSS/HEPES (20mM) buffer (con-
aining 0.02% bovine serum albumin fraction V). After placing both
lates (cell culture and master plate) into the ﬂuorometric imag-
ng plate reader FlexStation II (Molecular Devices, Sunnyvale, CA),
uorescence changes were measured. On-line additions were car-
ied out in a volume of 50l/well. To facilitate drug diffusion into
he wells in antagonist type experiments, the present studies were
erformed at 37 ◦C and three cycles ofmixing (25l from eachwell
oved up and down 3 times) were performed immediately after
ntagonist injection to the wells. Inhibition response curves were
etermined against the stimulatory effect of 30nM NPS. SHA 68
as injected into the wells 24min before adding NPS.
.2. Animals
All experimental procedures adopted for in vivo studies com-
lied with the standards of the European Communities Council
irectives (86/609/EEC) and national regulations (D.L. 116/92).
ale Swiss mice (30–38g, Morini RE, Italy) and male Wistar
ats (200g for DB and EPM studies and 300g for PFI studies,
harles River MI, Italy) were used. They were housed in Plexiglas®
ages (Tecniplast, MN, Italy), under standard conditions (22 ◦C, 55%
umidity, 12h light–dark cycle, lights on 7.00 am) with food (mice:
IL, standard diet Morini RE, Italy, rats: 4RF, Mucedola, Settimo
ilanese, MI, Italy) and water ad libitum for at least 5 days before
xperiments began. Each animal was used only once, with the
xception of PFI studies. NPS was given intracerebroventricularly
i.c.v.), while SHA 68 was injected intraperitoneally (i.p.) 10min
efore NPS. In mice, i.c.v. injections (2l per mouse) were given1 (2010) 915–925
under light (just sufﬁcient to produce a loss of the righting reﬂex)
isoﬂurane anesthesia, into the left ventricle according to the pro-
cedure described by [21] and routinely adopted in our laboratory
[36]. For i.c.v. injections in rats, stainless-steel guide cannula (23ga)
(Plastic One, Roanoke, VA, USA) were stereotaxically implanted in
the right lateral ventricle, to a depth of 0.5mm above the ventricle
(coordinates were taken from the rat brain atlas [32] and adjusted
for theanimal bodyweight), underketamineplusxylazine anesthe-
sia (115+2mg/kg i.p.; Farmaceutici Gellini, Aprilia, Italy and Bayer,
Milan, Italy, respectively) and ﬁxed in place with acrylic dental
cement and one skull screw. A removable plug was kept in place
except during the drug injections. In rats i.c.v. injections were in
a volume of 5l. After the end of the experiment, rats were i.c.v.
injected with 5l of Evans Blue and sacriﬁced under anesthesia.
The correct placement of the cannula was ascertained by inspec-
tion of dye diffusion in the right lateral ventricle. All procedures
were randomized across test groups.
2.3. Mouse locomotor activity
Experiments were performed during the light cycle (between
09.00 and 13.00) according to [15]. Naïve mice were treated i.c.v.
5min before the beginning of the test and LA was recorded for
60min. For these experiments the ANY-maze video tracking sys-
tem was used (Ugo Basile, application version 4.52c Beta). Mice
werepositioned ina squareplastic cage (40 cm×40 cm), onemouse
per cage. Four mice were monitored in parallel. Mouse horizon-
tal activity was monitored by a camera while vertical activity was
measured by an infrared beam array. The parameters measured
were cumulative distance traveled (total distance in m that the
animal traveled during the test), immobility time (the animal is
considered immobile when 90% of it remains in the same place
for a minimum of 2.5 s), and the number of rearings (the number
of beam breaks due to vertical movements). Previous studies per-
formed under the present experimental conditions demonstrated
that NPS-stimulated LA in a dose-dependent manner [15]; from
these studies the dose of 0.1nmol was selected as the lower dose
inducing statistically signiﬁcant effects. SHA 68 (10 and 50mg/kg,
i.p.) was administered 10min before NPS (0.1nmol, i.c.v.). In a sep-
arate series of experiments, to investigate the selectivity of action
of SHA 68, the NPSR antagonist (at 50mg/kg, 10min pretreatment)
was tested against the stimulatory effect of caffeine (20mg/kg, i.p.).
Caffeine was administered 5min before recording LA.
2.4. Mouse righting reﬂex recovery
This assay was performed according to the procedures pre-
viously described in detail [37]. Brieﬂy, mice were given an i.p.
injection of diazepam (15mg/kg). When the animals lost the RR,
they were placed in a plastic cage and the time was recorded
by an expert observer blind to drug treatments. Animals were
judged to have regained the RR response when they could right
themselves three times within 30 s. Sleep time is deﬁned as the
amount of time between the loss and regaining of the RR and was
rounded to the nearest minute. Previous studies performed under
the present experimental conditions demonstrated that NPS facil-
itated RR recovery in a dose-dependent manner [37]; from these
studies the dose 0.1nmol was selected as the lower dose inducing
statistically signiﬁcant effects. SHA 68 (10 and 50mg/kg, i.p.) was(0.1nmol) 5min before the injection of diazepam. In a separate
series of experiments in order to investigate in detail the possible
effects of the NPSR antagonist on benzodiazepine-induced sleep,
SHA 68 (50mg/kg, i.p.) was injected 10min before the administra-
tion of different doses (5, 10, and 15mg/kg) of diazepam.
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.5. Mouse open ﬁeld
Miceweremoved to the testing roomtoacclimate thedaybefore
he test. This assaywasperformedusing theANY-mazevideo track-
ng system (Ugo Basile, application version 4.52c Beta). Brieﬂy the
ouse was placed in a square plastic cage (40 cm×40 cm) and
mbulatory behavior was monitored for 10min. The central zone
f the open ﬁeld was deﬁned as the central 20 cm×20 cm square.
orizontal activity was monitored by a camera. Four mice were
onitored in parallel in each experiment. The parameters mea-
ured were the number of entries in the central zone and the time
pent by the animal in the central area of the ﬁeld. An entry in the
entral zone occurred when the entire area of the animal was in
he central square and the time in the central zone is deﬁned as
he amount of time in seconds that the animal spent in the central
quare. In the ﬁrst series of experiments the dose response curve to
PS (0.01, 0.1 and 1nmol)was evaluated. In these experimentsNPS
as given i.c.v. 15min before starting the test. From these studies
he dose of 0.1nmol was selected as the lower dose inducing sta-
istically signiﬁcant effects. In the second series of experiments,
he effects of SHA 68 per se and vs NPS 0.1nmol was evaluated. In
hese experiments SHA68 (50mg/kg, i.p.)was administered10min
eforeNPS, and thepeptidewasgiven i.c.v. (0.1nmol)15minbefore
tarting the test.
.6. Rat elevated plus maze
The rat EPM assay was carried out as previously described
43]. The rat EPM consisted of two open arms and two enclosed
rms each measuring 55 cm×10 cm, with black wooden ﬂoors,
manating from a common central platform (10 cm×10 cm) to
orm a plus shape. The open arms were bounded by 1 cm high
edges on the sides, but there were no ledges at the ends of
he arms. The closed arms had 40 cm high transparent Plexiglas
alls. The maze was elevated 80 cm above the ground. The rats
ere brought to the room in a clear plastic neutral box measur-
ng 32 cm×22 cm×11 cm. Five days after surgery, each animal
as treated with saline or increasing doses of NPS (0.1–10nmol,
.c.v.) and submitted to the EPM 15min thereafter. For antagonism
xperiments, SHA 68 (25–50mg/kg, i.p.) or its vehicle was admin-
stered 10min before NPS. Caffeine (20mg/kg, i.p.) and diazepam
1.5mg/kg, i.p.), injected 30min before the assay, were used in
arallel experiments as standard anxiogenic and anxiolytic drug,
espectively. The animal was placed in the center of the maze (cen-
ral platform=arena) facing an open arm and its behavior recorded
yanexpert groupofexperimenters, unawareof the treatments, for
period of 5min. At the end of each test, the animal was removed
nd the maze ﬂoor was thoroughly cleaned. The time spent in open
rms and the number of open arm entries (deﬁned as the move-
ents of all four paws from one arm to another) were recorded
33].
.7. Rat defensive burying
This assay was performed according to the procedures previ-
usly described in details [44]. A rectangular Plexiglas burying
pparatus consisting of an acrylic cage (27 cm×38 cm×38 cm),
ith the ﬂoor covered with ﬁne sawdust, was used. A continuously
lectriﬁed probe consisting of wires wrapped around a wooden
owel was positioned in the apparatus so that it protruded 10.3 cm
nto the chamber and was 7.5 cm from the bottom of the cham-
er. Contact with the probe produced a shock of 1mA. Bedding in
he chamber was approximately 5.0 cm in depth. After recovery
rom surgery, animals were habituated (three to four cagemates
ogether) to the apparatus, in the absence of the shock probe, for
min each day for 4 consecutive days. On the ﬁfth day, rats were1 (2010) 915–925 917
tested individually for 15min with the electriﬁed probe in place.
The height of bedding behind the probe was measured before test-
ing and at the end of each 30min test period and was expressed
as the height of bedding above the 5.0 cm of bedding already
placed in the chamber. Fresh bedding was placed in the appara-
tus before testing each animal. Behavior during the 30min test
periodwas recordedand later scoredby two independentobservers
unaware of the treatments. Behaviors measured were height of
buried bedding, duration of burying behavior, and duration of
immobility/freezing over the entire test period. In particular, the
cumulative time of burying behavior has been suggested to reﬂect
the rat anxiety levels in a speciﬁcmanner [42]. Previous studiesper-
formed under the present experimental conditions demonstrated
that NPS produced anxiolytic-like effects in this assay in a dose-
dependent manner [44]; from these studies the dose of 1nmol was
selected as the lower dose inducing statistically signiﬁcant effects.
Rats were treated and submitted to the test following the same
experimental procedures described for EPM experiments.
2.8. Rat palatable food intake
Experiments began 1 week after surgery and were performed
during the light phase of the light/dark cycle. Before the begin-
ning of the experiments, animals received i.c.v. injections of saline
to habituate them to the drug administration procedure. Palatable
food was prepared by mixing powdered normal dehydrated food
pellets, sweet condensed milk (Argenti Srl, Ponte Felcino, Perugia,
Italy) and water in the respective percent ratio: 50%, 33% and 17%.
To habituate animals to palatable food consumption, a group of
freely fed rats (n=8) received 4 palatable 1-h food meals. Three-
day intervals were allowed between palatable food presentations.
Once stable palatable food intake was established according to a
within subject design, animals were treated with SHA 68 (25 and
50mg/kg, i.p.) or its vehicle 10min before the i.c.v. injection of NPS
or saline. Normal food chow was removed from the animal cages
immediately before drug treatment and was returned to them at
the end of the experiment. Drug treatments were performed at
intervals of 3–4 days. Palatable food intake was measured at 15,
30 and 60min by weighing the food cups and taking into account
spillage. Water was offered in graduated drinking tubes, and its
intakewas recordedat the same timeas food intake. Foodandwater
intakes were expressed as g/kg to correct for the inﬂuence of body
weight differences.
2.9. Drugs and reagents
NPSwas synthesized according to publishedmethods [38] using
Fmoc/tBu chemistry with a SYRO XP multiple peptide synthesizer
(MultiSyntech, Witten Germany). Crude peptides were puriﬁed
by preparative reversed-phase HPLC and the purity checked by
analytical HPLC and mass spectrometry using a matrix-assisted
laser desorption ionization time of ﬂight (Bruker BioScience, Biller-
ica, MA, US) and an ESI Micromass ZMD-2000 mass spectrometer
(Waters Corporation, Milford, MA, US). SHA 68 was synthesized
using the procedures described by Okamura et al. [28]. All other
reagents, including caffeine and diazepam, were purchased from
Sigma Chemical Co (St Louis, MO, USA). The vehicle used for inject-
ing NPS was saline. For in vivo studies, SHA 68 was dissolved in
saline containing10%cremophorEL (Sigma) and3and1ml/kgwere
injected i.p. in mice and rats, respectively.2.10. Terminology and statistical analysis
The pharmacological terminology adopted in this paper is con-
sistent with IUPHAR recommendations [26]. In vitro data were
expressed as mean± sem of at least four independent experiments
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ade in duplicate. Maximum change in ﬂuorescence, expressed
n percent of baseline ﬂuorescence, was used to determine ago-
ist response.Non-linear regression analysis usingGraphPadPrism
oftware (v.4.0) allowed logistic iterative ﬁtting of the resultant
esponses and the calculation of agonist potencies and maximal
ffects. Agonist potencies are given as pEC50 (the negative loga-
ithm to base 10 of the molar concentration of an agonist that
roduces 50% of the maximal possible effect). SHA 68 antago-
ist properties were ﬁrst evaluated in inhibition experiments; the
ntagonist potency was expressed as pKB derived from the follow-
ng equation:
B =
IC50
(2 + ([A]/EC50)n)1/n − 1
here IC50 is the concentration of antagonist that produces 50%
nhibition of the agonist response, [A] is the concentration of ago-
ist, EC50 is the concentration of agonist producing a 50% maximal
esponse and n is the Hill coefﬁcient of the concentration response
urve to the agonist [20].Moreover to investigate the type of antag-
nism exerted by SHA 68 at NPSR the classical Schild protocol was
erformed; in this case the antagonist potency was expressed as
A2.
In vivo data are expressed as mean± sem of n animals. Data
ere analyzed using Students’ t-test, one-way ANOVA followed by
he Dunnett’s post hoc test, or two-way ANOVA followed by the
onferroni post hoc test as speciﬁed in ﬁgure legends. Differences
ere considered statistically signiﬁcant when p<0.05.
. Results
.1. Calcium mobilization assay
In the calcium mobilization assay performed on HEK293mNPSR
ells, NPS increased the intracellular calcium concentrations in
concentration-dependent manner with pEC50 and Emax values
f 8.30 and 236±15% over the basal values, respectively. Inhibi-
ion response curve to SHA 68 (0.01nM–10M) were performed
gainst the stimulatory effect of 30nM NPS, approximately cor-
esponding to the EC80 value for the agonist. As shown in Fig. 1,
HA 68 concentration-dependently inhibited 30nM NPS stimula-
ory effects with a pIC50 value of 7.37. A pKB value of 7.74 (CL95%
.44–8.04) was derived for SHA 68 from these experiments.In order to investigate the nature of the antagonist action
xerted by SHA 68 the classical Schild analysis was performed. As
epicted in Fig. 2 left panel, SHA 68 in the range of 10–1000nM
id not produce any effect per se but displaced the concentration
esponse curve to NPS to the right in a concentration-dependent
ig. 2. Calcium mobilization assay performed on HEK293mNPSR cells. The left panel shows
resence of increasing concentrations of SHA 68 (10–1000nM). The corresponding Schil
ade in duplicate. *p<0.05 vs control, according to ANOVA followed by Dunnett’s test foFig. 1. Calcium mobilization assay performed on HEK293mNPSR cells.
Inhibition–response curve to SHA 68 against the stimulatory effect of NPS
30nM. Data are mean± sem of 4 separate experiments made in duplicate.
and parallel manner. A slight but signiﬁcant depression of NPS
Emax was recorded in the presence of the highest concentrations of
antagonist (i.e. 100 and 1000nM). The corresponding Schild plot,
which was linear (r2 =0.97) with a slope of 1.00±0.18, is shown in
the right panel of Fig. 2. The extrapolated pA2 value was 8.06.
3.2. Mouse locomotor activity
As shown in Fig. 3 and in line with previous ﬁndings [37], NPS
injected i.c.v. at 0.1nmol evoked a stimulatory effect on mouse LA
by increasing cumulative distance traveled by the animals and their
numberof rearings, and reducing the total immobility time, in a sta-
tistically signiﬁcantmanner. SHA68 at 50mg/kg did notmodify per
se the animal behavior (Fig. 3). When challenged with NPS, SHA 68
at 10mg/kg displayed a trend toward inhibition of the stimulatory
effects evoked by the peptide. Statistically signiﬁcant effects were
obtained with SHA 68 50mg/kg (Fig. 3) although the antagonist did
not fully prevented the effects elicited by the peptide.
the concentration–response curve to NPS obtained in the absence (control) and in
d plot is shown in the right panel. Data are mean± sem of 4 separate experiments
r multiple comparisons.
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In order to investigate the in vivo selectivity of action of SHA
8, the NPSR antagonist was tested against the effect of caffeine
n LA experiments. Caffeine at 20mg/kg evoked a clear stimula-
ory effect on mouse locomotor activity by increasing cumulative
istance traveled by the animals and reducing the total time immo-
ile, in a statistically signiﬁcantmanner. SHA68 at 50mg/kgdidnot
ffect the stimulatory effects of caffeine (Fig. 4).
.3. Mouse righting reﬂex recovery
As shown in Fig. 5 and in line with previous ﬁndings [6,37],
.p. injection of diazepam at the hypnotic dose of 15mg/kg pro-
uced loss of the RR in all treated mice and approximately 100min
ere needed to regain this reﬂex. NPS injected i.c.v. at 0.1nmol
educedboth thepercent of animals responding to diazepambelow
5% and their sleep time to approximately 50min. The administra-
ion of SHA 68 (10 and 50mg/kg) did not signiﬁcantly modify the
ypnotic effect of diazepam either in terms of percent of animals
osing the RR or duration of their sleep time (Fig. 5). When SHA 68
10mg/kg) was co-administered with 0.1nmol NPS, it prevented
he NPS-mediated reduction in the percent of mice responding to
iazepam but did not modify their sleep time. On the contrary, SHA
8 50mg/kg fully prevented the arousal promoting effect of NPS; in
act results obtained inmice treatedwithNPSplus SHA6850mg/kg
ere superimposable to those of vehicle-treated animals (Fig. 5).
In order to investigate the possible effects of the NPSR antag-nist on the hypnotic action of diazepam, a separate series of
xperiments were performed by testing SHA 68 50mg/kg against
ifferent doses of the benzodiazepine. As shown in Fig. 6, 5mg/kg
iazepam was inactive in the RR paradigm. At 10mg/kg the benzo-
iazepine produced loss of the RR in 70% of the treated mice andtraveled is shown in the top left panel,while the other panels display the cumulative
e immobile (bottom left panel), and number of rearings (bottom right panel) over
ice per group). *p<0.05 vs control, #p<0.05 vs NPS 0.1nmol according to two-way
approximately 25min were needed to regain the reﬂex. Diazepam
at 15mg/kg produced loss of the RR in all treated mice and their
sleep time was approximately 110min. At 50mg/kg SHA 68 did
not modify the dose response curve to diazepam; in fact superim-
posable resultswere obtained in animals treatedwith saline or SHA
68 both in terms of percent of animals losing the RR and regarding
their sleep time (Fig. 6).
3.4. Mouse open ﬁeld
In a ﬁrst series of experiments the dose response curve to NPS
was assessed inmice subjected to the openﬁeld assay.Mice treated
with saline spent on average 18 s in the central zone and made
14 entries over the 10min observation period (Fig. 7). Supraspinal
administrationofNPS (0.01–1nmol) increased inadose-dependent
and statistically signiﬁcant manner the number of entries into the
central zone and the time spent by the animals in this area of the
ﬁeld (Fig. 7). From these experiments the NPS dose of 0.1nmol was
selected to be challenged with SHA 68. As shown in Fig. 8, SHA 68
50mg/kg did not signiﬁcantly modify per se the behavior of mice
subjected to the OF assay. Moreover, SHA 68 50mg/kg only coun-
teracted the effects elicited by NPS on time in the central area but
not on the number of entries (Fig. 8).
3.5. Rat elevated plus mazeIn the elevated plus maze test, rats injected with saline spent
approximately 20% of the time in the open arms and made on aver-
age 3 entries into open arms (Fig. 9). Under the same experimental
conditions caffeine (20mg/kg, i.p.) evoked clear anxiogenic-like
effects, reducing in a statistically signiﬁcant manner both the time
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Fig. 4. Effects of caffeine and SHA 68 on mouse locomotor activity. Time course of the distance traveled is shown in the top left panel, while the other panels display the
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eumulative effects exerted by caffeine and SHA 68 on distance traveled (top right pa
ver the 60min observation period. Data are mean± sem of 4 separate experiments
he Bonferroni test for multiple comparisons.
pent and number of entries in the open arms (data not shown).
n the contrary, diazepam (1.5mg/kg, i.p.) elicited opposite effects
y increasing in a statistically signiﬁcant manner both parameters
data not shown). Similar to diazepam, the administration of NPS
ose-dependently increased these behavioral parameters (Fig. 9).
he peptide was inactive at 0.1nmol while both at 1 and 10nmol
t produced statistically signiﬁcant anxiolytic-like effects (Fig. 9).
ig. 5. Recovery of righting reﬂex in mice. Effects of NPS and SHA 68 on the percent of an
nd on their sleep time (right panel). Sleep time is deﬁned as the amount of time betwe
xperiments (total 16 mice per group). *p<0.05 vs control, #p<0.05 vs NPS 0.1nmol accortal time immobile (bottom left panel), and number of rearings (bottom right panel)
16 mice per group). *p<0.05 vs control, according to two-way ANOVA followed by
From these experiments the NPS dose of 1nmol was selected to be
challenged with SHA 68. SHA 68 at 50mg/kg did not signiﬁcantly
modify per se animal behavior in the elevated plus maze (Fig. 10).
However, in the range 25–50mg/kg the compound antagonized the
action of 1nmol NPS. The time spent and the number of entries
in the open arms of animals treated with NPS 1nmol + SHA 68 at
50mg/kgwere similar to those of rats treatedwith vehicle (Fig. 10).
imals losing of the righting reﬂex in response to diazepam 15mg/kg i.p. (left panel)
en the loss and regaining of the righting reﬂex. Data are mean± sem of 4 separate
ding to two-way ANOVA followed by the Bonferroni test for multiple comparisons.
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Fig. 6. Recovery of righting reﬂex in mice. Effect of i.p. injection of SHA 68 (50mg/kg) on the percent of animals losing their righting reﬂex (left panel) and on their sleep
time (right panel) in response to diazepam 5, 10, and 15mg/kg i.p. Sleep time is deﬁned as the amount of time between the loss and regaining of the righting reﬂex. Data are
mean± sem of 4 separate experiments (total 16 mice per group).
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eld (right panel). Data are mean± sem of 5 separate experiments (total 20 mice pe
omparisons..6. Rat defensive burying
In the DB assay, control rats spent about 60 s in covering the
robe with bedding material (burying behavior) in response to
ig. 8. Open ﬁeld assay in mice. Effects of NPS and SHA 68 on the number of entries in the
re mean± sem of 5 separate experiments (total 20 mice per group). *p<0.05 vs control, #
est for multiple comparisons.ber of entries in the central zone (left panel) and the time spent in this are of the
p). *p<0.05 vs control, according to ANOVA followed by Dunnett’s test for multiplethe shocks with an average height of buried bedding of 5.6 cm;
moreover they displayed immobility/freezing behavior for approx-
imately 600 s (Fig. 11). In line with previous ﬁndings [44], 1 nmol
NPS produced a statistically signiﬁcant decrease of all these behav-
central zone (left panel) and the time spent in this are of the ﬁeld (right panel). Data
p<0.05 vs NPS 0.1nmol according to two-way ANOVA followed by the Bonferroni
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Fig. 9. Elevated plus maze in rats. Dose–response effects of NPS (0.1–10nmol) on the time spent in the open arms (left panel) and the number of entries into open arms
(right panel). Data are mean± sem of 8–10 rats per group. *p<0.05 vs control, according to ANOVA followed by Dunnett’s test for multiple comparisons.
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oral parameters, thus promoting anxiolytic-like effects (Fig. 11).
HA 68 (50mg/kg) did not produce any effect per se however, in
he dose range 25–50mg/kg, it counteracted the action of 1nmol
PS. At the higher dose tested (i.e. 50mg/kg) the antagonist fully
revented the effect of the peptide on immobility/freezing behav-
or while only partially counteracted those on burying behavior
nd height of buried bedding (Fig. 11).
.7. Rat palatable food intake
As shown in Fig. 12 left panel, vehicle-treated rats consumed
pproximately 30g/kg of palatable food over the time course of the
xperiments. In line with previous ﬁndings [11], i.c.v. injection of
nmol NPS produced a signiﬁcant and profound decrease of food
onsumption (Fig. 12, right panel). SHA 68 (25 and 50mg/kg) per
e did not affect palatable food intake (Fig. 12, left panel). The NPSR
ntagonist only slightly counteracted the anorectic action of NPS
roducing statistically signiﬁcant effect at 50mg/kg (Fig. 12, right
anel).
. Discussion
In the present study the in vitro and in vivo pharmacological
roﬁle of the NPSR ligand SHA 68 was investigated. Our ﬁndings
onﬁrmed and extended previous results [28] demonstrating that
HA 68 behaves in vitro as a pure and potent NPSR antagonist.
n vivo, in mice and rats, SHA 68 was investigated in a panel of
ssays sensitive to the stimulatory and arousal promoting (LA and
R [37,45]), anxiolytic-like (OF, EPM, and DB [44,45]) and anorectic
PFI [11]) actions of NPS. Depending on the assay, SHA 68 displayed
ifferent effectiveness: it fully blocked NPS effects in the RR and
PM assay, partially counteracted the actions of the peptide in then arms (left panel) and the number of entries into open arms (right panel). Data are
ng to two-way ANOVA followed by the Bonferroni test for multiple comparisons.
LA and DB assay, was barely active in the OF and PFI assay. The rea-
sons for this different pattern of action of SHA 68 are not known
but theymay likelybeattributed to itspoorpharmacokineticproﬁle
[28].
In HEK293mNPSR cells SHA 68 behaved as a pure antagonist.
Similar high values of potency were obtained in inhibition curve
experiments (pKB 7.74) and by performing the classical Schild pro-
tocol (pA2 8.06). Results obtained in the latter assay are however
not compatiblewith a simple competitive interaction between SHA
68 andNPS since the antagonist at the highest concentration tested
produced a slight but signiﬁcant depression ofNPSmaximal effects.
However, the following considerations suggest that the depres-
sion of NPS Emax caused by SHA 68 in the calcium mobilization
assay probably derives from hemiequilibrium conditions rather
than from a real insurmountable type of antagonism. In fact in a
pilot series of experiments performed at room temperature and
without three cycles of mixing, SHA 68 caused, in a concentration-
dependent manner, a profound depression of NPS maximal effects
(down to less than 50% Emax). This depression of Emax was strongly
reduced even if not completely eliminated (see Fig. 2) by perform-
ing the experiments at 37 ◦C and introducing three cycles ofmixing.
Similar results were obtained investigating the NPSR antagonist
properties of the NPS-related peptide [tBu-d-Gly5]NPS [14]. Thus,
the fact that antagonist-induced depression of agonist maximal
effects is highly sensitive to procedures which facilitate drug dif-
fusion (i.e. increase in temperature and cycles of mixing) strongly
suggests that this phenomenon is due to hemiequilibrium condi-
tions due to lack of stirring [20] and not to a real insurmountable
type of antagonism.
The value of SHA 68 potency at mouse NPSR obtained in the
present study is superimposable to those measured at human
NPSR isoforms Asn107 (pA2 7.77) and Ile107 (pA2 7.55) [28]
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Fig. 11. Defensive burying test in rats. Effects of NPS and SHA 68 on the height of
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ility/freezing behavior (bottom panel). Data are mean± sem of 8 rats per group.
p<0.05 vs control, #p<0.05 vsNPS0.1nmol according to two-wayANOVA followed
y the Bonferroni test for multiple comparisons.
ndicating that this NPSR ligand does not discriminate between
PSR species-speciﬁc proteins and isoforms. This is in contrast to
ndings for NPS [4,35] and NPS-related peptides [5] that displayed
igniﬁcantly higher agonist potencies at hNPSR Ile107 and mNPSR
that contains Ile at position 107) than at the hNPSR Asn107
soform. It would be interesting in future studies to analyze and
ompare the pharmacological proﬁle of NPSR peptide antagonists
i.e. [d-Cys(tBu)5]NPS [6], [d-Val5]NPS [15], [tBu-d-Gly5]NPS
14]) and non-peptide agonists (that are not yet described in the
iterature) at NPSR species-speciﬁc proteins and isoforms. Such
tudies may help to identify the speciﬁc binding site(s) recognized1 (2010) 915–925 923
by peptide and non-peptide ligands able of block or activate NPSR,
and thus facilitate molecular modeling studies and the rational
design of novel potent NPSR ligands.
In vivo SHA 68 was ﬁrst challenged against the LA stimulatory
effect of NPS. This action of NPS has been independently repli-
cated in several different laboratories (see for a review [16]). Data
obtained in LA experiments with SHA 68 are virtually superim-
posable to those previously published by Okamura et al. [28] and
recently conﬁrmed by Shaw and Gehlert [40]. SHA 68 at the higher
dose tested (50mg/kg) was inactive per se and only partially coun-
teracted the stimulatory effect elicited by the supraspinal injection
of NPS. The absence of a full block of NPS effects despite the rela-
tively high dose of antagonist used may likely be linked to the poor
pharmacokinetic properties of this molecule, in particular its very
high lipophilicity [28] that may reduce the ability of this molecule
to reach its target. Recent ﬁndings obtained by industrial investi-
gators corroborate this view [40]. In fact, ex vivo binding studies
demonstrated that only approximately 50% of [125I]NPS binding to
brain sections is inhibited by treating mice with SHA 68 50mg/kg.
The results obtainedwith the peptide NPSR antagonist [d-Val5]NPS
that fully blocked NPS stimulatory effects but being per se inactive
[15] parallel those of SHA 68. Thus ﬁndings obtained from different
laboratories using chemically unrelated molecules demonstrated
that the stimulatory effect of NPS on LA is solely due to NPSR acti-
vation. This has been recently conﬁrmed by knockout studies that
demonstrated that NPS can stimulate LA in NPSR(+/+) but not in
NPSR(−/−) mice [10]. In line with in vitro ﬁndings (SHA 68 does
not affect signaling at 14 unrelated G-protein-coupled receptors
[28]), the present in vivo results conﬁrmed that SHA 68 antagonist
properties are selective for the NPSR since the stimulatory effect of
caffeine on LA was not affected by this molecule.
Asmentioned in Section1 the supraspinal administration ofNPS
elicits a robust arousal-promoting action in rodents [16]. SHA 68
was able to fully prevent this NPS effect in the mouse RR assay.
This implies that NPSR regulating arousal might be more accessi-
ble to the antagonist than those stimulating LA. This result parallels
previous data obtained under the same experimental conditions
using the NPSR antagonist [d-Cys(tBu)5]NPS and investigating the
phenotype of NPSR(−/−) mice [6]. [d-Cys(tBu)5]NPS blocked the
arousal promoting effect of NPS and NPS elicited its stimulatory
effects in NPSR(+/+) but not in NPSR(−/−) mice [6]. In addition,
NPSR(+/+) and NPSR(−/−) animals were similarly sensitive to the
hypnotic effect of diazepam and the peptide NPSR antagonist did
notmodify per se the effect of the benzodiazepine. This latter result
has been conﬁrmed and extended in the present study by chal-
lenging SHA 68 vs increasing doses of diazepam. Thus collectively
these results demonstrated that (i) NPSR activation is involved in
the arousal-promoting action of NPS, and (ii) endogenous NPSR
is not tonically activated under the present experimental condi-
tions. Obviously this does not preclude the possibility that the
endogenous NPS/NPSR system might be important for controlling
circadian sleep/wakefulness cycles. In fact, NPSR(−/−) mice dis-
played reduced late peak wheel running (an index of activity of
the internal clock) compared to NPSR(+/+) mice [10] and, more
importantly, the functional hNPSR polymorphism Ile107 has been
associated with delayed average bedtime in humans [13].
In line with previous ﬁndings [19,22,37,44,45] the present data
conﬁrmed that the supraspinal injection of NPS elicited dose-
dependent anxiolytic-like actions in rodents. In fact, NPS increased
the time spent in and the number of entries into the central area
of the OF in mice, the time spent in and the number of entries into
open arms in the rat EPM, and reduced the duration of burying,
immobility, and height of buried bedding in the rat DB assay. These
actions of NPS were differently affected by SHA 68. This molecule
slightly and non-signiﬁcantly reduced the effects of the peptide in
the mouse OF, fully prevented the anxiolytic-like actions of NPS
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lig. 12. Palatable food intake in rats. Effects of SHA 68 alone (left panel) and in com
er group. *p<0.05 vs control, #p<0.05 vs NPS 0.1nmol according to two-way ANO
n the rat EPM, and partially (but signiﬁcantly) counteracted the
ffects of the peptide in the ratDB. The reasons for these differences
n SHA 68 effectiveness are not completely known, however they
ay likely be attributed to the pharmacokinetic rather than phar-
acodynamic properties of this molecule. Although the present
ata are not fully consistent, they still support the hypothesis that
he anxiolytic-like actions evoked by NPS in rodents are due to the
elective activation of the NPSR protein. This proposal should be
owever conﬁrmed in future studies with the use of chemically
nrelated peptide and non-peptide NPSR selective antagonists. It
s worthy of note that SHA 68 did not produce any effect per
e in the OF, EPM, and DB tests. These assays and experimental
onditions are able to detect anxiogenic-like actions of drugs as
emonstrated at least in the EPM (present study) and DB [44] with
he use of caffeine. Thus, based on these results and considera-
ion we should propose that endogenous NPS signaling does not
onically control anxiety levels. However the opposite is suggested
y the following ﬁndings: (i) the intra-amygdala administration of
HA 68 in mice subjected to the open ﬁeld test reduced the num-
er of entries and the time spent by the animal in the central area
i.e. elicited an anxiogenic-like response) [19], (ii) NPSR(−/−) mice
isplay increased levels of anxiety-like behaviors in the OF, EPM,
nd light dark box assays [10]. However the genetic background of
hese mice (129S6/SvEvTac) is known to generate highly anxious
nimals and this may represent a bias for this type of behavioral
xperiments. Collectively these latter ﬁndingsmay suggest that the
ack of anxiogenic effects of SHA 68 given systemically may derive
rom an incomplete occupation of brain NPSR controlling fear and
nxiety levels which are most probably located in the amygdala
19,25,31]. Clearly further studies performed with different NPSR
elective antagonists and the generation ofNPSR(−/−) and possibly
pNPS(−/−) mice backcrossed on genetic backgrounds suitable for
ehavioral investigations are needed before drawing ﬁrm conclu-
ions on the role of the endogenousNPS/NPSR system in the control
f fear and anxiety.
It is known that NPS inhibits food intake (see for a review of the
vailable evidence [16]) and it has been recently shown that NPS
xerts a robust inhibitory effect on palatable food intake in rats
robably acting on neurons located in the paraventricular nucleus
f thehypothalamus [11]. Therefore the effects of SHA68havebeen
lso investigated in the PFI assay in rats. NPS given i.c.v. at 1nmol
roduced a profound inhibition of PFI. SHA 68 at 25 and 50mg/kg
id not modify food intake per se and only slightly counteracted
he anorectic action of the peptide. These ﬁndings might be inter-
reted either assuming that SHA 68 after systemic administration
s not able to reach in sufﬁcient concentrations the NPSR regu-
ating palatable food intake or, alternatively, that this biologicaltion with NPS (right panel) on palatable food intake. Data are mean± sem of 8 rats
llowed by the Bonferroni test for multiple comparisons.
action of NPS is due to a mechanism different from NPSR activa-
tion. In this context it is worthy of mention that the peptide NPSR
antagonist [d-Cys(tBu)5]NPS has been reported to fully prevent the
inhibitory effect of NPS on PFI [11]; thus, this ﬁnding makes the
former hypothesis more likely.
In conclusion, this study conﬁrmed and extended previous ﬁnd-
ings demonstrating that the bicyclic piperazine derivative SHA 68
behaves as a selectiveNPSRantagonist in vitro and invivo.However
the usefulness of this research tool is limited by its poor pharma-
cokinetic properties. This may likely be one reason for the variable
effectiveness of SHA 68 in the different NPS-sensitive assays exam-
ined in the present study. Nevertheless SHA 68 can be successfully
used as a template for the identiﬁcation of non-peptideNPSR selec-
tive antagonists characterized by better pharmacokinetic features.
These kind of molecules should be used together with the available
NPSR peptide ligands [16] and genetic models [1] for perform-
ing detailed target validation studies that will hopefully allow to
ﬁrmly identify the therapeutic potential of innovative drugs acting
at NPSR.
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The piperazine moiety is an important pharmacophore which is
found in a large number of biologically active molecules. Pipera-
zines and their keto analogues are amongst the most important
scaffolds in today’s drug discovery industries.
Due to the high number of positive hits encountered in biolog-
ical screens with this heterocycle and its congeners, the piperazine
moiety is widely recognized as a ‘privileged scaffold’ in medicinal
chemistry.1,2
Moreover, piperazine ring systems are the key structural ele-
ments in a vast array of natural products as well as being a large
class of biologically active compounds. Examples include indinavir
1, an HIV-protease inhibitor,3 glivec 2, a potent antiproliferative
agent,4 several compounds acting at receptors in the CNS such as
arylpiperazines, powerful 5-HT1 ligands,5–7 lemonomycin 3,8,9
ecteinascidin 743 4,10 TAN-1251A 5,11 and dragmacidins B and C
6–712 (Fig. 1).ll rights reserved.
x: +39 0532 455953 (C.D.R.);
.
ife.it (G.P. Pollini).On the other hand, the related 2-oxopiperazine nucleus is a
common structural feature of a number of natural compounds such
as pseudotheonamides A1 and A2 8–9,13,14 (–)-A agelastatin A
10,15–17 marcfortine B 11,18 the Phakellin group 12–14,19–21 and
guadinomine C2 15,22 which are shown in Figure 2.
Furthermore, it is well known that 2-oxopiperazine derivatives
have been used as peptidomimetic moieties for the discovery of
novel, bioactive small molecules. Thus, the conversion of peptides
into conformationally restricted peptide analogues is a generally
accepted and widely used approach to design nonpeptide ligands
that target protein receptors.
Excellent examples of peptidomimetic drugs discovered using a
2-oxopiperazine template that conformationally mimics the dipep-
tide moiety include constrained substance P analogues,23 farnesyl-
transferase (FTase)24 and protein geranylgeranyltransferase-I
(PGGTase-I)25 inhibitors, compounds with dual farnesyltransfer-
ase/geranylgeranyltransferase-I inhibitory activity,26 elastase,27
factor Xa,28 renin29–31 and BACE132 inhibitors, melanocortin recep-
tors (MCRs) agonists,33 ﬁbrinogen glycoprotein IIb–IIIa,34,35 and
neuropeptide S (NPS) receptor36,37 antagonists.
Recently, an interesting review covering the importance of a-
ketoheterocycles in the discovery of potent enzyme inhibitors
has been published.38
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efﬁcient chiral ligands in enantioselective catalysis has been also
examined.39
Therefore, it is not surprising that there is a plethora of different
synthetic methods that allow for the fast and efﬁcient assembly of
these heterocyclic systems. All these methodologies have been
collected in three excellent reviews.40–42
Although the syntheses of piperazine derivatives have been
known for almost a century, the chiral syntheses of 2-oxopipera-
zines have rarely been reported and still remain a daunting chal-
lenge to organic chemists.
Chiral piperazines and related piperazinones are only now
beginning to make their mark as useful therapeutics. Therefore,
the search for efﬁcient routes toward these compounds with sub-
stitution at different ring positions are of crucial and particular sig-
niﬁcance in view of the importance of substituted piperazine ring
systems in medicinal chemistry and drug discovery.
The most interesting methods for the introduction of high
diversity around the piperazine scaffold is likely represented by
multicomponent reactions (MCRs) that seem to be particularly
well suited to assemble ketopiperazines.43 However, it is not suited
to control the stereospeciﬁcity with regard to the carbons in the
piperazine template, thus generating mixtures of stereoisomers.44
The need for viable routes to this class of compounds is well
illustrated by praziquantel, a well-known effective antihelminthic
drug used worldwide in the treatment of schistosomiasis. The
(S)-(+)-enantiomer is inactive and harmless, while the (R)-()-
enantiomer 16 is active (Fig. 3).45N
N
O
O
(-)-Praziquantel
16
Figure 3.The aim of this report is to focus on stereoselective routes to
chiral 2-oxopiperazine derivatives with substitution at various ring
positions. In the majority of cases, in the absence of an asymmetric
synthesis strategy, the ﬁnal stereochemistry is dependant on the
starting material’s conﬁguration.
The different strategies developed to obtain chiral 2-piperazi-
nones have been organized into sections according to the C–N
bond formation in the ring-forming reaction, a similar classiﬁca-
tion previously used by Dinsmore and Beshore.41
When more than one bond is required for the assembly of the
piperazinone ring system, usually a two-step sequence involving
an initial intermolecular reaction followed by the intramolecular
ring-forming step, the latter has been considered in the
classiﬁcation.
Section 2 has been dedicated to synthetic strategies proceeding
via the formation of the N1–C2 linkage, while Section 3 deals with
C3–N4 bond-forming reactions. Cyclization at N4–C5 is discussed in
Section 4, which has been organized into sub-sections (4.1–4.4)
depending on the different strategies used to prepare the pipera-
zine ring. Finally, C6–N1 bond construction has been covered in
Section 5.
Moreover, the positions of the substituents introduced through
the different methodologies for originating the chirality are also
emphasized.
For the sake of clarity, red and blue colors, respectively, have
been used to show the formed carbon–nitrogen bond and the
attacking nitrogen atom.
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The intramolecular reaction between an amino group and an es-
ter has been widely used to prepare 2-piperazinones. Several of
these methods are based on a ring-forming coupling reaction of a
primary amine with a doubly activated substrate. In almost all
these processes, the substituent on the amine reactant is destined
to be the amide substituent in the derived piperazinone.
Yamashita et al.46,47 have developed a simple way to obtain chi-
ral 1,3-disubstituted 2-oxopiperazines by acid-catalyzed lactami-
zation of easily accessible 3,6-diaza-1,8-octanedioic acids of
general structure 19, linear N,N0-ethylene-bridged bis-a-amino
acids, in turn prepared by reacting two enantiomerically pure ami-
no acids 17 and 18, and 1,2-dibromoethane (Scheme 1).R1
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Scheme 3.Acid-promoted cyclization of 19 proceeded with concomitant
esteriﬁcation to give piperazinones 20, which have been eventually
used to obtain constrained mimics of Met- and Leu-Enkephalin,46
biologically relevant pseudotetrapeptides47 and dermorphin
analogues.48
The use of two different amino acids furnished a mixture of 2-
oxopiperazines which could be separated by chromatography.
However, Yamashita’s approach is particularly suited for the prep-
aration of 2-oxopiperazine derivatives composed of two identical
amino acids, thus by-passing the tedious puriﬁcation step.
As shown in Scheme 2, the ethylene-bridged compounds 21 and
22, obtained from D-tryptophan and L-phenylalanine, respec-
tively,49,25 represent linear precursors of 2-oxopiperazines 23 and
24, which have been used to obtain constrained mimics of the
growth hormone secretagogue NN70349 and PGGTase-I inhibi-
tors,25 respectively.HO2C
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Scheme 4.Further studies in this area, allowed Goodman et al.50 to estab-
lish a convenient route to the piperazinone ring structure through
the reductive amination of a-amino aldehyde 25 with glycine
methyl ester followed by reaction of the released secondary amine
26 with Z-L-serine-b-lactone (Vederas lactone) 27 (Scheme 3).Subsequent coupling with H-Phe-Leu-OtBu by standard peptide
chemistry produced the linear precursor 28which underwent con-
comitant hydrogenolysis of the Z group and cyclization to give the
4,6-disubstituted piperazin-2-one derivative 29. This was eventu-
ally converted to an enkephalin analogue by TFA-mediated re-
moval of the remaining protecting groups.
Later, the same authors reported the solid-phase synthesis of a
series of piperazinone-derived Leu-enkephalin analogues,51 the
key step being represented by the reaction of Wang resin-bound
N-(4-tert-butyloxy-phenethyl)-glycine 30 with Boc-L-serine-b-lac-
tone 31 (Scheme 4). The released carboxylic acid was reacted with
diverse monosubstituted benzylamine derivatives in the presence
of a BOP reagent to produce resin-bound tertiary amides 32. Sub-
sequent treatment with 5% H2O in TFA-promoted sequential cleav-
age, deprotection, and cyclization to yield 4,6-disubstituted
piperazin-2-ones 33.Notably, the same synthetic sequence has been successfully ap-
plied to obtain the enantiomeric 2-oxopiperazines using Boc-D-ser-
ine-b-lactone as the counterpart of 30.
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the C-terminal D-phenylalanine group of NN703, namely (3R)-3-
benzyl-2-piperazinone 37. Thus, Boc-glycinal 34 was converted
via reductive alkylation with D-phenylalanine methyl ester into
secondary amine 35 (Scheme 5). Deprotection with TFA followed
by cyclization of the intermediate amine 36 with potassium car-
bonate in methanol at room temperature produced the 3-substi-
tuted piperazin-2-one 37.88%
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Scheme 5.2-Oxopiperazine derivatives have been often designed as mim-
ics of b- and c-turn conformationally constrained peptides.
In order to obtain 2-oxopiperazines as new c-turn mimics,52,53
epimeric mixtures of cyanomethyleneamino pseudopeptides 38
were reacted with amino acid derivatives to give the C-backbone
branched pseudopeptides 39 (Scheme 6). Notably, neither racemi-
zation at the inserted amino acid nor epimerization at the stereo-
genic centers of 38were observed during this step. Heating of 39 at
100 C in toluene afforded diastereomeric 1,3,5-trisubstituted 2-
oxopiperazines 40, which were eventually resolved by ﬂash
chromatography.BocHN N
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Scheme 8.Recently, Piarulli et al.54 have developed an easy entry to both
enantiomers of N-Boc-5-oxo-piperazine-2-carboxylic acid (PCA),
in order to evaluate their role as inducers of turn structures when
inserted into tetrapeptide sequences. Thus, the primary alcohol 41
obtained by reductive amination of L-serine methyl ester with
ethyl glyoxylate underwent Mitsunobu reaction using a solution
of hydrazoic acid in toluene to give azide 42 (Scheme 7). Other
methodologies are unsuitable, causing the elimination and forma-
tion of the corresponding dehydroalanine derivative as the major
reaction product. Catalytic hydrogenation of 42 and concurrent
cyclization of the resulting primary amine produced (S)-methyl
5-oxo-piperazine-2-carboxylate 43, which was converted into
(S)-N-Boc-5-oxo-piperazine-2-carboxylic acid 44 by one-pot
hydrolysis and N-Boc protection. The (R)-enantiomer was similarly
obtained using D-serine methyl ester as the starting material.Ketopiperazines represent valuable platforms for the develop-
ment of new synthetic methodologies entailing the N1–C2 bond-
forming reaction.
Giannis et al.55 reported the use of N-Z-D-glucosamine 45 as the
common starting material for the synthesis of diastereomeric 3,6-
disubstituted piperazin-2-ones 49 and 53 (Scheme 8).
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methyl ester gave the intermediate 46, which was cyclized to 47
by hydrogenolytic removal of the Z-protecting group. Subsequent
N-Boc protection, oxidative cleavage of the polyol moiety of inter-
mediate 48 and rapid reduction of the corresponding aldehyde
yielded the piperazinone derivative 49 without detectable
racemization.
The synthesis of diastereomeric piperazinone 53 required the
conversion of N-Z-D-glucosamine 45 into N-Z-L-serinal 50, followed
by reductive amination with L-phenylalanine methyl ester to yield
diamine 51. Protection of the secondary amino group as the corre-
sponding tert-butoxycarbonyl derivative produced compound 52
which took part in the catalytic hydrogenation leading to the con-
comitant removal of the Z-protecting group and spontaneous
cyclization.
Later, the same authors used N-Z-D-glucosamine 45 as the start-
ing point for the synthesis of either 6-substituted piperazin-2-one
56 or 3,6-disubstituted piperazin-2-ones 60 and 61 (Scheme 9).56 1. Gly-OMe, NaCNBH3
 MeOH, reflux,
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Thus, the secondary amine 54 was prepared by the reductive
amination of 45 with glycine methyl ester and subsequent deriva-
tization, with the introduction of the tert-butoxycarbonyl-protect-
ing group being crucial for the ﬁnal cyclization step. An oxidative
cleavage/reduction sequence performed on 54 yielded the amino
alcohol 55, which underwent the well-established deprotection/
cyclization protocol leading to 56.
Analogously, the secondary amine 57, generated by the amina-
tion of 45with L-e-Boc-lysine methyl ester followed by Boc protec-tion, was cyclized to compound 58 after the removal of the Z group.
Oxidative cleavage of the polyol side chain produced the aldehyde
59, which was used directly to obtain methyl ester 60 and the
vinylogous derivative 61.
A highly efﬁcient triﬂate alkylation has been used by Jacob-
sen57,58 as the key step in the synthesis of enantiomeric trans-
3,5-dimethylpiperazin-2-ones, which represent suitable precur-
sors of trans-2,6-dimethylpiperazines.
As outlined in Scheme 10, the dibenzylamide 62, obtained from
Boc-L-alanine, was subjected to TFA-promoted deprotection and
borane–methyl sulﬁde reduction to give the diamine 63 in high
ee (>98%).57 Its reaction with methyl (R)-2-[(triﬂuoromethylsulfo-
nyl)oxy]propionate proceeded uneventfully with inversion of con-
ﬁguration to produce a 94% yield of the ester 64. Hydrogenolytic
monodebenzylation and subsequent acid-catalyzed cyclization
provided 3,5-disubstituted piperazin-2-one 65 in 81% yield.The corresponding enantiomer has been similarly obtained
using Boc-D-alanine and methyl (S)-2-[(triﬂuoromethylsulfonyl)-
oxy]propionate.58
This chemistry has also been applied to the enantioselective
synthesis of (R)-3,5,5-trimethylpiperazin-2-one 69.57 The starting
point was the diamine 67 in turn obtained by tritylation of 1,2-dia-
mino-2-methylpropane 66. Reaction of 67 with methyl (S)-2-[(tri-
ﬂuoromethylsulfonyl)oxy]propionate produced the intermediate
68 which was converted by a one-pot deprotection/cyclization se-
quence to the piperazinone 69 (Scheme 11).Similarly, the corresponding enantiomer was prepared using
methyl (R)-2-[(triﬂuoromethanesulfonyl)oxy]propionate as the
alkylating agent.
A three-component process involving the one-step condensation
of alkenyl, aryl, or heteroaryl boronic acids with 1,2-diamines and
glyoxylic acid has been introduced for the direct synthesis of piper-
azinones.43 The organoboronic acids act as both reactants and cata-
lysts in the cyclization of the intermediate amino acid adducts.
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reaction between secondary 1,2-diamine 70, heteroaryl boronic
acid 71, and glyoxylic acid in acetonitrile at 80 C leading to 2-pip-
erazinone 72 in 65% yield and 40% de (Scheme 12).Bn N
O
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Scheme 12.Unfortunately, the stereochemistry of the major isomer of 72
could not be determined since the authors did not provide any
data.
Figueroa-Peréz et al.59 described the solid-phase synthesis of
3,6-disubstituted 2-oxopiperazines featuring three rapid and efﬁ-
cient steps, namely: (1) reductive alkylation of a resin-bound a-
amino acid with a freshly prepared N-protected-a-amino alde-
hyde; (2) N-deprotection; and (3) cyclitive cleavage of the acyclic
resin-bound amine precursor to give the target compounds.
As outlined in Scheme 13, Fmoc-L-phenylalaninal 73, easily ob-
tained by oxidation of the corresponding commercially available
Fmoc-L-phenylalaninol with a polymer-bound diacetoxybromite,
wasmixedwithasuspensionoftheWangresin-boundO-tBu-tyrosine
74intrimethylorthoformiate(TMOF)andtheresultingiminereduced
in situ by adding an excess of Na(AcO)3BH to yield the intermediate
amine75.N-Deprotectionandsubsequentcyclizationgavethepipera-
zin-2-onederivative76withveryhighpurity(96%).Ph
NHFmoc
O
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Scheme 15.Similar results were obtained using Merriﬁeld resin-bound
O-tBu-tyrosine and Boc-L-phenylalaninal as convenient starting
materials.
Dinsmore et al.60 discovered a novel approach to the synthesis
of piperazin-2-one derivatives entailing on a one-pot, tandem
reductive amination–transamidation–cyclization reaction
(Scheme 14).Thus, the reductive amination of anN-(2-oxoethylamide)77with
a-amino esters 78 produced the secondary amines 79 which are
pronetogiveamides80byan intramolecularN,N0-acyl transfer. Their
subsequent intramolecular cyclization led to piperazin-2-ones 81.
The wide availability of natural and unnatural a-amino acids
makes this approach very effective for the synthesis of 2-oxopiper-
azine derivatives bearing variable substituents at C-3.
This methodology has been successfully applied to the synthe-
sis of the conformationally restricted FTase inhibitor 86,60 as
shown in Scheme 15.The amino alcohol 82, readily prepared from 4-chloro-3-methyl-
phenol by standard chemistry, was transformed into the key alde-
hyde 84 by reaction with the acid 83 and Swern oxidation of the
primary alcohol moiety. Subsequent reductive amination with D-
alanine methyl ester gave piperazin-2-one 85, which underwent
tandemdeprotection-macrocyclization in the presence of KF on alu-
mina in reﬂuxing acetonitrile, provided the target FTase inhibitor86.
The 3-substituted piperazin-2-one 8927 has been conveniently
prepared by starting from compound 87 obtained in rather low
yield (33%) by the alkylation of L-isoleucine tert-butyl ester with
N-(tert-butoxycarbonyl)-2-chloroethylamine. The TFA-promoted
deprotection furnished the linear precursor 88, which was cyclized
to the d-lactam 89 by treatment with DCC and pyridine
(Scheme 16).
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protection, the presence of electron-withdrawing groups (e.g., p-
toluenesulfonyl) on the primary amine of the cyclization precursor
severely hampers lactam formation in sufﬁciently high yield.
The reactivity of a-amino esters toward 1,2-cyclic sulfamidates
has been successfully used to open a ﬂexible entry to piperazin-2-
one derivatives bearing substituents at various positions
(Scheme 17).61 Thus, the use of the L-phenylalanine-derived 1,2-
sulfamidate 90 as a prototype in the reaction with N-tosyl glycine
ethyl ester gave a 84% yield of the differently protected 6-substi-
tuted piperazin-2-one 92 via the intermediate 91.O
S
N
O O
N
Ph
N
1. 5M HCl, rt
then NaHCO3
2. PhMe, reflux
NHTs
NaH or Cs2CO3
        DMF
N
N
O
Ph
Ph
EtO2C
84%
NHTsMeO2C
N
N
O
Ph
71%
90%
Bn
Ts
Bn
Ts
O3S Bn CO2Et
Bn
90
Ts
91
92
93
N
N
O
Ph
Bn
Ts
94
NHTsEtO2C
Scheme 17.
O
N
Boc
  NaCNBH3
AcOH, MeOH O
N
Boc
N
Bn
EtO2C
aq. HCl
MeOH/H2O
    reflux
69%
N
H
N
Bn
OH
O
N
N
Boc
OH
O
OH
O
98
99
100
101
Bn-Gly-OEt
Scheme 19.
fast (> 95%)
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Scheme 18.The reaction of 90 with N-tosyl-a-amino esters derived from D-
and L-alanine, respectively, exclusively gave the corresponding
trans- and cis-3,6-disubstituted piperazin-2-ones 93 and 94, thus
demonstrating the stability of epimerizable substrates in the con-
ditions used in this approach.
However, some problems were encountered in the reaction of
90 with L-proline ethyl ester, as shown in Scheme 18.
Thus, the initial adduct 95 underwent slow and very inefﬁcient
thermal lactamization in reﬂuxingxyleneproducing96without epi-
merization at C(8a), while a fast and essentially quantitative lacta-
mization was achieved using NaOMe in MeOH giving rise to 96 as
a 1:1 mixture of diastereomers at C(8a). However, the latter could
be obtained as a single diastereomer in 50% yield performing the ﬁ-
nal ring-closure step in the presence of catalytic sodium cyanide.
Analogously, when ethyl L-pyroglutamate was employed as the
counterpart of 90, the bicyclic adduct 97 could be isolated as a sin-
gle diastereomer in 63% overall yield.
Garner’s aldehyde 98 has been utilized as the source of the C-6
stereogenic center for 6-substituted 2-oxopiperazines.62
The synthetic sequence involved the reductive amination with
ethyl N-benzylglycine to give 99 followed by the one-pot removalof the N-Boc-protecting group and cyclization by treatment with
hydrochloric acid in reﬂuxing methanol furnishing the chiral 2-
oxopiperazine 100 in an excellent yield. The latter could be con-
verted into chiral 1-aryl-6-hydroxymethyl-2-oxopiperazine 101
(Scheme 19).A simple entry to 3-substituted piperazin-2-one 10363 was
based on the use of optically active nitroester 102, easily obtained
through an intermolecular Michael reaction between N-benzyl-L-
aspartic acid dimethyl ester and nitroethylene (Scheme 20). Cata-
lytic reduction of the nitro group and intramolecular cyclization
of the intermediate primary amine provided 2-oxopiperazine 103.
An appropriate choice of the starting a-amino ester allowed the
preparation of chiral non-racemic piperazin-2-ones bearing vari-
able substituents at the 3-position of the heterocyclic nucleus.
Furthermore, this chemistry is also suitable for the synthesis of
heterocyclic scaffolds bearing amino- and hydroxy-substituted
side chains at the 4-nitrogen atom.
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262 C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274Orthogonally protected enantiomerically pure 2-oxopiperazine
building blocks for peptidomimetic combinatorial chemistry have
been prepared starting from accessible chiral a-amino aldehydes
bearing a-Boc and x-Alloc or Z orthogonal protecting groups.64,65
A representative application of this approach is depicted in
Scheme 21.CH2Ph
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Scheme 21.Sequential reductive alkylation of the a-amino aldehyde 104
derived from L-ornithine with L-Glu(OtBu)-OMe and Fmoc protec-
tion of the resulting dipeptide 105 furnished the linear precursor
106, which was deprotected and cyclized to the corresponding
3,6-disubstituted 2-oxopiperazine derivative 107 by standard
chemistry.
Interestingly, the chemistry involved is general and applicable
for the preparation of a diverse library of scaffolds, controlling chi-
rality, arm position and length as well as the nature of functional
moieties at the arms for further diversiﬁcation in three indepen-
dent directions.
A recent paper described a convenient way to assemble 3-
substituted-6-phenylpiperazin-2-ones via a two-step procedure
involving an initial alkylation of 2-bromoacetophenone with an
a-amino ester followed by a one-pot reductive amination and
cyclization step.66
As shown in Scheme 22, the b-ketoamine 108 obtained by the
reaction of L-alanine methyl ester with 2-bromoacetophenone
underwent reductive amination with benzylamine and cyclization
to produce piperazinone 109 as a 1:1 mixture of diastereomers,
with no epimerization at C-3 being observed.O
AcOH, NaCNBH3
  MeOH, 50 °C
BnNH2
N
HN
Bn
O
73%
HN
CO2Me
901801
Scheme 22.An N1–C2 bond-forming reaction between an amino group and
an amide moiety was the featuring step in the solid-phase synthe-
sis of ketopiperazines bearing up to four points of diversity.67 Thestarting point was the sulfonamide resin 110 possessing a 2,4-
dimethoxybenzyl arylhydrazine (DMBAH) linker.
As illustrated in Scheme 23 for a selected example, alkylation of
110 with N-Dde L-phenylalaninol 111 under Mitsunobu conditions
gave 112 which was subsequently N-deprotected to produce the
resin-bound secondary amine 113. Acylation with 2-naphthoyl
chloride and hydrazine-promoted N-deprotection yielded amino
derivative 114 which took part in a cyclitive cleavage furnishing
3,4,6-trisubstituted 2-oxopiperazine 115 by sequential treatment
with TFA and copper(II)/pyridine.3. Cyclization at C3–N4
As already noted, the cyclization of a linear peptide dimer deriv-
ing from two different amino acids produces a mixture of 2-oxo-
piperazines, requiring a further separation step.46,47 Thus, the
development of convenient and easy methods for generating such
compounds from two different amino acids represents a major aim
with regard to the synthesis of chiral piperazinones.
A convenient method for generating piperazinones from two
different amino acids involved the reductive alkylation of Boc-glyc-
inal 34 with peptide 116 followed by acylation with chloroacetic
anhydride to produce the intermediate acylated derivative 117
(Scheme 24).49 After removal of the Boc-protecting group with
TFA, cyclization of the derived 118 occurred smoothly simply by
adjusting the pH to neutral, yielding the 1-substituted piperazin-
2-one 119, which could be then elongated by ordinary peptide cou-
plings to give a NN703 analogue.
A simple piperazinone could be considered as a versatile and
useful synthon for the enantioselective synthesis of more substi-
tuted piperazinones through diastereoselective alkylation.
A general synthetic pathway involving piperazinone assembly
via C3–N4 cyclization followed by a stereoselective alkylation step
has been widely used for the preparation of chiral disubstituted 2-
oxopiperazines incorporating a large diversity of substituents at
the 3-position.
The asymmetric synthesis of 1,3-disubstituted 2-oxopipera-
zines has been achieved by the stereoselective alkylation of a suit-
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alcohol as a chiral inductor, in turn assembled from L-phenylgly-
cinol,68,69 L-leucine methyl ester,70 or O-benzyl-L-serine methyl es-
ter,71 whose nitrogen atom is part of the heterocyclic nucleus.
As shown in Scheme 25, the DCC-promoted condensation of L-
phenylglycinol 120 and L-leucine methyl ester with Boc glycine
gave amides 121 and 122,68–70 which were submitted to a reduc-
tion/protection sequence leading to silyl ethers 123 and 124.
Selective condensation with bromoacetic acid furnished the
intermediate bromomethylacylated derivatives 125 and 126,
which were subsequently cyclized to the piperazinones 127 and
128 on treatment with NaH in a DMF/THF mixture.
Both these compounds were deprotected to produce 129 and
130, convenient substrates for the stereoselective alkylation at C-
3 with various electrophiles.
Thus, the enolates generated by treatment with tert-BuLi
(2.0 equiv) in THF at 78 C in the presence of HMPA reacted with
halogeno compounds to provide derivatives 131 and 132with very
high chiral induction (>90% de).
The observed diastereoselectivity has been accounted for by the
rigid intermediate that forces the approach of the electrophile from
the face opposite to a lithium chelate involving N1 and the alcohol
appended to the 10-substituent.70,72
However, only one diastereomer is directly accessible since the
conﬁguration at the 3-position of the 2-oxopiperazine is totally
governed by the conﬁguration of the chiral inductor.
This limitation has been overcome by using orthogonally pro-
tected serinol-based 2-oxopiperazines 136 and 13771 (Scheme 26).
The synthetic pathway required the conversion of the O-benzyl-
L-serine methyl ester to compound 133, which was transformed
into 134 by a number of steps including: (a) concomitant amide
and ester lithium aluminum hydride reduction; (b) silyl etheriﬁca-
tion; and (c) coupling with bromoacetic acid. Subsequent base-in-
duced cyclization of intermediate 134 furnished piperazinone 135.
Its selective O-deprotection could give rise to compounds 136 and
137, which underwent C-3 alkylation with halide derivatives to
yield (3S)- or (3R)-1,3-disubstituted 2-oxopiperazines 138 and
139, respectively, in high diastereomeric purity (>95% de).
Unfortunately, the chiral auxiliary cannot be removed, and this
represents a major drawback of this interesting methodology.
Highly stereoselective approaches based on synthetic elabora-
tion of amino acids have been used to obtain enantiomerically en-riched 5-substituted 2-oxopiperazines, which are further
functionalized at C-3.24,73
Key intermediates in these processes were vicinal diamines, a
class of compounds commonly encountered as synthons, easily
prepared by the reductive amination of enantiomerically pure a-
amino aldehydes with suitable amines.
Thus, a-amino aldehyde 140 derived from Boc-(S)-allylglycine
was used in a reductive amination with 2,4-dimethoxybenzyl-
amine to produce 141.24 Its chloroacetylation produced 142 which
provided the 5-allyl 2-oxopiperazine 143 through base-promoted
cyclization, as shown in Scheme 27. Subsequent alkylation at the
3-position with benzyl bromide provided the trans-disubstituted
derivative 144 (diastereoselectivityP 95:5). This compound is a
convenient precursor of the constrained bicyclic analogue 145 fea-
turing a 3,8-diazabicyclo[3.2.1]octan-2-one framework.
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264 C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274A similar approach based on the use of a-amino aldehydes de-
rived from Boc protected naturally occurring amino acids73 is
shown in Scheme 28.
Thus, reductive amination of Boc-L-alaninal 146 with benzyl-
amine produced diamine 147, which was reacted with bromoacetic
acid to give the intermediate amide 148. The latter was used to ob-
tain 5-methyl 2-oxopiperazine 149 by base-promoted cyclization.
Treatment of the derived enolate [tert-BuLi (2 equiv)/HMPA (4
equiv) mixture in THF at 78 C] with allylbromide quantitativelyafforded the 3-allylated 2-oxopiperazine 150. Remarkably, only
one diastereoisomer could be found in the ﬁnal reaction mixture.
The relative anti stereochemistry between substituents at C-3
and C-5 was deduced by NOE difference experiments, accounting
for a conventional 1,3-asymmetric induction.74
This approach allowed differently decorated 3-substituted 5-
methyl-2-oxopiperazines to be obtained by using suitable electro-
philes, a double functionalization at the 3-position also being
accomplished.
The reductive alkylation of amino aldehydes derived for natural
amino acids with appropriate amine counterparts has been widely
used as a convenient tool for the assembly of chiral 2-oxopiper-
azine precursors.75,65
The solid-phase preparation of 1,4,5-substituted 2-oxopipera-
zines has been achieved via on-bead intramolecular cyclization of
suitable precursors obtained by a reductive alkylation of resin-
bound amino acids with N-protected a-amino aldehydes,75 fol-
lowed by acylation with a-chloroacetyl chloride.
The synthesis of 2-oxopiperazine 161 serves as an illustrative
example of this synthetic route (Scheme 29).
TheWang resin-immobilized Fmoc-L-leucine 151was deprotec-
ted to amine 152 which in turn was treated with Fmoc-L-phenyla-
laninal 73. The resulting imine could be removed from the excess
aldehyde by ﬁltration. The subsequent reduction produced a 1:1
diastereomeric mixture of pseudodipeptides 153 and 154, owing
to epimerization of the a-amino aldehyde during the amination
step. After acylation to 155 and 156, Fmoc deprotection produced
a mixture of primary amines 157 and 158.
At this stage, on-bead intramolecular cyclization, treatment
with p-toluenesulfonylchloride and TFA cleavage allowed piperaz-
inone (2S,50R)-161 to be obtained as the sole product, while the
corresponding (2S,50S) diastereomer was not obtained.
This result has been explained as being due to the conversion of
amine (2S,50S)-158 into cleaved piperazinone 160 through an
intramolecular N-acylation process which is likely to proceed fas-
ter than on-bead SN2 intramolecular cyclization. The detection of
compound 160 in the ﬁltrate (LC–MS analysis) corroborated this
hypothesis.
The Fmoc/Alloc orthogonally protected 1,5-disubstituted 2-oxo-
piperazine 165 was prepared starting from the pseudodipeptide
162 simply obtained by reductive amination between glycine
tert-butyl ester and a-amino aldehyde 104 derived from L-orni-
thine (Scheme 30).65
Treatment of 162 with a-bromoacetyl chloride gave the corre-
sponding acylated derivative 163, which underwent smooth cycli-
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Boc/Alloc-protected ketopiperazine 164, suitable for Boc
chemistry.
This compound can be adapted to Fmoc chemistry (Fmoc on the
secondary ring amine and Alloc on the side chain primary amine)
through the interchange of Boc/Fmoc-protecting groups accom-
plished by standard Boc removal and subsequent Fmoc reprotection
of the crude-derivedamine toyieldpiperazinone165. Similar results
have been obtained using L-lysinal as the starting amino acid.
An efﬁcient route for the preparation of piperazinones featuring
a C3–N4 ring-forming reaction involves a tandem reductive cou-
pling and SN2-cyclization of a 2-chloro-N-(2-oxoalkyl)acetamide
and a primary amine.76
This approach has been adopted to achieve the asymmetric syn-
thesis of (5R)-1-benzyl-5-methyl-2-oxopiperazine 168 starting
from b-amidoketone 166 and (R)-a-methylbenzylamine as the chi-
ral auxiliary (Scheme 31).
Thus, the tandem process proceeded smoothly to give a 6:1 dia-
stereomeric mixture from which the major isomer 167 can be eas-ily separated. Its hydrogenolysis allowed 168 to be obtained, with
the stereochemical assignment being made by the analysis of
Mosher’s amide derivatives.
Interestingly, the use of an a-amino ester instead of a simple
amine component in the reductive amination step led to the for-
mation of a mixture of piperazinones, as shown in Scheme 32.Accordingly, the reductive amination of 169 with L-phenylala-
nine methyl ester produced 170, its cyclization leading to the for-
mation of the same amounts of the expected product 172, as well
as of the piperazinone 173.
The formation of the latter has been ascribed to an intramolec-
ular N,N0-acyl transfer converting the intermediate 170 into 171,
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266 C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274which gave rise to a concurrent N1–C2 cyclization occurring via N-
acylation rather than N-alkylation.
Chiral sulﬁnimines, readily available in both enantiomeric
forms, have proven to be valuable intermediates for the synthesis
of different nitrogen-containing targets.77
Viso et al.78–80 reported the asymmetric synthesis of enantio-
pure N-sulﬁnyl imidazolidines 176 via a diastereoselective 1,3-
dipolar cycloaddition between readily available p-toluenesulﬁni-
mines 174 and glycine iminoester enolates 175 (Scheme 33).ClCH2COCl
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Scheme 35.The enantiopure p-toluenesulﬁnimines displayed a moderate to
high facial selectivity producing the corresponding N-sulﬁnyl imi-
dazolidines in good to excellent diastereomeric excess. The chiral-
ity of sulfur has been transferred to three asymmetric centers in a
single synthetic operation with almost complete stereocontrol.
Reductive78–80 or hydrolytic cleavage81 of the aminal moiety
transformed N-sulﬁnyl imidazolidines 176 into differently pro-
tected vicinal diamino alcohols 177 and N-sulﬁnyl diamino esters
179, respectively. These classes of compounds are potential sub-
strates for the synthesis of enantiopure N-sulﬁnyl piperazinones
178 and 180, respectively, bearing suitable arms for further
functionalizations.
This synthetic pathway could give access to a wide range of N-
sulﬁnyl-5,6-disubstituted 2-oxopiperazines82,83 by varying the
nature of the p-toluenesulﬁnimines and glycine iminoester eno-
lates. A representative example is shown in Scheme 34.
Thus, substrate 186 has been obtained by a ﬁve-step sequence
featuring cycloaddition between 181 and 182 to produce 183, then
taken to 184 by reduction80 and silylation.83 This compound was
N-acylated to 185 and cyclized in basic media to produce 186.83
It is noteworthy that the treatment of 186with NaH in reﬂuxing
THF promoted a clean elimination of the sulfur moiety to give 5,6-
dihydropyrazin-2(1H)-one 187, useful intermediate for further
functionalization of the heterocyclic nucleus through nucleophilic
additions83,84 and Staudinger reactions.85
Attempts to obtain N-sulﬁnyl ketopiperazines from N-sulﬁnyl
diamino esters,83 available via a selective imidazoline hydrolysis,
failed in most cases, although the N-acylation step gave good
yields. The authors speculated on the origin of these results, a plau-
sible explanation was the acidity of the amide and the hydrogen
bound to the carbon a- to the ester group.
The 2-oxopiperazine nucleus is widely found as a core fragment
in a variety of natural and biologically important products, their
synthesis representing a test bed for new methods for the con-
struction of the piperazinone moiety.
The asymmetric total synthesis of guadinomine C2, an inhibitor
of type III secretion system (TTSS) of bacteria, has been successfullyachieved through a novel concise entry to 3,5,6-trisubstituted pip-
erazinone cores in enantiomerically pure forms.22
As shown in the selected example depicted in Scheme 35, the
Evans aldol reaction of valeraldehyde with (R)-oxazolidinone 188,
followed by hydrolytic removal of the chiral auxiliary, produced
the a-chloro-b-hydroxy acid 189 as a single enantiomer which
was condensed with the known peptide section NH2-L-Ala-L-Val-
OtBu to give 190.
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C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274‘ 267Subsequent epoxide formation under mild basic conditions and
azidolysis produced intermediate 191, which on reduction and
aziridination gave rise to the Ns-aziridine 192. Its regioselective
azidolysis furnished the corresponding b-azide 193. Staudinger
amination and condensation of the released amine with (R)-2-
bromopropionic acid yielded the intermediate derivative 194,
which took part in an intramolecular SN2 cyclization leading to
the formation of piperazinone 195.
A similar reaction sequence has been used for the preparation of
a structurally related (3R,5R,6R)-5,6-cis-3,6-syn-diastereomer.
The piperazinone core of (R)-()-praziquantel 16, a powerful
anti-worm drug, has been assembled through a six-step sequence
starting with the easily available N-phthaloylglycine chloride 196
and phenethylamine to give imine 197 (Scheme 36).45HN
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Figure 4.The asymmetric transfer hydrogenation of 197, in the presence
of a ruthenium catalyst, gave rise to the formation of 198. Depro-
tection and amidation of the derived primary amine furnished
compound 199. Its reaction with a-chloroacetyl chloride under
Schotten–Baumann conditions completed the synthesis of 16.
4. Cyclization at N4–C5
The synthetic approaches to 2-oxopiperazine ring systems fea-
turing N4–C5 bond formation have been organized in sub-sections
according to the different strategies by which the C–N bond has
been formed.
4.1. Reductive amination
DiMaio and Belleau86 described the enantiospeciﬁc synthesis of
two interesting piperazinone synthons, (3S,6R)-6-ethoxycarbonyl-
3-(p-hydroxybenzyl)piperazin-2-one 203 and (3S)-1-(ethoxycar-
bonylmethyl)-3-(p-hydroxybenzyl)piperazin-2-one hydrochloride
207, used as peptidomimetics for the ﬁrst and second residue of
Leu-enkephalin.
Synthon 203 was prepared as described in Scheme 37. Coupling
between Z-L-tyrosine and ethyl 2-amino-3,3-diethoxypropionate200 in the presence of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydro-
quinoline (EEDQ) produced the dipeptide 201 as a diastereomeric
mixture. Acid hydrolysis afforded vinylogous amide 202, with the
best results being observed with TFA, while the use of AcOH or
HCl promoted partial hydrolysis of the acetal and no cyclization.
The catalytic reduction of 202 in the presence of a slight excess
of HCl and subsequent neutralization gave 3,6-disubstituted pip-
erazin-2-one 203.
Only one diastereoisomer was detected in the product mixture,
its formation being accounted for the removal of the Z group fol-
lowed by enantiospeciﬁc electrophilic attack of the proton a to
the ethoxycarbonyl group and catalytic reduction of the intermedi-
ate iminium ion.87
Similarly, the TFA-promoted cyclization of the dipeptide 205, in
turn obtained from Z-L-tyrosine and ethyl N-(2,2-dimethoxyeth-
yl)glycinate 204, followed by one-pot deprotection and reduction
of the cyclic enamide 206, afforded the amine hydrochloride 207
in 80% yield.
Since then, the incorporation of these synthons into biologically
active peptides has gained wide acceptance, with the 2-oxopiper-
azine ring being used as a model template in which two nitrogen
atoms of the dipeptide backbone are linked by an ethylene bridge
and consequently the torsion anglesx, u, and / are restricted com-
pared to the parent peptide (Fig. 4).The original DiMaio’s route86 has been successfully extended to
the preparation of a large variety of substituted
piperazinones.25,28,34,35,88
A representative application of this approach is illustrated in
Scheme 38.
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268 C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274Thus, condensation of Z-L-aspartic acid tert-butyl ester with tert-
butyl N-(2,2-dimethoxyethyl)glycinate 208 produced the acetal
amide 209, which underwent an acid-catalyzed cyclization/reduc-
tion sequence to afford 1,3-disubstituted piperazin-2-one 210.34
This chemistry has been successfully applied to the synthesis of
enantiomerically pure 1,3-disubstituted 2-oxopiperazine deriva-
tives, used as precursors of non-peptide glycoprotein (GP) IIb–IIIa
antagonists,34,35 starting from diverse N-substituted N-(2,2-dialc-
oxyethyl)-amides derived from Z-protected L-amino acids.
Recently, 2,2-dimethoxyethylamine derivatives have been used
as convenient starting materials for the preparation of 1,3-disub-
stituted piperazinone precursors of PGGTase-I inhibitors.25
As an example, the secondary amine 211 obtained by a reduc-
tive amination of 2,2-dimethoxyethylamine with p-ﬂuorobenzal-
dehyde was coupled with Z-L-leucine to give intermediate 212.
Acid-promoted cyclization to enamide 213 followed by one-pot
deprotection and reduction produced 2-oxopiperazine 214
(Scheme 39).MeO
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Scheme 41.An alternative approach to the synthesis of the piperazinone
nucleus involves the use of suitable N-allylic amides, with the alde-
hyde required for the cyclization step being generated by oxidation
of the alkene functionality.23,90
As reported by Just et al.,89 NaBH4 reduction of the imine 215
resulting by reductive amination of 4-methoxycinnamaldehyde
with L-valine methyl ester furnished N-allyl derivative 216
(Scheme 40). Its coupling with Z-L-phenylalanine by activating
the carboxylic acid as the corresponding ﬂuoride proceeded
smoothly to give the derivatized dipeptide 217. Ozonolysis fol-
lowed by hydrogenation produced the 1,3-disubstituted 2-oxopip-
erazine 218, thus accounting for an intramolecular reductive
amination reaction.
In a parallel synthetic pathway, a suitable N-allyl derivative has
been prepared via a sulfonamide approach, based on the use of N-
4-nitrosulfonamide as an activating group for achieving mono-N-
allylation.89These methods seem to represent valuable alternatives to the
classical reaction of dipeptides with 1,2-dibromoethane, which
failed to give high yields of the desired products.
The synthetic strategy based on intramolecular amination reac-
tion via a N-allyl substrate has been used to obtain a piperazinone-
based building block precursor of a substance P analogue having
the Phe7-Phe8 region constrained.23
As illustrated in Scheme 41, the protection of (3R)-phenylpro-
line 219 followed by electrochemical oxidation gave the methoxy-
lated product 220. Its treatment with BF3Et2O and
allyltrimethylsilane produced compound 221, with the allyl substi-
tuent trans to the phenyl ring and cis to the methyl ester. Cleavage
of the double bond by ozonolysis, reduction of the resulting alde-
hyde and elimination allowed the installation of a vinyl substituent
at C-5 leading to 222.Deprotection of 222 and coupling of the released amine with Z-
L-phenylalanine acid ﬂuoride gave access to dipeptide 223, which
underwent ozonolysis/reduction sequence to furnish the bicyclo-
piperazine building block 224, removal of the Z protecting group
occurring during the reductive step.
Intramolecular reductive amination entailing on the use of D-
glucosamine-derived amide 225 as the starting material repre-
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ready obtained through a N1–C2 bond-forming strategy.
As shown in Scheme 42, compound 225 underwent a one-pot
hydrogenolytic removal of the Z group, cyclization and reduction
of the intermediately formed imine. Boc protection to give 48 fol-
lowed by an oxidation/reduction sequence yielded the piperazi-
none 49 without any detectable racemization.99% LiAlH4, THF
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236It is noteworthy that the ring-closure step could be efﬁciently
promoted by the addition of molar or catalytic amounts (10%) of
hydroxylamine.
Moreover, the sequential transformation of 225 into conﬁgura-
tionally stable a-amino aldehyde 226, hydrogenation and Boc pro-
tection gave access to (6R)-conﬁgured piperazinone 53.
4.2. Nucleophilic substitution
The N4–C5 bond-forming strategy centered on an intramolecu-
lar Mitsunobu reaction was ﬁrstly used by Jacobsen et al.57 for
the preparation of (3R)-1-benzyl-3-methyl-piperazin-2-one 229
starting from amide 227 prepared by coupling Boc-D-alanine and
N-benzylethanolamine (Scheme 43). Removal of the Boc-protect-
ing group produced an intermediate amine 228, which underwent
Mitsunobu cyclization (PPh3, DEAD) to give 229.N NHBoc
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Scheme 45.Later, Schoﬁeld et al.27 further assessed the Jacobsen approach
as a straightforward and ﬂexible route for the synthesis of N-ben-
zyl piperazinones bearing variable substituents at C-3 starting
from protected a-amino acids and N-benzylethanolamine.
The Mitsunobu reaction has been successfully applied to install
the N4–C5 bond of 1,3-disubstituted 2-oxopiperazine 234 throughcyclization of the key amino alcohol 233,88 its preparation being
achieved by a six-step sequence starting from (S)-a-methylbenzyl-
amine (Scheme 44).Thus, the reaction of (S)-a-methylbenzylamine with chloroethyl
oxalate and reduction of the derived amide 230 furnished alcohol
231, which was sequentially protected and coupled to Z-D-trypto-
phan. The resulting amide 232 was deprotected to release both the
alcohol and amino groups to give 233which in turn was submitted
to Mitsunobu conditions to give piperazinone 234.
Recently, a library of spirocyclopropanated 2-oxopiperazine-5-
carboxylates has been developed starting from methyl 2-chloro-
2-cyclopropylidene-acetate 23590 by sequential conjugate addi-
tion, acylation, and tandem nucleophilic substitution. A typical
application of this approach is outlined in Scheme 45.Thus, the Michael addition of 4-chlorobenzylamine onto 235
followed by coupling with a-bromoacetyl chloride under modiﬁed
Schotten–Baumann conditions yielded the stable acyclic bishalide
236.
Subsequent treatment with L-valine methyl ester triggered a
tandem nucleophilic substitution occurring via intermolecular
substitution of the bromide giving transient 237 followed by a
NH
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O
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85%247 248
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O
270 C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274ring-closing intramolecular nucleophilic substitution of the chlo-
rine atom to produce piperazinone 238 as a 1:1 diastereomeric
mixture, which could be separated by column chromatography.
Bicyclic oxopiperazines were obtained when 236 was reacted
with pure b-amino alcohols, with an intramolecular transesteriﬁ-
cation taking place after piperazinone ring formation.
4.3. Michael addition
Intramolecular Michael addition has been established as a con-
venient tool for piperazinone synthesis through N4–C5 cyclization.
In this context, Goff and Zuchermann91,92 have reported the efﬁ-
cient synthesis of piperazinones on solid support with an intramo-
lecular Michael ring closure as the key step.
As shown in Scheme 46, the acylation of dipeptoid 239 with
Fmoc-L-phenylalanine produced 240. Removal of the Fmoc group
produced resin-bound derivative 241 through Michael addition
of the released amine onto the a,b-unsaturated system. Subse-
quent detachment of the solid support produced piperazinones
242 (3:1 diastereomeric mixture) which contain two ring substitu-
ents and a free secondary amino group to be used for further
functionalization.H
N
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N
O
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Scheme 47.Alternatively, compound 239 was coupled with (S)-2-bromo-
propionic acid to furnish the supported amide 243. Subsequent
reaction with cyclopentylamine promoted a tandem SN2 displace-
ment/Michael addition leading to solid-supported intermediate
244. Final acid treatment gave 3,4,5-trisubstituted 2-oxopiperazine
245 as a 88:12 mixture of two diastereomers, which were easily
separated.This chemistry was feasible for combinatorial synthesis, since
the substitution around the ring could be varied by the appropriate
choice of the starting peptoid, the Fmoc amino acid, the a-haloacid,
and the amine used for the cyclization step. Furthermore, the free
secondary amine of the intermediate 241 permitted further substi-
tution by reaction with different acylating agents.
The tricyclic A–B–C ring system of ()-agelastatin A 10 featur-
ing a piperazinone core has been assembled by a Cs2CO3-mediated
intramolecular Michael cyclization of compound 249 to produce
the key intermediate 250 (Scheme 47).15 The preparation of 249
has been achieved by ring-closing metathesis of diamino ketodiene
248, in turn obtained from compound 246 via 247.Recently, Dickson and Wardrop17 reported a similar approach
based on an intramolecular Michael reaction for the assemblage
of the A–B–C ring system of racemic agelastatin A, the key ring-clo-
sure step being achieved using K2CO3 as the base in DMSO at
100 C for 1 h.
Anefﬁcient synthesisof thepiperazinone fragmentofpseudothe-
onamide A1, a potent serine protease inhibitor, has been accom-
plished via a stereoselective intramolecular Michael ring closure of
dipeptide 253,14 which has been obtained starting from O-2,6-
dichlorobenzyl(Cl2Bn)-Boc-L-tyrosine (Scheme 48). Thus, conver-
sion into c-amino-a,b-unsaturated ester 251 followed by coupling
with Boc-D-phenylalanine afforded 252. The subsequent Boc-depro-
tection gave253, which took part in an intramolecularMichael reac-
tion by stirring in methanol at room temperature to yield 254.
4.4. Miscellaneous
During their studies toward the synthesis of pseudotheona-
mides A1 and A2, Gurjar et al.13 developed a novel approach for
the construction of the 3,5,6-trisubstituted piperazinone ring sys-
tem of the natural products using an intramolecular [3+2] cycload-
dition reaction between an azide and an a,b-unsaturated ester. The
azido ester 259was the key intermediate in this approach summa-
rized in Scheme 49.
Its preparation has been conveniently accomplished by cou-
pling between the (R)-a-azido acid 255 and p-methoxyphenylalan-
inol 256 to provide dipeptide 257 along with the corresponding
dipeptide ester as a minor component, which could furnish addi-
tional 257 upon hydrolysis.
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reagent gave the corresponding aldehyde 258 which underwent a
two-carbon homologation via a Wittig reaction to give the a,b-
unsaturated ester 259.CO2H
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Scheme 49.The latter was subjected to the key cycloaddition step to pro-
duce the enamine 260 which was subsequently reduced with so-
dium cyanoborohydride to give an easily separated 3:7 mixture
of piperazin-2-ones 261 and 262.
The piperazinone ring B moiety of dibromophakellstatin19,20
and related marine sponges alkaloids bromophakellin and phakel-
lin21 has been assembled through a two-step synthetic sequence
entailing a key oxidative cyclization.
Thus, condensation of 2-(trichloroacetyl) pyrrole with L-prolinol
followed by oxidation of intermediate amide 263 produced a 3:1
diastereomeric mixture of N,O-hemiacetals 264 (Scheme 50). These
compounds have been successfully converted into 265, which has
been used as a common starting material to give the ﬁrst enantio-
selective synthesis of (+)-bromophakellin ent-13 and (+)-phakellin
ent-14.21  Zn, AcOH
56%
HN
NTces
85%
MeOH, 40 °C
(+)-phakellin
    ent-14
265
MeOH, 40 °C
Scheme 50.Poli et al.93 developed an elegant and original strategy for the
synthesis of piperazin-2-one derivatives entailing on a 6-exo intra-
molecular Pd(0)-catalyzed allylic amination of N-tosyl derivatives
266 giving rise to cyclic compounds 267 as a mixture of the two
possible diastereomers in high yield (Scheme 51).N
NH
OAc
Ts
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O
Bn
5% Pd(OAc)2, 10% dppe
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> 98%
N
N
Ts
R
O
Bn266
267
Scheme 51.The authors presented convincing evidence that this cyclization
is a reversible process, constantly favoring the thermodynamically
more stable cis isomer, and that the cis/trans ratio increases with
the size of the amino acid residue.
In order to enhance the diastereoselectivity of the cyclization
process and to circumvent the equilibration between the two epi-
mers, the same authors envisioned an alternative route,94 the
intramolecular Pd(II)-catalyzed allylic amination in the presence
of LiCl and without a reoxidizing system. These conditions allowed
higher diastereoselectivities than those reported using Pd(0) and
produced an irreversible process, with the stereoselectivity being
conveniently reversed when the reaction was performed in the ab-
sence of LiCl.
5. Cyclization at C6–N1
The cyclization of suitable dipeptides with 1,2-dielectrophiles
has been extensively used to achieve the synthesis of substituted
NO
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O
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O
H2N
276
272 C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–2742-oxopiperazines.33,70,95–97 This approach usually takes place via a
two-step sequence involving an initial intermolecular N4–C5 bond-
forming reaction followed by an intramolecular C6–N1 bond-form-
ing step.
The reaction of dipeptide 122 with ethylene glycol bis-triﬂate
gives 2-oxopiperazine 268 (Scheme 52),70 while other 1,2-dielec-
trophiles, such as ethylene sulfate, were completely uneffective.1. piperidine, DMF, rt
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Scheme 52.The preparation of 1,3-disubstituted 2-oxopiperazines by the
cyclization of sulfonamide dipeptides with 1,2-dibromoethane
was reported 20 years ago by Just et al.95 along the pathway illus-
trated in Scheme 53 as a selected example.BocHN
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Scheme 55.Removal of the Boc-protecting group from peptide 269, ob-
tained by classical peptide coupling between Boc-L-alanine and L-
phenylalanine methyl ester, followed by sulfonamide formation
gave the key sulfonamide dipeptide 270. This compound under-
went reaction with excess 1,2-dibromoethane and K2CO3 in DMF
at 60 C to yield the sulfonamide 2-oxopiperazine 271, which
was eventually deprotected to give 272.
Interestingly, the same compound 272 has been prepared start-
ing from the 2-nitrobenzenesulfonamide analogue of 270 through
a sequential Mitsunobu reaction with 2-bromoethanol, base-pro-
moted cyclization and deprotection.
A successful application of the approach based on cyclization of
sulfonamides with 1,2-dibromoethane has been achieved by the
same authors on solid support (Scheme 54).95 Resin-bound 2-
nitrobenzenesulfonamide dipeptide 274, in turn obtained from
Fmoc derivative 273, reacted with excess 1,2-dibromoethane. Sub-
sequent deprotection furnished the resin-bound piperazinone 275,
which could be converted into 1,3,4-trisubstituted 2-oxopiper-
azine 276 through sequential functionalization of the free second-
ary amino group and cleavage of the resin.
Similar routes via piperazinone ring assembly by treatment of a
suitable sulfonamide dipeptide with 1,2-dibromoethane have been
used to obtain key intermediates for the synthesis of a thyrotropinreleasing hormone (TRH) analogue96 and 1,3,4-trisubstituted 2-
oxopiperazine based melanocortin-4 (MC4) agonists.33
Studies directed toward the development of a short and efﬁ-
cient route for the preparation of piperazinone 136,97 led to the
discovery of the synthetic pathway outlined in Scheme 55.Condensation of O-benzyl-L-serine methyl ester with N-nosyl
glycine in the presence of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM) 277 produced sulfon-
amide 278, which was reacted with an excess of 1,2-dibromoeth-
ane producing satisfactorily the 1-substituted piperazin-2-one
279. Reduction of the ester group, deprotection, and Boc-reprotec-
tion completed the synthesis of 136.
It is noteworthy that the direct cyclization of the Boc analogue
of 278 using ethylene glycol bis-triﬂate as a dielectrophile proved
to be unsuccessful, as the hydrogen bound to the carbamate nitro-
gen was not acidic enough.
An operationally simple 6-exo epoxide ring-opening cyclization
allowed chiral 1-aryl-6-(hydroxymethyl)-2-ketopiperazine 283 to
be obtained in high yields and with excellent enantiomeric pur-
ity,62 through the synthetic pathway depicted in Scheme 56.
This approach utilized (S)-epichlorohydrin instead of Garner’s
aldehyde as the source of the C-6 chirality as previously illustrated
for the N1–C2 bond-forming reaction depicted in Scheme 19.
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C. De Risi et al. / Tetrahedron: Asymmetry 21 (2010) 255–274‘ 273Thus, the reaction of 4-benzyloxyaniline with a-chloroacetyl
chloride followed by alkylation of the intermediate chloromethyla-
cylated derivative with benzylamine gave an 87% overall yield of
the secondary amine 280. Its reaction with (S)-epichlorohydrin in
the presence of MgSO4 produced chlorohydrin 281, which was
used in the next step without further puriﬁcation. Basic treatment
of crude 281 (5% NaOH, room temperature) allowed the rapid for-
mation of epoxide 282which took part in a slow cyclization to give
ketopiperazine 283 in 77% yield over the two steps. Finally, hydro-
genation of 283 in the presence of Boc2O proceeded smoothly to
yield compound 101.
The authors outlined that the treatment of 281with an aqueous
NaOH solution followed by NaH-promoted cyclization in anhy-
drous DMF produced the desired piperazinone 283 in 26% yield to-
gether with 4-benzyloxyaniline and various unidentiﬁed polar
byproducts, while other solvents exclusively gave the formation
of polar byproducts.
A noteworthy application to natural product synthesis of C6–N1
bond-forming reaction has been described by Trost and Dong16
who demonstrated that pyrroles and N-methoxyamides could be
employed as nucleophiles in the functionalization of cyclopentenes
through Pd-catalyzed asymmetric allylic alkylation reactions in the
presence of C2-symmetric bisphosphine ligand (R,R)-284.
As shown in Scheme 57, the Pd-catalyzed reaction between
Boc-activated cyclopentene 1,4-diol 285 and methyl 5-bromopyr-
role-2-carboxylate 286 in the presence of Cs2CO3 gave N-alkyl pyr-
role 287 in 83% yield and 92% ee. A two-step hydrolysis/
condensation process allowed the transformation of 287 into N-
methoxyamide 288 which underwent an intramolecular Pd-cata-
lyzed asymmetric allylic alkylation leading to piperazin-2-one
289, eventually elaborated to the potent cytotoxic agent (+)-age-
lastatin A ent-10.
It is noteworthy that the chiral ligand was not necessary to
achieve piperazinone formation. However, the use of (R,R)-284 as
a catalyst gave higher yields (91%) compared to dppp (70%).
Furthermore, when N-methoxyamide 290 was used as the
counterpart of 285 (Scheme 58), a palladium-catalyzed cascadereaction using two sequential allylic displacement reactions led
to a highly enantioselective, one-pot assemblage of the regioiso-
meric piperazinone 291 (98% ee), which allowed to obtain the nat-
ural ()-enantiomer of agelastatin A.
Note added in proof: after submission of the manuscript to the
Editor, an additional nice paper has appeared (Baran et al. Angew.
Chem., Int. Ed. 2010, 49, 1095–1098). This work reported the total
synthesis of palau’amine using a remarkable transannular cycliza-
tion of a suitable macrocycle as the key step to assemble the pip-
erazinone moiety of the natural compound.
6. Outlook
The present report highlights the synthetic routes toward chiral
2-ketopiperazines, which feature a particular backbone which can
be assembled in different and complementary ways. This greatly
helps medicinal, combinatorial, and natural product chemists to
cover a certain activity space in an optimum fashion. Moreover it
can be anticipated that even more routes toward piperazines as
privileged scaffolds will be discovered in the future.
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Abstract 
 
This study reports the synthesis, chromatographic separation and pharmacological evaluation of the 
two enantiors of the neuropeptide S receptor (NPSR) antagonist (9R/S)-3-oxo-1,1-diphenyl-
tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). The (9R)-3-
oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide 
(compound 10) and (9S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 
4-fluoro-benzylamide (compound 10a) were synthesized and their purity assessed by chiral 
chromatography. The absolute configuration of the enantiomer 10 has been assigned from the 
crystal structure of the corresponding (S)-phenyl ethyl amine derivative 8. Calcium mobilization 
studies performed on cells expressing the recombinant NPSR demonstrated that compound 10 is the 
active enantiomer while the contribution of 10a to the NPSR antagonist properties of the racemic 
mixture is negligible. 
 
Introduction 
 
Neuropeptide S (NPS) is the last neuropeptide identified via the reverse pharmacology approach.1 
NPS selectively binds and activates a previously orphan GPCR receptor now referred to as NPSR.1 
NPSR is widely distributed in the brain while the expression of the NPS peptide precursor is limited 
to few discrete brain areas.1, 2 The supraspinal administration of NPS in rodents produces a rather 
unique pattern of actions: stimulation of wakefulness associated with anxiolytic-like effects.1 In 
addition, NPS has been reported to inhibit food intake, facilitate memory, elicit antinociceptive 
effects, and recent evidence suggests an involvement of the NPS/NPSR system in drug addiction 
(see for a review 3). 
Potent and NPSR selective antagonists are now required for understanding the biological functions 
controlled by the NPS/NPSR system. As far as peptide antagonists are concerned, these molecules 
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were recently discovered by replacing Gly5 in the natural peptide sequence with a D-amino acid. 
Examples of such compounds are [D-Cys(tBu)5]NPS4, [D-Val5]NPS5 and more recently [tBu-D-
Gly5]NPS.6 The first example of non-peptide molecules able to interact with the NPSR was reported 
in the patent literature by Takeda researchers.7 Among the different molecules described in the 
patent, the compound (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic 
acid 4-fluoro-benzylamide (SHA 68; compound 1) has been pharmacologically characterized. In 
vitro, compound 1 behaves as a selective, potent (pA2 ≅ 8) and competitive antagonist at human8 
and murine9 NPSR. In vivo, compound 1 has been reported to prevent the arousal promoting and 
anxiolytic-like effects elicited by NPS in mice and rats.8, 9 In addition, compound 1 reversed the 
protective effect of NPS on the NMDA receptor antagonist MK-801-induced neurotoxicity in rats.10 
Finally recent findings indicate that in the rat intracerebroventricular injection of NPS increased 
conditioned reinstatement of cocaine seeking, whereas peripheral administration of compound 1 
reduced it.11 These pharmacological investigations were performed using the racemic compound 1. 
Molecular modelling studies investigated non-peptide ligand binding to NPSR.12 In the frame of 
these studies, docking analyses were performed and a defined NPSR binding pocked was proposed; 
of note, only the (S) enantiomer of compound 1 was used in such simulations. The importance of 
ligand chirality for NPSR interaction has been recently supported by the identification of two novel 
classes of non-peptide NPSR antagonists: the quinoline13 and the tricyclic imidazole14 based 
compounds. In both cases, a single bioactive enantiomer was obtained by chiral chromatography 
separation from the corresponding racemic mixture.  
In the present study, we report the synthesis, chiral HPLC analysis, X-ray crystallographic 
assignment and in vitro pharmacological evaluation of the two compound 1 enantiomers.  
 
Results and Discussion  
The reference compound 1 was synthesized following the procedures reported by Okamura et al.8 In 
Scheme 1 is described the synthetic approach adopted for the synthesis of 10 and 10a starting from 
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(S)-phenyl ethyl amine. As reported in literature15, 16 the use of phenyl ethyl amine was expected to 
induce the stereochemistry of C9 of the tetrahydro-oxazolo[3,4-a]pyrazine nucleus. Unfortunately, 
we obtained only a slight chiral induction corresponding approximately to a 60 / 40% ratio 
determined by NMR spectroscopy. Similar results were obtained using (R)-phenyl ethyl amine as 
chiral auxiliary. Nevertheless, diastereomers 8 and 8a were successfully separated in good yield by 
flash chromatography. The removal of the chiral auxiliary to obtain 9 and 9a and the acylation of 
N7 with p-fluoro-benzylisocyanate to obtain final compounds were achieved using the procedure 
reported by Okamura et al.8 The purity grade and enantiomeric excess of 10 and 10a were 
determined by chiral HPLC analysis. The top panel of Figure 1 shows the chromatogram for the 
single enantiomer 10a (first eluted component), the middle panel that of 10 (second eluted species) 
and the bottom panel of the figure displays the chromatogram for the racemate. As it is evident 
from this figure, there is no trace of 10 in the chromatogram corresponding to the elution of 10a, 
nor of 10a in that of 10. In order to define the absolute configuration of the C9 chiral centre, we 
explored different crystallization conditions for compounds 8, 8a, 9, 9a and for the final products. 
Only with compound 8 we were able to obtain crystals suitable for further X-ray investigation. In 
particular, compound 8 was crystallized from ethanol/ ethyl acetate and its X-ray analysis 
demonstrated the absolute configuration R at the chiral center C9. The absolute C9 configuration of 
compound 8 has been assigned by reference to the unchanged chiral centre C10 in configuration S 
(Figure 2). On the basis of the absolute configuration of 8, we were able to assign the absolute C9 
configuration to compounds 8a, 9, 9a and that to the final products 10 and 10a. 
 
In parallel, we performed a series of NMR experiments. In Figure 3 the enlarged [1H]NMR spectra 
of the C9 proton region of the 10a and 10 isomers are depicted. The coupling constant analysis 
between Hx and Ha/Hb C8 protons are very similar (11.3/3.7 Hz for 10a, panel A and 11.2/3.7 Hz 
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for 10, panel B) in both compounds. This result together with X-ray data of 8 (see Figure 2), 
confirms the axial position of C9 proton in both enantiomers.  
Next, we evaluated and compared the in vitro NPSR antagonist properties of compound 1, 
compound 10, and compound 10a. The three samples were tested in calcium mobilization studies 
performed on HEK293 cells expressing the murine NPSR or the two isoforms of the human 
receptor (hNPSRAsn107 and hNPSRIle107).17 
The natural peptide NPS was able to induce calcium mobilization in a concentration dependent 
manner in HEK 293 mNPSR (pEC50 8.97 ± 0.11; Emax 250 ± 11%), hNPSRAsn107 (pEC50: 9.07 ± 
0.11; Emax 316 ± 13%) and hNPSRIle107 (pEC50: 9.17 ± 0.15; Emax 333 ± 17%). The three samples 
were challenged against the stimulatory effect of 10 nM NPS in inhibition response curves (Figure 
4). Compound 1, compound 10, and compound 10a did not stimulated per se calcium mobilization 
up to 10 µM. Compound 1 inhibited in a concentration dependent manner the stimulatory effect of 
NPS showing similar high values of potency (pKB ≅ 8). These values of potency are 
superimposable to those previously published.8, 9 Compound 10 was also able to antagonize in a 
concentration dependent manner the stimulatory effect of NPS displaying values of potency similar 
or slightly higher than the racemic mixture. By contrast, compound 10a showed a slight inhibitory 
effect only at micromolar concentrations. The values of potency of the three compounds in the three 
cells lines are summarized in Table 1. Collectively, these results demonstrated that compound 10 is 
the active enantiomer while the contribution of compound 10a to the biological activity of the 
racemic mixture is negligible. This information can be extremely useful for the refinement of the 
recently proposed molecular models of NPSR and its binding pocket.12 As already mentioned in the 
introduction, the relevance of ligand chirality for NPSR binding is also corroborated by the fact that 
the biological activity of chemically different molecules, such as the quinoline13 and the tricyclic 
imidazole14 compounds, could be attributed to a single bioactive enantiomer.  
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In conclusion, the present study described the synthesis and separation of the two compound 1 
enantiomers. The synthetic scheme we used can be easily scaled up to multi-grams. Compound 10 
was demonstrated to be the bioactive enantiomer. Nowadays this molecule represents the standard 
non peptide NPSR antagonist that has been, and surely will be, used to investigate the biological 
functions controlled by the NPS / NPSR system and to evaluate the therapeutic potential of 
innovative drugs acting as NPSR selective ligands. 
 
Experimental Section 
 
Materials. HPLC grade solvent were purchased from Sigma Aldrich (Steinheim, Germany). The 
purity of the tested compound 1, compound 10 and compound 10a has been assessed by RP-HPLC. 
All compounds showed >95% purity. One-dimensional and two dimensional NMR spectra were 
recorded on a VARIAN 400 MHz instrument. Chemical shifts are given in ppm (δ) relative to TMS 
and coupling constants are in Hz. MS analyses were performed on a ESI-Micromass ZMD 2000. 
Optical rotation data were recorded on a Perkin-Elmer polarimeter 241. Flash chromatography was 
carried out on a silica gel (Merck, 230–400 Mesh). Silica gel (Polygram SIL G/UV254) was used 
for thin layer chromatography. 
Typical Procedures for the Synthesis of 10 and 10a. 
[(1-Phenyl-ethylcarbamoyl)-methyl]-carbamic acid tert-butyl ester (3). To a stirred solution of 
Boc-Gly-OH (5 g, 28.5 mmol) in CH2Cl2 (50 mL), WSC (3.64 g, 19 mmol) and (S)-phenylethyl 
amine (3.45 g, 28.5 mmol) were added. After 24 h at room temperature the reaction was monitored 
by TLC (EtOAc/light petroleum 2:1). The organic layer was washed with 10% citric acid (20 mL), 
5% NaHCO3 (20 mL) and brine (20 mL). The organic phase was dried, concentrated in vacuo and 
purified by flash chromatography (EtOAc/light petroleum 2:1) to obtain 3 in 60% yield.1H NMR 
(400MHz, CDCl3): δ 7.31-7.24 (m, 5H, Ar); 6.62 (bs, 1H, NH-CO); 5.31 (bs, 1H, NH-Boc); 5.11 
(m, 1H, CH-CH3); 3.75 (m, 2H, CH2-NH-Boc); 1.47 (d, 3H, CH3-CH-Ar, J=6.8 Hz); 1.42 (s, 9H, 
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tbu-); 13C NMR (100MHz, CDCl3): δ 168.6, 156.2, 143.0, 128.7, 127.4, 126.1, 80.2, 48.7, 44.6, 
28.3, 21.9; MS (ESI): [M+H]+ =279; [α]D20 = -41 (c = 0.121g/100 ml, chloroform).  
[2-(1-Phenyl-ethylamino)-ethyl]-carbamic acid tert-butyl ester (4). To a stirred suspension of 
LiAlH4 (0.85g, 22.38mmol) at 0 °C in anhydrous THF, a solution of 3 (3.11 g, 11.19 mmol) was 
added drop wise. The reaction was monitored by TLC (EtOAc/light petroleum 3:1) and  after 24 
hours the excess of hydride was quenched with water and the salts were filtered trough a celite pad. 
The solvent was evaporated in vacuo to yield 4 (2.66 g, 10.07 mmol) in 90% yield. 1H NMR 
(400MHz, CDCl3): δ 7.32-7.27 (m, 5H, Ar); 4.96 (bs, 1H, NH-Boc); 3.77-3.73 (q, 1H, CH3-CH-Ar, 
J=6.6 Hz); 3.16-3.13 (m, 2H, NH-CH2-CH2); 2.59-2.51 (m, 2H, NH- CH2-CH2); 1.75 (bs, 1H, -NH); 
1.42 (s, 9H, tbu-); 1.36-1.33 (d, 3H, CH3-CH-Ar, J=6.6 Hz);. MS (ESI): [M+H]+ = 265; [α]D20 = -
29° (c = 0.11 g/100 mL, chloroform). 
{2-[(2-Chloro-acetyl)-(1-phenyl-ethyl)-amino]-ethyl}-carbamic acid tert-butyl ester (5). To a 
stirred solution of 4 (1.94 g, 7.34 mmol) in EtOAc (50 mL)  at 0 °C, satured solution of NaHCO3 (5 
mL) was added. After 10 min, chloroacetyl chloride (1.17 mL, 14.68 mmol) was added drop wise. 
The reaction was monitored by TLC (EtOAc/light petroleum 3:1) and after 24 h at room 
temperature, NaHCO3 (2 mL) was added to the organic phase. The organic layer was separated and 
the aqueous phase was extracted twice with EtOAc (50 mL). The combined organic phases were 
concentrate to dryness to obtain 5 in quantitative yield. 1H NMR (400MHz, CDCl3): δ 7.22-6.98 (m, 
5H, Ar); 5.59-5.43 (q, 1H, CH3-CH-Ar, J=8 Hz); 4.85 (bs, 1H, NH-Boc); 4.10-3.97 (m, 2H, NH-
CH2-CH2); 3.76 (s, 2H, C=O-CH2-Cl); 3.18-3.15 (m, 2H, NH- CH2-CH2); 1.40-1.25 (d, 3H, CH3-
CH-Ar, J=8 Hz); 1.06 (s, 9H, tbu). 13C NMR (100MHz, CDCl3): δ 170.12, 155.85, 139.47, 128.45, 
128.20, 128.03, 80.69, 59.44, 42.86, 41.14, 38.24, 27.48, 19.98. MS (ESI): [M+H]+ = 341.  
3-oxo-4-(1-phenyl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester (6). To a stirred 
suspension of 60% NaH (1.14 g, 28.61 mmol) in a mixture of THF/DMF 1/1 (20 mL) at 0 °C, a 
solution of 5 (3.25 g, 9.54 mmol) in THF/DMF 1/1 (10 mL) was added. After 24 h the reaction was 
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 8 
quenched by adding NH4Cl satured solution (15 mL) and the solvent was removed in vacuo. The 
residue was dissolved in EtOAc (50 mL) and washed twice with water (20 mL). The organic layer 
was dried, evaporated under reduced pressure and the crude product purified by flash 
chromat graphy (eluent: EtOAc/light petroleum 1:1) to obtain 6 in 45% yield. 1H NMR (400MHz, 
CDCl3): δ 7.36-7.28 (m, 5H, Ar); 6.08 (q, 1H, CH3-CH-Ar, J=8Hz); 4.23-4.18 (d, 1H, N-CHeHa-
C=O, J=20Hz); 4.10 (d, 1H, N-CHeHa-C=O, J=20Hz); 3.62 (bs, 1H, CH2 Piperazine); 3.27 (bs, 1H, 
CH2 Piperazine); 3.19 (bs, 1H, CH2 Piperazine); 2.83 (bs, 1H, CH2 Piperazine); 1.53-1.51 (d, 3H, 
CH3-CH-Ar, J=8Hz); 1.45 (s, 3H, tbu-). 13C NMR (100MHz, CDCl3): δ 165.44, 153.78, 139.41, 
128.63, 127.68, 127.36, 80.69, 50.08, 47.98, 40.24, 28.32, 15.34. MS (ESI): [M+H]+ = 305; [α]D20 = 
-116.0 ° (c = 0.318 g/100 mL, chloroform).  
4-(1-phenyl-ethyl)-piperazine-carboxylic acid tert-butyl ester (7). To a stirred suspension of 
LiAlH4 (453 mg, 18.9 mmol) in anhydrous THF (20 mL) at room temperature, a solution of 6 (1.15 
g, 3.78 mmol) in THF (10 mL) was added. After 30 minutes the reaction was completed as showed 
by TLC analysis  (EtOAc/light petroleum 1:2). The reaction was quenched by adding 15% NaOH 
(1 mL) and Et2O (20 mL). The resulting precipitate was filtered through a Celite pad and the 
solvent was concentrate to dryness. The crude product was purified by flash chromatography 
(eluent: EtOAc/light petroleum 1:2) to give 7 (920 mg, 3.17 mmol) in 84% yield. 1H NMR 
(400MHz, CDCl3): δ 7.31-7.25 (m, 5H, Ar); 3.41-3.35 (m, 5H, CH2-N-Boc, CH-CH3); 2.41-2.33 (m, 
4H, CH2-N); 1.43 (s, 9H, tbu-); 1.36 (d, 3H, CH3-CH-Ar). 13C NMR (100MHz, CDCl3): δ 146.80, 
134.13, 128.38, 127.74, 127.10, 85.27, 50.36, 29.78, 28.49, 27.48. MS (ESI): [M+H]+ = 291; [α]D20 
= -32° (c = 0.0104 g/100 mL, chloroform). 
1,1-Diphenyl-7-(1-phenyl-ethyl)-hexahydro-oxazolo[3,4-a] pyrazin-3-one (8 and 8a). To a 
stirred solution of 7 (380 mg, 1.31 mmol) in anhydrous THF (5 mL), TMEDA (0.53 mL, 3.54 
mmol) was added. The reaction was cooled at -78 °C and sec-BuLi 1.4M in exane (2.53 mL, 3.54 
mmol) was added. The reaction was heated at -35 °C and after 2 h a solution of benzophenone (480 
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mg, 2.62 mmol) in anhydrous THF (7 mL) was added drop wise. The reaction became green and 
was stirred at room temperature for 24 h. After this time the reaction was monitorated by TLC 
(EtOAc/light petroleum 1:2) and quenched by adding NH4Cl satured solution (20 mL). The solvent 
was rem ved in vacuo and the aqueous phase extracted 3 times with EtOAc (30 mL). The combined 
organic layer was dried and evaporated to dryness. The crude diastereomers mixture was purified 
by flash chromatography using EtOAc/light petroleum 1:2 as eluent to obtain the fast running 
diastereomer 8a in 40% yield and the low running distereomer 8 in 45% yield. 
8a: 1H NMR (400 MHz, CDCl3): δ 7.55 - 7.49 (m, 2H), 7.41 - 7.21 (m, 11H), 7.19 - 7.14 (m, 2H), 
4.51 (dd, 1H, J = 10.9, 3.6 Hz), 3.74 (ddd, 1H, J = 13.2, 3.5, 1.3 Hz), 3.34 (q, 1H, J = 6.7 Hz), 3.04 
(ddd, 1H, J = 13.0, 12.1, 3.6 Hz), 2.70 - 2.61 (m, 2H), 1.86 (td, 1H, J = 11.9, 3.6 Hz), 1.50 - 1.41 (m, 
1H), 1.22 (d, 3H, J = 6.7 Hz). 13C NMR (100 MHz, CDCl3): δ 156.17, 142.85, 142.52, 138.91, 
128.69, 128.58, 128.50, 128.35, 128.01, 127.51, 127.37, 126.19, 125.95, 85.50, 64.52, 61.56, 52.66, 
49.30, 42.07, 19.34. MS ESI [M+H+]= 399; [α]D20= +216 (c = 0.108 g/100 mL, chloroform). 
8: 1H NMR (400 MHz, CDCl3): δ 7.50 - 7.45 (m, 2H), 7.39 - 7.20 (m, 11H), 7.18 - 7.14 (m, 2H), 
4.44 (dd, 1H, J = 3.56, 10.93 Hz), 3.86 - 3.79 (m, 1H), 3.48 (q, 1H, J = 6.8 Hz), 3.11 (ddd, 1H, J = 
13.0, 12.0, 3.81 Hz), 2.80 - 2.73 (m, 1H), 2.44 (ddd, 1H, J = 11.5, 3.5, 1.6 Hz,), 2.07 - 1.97 (m, 1H), 
1.50 (m, 1H), 1.27 (d, 3H, J = 6.8 Hz). 13C NMR (100 MHz, CDCl3): δ 156.20, 142.48, 142.28, 
138.81, 128.65, 128.51, 128.32, 127.98, 127.59, 127.28, 126.11, 125.92, 125.84, 85.39, 63.86, 
61.67, 53.24, 47.58, 42.11, 17.16; MS ESI [M+H+]= 399; [α]D20= -132°(c = 0.11 g/100 mL, 
chloroform). 
3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 9H-fluoren-9-
ylmethyl ester (9 and 9a). To a stirred solution of 8 or 8a (200 mg, 0.52 mmol) in acetonitrile (10 
mL) at reflux, Fmoc-Cl (148 mg, 0.57 mmol) dissolved in acetonitrile (7 mL) was added. The 
reaction, monitored by TLC (EtOAc/light petroleum 1:2), was completed in 12 h. The desired 
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precipitate was filtered off to obtain 9 or 9a in about 67% yield and pure enough to be used in the 
next reaction. 
3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-
benzylamide (10 and 10a). To a stirred solution of 9 (59 mg, 0.11 mmol) in anhydrous THF (15 
mL) p-fluoro-benzylisocianate (34.4 mg, 0.228 mmol) and DBU (19.2 mg, 0.126 mmol) were 
added. The reaction was monitored by TLC (EtOAc/light petroleum 1:2) and by mass spectrometry. 
After 24 h the reaction was treated as for 8 and 8a. The organic phase was dried and evaporate to 
dryness to give 10 in 76% yield after column chromatography using EtOAc/light petroleum 1/1 as 
eluent. 1H NMR (400 MHz, CDCl3): δ 7.51 - 7.47 (m, 2H), 7.41 - 7.18 (m, 10H), 7.03 - 6.94 (m, 
2H), 4.95 (t, 1H, J = 5.5 Hz), 4.45 - 4.27 (m, 3H), 4.03 (ddd, 1H, J = 13.5, 3.5, 1.2 Hz), 3.81 (dd, 
1H, J = 13.1, 2.7 Hz), 3.69 - 3.60 (m, 1H), 3.05 (td, 1H, J = 12.7, 3.7 Hz), 2.93 - 2.82 (m, 1H), 2.14 
(dd, 1H, J = 13.3, 11.3 Hz). 13C NMR (100 MHz, CDCl3): δ 157.20, 156.11, 141.81, 138.30, 134.91, 
129.48, 129.41, 129.17, 129.09, 128.82, 128.72, 128.37, 125.99, 125.85, 115.70, 115.48, 85.90, 
60.55, 46.58, 44.47, 43.76, 41.37. MS ESI [M+H+]= 445.9; [α]D20= +92 (c= 0.1 g/100 mL, MeOH). 
Compound 10a was obtained in the same manner, starting from 9a. Analytical data: Yield: 83%; 1H 
NMR (400 MHz, CDCl3): δ 7.51 - 7.47 (m, 2H), 7.41 - 7.18 (m, 10H), 7.03 - 6.94 (m, 2H), 4.95 (t, 
1H, J = 5.5 Hz), 4.45 - 4.27 (m, 3H), 4.03 (ddd, 1H, J = 13.3, 3.6, 1.3 Hz), 3.81 (dd, 1H, J = 13.1, 
2.7 Hz), 3.69 - 3.60 (m, 1H), 3.05 (td, 1H, J = 12.7, 3.7 Hz), 2.93 - 2.82 (m, 1H), 2.14 (dd, 1H, J = 
13.3, 11.3 Hz). 13C NMR (100 MHz, CDCl3): δ 157.20, 156.11, 141.81, 138.30, 134.91, 129.48, 
129.41, 129.17, 129.09, 128.82, 128.72, 128.37, 125.99, 125.85, 115.70, 115.48, 85.90, 60.55, 
46.58, 44.47, 43.76, 41.37. MS ESI [M+H+]= 445.9; [α]D20= -91 (c= 0.12 g/100 mL, MeOH). 
Chiral chromatography analysis. A micro HPLC (Agilent 1100 micro series, Agilent 
Technologies) equipped with a micro diode array detector was employed. A 150mm × 2mm 
stainless steel column packed with Lux Cellulose-1 (cellulose tris 3,5-dimethylphenylcarbamate 
from Phenomenex) was used for all the measurements. The average size of the packing material 
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was 3 µm. The mobile phase was a binary mixture of hexane/isopropyl alcohol (80/20 v/v). Flow 
rate was 200uL/min. Injection volume was 3µL. Analyte solutions were filtered with PFTE filters 
(0.45µm, Supelco, Bellefonte, PA, USA) before injection. All chromatograms were recorded at 230 
nm. The retention times for the first (10a) and second (10) eluted enantiomers were 6.5 and 7.9 min, 
respectively. 
Crystal structure determination of compound 8. 
The crystal data of compound 8 were collected at room temperature using a Nonius Kappa CCD 
diffractometer with graphite monochromated Mo-Kα radiation. The data sets were corrected for 
Lorentz and polarization effects. The structure was solved by direct methods18 and refined using 
full-matrix least-squares with all non-hydrogen atoms anisotropically and hydrogens included on 
calculated positions, riding on their carrier atoms. All calculations  were performed using SHELXL-
9719and PARST20implemented in WINGX21 system of programs. 
Crystal Data: C26H26N2O2, orthorhombic, space group P212121, a = 11.2339(2), b = 11.6808(3), c = 
16.4783(5) Å, V = 2162.30(9) Å3, Z = 4, Dc = 1.224 g cm-3, intensity data collected with θ ≤ 26°, 
4215 independent reflections measured, 3460 observed reflections [I > 2σ(I)], final R index = 
0.0365 (observed reflections), Rw = 0.0904 (all reflections), S = 1.048. The absolute configuration 
has not been established by anomalous dispersion effects in diffraction measurements on the crystal. 
The enantiomer has been assigned by reference to an unchanging chiral centre in the synthetic 
procedure. ORTEP22 view of compound 8 is shown in Figure 2. 
CCDC deposition number: 810351. 
Calcium mobilization experiments. HEK293 cells stably expressing the murine NPSR or the 
human receptor isosforms NPSRIle107 and NPSRAsn107
 
were generated as previously described.17 
HEK293mNPSR and HEK293hNPSRIle107 cells were  maintained in DMEM medium supplemented with 
10% fetal bovine serum, 2mM l-glutamine, hygromycin B (100 mg/L).  HEK293hNPSRAsn107 cells 
were maintained in DMEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 
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zeocin (100 mg/L). Cells were cultured at 37 °C in 5% CO2 humidified air. Cells were seeded at a 
density of 50,000 cells/well into poly-D-lysine coated 96-well black, clear-bottom plates. The 
following day, the cells were incubated with medium supplemented with 2.5 mM probenecid, 3 µM 
of the calcium sensitive fluorescent dye Fluo-4 AM and 0.01% pluronic acid, for 30 min at 37 °C. 
After that time the loading solution was aspirated and 100 µL/well of assay buffer (Hank’s 
Balanced Salt Solution; HBSS) supplemented with 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 2.5 mM probenecid and 500 µM Brilliant Black (Aldrich) 
was added. Concentrated solutions (1 mM) of NPS were made in bidistilled water and kept at −20 
◦C. Compound 1, compound 10 and compound 10a were dissolved DMSO at a final concentration 
of 10 mM and stock solutions were kept at -20 °C until use. The successive dilutions were carried 
out in HBSS/HEPES (20mM) buffer (containing 0.02% bovine serum albumin fraction V). After 
placing both plates (cell culture and master plate) into the fluorometric imaging plate reader 
FlexStation II (Molecular Devices, Sunnyvale, CA), fluorescence changes were measured. On-line 
additions were carried out in a volume of 50 µL/well. To facilitate drug diffusion into the wells in 
antagonist type experiments, the present studies were performed at 37 °C and three cycles of mixing 
(25 µL from each well moved up and down 3 times) were performed immediately after antagonist 
injection to the wells. Inhibition response curves were determined against the stimulatory effect of 
10 nM NPS. Compound 1, compound 10 and compound 10a were injected into the wells 24 min 
before adding NPS. 
Data analysis and terminology. The pharmacological terminology adopted in this paper is 
consistent with IUPHAR recommendations. Data were expressed as mean ± sem of at least four 
independent experiments made in duplicate. Maximum change in fluorescence, expressed in percent 
of baseline fluorescence, was used to determine agonist response. Non-linear regression analysis 
using GraphPad Prism software (v.4.0) allowed logistic iterative fitting of the resultant responses 
and the calculation of agonist potencies and maximal effects. Agonist potencies are given as pEC50 
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(the negative logarithm to base 10 of the molar concentration of an agonist that produces 50% of the 
maximal possible effect). Compound 1, compound 10 and compound 10a antagonist properties 
were evaluated in inhibition response curve experiments; the antagonist potency, expressed as pKB, 
was derived from the following equation: 
KB = IC50/([2 +([A]/EC50)n]1/n – 1) 
where IC50 is the concentration of antagonist that produces 50% inhibition of the agonist response, 
[A] is the concentration of agonist, EC50 is the concentration of agonist producing a 50% maximal 
response and n is the Hill coefficient of the concentration response curve to the agonist. 
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Table 1. Potencies (pKB) of compound 1 (SHA 68), compound 10 and compound 10a in HEK293 
cells expressing the murine NPSR and the human NPSR isoforms 
 
Compound mNPSR hNPSR Ile107  hNPSR Asn107  
 pKB pKB pKB 
1 8.16 
(7.79 - 8.53) 
 
8.03 
(7.77 - 8.37) 
7.99 
(7.73 - 8.25) 
10 8.29 
(7.93 - 8.65) 
 
8.18 
(7.90 - 8.46) 
8.28 
(7.72 - 8.84) 
10a <6 <6 <6 
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Figure 1. Chromatograms of compound 10a (top panel) and 10 (middle panel) in comparison with 
the racemate (bottom panel). 
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Figure 2. ORTEP view of compound 8. The thermal ellipsoids are drawn at 30% probability level. 
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Figure 3. Enlarged [1H]NMR spectra of the C9 proton region of the 10a (panel A) and 10 (panel B) 
isomers 
 
 
 
 
Panel A      Panel B     
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Figure 4. Inhibition response curves to compound 1 (SHA 68), compound 10 and compound 10a in 
HEK293 cells expressing the murine NPSR and the human NPSR isoforms. Data are mean ± s.e.m. 
of four separate experiments made in duplicate. 
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Scheme 1. Synthesis of compound 10 and 10a 
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